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Colorectal cancer is a cancer that forms in the tissues of the colon and/ or rectum and 
more than 95% of colorectal cancers are adenocarcinomas. It is the third most common 
cancer in incidence and mortality rates, accounting for 9% of all cancer cases and for 8% 
of all cancer related deaths (2002). The established risk factors of colorectal cancer 
include personal or family history of previous colorectal cancer or adenomatous polyps, 
chronic bowel inflammatory disease and presence of any of the hereditary syndromes. In 
addition, due to the fact that the majority of colorectal cancer cases (approximately 90%) 
occur after the age of 50, advanced age is also considered as a risk factor. Finally, 
evidence for significant associations between colorectal cancer and other risk factors, 
including diet, body weight, physical activity, smoking, alcohol intake, NSAIDs intake 
and HRT in post-menopausal women, is promising and increasing. 
Aims and objectives 
The main aims of this project were: 1) to investigate the associations between colorectal 
cancer and specific nutrients, including flavonoids, fatty acids, folate, vitamin B2, 
vitamin B6, vitamin B12, alcohol, vitamin D and calcium (prior hypotheses 1-4) and 2) 
to conduct an overall as well as forward and backward stepwise regression analyses of 
demographic, lifestyle and dietary risk factors. 
Methods 
The analysis of this thesis was based on a population-based case-control study of 
colorectal cancer (Scottish Colorectal Cancer Study; SOCCS). In total 3,417 colorectal 
cancer cases and 3,396 controls were recruited in the study. Dietary and lifestyle data 
were collected by two questionnaires (Lifestyle & Cancer and Food Frequency 
Questionnaire) and were available for 2,061 cases and 2,776 controls. For the analysis of 
the first two hypotheses (flavonoids and fatty acids) a matched dataset of 1,489 case-
control pairs was used and conditional logistic regression models were applied, whereas 
for the analysis of the last two hypotheses (folate, vitamin B2, vitamin B6, vitamin B12, 
alcohol, vitamin D and calcium) an unmatched dataset including 2,061 cases and 2,776 
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controls was used and unconditional logistic regression models were applied. For the 
overall and stepwise regression analyses the unmatched dataset was used (2,061 cases 
and 2,776 controls). Forward and backward stepwise regression was applied on three 
different sets of variables and the stability of the resultant models was checked in 100 
bootstrap samples. 
Results 
Regarding the first two hypotheses, statistically significant odds ratios (ORs) (matched 
on sex, age and health board are and adjusted for family history of cancer, BMI, physical 
activity, smoking, and intakes of total energy, fibre, alcohol and NSAIDs) for highest 
versus lowest intakes (quartiles) were observed for flavonols OR (95% CI), p-value for 
trend: 0.78 (0.60, 0.99), 0.08) and for the individual flavonoid compounds quercetin and 
catechin (OR (95% CI), p-value for trend: 0.77 (0.60, 0.99), 0.04; 0.75 (0.58-0.97), 0.02; 
respectively); for the ω3PUFAs fatty acids (OR (95% CI), p-value for trend: 0.75 (0.59, 
0.97), 0.01) and for the individual fatty acids stearic acid, EPA and DHA (OR (95% CI), 
p-value for trend: 1.46 (1.11, 1.91), 0.01; 0.74 (0.58, 0.95), 0.02; 0.74 (0.58, 0.95), 0.02; 
respectively). Regarding the last two hypotheses, statistically significant odds ratios 
(ORs) (adjusted for age, sex, deprivation score, family history of cancer, BMI, physical 
activity, smoking, and intakes of total energy, fibre, alcohol and NSAIDs) for highest 
versus lowest intakes (quartiles) were observed for vitamin B6, vitamin B12 and alcohol 
(OR (95% CI), p-value for trend: 0.86 (0.72, 1.03), 0.08; 0.80 (0.67, 0.97), 0.05; 0.83 
(0.68, 1.00), 0.03); and for vitamin D (OR (95% CI), p-value for trend: 0.83 (0.69, 0.99), 
0.03).  
Regarding the second aim of the project, several risk factors were found to be 
significantly associated with colorectal cancer in the overall analysis including 
demographic and lifestyle factors (family history of cancer, NSAIDs intake, dietary 
energy intake, HRT intake and physical activity), food group variables (vegetables, eggs, 
sweets, fruit/ vegetable juice, oily fish, coffee, fruit, savoury foods and white fish) and 
nutrient variables (tMUFAs, ω3PUFAs, SFAs, tFAs, MUFAs, quercetin, catechin, 
phytoestrogen, cholesterol, fibre, protein, starch, magnesium, potassium, manganese, 
copper, iron, zinc, phosphorus, selenium, niacin, vitamin B6, carotenes, vitamin C, 
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vitamin A, potential niacin, biotin, folate, pantothenic acid, vitamin D, vitamin B1 and 
vitamin B12). In addition, the variables that were selected to be included in 100% of the 
models after applying forward and backward stepwise regression analyses were family 
history, NSAIDs, sweets and fruit/ vegetable juice. Finally according to the findings 
from the bootstrap analysis, the variables that were selected to be included in models for 
the majority of the bootstrap samples (more than 90%) were family history, NSAIDs, 
dietary energy, eggs, sweets, fruit/ vegetable juice and white fish. 
Discussion 
The particular dietary factors that were found to be inversely associated with colorectal 
cancer after applying several multivariable logistic regression models were: flavonols, 
quercetin, catechin, ω3PUFAs, EPA, DHA, vitamin B6, vitamin B12 and vitamin D. In 
addition, high intakes of stearic acid were found to be positively associated with 
colorectal cancer. In contrast, high intakes of dietary and total folate were associated 
with a decreased colorectal cancer risk in the energy-adjusted model, but this inverse 
association was attenuated after further adjustment for several confounding factors 
including fibre. Regarding alcohol intake, when it was divided into quartiles, high 
alcohol consumption was associated with a statistically significant and dose-dependent 
decreased colorectal cancer risk. However, when alcohol intake was divided in 
categories an increased colorectal cancer risk for intakes of higher than 60 g/day was 
observed. Intakes of ω3PUFAs, vitamin D and vitamin B12 were highly correlated due 
to having the same food source (oily fish) and therefore it is difficult to draw specific 
conclusions regarding which nutrient is truly associated with colorectal cancer and 
which not. Finally, it was observed that for calcium intakes to be inversely associated 
with colorectal cancer, a dosage of 1500mg/day or higher was necessary.  The majority 
of these results are in accordance with results of previous epidemiological and 
laboratory studies; however their confirmation in further large-scale studies is required. 
Results from the overall and stepwise regression analysis supported previous findings of 
an increased colorectal cancer risk due to a high or moderate family history risk. In 
addition, high intakes of dietary energy were found to be positively associated with 
increased colorectal cancer risk in the overall analysis and in addition dietary energy was 
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selected to be included in the majority of the stepwise regression models. On the other 
hand, regular intake of NSAIDs was found to be inversely associated with colorectal 
cancer risk in the overall analysis and in the majority of the stepwise regression models. 
Finally, the overall and stepwise regression analyses generated a few new hypotheses 
suggesting that low intakes of fruit/ vegetable juice, eggs, white fish and sweets (a 
combined variable of high-fat and high-sugar foods) and high intakes of coffee and 
magnesium were associated with a decreased colorectal cancer. These findings, though 
interesting and important for generation of new hypotheses, need further investigation 
(as prior hypotheses) in large-scale observational studies. 
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1 COLORECTAL CANCER 
1.1 Introduction 
This chapter describes the epidemiology, natural history and progression of colorectal 
cancer. In addition, the prevalence, incidence and survival rates as evaluated in 
epidemiologic research are presented. Finally, the established genetic and non-genetic 
(environmental) risk factors are summarised.  
1.2 Large intestine 
The large intestine is the most distal part of the lower gastrointestinal tract and its main 
roles are: to absorb vitamins that are created by the colonic bacteria (over 700 different 
species), to absorb the remaining water from indigestible food matter, to maintain the 
fluid balance of the body and to compact and store faecal material until eliminated 
through the anus. 
The main parts of the large intestine are the caecum, the appendix, the colon and the 
rectum. The caecum is the connection between the small and large intestines and its 
main role is to accept and store processed material of undigested food, water, vitamins 
and minerals and to move it towards the colon. The appendix is a small projection 
emerging from the caecum and it has no known function. The colon is the largest part of 
the large intestine and it has 4 sections (ascending, transverse, descending and sigmoid) 
that are located in the abdominal cavity. Within the colon, the processed material mixes 
with mucus and colonic bacteria to form faeces. In addition, the lining of the colon 
absorbs most of the water, some vitamins and minerals and the colonic bacteria 
chemically break down part of the fibre to produce nutrients for their own survival and 
to nourish the cells lining the colon. Through muscular movements of the colon, faeces 
are pushed along the colon and move into the rectum, which is the final part of the large 
intestine and where the faeces are stored before being excreted as a bowel motion. 
Regarding the histology of the large intestine, the intestinal wall has four primary layers: 
1) Serosa or adventitia, which is the outer layer responsible for keeping the digestive 
tract in the right position inside the body; 2) Muscularis externa, which is composed of a 
continuous inner layer of circular muscle and a discontinuous outer layer of longitudinal 
Chapter one  Colorectal cancer 
 8 
muscle responsible for the motility of the lumen contents; 3) Submucosa, which is the 
connective tissue located between the layer of circular muscle and the mucosa; 4) 
Mucosa, which is the inner layer of the intestinal wall comprising a single layer of 
columnar epithelium (surface epithelium), connective tissue (lamina propria) and an 
outer muscle layer (lamina muscularis mucosa) and is characterised by the presence of 
numerous invaginations of the surface epithelium into the lamina propria glands, which 
are approximately 50 cells deep (crypts of Lieberkühn). These crypts are used mainly for 
water absorption. In addition, colon cells proliferate and differentiate (from stem cells) 
in the lower parts of the crypts and then migrate to the upper part of the crypts to renew 
the superficial epithelial cells (approximately every six days) (1). Several problems or 
disorders can arise in the large intestine including irritable bowel syndrome, 
inflammatory bowel disease (including Crohn’s disease and ulcerative colitis), colorectal 
polyps and colorectal cancer.  
1.3 Clinical characteristics of colorectal cancer 
1.3.1 Definition of colorectal cancer 
“Colorectal cancer is a cancer that forms either in the tissues of the colon, the longest 
part of the large intestine, or in the tissues of the rectum, the last part of the large 
intestine before the anus” (definition taken from National Cancer Institute; 
www.cancer.gov).  
1.3.2 Types of colorectal cancer 
The main types of colorectal cancer are: 1) adenocarcinomas, 2) squamous cell 
carcinomas, 3) carcinoid tumours, 4) sarcomas and 5) lymphomas. More than 95% of 
colorectal cancers are adenocarcinomas with the cancer starting in the gland cells in the 
lining of the intestinal wall. Colorectal adenocarcinomas can be of two types according 
to the microbiology of the cancer cells: mucinous (98-99% of adenocarcinomas; cancer 
cell in pools of mucus) or signet-ring tumours (1-2% of adenocarcinomas; mucus inside 
the cancer cells). This thesis will be examining the epidemiology of adenocarcinomas of 
the large intestine (colon and rectum). 
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Briefly the main characteristics of the other types are: squamous cell carcinomas, 
carcinoids, sarcomas and lymphomas. Squamous cell carcinomas are cancers that start 
from the skin-like cells that make up the bowel lining together with the gland cells. 
Carcinoid is an unusual type of slow growing tumour and is called a neuroendocrine 
tumour. These cancers grow in hormone producing tissues, usually in the digestive 
system and they are rare. Sarcomas are cancers of the supporting cells of the body (bone, 
muscle, etc.) and most of the colorectal sarcomas are leiomyosarcomas (started in the 
smooth muscle of the large intestine). Finally, lymphomas are cancers of the lymphatic 
system and only 0.01% of colorectal cancers are of lymphatic origin. 
1.3.3 Classification of colorectal cancer 
Colorectal cancer can be classified into three forms according to the way that is 
developed. In particular the three major forms are hereditary, familial and sporadic 
colorectal cancer. The proportion of each form may be different in different populations, 
but generally the majority of colorectal cancer cases in all populations are considered 
sporadic, whereas hereditary colorectal cancer is the least common form. Finally, 10-
30% of colorectal cancer cases are considered to be linked to a familial risk (2).  
1.3.3.1 Hereditary colorectal cancer syndromes 
Colorectal cancer hereditary syndromes that result from inherited susceptibility due to 
rare high penetrance mutations may account for up to 5% of all cases. The most 
common hereditary syndrome is Hereditary Non-Polyposis Colorectal Cancer (HNPCC), 
also known as Lynch syndrome (2-5% of colorectal cancer cases). One of the 
characteristics of this syndrome is an unusually high occurrence of colorectal and 
specific extra-colonic cancers. In addition, the HNPCC syndrome has an earlier age of 
onset. Highly penetrant germline mutations in mismatch repair genes, hMLH1 (located 
at chromosome 3p21–23) and hMSH2 (located at chromosome 2p21) resulting in 
microsatellite instability in the tumour are responsible for the majority of the HNPCC 
cases. These genes are part of the DNA mismatch repair pathway and a HuGE review 
published in 2002 identified 45 polymorphisms in hMLH1 and 55 polymorphisms in 
hMSH2 (3). Regarding the population prevalence of hMLH1/hMSH2 mutation carriers, it 
has been estimated to be 1 in 3,139 in a Scottish population aged 15–74 years (4). In 
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addition, according to available gene variant data there is no evidence suggesting any 
differences in frequency between populations, or between ethnic groups (3). It has been 
reported that the standardised incidence ratio for colorectal cancer for carriers of hMLH1 
or hMSH2 mutations when compared with the general population is 68 (5) and the 
relative risk for colorectal cancer for first-degree relatives of mutation carriers compared 
with first degree relatives of non-carriers is 8.1 (6).  
The second most common hereditary syndrome is a highly penetrant autosomal 
dominant cancer syndrome known as Familial Adenomatous Polyposis Coli (FAP; 1% 
of colorectal cancer cases) and it occurs due to germline mutations of the Adenomatous 
Polyposis Coli (APC) gene (tumour suppressor gene located at chromosome 5q21-22) 
(7). APC protein down-regulates the Wnt signalling pathway through its binding to β-
catenin and axin and loss of the APC protein function due to APC mutations is 
associated with carcinogenesis (8). The main characteristic of FAP is the appearance of 
hundreds and in some cases of thousands of colorectal adenomas, which can develop 
into carcinomas if left untreated (9). 
There are a number of rarer autosomal dominant disorders, including Juvenile Polyposis 
Syndrome, Cowden syndrome and Peutz-Jeghers syndrome. Juvenile Polyposis 
Syndrome appears usually under the age of 20 years old and it has been suggested that 
mutations in SMAD4 (18q), PTEN (10q22-24) and BMPR1A genes are associated with 
this syndrome (10;11). Cowden syndrome, on the other hand is characterised by multiple 
hamartomas and it has been found to be associated with PTEN mutations (12). Finally, 
the Peutz-Jeghers syndrome has been suggested to be associated with mutations in the 
LKB/STK11 gene (19p13.3) (13).  
1.3.3.2 Familial colorectal cancer 
An additional 20% of colorectal cancer cases are associated with a family history of 
colorectal cancer (with first degree relatives of a patient with colorectal cancer case 
having approximately a 2-4 times increased risk) and comprise the familial colorectal 
cancer cases. Low-penetrance APC mutations have been found to be associated with 
some types of familial colorectal cancer (14). In particular, the most common APC 
mutations that have been found to be associated with familial colorectal cancer include 
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I1307K (15) and E1317Q (16), whereas at least 12 additional variants of APC (8 of them 
being in exon 15) have been identified (17).  
Another familial form of colorectal cancer which was first described in 2002, is MYH 
associated polyposis (MAP), (18). This form of colorectal cancer is due to bi-allelic 
mutations in MUTYH gene and its phenotype is clinically comparable to the FAP 
phenotype (18;19). However, MAP, which is recessively transmitted, generally results in 
a smaller number of adenomas and has a later age of onset (20). MUTYH (1p32.1-34.3) 
(21) is a base excision repair gene (21;22) and the two most common MUTYH variants 
accounting for >80% of disease causing alleles in whites are Y165C and G382D, 
whereas the  E466X nonsense mutation has been identified in Indian families and the 
Y90X in Pakistani families (21). Finally, approximately 30 mutations 52 missense 
variants and three inframe insertions/ deletions have been identified (23).  
1.3.3.3 Sporadic colorectal cancer 
Most cases of colorectal cancers arise sporadically, namely with no background of a 
family history of the disease, and genetic and environmental factors are important (24). 
Somatic (occurring during an individual’s lifetime) rather than germline (inherited) 
mutations in these genes play role in sporadic cancer, with somatic mutations of the APC 
gene to be found in as many as 80% of sporadic tumours (25). 
1.3.4 Natural history of colorectal adenocarcinoma 
1.3.4.1 Adenoma-carcinoma sequence 
Colorectal adenocarcinomas start in the innermost layer and can grow through some or 
all of the other layers. The vast majority of them derive from adenomatous polyps, 
which are circumscribed aggregations of epithelial tissue characterised by uncontrolled 
cell division, following a sequence known as the adenoma-carcinoma sequence (1). 
Briefly, the first step in the development of tumours from normal epithelium is usually 
the onset of dysplasia. In particular, in the colonic crypt, the normal sequence of 
proliferation-differentiation of the colonic cells alters. Proliferated cells fail to 
differentiate taking up the whole crypt (dysplastic crypt). Single dysplastic crypts 
(unicryptal adenomas) are thought to be the first manifestations of tumour development 
(hyperproliferative epithelium). Adenomas (adenomatous polyps) can then gradually 
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grow in size and change from a tubular to a villous architecture. The cells show first 
mild then moderate and then severe dysplasia followed by malignant change resulting in 
local invasion with eventual metastasis to distant sites (24). However, most of the 
adenomatous polyps do not develop into malignant carcinomas, but they remain benign 
and asymptomatic (1). There is evidence suggesting that colorectal carcinomas can 
derive from other types of colorectal lesions besides the adenomatous polyps including 
serrated polyps and flat adenomas (1). Briefly, serrated polyps include several different 
types of lesions such as aberrant crypt foci, hyperplastic polyps, mixed polyps, serrated 
adenomas and sessile serrated adenomas. These lesions are normally small, smooth and 
sessile and occur mainly in the rectum and sigmoid colon. Recently, a serrated colorectal 
carcinogenesis pathway has been described, with some molecular differences with the 
conventional adenoma-carcinoma sequence (26). Regarding flat adenomas, they are 
superficial, non-polypoidal lesions and their malignant potential is considerably higher 
than the malignant potential of adenomatous or serrated polyps. In addition, it has been 
proposed that colorectal carcinomas deriving from flat adenomas also follow a different 
molecular pathway (27). 
1.3.4.2 Molecular genetics of sporadic colorectal carcinogenesis 
Like in many other tumour types, colorectal carcinogenesis derives from mutations in 
mainly oncogenes and tumour suppressor genes and in comparison to the inherited and 
familial colorectal cancer (germline mutations), sporadic colorectal cancer results from 
the accumulation of multiple somatic mutations. In addition sporadic colorectal cancer 
can have two different genomic profiles, which are known as: 1) chromosomal 
instability neoplasia (CIN) and 2) microsatellite instability neoplasia (MIN) (28). 
The majority of sporadic colorectal cancers (85-90%) initiate due to mutation in the APC 
gene and are characterised by chromosomal instability. These tumours are generally 
associated with hyperploidy, allelic losses, frequent tumour suppressor gene mutations 
(APC, p53) and are mainly located in the left part of the colon. Mutations in the APC 
gene (loss of heterozygosity on chromosome 5q: 5qLOH) occur early in the colorectal 
carcinogenesis and they are normally followed by mutations in the k-ras gene and later 
in the p53 gene (17pLOH). In addition, mutations in three additional genes (DCC, 
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SMAD4, SMAD2) on chromosome 18q (18qLOH) have been found in advanced 
adenomas. The remaining 10-15% of sporadic colorectal tumours are characterised by 
microsatellite instability (MIN) and are mainly located in the proximal colon. They are 
euploid tumours without allelic losses, present infrequent suppressor gene mutations 
(p53, APC) and more frequent mutations in the BRAF and PI3KCA oncogenes and some 
other genes (TGBβ-RII, BAX, TCF4, Caspase5, HIF1α) (29).  
1.3.5 Clinical grading and staging of colorectal cancer 
Two systems can be applied to describe the extent of colorectal cancer in the body:  the 
Dukes’ and the American Joint Committee on Cancer (AJCC) systems. Modified Dukes’ 
staging, which was originally published by Dukes CE (1932), is a pathological staging 
based on resection of the tumour and measures the depth of invasion through the mucosa 
and bowel wall. However, it does not take into account the level of nodal involvement or 
the grade of the tumour. There are four modified Dukes’ stages (A-D): 1) Stage A, 
where the tumour penetrates into the mucosa of the bowel wall; 2) Stage B, where the 
tumour penetrates into (B1) and through (B2) the muscularis propria (the muscular 
layer) of the bowel wall; 3) Stage C, where the tumour penetrates into (C1) and through 
(C2) the muscularis propria of the bowel wall and there is pathologic evidence of colon 
or rectal cancer in the lymph nodes; 4) Stage D, where the tumour has spread beyond the 
borders of the lymph nodes (to organs such as the liver, lung or bone; Table 1). 
The AJCC system is based on the TNM classification. In TNM classification, T stands 
for tumour and describes the extent of the tumour spread through the layers that form the 
bowel wall, N stands for nodes and indicates whether or not the cancer has spread to 
nearby lymph nodes and, if so, how many lymph nodes are affected and M stands for 
metastasis and indicates whether or not the cancer has spread to distant organs. Each of 
these three elements is categorised separately and classified with a number. There are 
five stages for tumour describing its extent through the bowel wall (Tis, T1-T4): 1) Tis, 
where tumour involves only the mucosa; 2) T1, where tumour invades submucosa; 3) 
T2, where tumour invades muscularis propria; 4) T3, where tumour invades through the 
muscularis propria into the subserosa, or into the pericolic or perirectal tissues; 5) T4, 
where tumour directly invades other organs or structures, and/or perforates. There are 
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three stages for node describing the cancer spread to nearby lymph nodes (N0-N2): 1) 
N0, where there is no spread in regional lymph node; 2) N1, where there is spread in one 
to three regional lymph nodes; 3) N2, where there is spread in four or more regional 
lymph nodes. Finally, there are two stages for metastasis describing the cancer spread to 
distant organs (M0-M1): 1) M0, where there is no distant metastasis; 2) M1, where 
distant metastasis is present. In case of incomplete information regarding the tumour 
invasion, nodes affected and presence or not of metastasis, the stage code becomes Tx, 
Nx or Mx, respectively (Table 2). 
When the three TNM numbers are combined (stage grouping), the AJCC stage is formed 
(0, I-IV): 1) Stage 0 for Tis, N0 and M0; 2) Stage I for T1, N0 and M0 or T2, N0 and 
M0; 3) Stage IIA for T3, N0 and M0; 4) Stage IIB for T4, N0 and M0; 5) Stage IIIA for 
T1, N1 and M0 or T2, N1 and M0; 6) Stage IIIB for T3, N1 and M0 or T4, N1 and M0; 
7) Stage IIIC for any T, N2 and M0; 8) Stage IV for any T, any N and M1 (Table 3); 
(information taken from the American cancer society; http://www.cancer.org/). 
 
Table 1 Summary of Duke’s staging system* 
Stage Description 
A tumour penetrates into the mucosa of the bowel wall 
B1 tumour penetrates into the muscularis propria (the 
muscular layer) of the bowel wall 
B2 tumour penetrates into and through the muscularis 
propria (the muscular layer) of the bowel wall 
C1 tumour penetrates into the muscularis propria of the 
bowel wall  
pathologic evidence of colon or rectal cancer in the 
lymph nodes 
C2 tumour penetrates into and through the muscularis 
propria of the bowel wall  
pathologic evidence of colon or rectal cancer in the 
lymph nodes 
D tumour has spread beyond the confines of the lymph 
nodes (to organs such as the liver, lung or bone) 
                                               
*  Information taken from http://www.cancer.org/ 
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Table 2 Summary of TNM classification*  
Tumour (T) Lymph nodes (N) Distant metastasis (M) 
Tis  tumour involves only the 
mucosa 
N0 there is no metastasis in 
regional lymph node 
M0 there is no distant 
metastasis 
T1 tumour invades 
submucosa 
N1 there is metastasis in 1 to 
3 regional lymph nodes 
M1 there is distant 
metastasis 
T2 tumour invades 
muscularis propria 
N2 there is metastasis in 4 or 
more regional lymph 
nodes 
Mx incomplete information 
regarding distant 
metastasis 
T3 tumour invades through 
the muscularis propria into 
the subserosa, or into the 
pericolic or perirectal 
tissues 
Nx incomplete information 
regarding number of 
affected lymph nodes 
  
T4 tumour directly invades 
other organs or structures, 
and/or perforates 
    
Tx incomplete information 
regarding tumour invasion 
    
 
Table 3 Summary of AJCC staging system* 
Stage TNM stage equivalent  Description 
0 Tis,  N0, M0 carcinoma in situ or intramucosal carcinoma 
I T1, N0, M0 or  
T2, N0, M0 
Cancer has begun to spread, but is still in the 
inner lining 
IIA T3, N0, M0 Cancer has spread to other organs near the 
colon or rectum, but it has not reached lymph 
nodes 
IIB T4, N0, M0 
IIIA T1, N1, M0 or 
T2, N1, M0 
Cancer has spread to lymph nodes, but has 
not been carried to distant organs of the 
body IIIB T3, N1, M0 or 
T4, N1, M0 
IIIC any T, N2, M0 
IV any T, any N, M1 Distant organs metastasis (i.e. lungs and 
liver) 
                                               
* Information taken from http://www.cancer.org/ 
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1.4 Epidemiology of colorectal cancer 
1.4.1 Prevalence of colorectal cancer 
According to the International Agency for Research on Cancer (IARC) 5-year world 
prevalence of colorectal cancer in 2002 was approximately 0.05%. For more developed 
countries (including all countries of Europe, all countries of North America, Japan, 
Australia and New Zealand) 5-year prevalence was higher than for less developed 
countries (including all countries of Africa, Latin America, the Caribbean, Asia -
excluding Japan, Micronesia, Polynesia and Melanesia) (0.17% and 0.016% 
respectively) (IARC). In particular, 5-year prevalence of colorectal cancer for Europe 
and the UK in 2005 were 0.12% and 0.15% respectively (IARC). In addition, according 
to the Scottish Cancer Registry, 5-year prevalence of colorectal cancer in 2005 in 
Scotland was 0.14% (0.15% for men and 0.12% for women). 
1.4.2 Incidence of colorectal cancer  
1.4.2.1 Geographical trends 
Colorectal cancer is the third most common cancer in Scotland for both males and 
females (12.9% of all cancers, 2005), with 3,412 individuals (1,854 men and 1,558 
women) affected in 2005 (Scottish Cancer Registry). The crude incidence rates were 
75.5/100,000 for men and 59.0/100,000 for women. Age-standardised (European 
standard population) incidence rates (EASR) by sex are presented separately for each 
Scottish Health Board (Figure 1) as well as for North, South East and West of Scotland 
(Figure 2). The EASR incidence for Scotland in 2005 was 61.3/100,000 for men and 
38.1/100,000 for women. Age-standardised (World standard population) incidence rate 
(WASR) for Scotland in 2005 was 40.2/100,000 for men and 25.2/100,000 for women. 
The highest EASR incidence rates were observed in the West of Scotland for men 
(62.4/100,000) and in the North of Scotland for women (39.5/100,000) (Scottish Cancer 
Registry). 
Incidence rates for the UK and separately for England, Wales, Scotland and N. Ireland 
were obtained from Cancer Research UK (2004). In 2004, 36,109 British individuals 
were affected from colorectal cancer (19,657 men and 16,452 women) and the crude 
incidence rate was 67.2/100,000 for men and 53.9/100,000 for women. EASR incidence 
rates for the UK, England, Wales, Scotland and N. Ireland are presented in Figure 3.  
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The EASR incidence rate for the UK was 55.3/100,000 for men and 35.5/100,000 for 
women. The highest EASR incidence rate was observed in Scotland for men 
(65/100,000) and in N. Ireland for women (40.5/100,000). Colorectal cancer incidence 
rates for 2005 were available for Scotland (Scottish Cancer Registry), Wales (Welsh 
Cancer Intelligence & Surveillance Unit) and for N. Ireland (N. Ireland Cancer 
research). However, at the point that this thesis was written, 2005 data were not 
available for England. EASR incidence rates for 2005 were 61.3/100,000 (men) and 
38.1/100,000 (women) for Scotland, 58.8/100,000 (men) and 34.4/100,000 (women) for 
Wales and 64.2/100,000 (men) and 35.4/100,000 (women) for N. Ireland.   
Incidence rates of colorectal cancer in countries of the European Union (EU) according 
to the 2006 estimates (Cancer Research UK) varied by a factor of 3 for men and a factor 
of 2 for women, with the lowest EASR incidence rates to be observed in Greece 
(31/100,000 for men and 21.3/100,000 for women) and the highest EASR incidence 
rates to be observed in Hungary (106/100,000 for men and 50.6/100,000 for women). 
EASR estimates for the EU are 59/100,000 for men and 35.6/100,000 for women and 
together with the EASR 2006 estimates for each country member of the EU are 
presented in Figure 4. 
According to the IARC, approximately 1,023,152 new cases of colorectal cancer were 
diagnosed in 2002 (9% of all new cancer cases) making colorectal cancer the third most 
common cancer worldwide. 65% of the new cases of colorectal cancer in 2002 were 
recorded in the more developed regions. Large variations in incidence rates were 
observed with the lowest WASR incidence rate to be observed in Africa (WASR 
incidence rate in middle Africa: 2.3/100,000 for men and 3.3/100,000 for women) and 
the highest to be observed in Australia, N. America and Europe (highest WASR 
incidence rate in Australia/ N. Zealand: 48.2/100,000 for men and 36.9/100,000 for 
women). WASR incidence rates are presented in a bar chart in Figure 5 and in a world 
map in Figure 6 separately for men and women. 
1.4.2.2 International temporal trends 
In Scotland male colorectal cancer incidence rates rose slowly each year between 1982 
and 1995 (1982 EASR incidence rate: 51.2/100,000; 1995 EASR incidence rate: 
62.0/100,000). In 1996 there was an almost 6% increase in colorectal cancer incidence 
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reaching a 69.7/100,000 EASR incidence rate (highest EASR incidence rate from 1982 
to 2005). Since 1997, there has been an almost constant gradual decrease of EASR 
incidence rates (2005 EASR incidence rate: 61.3/100,000). The lowest male colorectal 
cancer EASR incidence rate was observed in 1982 (51.2/100,000) (Figure 7). Over the 
same period female colorectal cancer incidence rates were generally constant, with slight 
fluctuations. The highest EASR incidence rate was observed also in 1996 (45.6/100,000) 
and the lowest EASR incidence rate was observed in 2005 (38.1/100,000) (Figure 7). 
According to Cancer Research UK, male colorectal cancer incidence rates in Great 
Britain rose slowly by an average of 1% each year between 1982 and 1999. Since 1999 
and until 2004 there has been a slight decrease. The highest EASR incidence rate was 
observed in 1999 (58.2/100,000) and the lowest in 1982 (48.8/100,000) (Figure 8). Over 
the same period the female colorectal cancer incidence rates have changed very little. 
The highest EASR incidence rate was observed in 1992 (38.16/100,000) and the lowest 
EASR incidence rate was observed in 2003 (34.9/100,000) (Figure 8). 
There is no clear trend in global age standardised incidence rates of colorectal cancer. In 
countries of relatively low-income economy, which have recently made a transition to a 
higher-income economy (e.g. eastern and southern European countries, Japan, 
Singapore), a rapid increase in incidence rates has been observed (30). However in 
countries with traditionally high colorectal cancer incidence rates a slight decrease has 
been observed in the last few years (e.g. Canada, USA and New Zealand/Australia) (30). 
Trends in age standardised incidence rates for male and female colorectal cancer are 
presented in Figure 9 and Figure 10 for selected countries. 
Despite the decrease of the age-standardised incidence rates particularly in countries of 
high-income economy, the absolute number of colorectal cancer cases continues to 
increase, mainly because of the increasing age of the population. For Scotland, in 
particular, in 1982 2,726 men and women were diagnosed with colorectal cancer, 
whereas in 2005 3,412 people were diagnosed with, a 25.2% increase. In addition, a 
report published in 2006 from the European
 
Network of Cancer Registries (ENCR), 
estimated that between 2004 and 2006 there was a 10.3% increase in absolute number of 
all cancers in Europe and concluded that absolute numbers of cancer will continue to 
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increase even if age-specific incidence rates remain constant or decrease, mainly due to 
the ageing European population (31). 
 
 
Figure 1 Age standardised (European standard population) incidence rates of colorectal cancer (per 
100,000) in Scottish Health Boards by sex. Incidence rates marked with a star (*) were based on low 
numbers (≤50); (2005, Cancer Registry Scotland, ISD). 




Figure 2 Age standardised (European standard population) incidence rates of colorectal cancer (per 
100,000) in Scotland by sex (2005; Cancer Registry Scotland, ISD) 
 
Figure 3 Age standardised (European standard population) incidence rates of colorectal cancer (per 
100,000) in the UK by sex (2004; Cancer Research UK) 




Figure 4 Age standardised (European standard population) incidence rates of colorectal cancer (per 
100,000) in Europe by sex (2006 estimates; Cancer Research UK) 
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Figure 5 Age standardised (World standard population) incidence rates of colorectal cancer (per 
100,000) worldwide by sex (2002 estimates; International Agency for research in cancer); (*More 
developed regions include: all countries of Europe, Japan, Australia, New Zealand and all countries 
of North America; Less developed regions include all countries of: Africa, Latin America, the 
Caribbean, Asia -excluding Japan, Micronesia, Polynesia and Melanesia) 
 




Figure 6 Maps of age standardised incidence rates of colorectal cancer (World Standard population) 
separately for men and women; Source: International Agency for research on cancer (2002 
estimates) 
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Figure 7 Age standardised (European standard population) incidence rates of colorectal cancer (per 
100,000) in Scotland by sex from 1982 to 2005 (Cancer Registry Scotland, ISD) 
 
 
Figure 8 Age standardised (European standard population) incidence rates of colorectal cancer (per 
100,000) in Great Britain by sex from 1982 to 2005 (Cancer Research UK) 
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Figure 9 Age standardised (World standard population) incidence rates of male colorectal cancer 
(per 100,000) in selected countries from 1982 to 2002 (International Agency for research on cancer) 
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Figure 10 Age standardised (World standard population) incidence rates of female colorectal cancer 
(per 100,000) in selected countries from 1982 to 2002 (International Agency for research on cancer)
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1.4.3 Mortality rates of colorectal cancer 
1.4.3.1 Geographical trends 
Colorectal cancer was the second most common cause of death from cancer in Scotland 
for males and the third for females (10.3% of all deaths from cancer for both sexes, 
2005), with 1,550 individuals (835 men and 715 women) having died in 2006 (Scottish 
Cancer Registry). Crude mortality rate was 33.8/100,000 for men and 27.0/100,000 for 
women. EASR mortality rates by sex are presented separately for each Scottish Health 
Board (Figure 11) as well as for North, South East and West of Scotland (Figure 12). 
The EASR and WASR mortality rates for Scotland in 2006 was 27.0/100,000 and 
17.2/100,000 for men and 15.8/100,000 and 10.0/100,000 for women. The highest 
EASR mortality rates were observed in the West of Scotland for men (28.3/100,000) and 
in the North of Scotland for women (17.3/100,000) (Scottish Cancer Registry). 
Mortality rates for the UK and separately for England, Wales, Scotland and N. Ireland 
were obtained from Cancer Research UK (2005). In 2005, 16,092 British individuals 
died from colorectal cancer (8,637 men and 7,455 women) and the crude mortality rate 
was 29.4/100,000 for men and 24.3/100,000 for women. EASR mortality rates for the 
UK, England, Wales, Scotland and N. Ireland are presented in Figure 13. The EASR 
mortality rate for the UK was 23.3/100,000 for men and 14.3/100,000 for women and 
geographic distribution was similar with a relatively small variation. The highest EASR 
mortality rates for both men and women were observed in N. Ireland (16.1/100,000 and 
11.7/100,000 respectively). Colorectal cancer mortality rates for 2006 were available for 
Scotland (Scottish Cancer Registry) and for N. Ireland (N. Ireland Cancer research). 
However, at the point that this thesis was written 2006 mortality data were not available 
for England and Wales. EASR mortality rates for 2006 were 27.0/100,000 (men) and 
15.8/100,000 (women) for Scotland and 24.6/100,000 (men) and 13.7/100,000 (women) 
for N. Ireland. 
Mortality rates of colorectal cancer in countries of the EU according to the 2002 data 
from the IARC varied by a factor of 3 for both men and women, with the lowest WASR 
mortality rates to be observed in Greece (9.7/100,000 for men and 8.0/100,000 for 
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women) and the highest WASR mortality rates to be observed in Hungary (35.6/100,000 
for men and 21.2/100,000 for women). WASR mortality rates for 2002 estimates of each 
country member of the EU are presented in Figure 14. 
According to the IARC, approximately 528,978 individuals died from colorectal cancer 
in 2002 (8% of all cancer related deaths) and 60% of colorectal cancer deaths were 
recorded in the more developed regions. Large variations in mortality rates were 
observed with the lowest WASR mortality rate to be observed in Africa (WASR 
mortality rate in middle Africa: 2.2/100,000 for men and 3.0/100,000 for women) and 
the highest to be observed in Europe, Australia, N. America (highest WASR mortality 
rate in Central and Eastern Europe: 19.7/100,000 for men and 12.9/100,000 for women). 
WASR incidence rates are presented in a bar chart in Figure 15 and in a world map in 
Figure 16 separately for men and women. 
1.4.3.2 International temporal trends 
In Scotland male colorectal cancer mortality rates were unstable from 1983 to 1997, 
with moderate fluctuations. Since 1997, a steady decline in EASR male mortality rates 
has been observed (18% difference between 1997 and 2006). The lowest EASR 
mortality rate in male colorectal cancer was observed in 2006 (27.0/100,000) and the 
highest was observed in 1993 (34.4/100,000) (Figure 17). Over the same period (1983-
2006), there was a constant decline in female colorectal cancer mortality rates with 
slight fluctuations (38% difference between 1983 and 2006). The highest EASR 
mortality rate was observed also in 1983 (25.3/100,000) and the lowest were observed in 
2004 and 2005 (15.7/100,000) (Figure 17). Regarding the absolute number of deaths, 
1,714 men and women died from colorectal cancer in Scotland in 1983, whereas there 
was a 9.6% decrease in 2006, with 1,550 colorectal cancer deaths. 
Male colorectal cancer mortality rates in the UK were generally constant from 1982 to 
1992 with two peaks in 1984 (EASR mortality rate: 33.0/100,000) and in 1992 (EASR 
mortality rate: 31.9/100,000). Since 1992 there has been a constant decline in mortality 
rates with an almost 27% difference between the years 1992 and 2005. The highest 
EASR mortality rate was observed in 1984 (33.0/100,000) and the lowest in 2005 
(23.3/100,000) (Figure 18). Over the same period (1982-2005), there was a constant 
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decline in female colorectal cancer mortality rates (36% difference between 1982 and 
2005). The highest EASR mortality rate was observed in 1995 (23.4/100,000) and the 
lowest EASR mortality rate was observed in 2005 (14.3/100,000) (Figure 18). 
Generally global mortality rates of colorectal cancer for both men and women have been 
either constant or slightly increasing over time. However there are some exceptions with 
greater increase in colorectal cancer mortality rates especially in countries that have 
recently adopted a more western type of lifestyle (e.g. Japan and countries of the Eastern 
and Southern Europe). In contrast decreases in mortality rates have been observed over 
time for some countries (e.g. the UK, Sweden). 
According to the ENCR report, in contrast to what was observed in Scotland, a 1.8% 
increase in absolute number of deaths from colorectal cancer for men and women was 
reported from 2004 to 2006 (31). Changes in absolute numbers of colorectal cancer 
deaths for selected countries are presented in Figure 19 and Figure 20. 
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Figure 11 Age standardised (European standard population) mortality rates of colorectal cancer 
(per 100,000) in Scottish Health Boards by sex. Mortality rates marked with a star (*) were based on 
low numbers (≤50); (2006, Cancer Registry Scotland, ISD) 
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Figure 12 Age standardised (European standard population) mortality rates of colorectal cancer 
(per 100,000) in Scotland by sex (2006; Cancer Registry Scotland, ISD) 
 
 
Figure 13 Age standardised (European standard population) mortality rates of colorectal cancer 
(per 100,000) in the UK by sex (2005; Cancer Research UK) 
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Figure 14 Age standardised (World standard population) mortality rates of colorectal cancer (per 
100,000) in Europe by sex (2002 estimates; International Agency for research on cancer) 
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Figure 15 Age standardised (World standard population) mortality rates of colorectal cancer (per 
100,000) worldwide by sex (2002 estimates; International Agency for research on cancer); (*More 
developed regions include: all countries of Europe, Japan, Australia, New Zealand and all countries 
of North America; Less developed regions include all countries of: Africa, Latin America, the 
Caribbean, Asia -excluding Japan, Micronesia, Polynesia and Melanesia) 
 
 




Figure 16 Maps of age standardised mortality rates of colorectal cancer (World Standard 
population) separately for men and women; Source: International Agency for research on cancer 
(2002 estimates) 
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Figure 17 Age standardised (European standard population) mortality rates of colorectal cancer 
(per 100,000) in Scotland by sex from 1983 to 2006 (Cancer Registry Scotland, ISD) 
 
 
Figure 18 Age standardised (European standard population) mortality rates of colorectal cancer 
(per 100,000) in the UK by sex from 1982 to 2005 (Cancer Research UK) 




Figure 19 Number of deaths from colorectal cancer for men in selected countries from 1983 to 2003 
(International Agency for research in cancer) 




Figure 20 Number of deaths from colorectal cancer for women in selected countries from 1983 to 
2003 (International Agency for research in cancer) 
Chapter one  Colorectal cancer 
 38 
1.4.4 Survival rates: Geographical and temporal trends 
Survival rates for colorectal cancer have been significantly improved the last 25 years 
both for Scotland and the UK, a pattern that has been observed for many cancers. In 
particular, 1-year and 5-year relative survival rates in Scotland were 75.8% and 54.9% 
for men and 74.1% and 55.1% for women (time period 2000-2004; Scottish Cancer 
Registry, ISD). One year relative survival rates in Scotland have increased by 30% for 
men and by 26% for women and 5-year relative survival rates have been increased by 
50% for men and 51% for women (relative increases, time period 1980-2004; Figure 
21). In addition median survival after diagnosis has been increased from 1.9 years in 
1980-1984 to 4.1 years in 1995-1999. Survival rates and survival rate changes were 
similar for England, Wales and the N. Ireland. In particular, 1- and 5-year relative 
survival rates in 2000-2001 were 74% and 52% for men and 73% and 53% for women 
(Cancer Research UK, N. Ireland Cancer Registry; Figure 22). Survival has been 
considered to depend highly on stage at diagnosis, with more advanced cancers having 
poorer prognosis. In particular, approximate 5-year survival rates for the UK have been 
estimated to be 83% for Dukes’ stage A, 64% for stage B, 38% for stage C and 3% for 
stage D (Cancer Research UK).  
According to the EUROCARE study, the mean age-adjusted 5-year survival rate for 
colorectal cancer in Europe was 53.8% in the time period 1995-1999, a rate which is 
significantly higher than the survival rates that were observed in previous time periods. 
In particular the relative difference in 5-year survival rates in Europe between the time 
periods 1990-1994 and 1995-1999 was 8.5% (32). The European 5-year survival rates 
were higher than those observed in Great Britain in the same time-period (32). The 
variation of colorectal cancer survival with geography was similar to other common 
cancers (including lung, breast, and prostate). In particular, the highest 5-year survival 
rates were observed in Nordic countries (except Denmark) and central Europe, 
intermediate in southern Europe, low in the UK and Ireland, and the lowest in Eastern 
Europe (32). It has been suggested that these differences within Europe are mainly due 
to the stage at diagnosis as well as due to less effective treatments (Cancer Research UK, 
(33;34)). However, the between-countries and inter-regional differences in colorectal 
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cancer survival rates that were observed in 1995-1999 have been narrowed significantly 
compared to previous years (33;35;36).  
Colorectal cancer survival rates in other parts of the world show a similar pattern of 
increase. In particular, 5-year relative survival rates in USA in 1996-2004 were 65.4% 
for men and 65.2% for women, showing an 8% and a 6% relative increase when 
compared to survival rates in 1993-1995 (Surveillance Epidemiology and End Results, 
National Cancer Institute). In Australia, 5-year survival rates in 1998-2004 were 61.3% 
for men and 62.4% for women, showing an 8% and 9% relative increase when compared 
to survival rates in 1992-1997 (Australia’s Health 2008, Australian Institute of Health 
and Welfare). Finally, 5-year survival rate for colorectal cancer in Japan in 1993-1996 
was 64.6% for both sexes (National Cancer Centre, Japan).  
   





Figure 21 Age standardised one-year and five-year relative survival rates (European Cancer Patient 
Population - EUROCARE-4) for patients diagnosed in Scotland, 1980-2004 (Cancer Registry 
Scotland, ISD). (Note: 5-year survival rates for time period 2000-2004 are based on estimates). 





Figure 22 Age standardised one-year and five-year relative survival rates for patients diagnosed in 
England, Wales and N. Ireland, 1981-2001 (Cancer Research UK). (Note: 1- and 5-year survival 
rates for time period 2000-2001 are based on estimates). 
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1.4.5 Colorectal cancer projections for Scotland 
In 2004 the updated cancer incidence projections for Scotland (2001-2020) were 
released from Scottish government. It is estimated that over 168,000 adult individuals 
will be diagnosed with cancer during 2016-2020 (approximately 33,700 new cases per 
year), which represents a 28% increase in the number of cancer cases (comparing 
number of cases in 2001 with number of cases in 2020). An increase in the number of 
cases is predicted for several types of cancer (including colorectal) with notable 
exceptions being stomach, lung and cervical cancers, which are predicted to decline. 
Most of the estimated increase is predicted to be due to the growing number of elderly 
people in the Scottish population, but for some types of cancer risk is thought to increase 
independently of the the high number of elderly people (The Scottish Government, 
Statistics). 
For colorectal cancer, during 2016-2020 24,643 cases are predicted to be diagnosed 
(42.4% more than the number of colorectal cancer cases diagnosed in 1996-2000). This 
number comprises 12,472 individuals younger than 75 years old (50.6%) and 12,171 
individuals older than 75 years old (49.4%) (The Scottish Government, Statistics). 
Incidence projections of colorectal cancer for the years 2001-2005, 2006-2010, 2011-
2015 and 2016-2020 are presented in Figure 23 for the whole population and separately 
for individuals younger and older than 75 years old. 
 
Figure 23 Colorectal cancer incidence projections for Scotland (2001-2020) for the whole population 
and after age stratification (<75, 75+ years old). (The Scottish Government Statistics) 
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1.5 Main risk factors 
1.5.1 Introduction 
Many factors have been found to be positively or inversely associated with colorectal 
cancer. Age, personal history of previous colorectal cancer or adenomatous polyps, 
family history of colorectal cancer, chronic bowel inflammatory disease, and presence of 
either HNPCC or FAP are considered as established risk factors of colorectal cancer. 
According to the American Cancer Society, individuals that: 1) have a personal history 
of colorectal cancer, 2) have a personal history of adenomatous polyps, or 3) have a 
family history of colorectal cancer, are at increased risk of developing colorectal cancer. 
Individuals that: 1) have a history of inflammatory bowel disease (including ulcerative 
colitis and Crohn’s disease) of significant duration or 2) have one of the two hereditary 
syndromes (HNPCC or FAP), are at high risk of developing colorectal cancer. For 
individuals at increased and high colorectal cancer risk screening and surveillance 
techniques should be provided to decrease incidence and mortality rates (37). Finally, it 
has been suggested that colorectal cancer risk rises significantly from the age of 50 and 
therefore in many countries screening programmes for those older than 50 years old 
have been recommended. In Scotland in particular, individuals aged from 50 to 74 years 
old are invited every two years for bowel screening.  
Evidence for other risk factors, including diet, body weight, physical activity, smoking, 
alcohol intake, non steroidal anti-inflammatory drugs (NSAIDs) intake and hormone 
replacement therapy (HRT) in post-menopausal women will be described in this chapter.  
1.5.2 Age 
Colorectal cancer risk increases with age and it is more likely to occur in individuals 
older than 50 years old (National Cancer Institute). In Scotland in 2005, 95% of 
colorectal cancer cases were older than 50 years old (95.3% for men and 94.5% for 
women) and the distribution of patients and incidence rates according to age separately 
for men and women are presented in Figure 24 (Cancer Registry Scotland, 2005). The 
distribution of colorectal cancer cases according to age in the UK (Cancer Research UK, 
2004) and selected countries of the world (IARC, 2002) is similar to the Scottish 
distribution (Figure 25, Figure 26, Figure 27). 
In addition, age affects survival rates with older patients having poorer prognosis. This 
might be due to various reasons. For example they may seek medical advice at a later 
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stage of the disease or due to advanced age they may not be able to receive the 
appropriate treatment or they may have poorer surgical prognosis (33). Age specific 
colorectal cancer 1-year and 5-year survival rates for Scotland, England and Wales are 
presented in Figure 28 and Figure 29. 
 
Figure 24 Numbers of new cases and age-specific incidence rates by sex for colorectal cancer in 
Scotland (2005, Cancer Registry Scotland, ISD) 
 
Figure 25 Numbers of new cases and age-specific incidence rates by sex for colorectal cancer in the 
UK (2004, Cancer Research UK) 
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Figure 26 Numbers of new cases and age-specific incidence rates for colorectal cancer in men in 
selected countries (2002, International Agency for research in cancer) 
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Figure 27 Numbers of new cases and age-specific incidence rates for colorectal cancer in women in 
selected countries (2002, International Agency for research in cancer) 
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Figure 28 Age specific 5-year relative survival (%) in Scotland for 1995-1999 (Cancer Registry 
Scotland, ISD) 
 
Figure 29 Age specific 5-year relative survival (%) in England and Wales for 1996-1999 (Cancer 
Research, UK) 
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1.5.3 Previous colorectal cancer or adenomatous polyps 
Patients with previous colorectal cancer are at risk of developing recurrent or 
metachronous cancers and therefore long-term colonoscopic surveillance is necessary 
(38). However, the frequency and epidemiological characteristics of metachronous (a 
new primary cancer in a person with a history of cancer) colorectal cancers is still 
unknown. According to the findings of a recent population-based study in France, the 
cumulative risk of metachronous cancers was 2% among 5-year survivors and 7% 
among 20-year survivors (39). In addition, a two to three fold increased incidence risk of 
colorectal cancer was observed in four other population-based studies (Connecticut, 
Utah, Sweden and Finland) (40-43). 
Adenomatous polyps are neoplastic benign epithelial tumours and most 
adenocarcinomas of the colon and rectum arise from pre-existing adenomatous polyps 
via the adenoma–carcinoma sequence (44). Numerous studies have demonstrated that 
these patients have a higher risk of recurrent adenomas and/ or of developing colorectal 
cancer than the general population (45). Both the risk of adenomas recurrence and 
colorectal cancer is associated with the size and number of the initially detected 
adenomas (46). Approximately between 15 to 60% of polypectomy patients develop a 
recurrence and the risk of colorectal cancer for these patients has been estimated to be at 
least twice the risk of the general population (46). Regarding the other types of 
adenomas, serrated adenomas are considered as lesions of non-neoplastic characteristics 
and with no or low malignant potential. (26). In contrast, the colorectal cancer risk of 
flat adenomas is considerably higher than for adenomatous or serrated polyps (27). 
1.5.4 Family history of colorectal cancer  
According to the Scottish Executive cancer guidelines (http://www.sehd.scot.nhs.uk/), 
the criteria for high family history risk of colorectal cancer are: 1) at least three family 
members affected by colorectal cancer or at least two with colorectal cancer and one 
with endometrial cancer in at least two generations; one affected relative must be ≤50 
years old at diagnosis and one of the relatives must be a first degree relative of the other 
two; or 2) presence of the HNPCC syndrome; or 3) untested first degree relatives of 
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known gene carriers. The criteria for moderate risk are: 1) one first degree relative 
affected by colorectal cancer when aged <45 years old; or 2) two affected first degree 
relatives with one aged <55 years old; or 3) three affected relatives with colorectal or 
endometrial cancer, who are first degree relatives of each other and one a first degree 
relative of the consultant. Individuals that do not fulfil all the above criteria are classified 
as low family history risk (Scottish Executive cancer guidelines). According to a meta-
analysis, which was published in 2006 and included 59 studies (published from 1958 to 
2004), the pooled colorectal cancer relative risk estimate when at least one first degree 
relative was affected was 2.24 (95% CI 2.06, 2.43) and it rose to 3.97 (95% CI 2.60, 
6.06) when there were at least two affected relatives. In addition, the absolute risk by 
age of 70 for a 50-year old individual was 3.4% (95% CI 2.8 to 4.0) with at least one 
affected relative or 6.9% (95% CI 4.5 to 10.4) with two or more, which is considerable 
higher than the 1.8% population lifetime risk for a 50-year old (47). 
1.5.5 Inflammatory bowel disease 
Inflammatory bowel disease is a group of idiopathic (of unknown cause) inflammatory 
conditions of the large intestine and it comprises ulcerative colitis and Crohn’s disease. 
Ulcerative colitis mainly affects the large intestine and it mainly occurs with 
inflammation of the mucosa. In contrast, Crohn's disease can develop in any part of the 
gastrointestinal tract but most commonly affects the distal part of the small intestine and 
parts of the large intestine. In addition, inflammation in Crohn’s disease extends much 
deeper into the layers of the intestinal wall than in ulcerative colitis (48).  
According to a meta-analysis of 116 studies, the overall prevalence of colorectal cancer 
in patients with ulcerative colitis is 3.7%. In addition, an estimation of the
 
cumulative 
colorectal cancer risk according to the duration of ulcerative colitis was calculated to be 
2% at 10 years,
 
8% at 20 years, and 18% at 30 years (49). The evidence for the link 
between Crohn’s disease and colorectal cancer is less clear than for ulcerative colitis. 
According to a meta-analysis conducted in 2007, patients with Crohn’s disease were 
found to have a 2.4-fold increase in risk of colorectal cancer, which was however 
associated with significant heterogeneity. After cancer site stratification, the risk of 
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colon cancer was found to increase by a factor of 2.59 (no significant heterogeneity) but 
rectal cancer risk was not significantly associated with Crohn’s disease (50).  
When considering geographic variations the risk of colorectal cancer was found to be 
significantly higher in North America and the United Kingdom compared with 
Scandinavian and other countries for both patients with ulcerative colitis and Crohn’s 
disease (49;50). Compared with sporadic colorectal cancer, colorectal cancer arising in 
patients with inflammatory bowel disease affects individuals at a younger age, 
progresses to invasive adenocarcinoma from flat and non-polypoid dysplasia more 
frequently and exhibits a mucinous and signet ring cell histology in a higher proportion 
of cases (48). 
1.5.6 Diet 
According to the second report of Food, Nutrition, Physical Activity and the Prevention 
of Cancer of the American Institute for Cancer Research / World Cancer Research Fund 
(AICR/WCRF), which was released in November of 2007 diet has a very important role 
in the prevention and causation of colorectal cancer (30). It has also been thought that 
the role of diet in colorectal carcinogenesis is particularly important when a poor diet is 
combined with a generally unhealthy lifestyle, consisting of excess calorie
 
intake and 
weight gain, physical inactivity and high consumption of alcohol (51). The roles of 
several foods and nutrients in colorectal carcinogenesis have been investigated in many 
observational studies; however the evidence regarding the effect of particular dietary 
factors is still generally inconsistent. The foods and nutrients, on which there is most 
published data, are red and processed meat, dietary fibre, fruit and vegetables, folate, 
vitamin D and calcium.  
In this chapter, findings regarding red and processed meat, dietary fibre and fruit and 
vegetables will be summarised. Evidence regarding specific nutrients, which 
associations with colorectal cancer were investigated in this thesis will be presented in 
chapter 3. Thus a detailed literature search will be presented for the following nutrients: 
a) flavonoids, b) fatty acids, c) folate, vitamin B2, vitamin B6 and vitamin B12 and d) 
vitamin D and calcium (see chapter 3 on page 66). 
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1.5.6.1 Red and processed meat 
Evidence regarding the positive association between colorectal cancer and intake of red 
and processed meat is quite consistent. In the second report of AICR/WCRF, a 
systematic review and meta-analysis of observational analytical studies of risks 
associated with intake of red meat and processed meat showed a positive association 
with colorectal cancer (30). Regarding red meat, 16 cohort and 71 case-control studies 
were included with nearly all of them showing a positive association with colorectal 
cancer. A meta-analysis of the cohort data showed that every 50g/day increase of red 
meat intake was associated with a 15% increase in colorectal cancer risk. Fourteen 
cohort and 44 case-control studies investigating the association with processed meat 
were included in this report and meta-analysis of the cohort studies showed a positive 
association with colorectal cancer risk (30). Another recent meta-analysis of prospective 
studies of meat and colorectal cancer reported a significantly elevated summary relative 
risks for both red meat (RR (95% CI): 1.28 (1.15, 1.42)) and processed meat (1.20 (1.11, 
1.31)) in the highest versus lowest category of intake (52). Finally, results from a recent 
large prospective study (NIH-AARP Diet and Health Study, USA), which included over 
5,000 colorectal cancer cases reported a statistically significant positive association 
between colorectal cancer risk and intakes of both red (HR (95% CI): 1.24 (1.12, 1.36)) 
and processed meat (1.20 (1.09, 1.32)) (53). 
1.5.6.2 Dietary fibre 
The first observation that high fibre intake may decrease colorectal cancer risk was 
published in 1969 (54). Since then many studies (case-control studies, cohort studies and 
meta-analyses) have been published, but the relationship of dietary fibre intake with the 
development of colorectal cancer is still not completely understood. In the second 
AICR/WCRF report, 16 cohort and 91 case-control studies were investigated and meta-
analysis of the cohort studies showed a 10% decreased risk per 10g/day of fibre intake 
(30). However, a pooled analysis of 8,100 colorectal cancer cases, followed up for 6–20 
years, showed a statistically non-significant decreased risk for the groups that consumed 
the most dietary fibre (55). Recent results from the Multiethnic Cohort study in Hawaii 
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and Los Angeles (2,110 cases) showed that fibre was inversely associated with 
colorectal cancer for both men and women (age and ethnicity adjusted model: RR (95% 
CI): men: 0.49 (0.41, 0.60); women: 0.75 (0.61, 0.92)). However after further adjustment 
(family history of colorectal cancer, history of colorectal polyp, pack-years of cigarette 
smoking, BMI, hours of vigorous activity, aspirin use, multivitamin use, HRT, alcohol, 
red meat, folate and vitamin D) this inverse association remained statistically significant 
only in men (RR (95% CI): 0.62 (0.48, 0.79)) (56). In the Pooling Project of Prospective 
Studies of Diet and Cancer (8,081 colorectal cancer cases; 13 cohort studies) a 
statistically significant inverse association was found in an age-adjusted model (RR 
(95% CI): 0.84 (0.77–0.92)), but the association was diluted after further adjustment 
(RR (95% CI): 0.94 (0.86, 1.03); adjusted for: age, body mass index, height, education, 
family history of colorectal cancer, use of postmenopausal hormone therapy, oral 
contraceptive use, use of NSAIDs, multivitamin use, smoking, and intake of dietary 
energy, dietary folate, red meat, total milk and alcohol) (55). Further analyses of the 
Pooling Project though showed a statistically significant increased risk for colorectal 
cancer among participants with a very low intake of fibre (dietary fibre intake of 
<10 g/day versus intake of ≥30 g/day, RR (95% CI): 1.18 (1.05–1.31)). Finally, results 
from the European Prospective Investigation into Cancer and Nutrition (EPIC; 1,721 
cases, nine European countries) showed a statistically significant lower risk for 
colorectal cancer associated with high-fibre intake (model adjusted for age, sex, energy 
from fat and non-fat sources, height, weight, folate, physical activity, alcohol, smoking, 
educational level, and intake of red and processed meat; RR (95% CI): 0.79 (0.63–0.99)) 
(57).  
1.5.6.3 Fruit and vegetables 
According to the results of the first AICR/WCRF published in 1997, evidence that 
vegetables protect against colorectal cancer was judged as convincing (58). However, 
analysis of more recent cohort and case-control studies challenged this hypothesis of 
reduced risk and the conclusion of the second AICR/WCRF report (2007) suggested that 
there is limited evidence of a protective colorectal cancer effect of both fruit and 
vegetables (30). In particular, 17 cohort and 71 case-control studies investigating the 
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effect of non-starchy vegetables were included in the second AICR/WCRF report (2007) 
and meta-analysis of the cohort data produced no evidence of an inverse association. 
Similarly, analysis of 20 cohort and 57 case-control studies, which have investigated the 
effect of fruit intakes showed no clear evidence of an overall association (30). However, 
a comparison of the groups of the highest vegetable intakes against those with the lowest 
suggested a possible inverse association. In addition, fruit intake in women was 
inversely associated with colorectal cancer risk (30). A review of nine case-control
 
studies conducted from the International Agency for Research on Cancer in 2003 (59) 
summarised that colorectal cancer risk was lowered
 
by 13% (odds ratio (OR) (95% CI): 
0.87, (0.78, 0.97))
 
and 37% (OR (95% CI): 0.63 (0.56, 0.70))
 
when the highest versus 
the lowest category of respectively fruit and vegetable
 
intakes were compared. However, 
a review of 11 prospective cohort
 
studies published in the same report (59) found that 
fruit and
 
vegetable intakes were not related to risk of colorectal cancer. Finally, the 
Women's Health Initiative Randomised Controlled (WHI)
 
Dietary Modification Trial 
concluded that daily intake of
 
at least five servings of fruits and vegetables along with a
 




1.5.7 Dietary energy intake 
Specific biological functions of the body need the intake of energy to be performed. 
These include body’s functions and processes at rest (basal metabolic rate - BMR), 
digestion and assimilation of food and physical activities (30). Energy requirements of 
the individuals depend on their sex, age, size and physical exercise levels (30). Positive 
energy balance, which leads to weight gain, occurs when an individual consumes more 
energy than the energy that is expended by his or her biological functions. On the other 
hand, negative energy balance, which leads to weight loss, occurs when an individual 
consumes less energy than the energy that is expended by his or her biological functions 
(30). A number of observational studies have investigated the effect of high dietary 
energy intake on colorectal cancer (61). In particular, findings from case-controls studies 
suggest that there is a positive and dose-dependent association between dietary energy 
intake and colorectal cancer risk, whereas findings from prospective studies, do not 
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support strong inverse associations, suggesting that the case-control findings might be 
biased (62-69). A recent case-control investigated the joint effect of energy intake, body 
mass index (BMI) and physical activity and suggested that dietary energy intakes are 
inversely associated with colorectal cancer only among the individuals of low physical 
activity, a finding that might explain the inconsistent results (70). 
1.5.8 Obesity 
Results from observational studies have concluded that obesity is an important risk 
factor in several cancers, including colorectal cancer (71). In the second AICR/WCRF 
(2007), analysis of 68 cohort and of 86 case-control studies that investigated the effect of 
body fatness measured by BMI (kg/m
2
), showed a strong positive association (meta-
analysis of cohort data: 15% increase in risk per 5 kg/m
2 
increase in BMI). In addition, 
analysis of 13 cohort and six case-control studies investigating abdominal fatness 
measured by either waist circumference or waist to hip ratio also showed a strong 
positive association (30). Therefore, the panel of the second AICR/WCRF report (2007) 
concluded that the evidence that obesity (both body and abdominal) is causally linked 
with colorectal cancer is convincing (30). In addition, results from the EPIC study, 
published in 2006 showed that the highest quintile of waist circumference was 
associated with a RR for colon cancer of 1.4 (95% CI 1.0, 1.9) in men and 1.5 (95% CI 
1.1, 2.0) in women (72). One recent meta-analysis, which was published in 2007 and 




in BMI was related to an increased risk of colon cancer in both
 
men (RR (95% CI): 1.30 
(1.25, 1.35)) and women (RR (95% CI): 1.12 (1.07, 1.18)). BMI was positively 
associated with rectal cancer
 
in men (RR (95% CI): 1.12 (1.09, 1.16)) but not in women 
(RR (95% CI): 1.03 (0.99, 1.08)). Regarding abdominal fatness, colon cancer risk 
increased with increasing
 
waist circumference (per 10 cm increase) in both men and 
women (RR (95% CI): 1.33 (1.19, 1.49); 1.16 (1.09, 1.23), respectively) (73). Results 
from a second meta-analysis also published in 2007 (31 studies: 23 cohort, 8 case-
control) indicated that the RR of colorectal cancer for the obese (BMI≥ 30 kg/m
2
) versus 
the normal weight individuals (<25 kg/m
2
) was 1.19 (1.11, 1.29) and the RR comparing 
those with the highest, to the lowest, level of central obesity was 1.45 (1.31, 1.61) (74). 
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Finally, a third meta-analysis published in 2008, reported a strong association between 
BMI and colon cancer (per 5 kg/m
2
 increase in BMI: RR (95% CI), p-value: 1.24 (1.20, 
1.28), <0.0001) and a weak association between BMI and rectal cancer in men (per 5 
kg/m
2
 increase in BMI: RR (95% CI), p-value: 1.09 (1.06, 1.12), <0.0001). In addition, 
it reported a weak association between colon cancer and a 5 kg/m
2
 increase in BMI in 
women (RR (95% CI): 1.09 (1.05, 1.13), <0.0001) (75). 
1.5.9 Physical activity 
Results from both cohort and case-control studies have consistently indicated that 
increased physical activity is inversely associated with male colon cancer risk, reporting 
risk reductions of about 40% with high versus low levels of physical activity (76). In 
addition, results of observational studies regarding the relationship between physical 
activity and female colon cancer have reported less strong but similar associations (76). 
However, results for the association between physical activity and rectal cancer are 
much less consistent, with only a small proportion of the published studies showing a 
statistically significant inverse association (77). The second AICR/WCRF report (2007), 
after reviewing evidence from 11 cohort studies of total physical activity, 12 cohort 
studies of occupational physical activity and 24 cohort studies of recreational physical 
activity, concluded that there is enough evidence that high levels, greater frequency and 
greater intensity of physical activity lowers colon cancer risk, but there is not enough 
evidence regarding rectal cancer risk (30). In addition, a meta-analyses of 19 cohort 
studies published in 2005 reported that increased physical activity was linked to a 
statistically significant reduction in the risk of male colon cancer (RR (95% CI): 
occupational physical activity 0.79 (0.72, 0.87); recreational physical activity 0.78 (0.68, 
0.91). For women though, only recreational physical activity was protective against 
colon cancer (RR (95% CI): 0.71 (0.57-0.88). In addition, no protection against rectal 
cancer was observed in either sex (78). Finally, results from the EPIC study including 
1,094 colon and 599 rectal cases, showed an inverse association between physical 
activity and colon cancer (RR (95% CI): 078 (0.59, 1.03)), but no association with rectal 
cancer (77).  
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1.5.10 Alcohol 
In a recent monograph by WHO International Agency for Research on Cancer (IARC) it 
was stated that colorectal cancer is causally related to alcohol consumption (79), a 
conclusion that is in accordance with the conclusion from the second AICR/WCRF 
report (2007). In particular, in the second AICR/WCRF (2007) report meta-analysis 
from 24 cohort studies investigating consumption of alcoholic drinks and from 13 cohort 
studies investigating ethanol intakes showed that intake of more than 30g per day of 
ethanol is causally linked with male colorectal cancer and probably linked with female 
colorectal cancer (30). Results from the EPIC study suggested that both lifetime and 
baseline  alcohol intake were significantly associated with colorectal cancer incidence 
for alcohol intakes of 30-59.9 g/day compared to 0.1-4.9 g/day (23% and 26% increase 
in risk, respectively) (80). In addition, a recent meta-analysis, which included 16 
prospective cohort studies of colorectal cancer reported that high alcohol intake was 
significantly associated with increased risk of both colon and rectal cancer (highest 
versus lowest category of alcohol intake RR (95% CI): 1.50 (1.25, 1.79); 1.63 (1.35, 
1.97); respectively) (81). Finally, another recent pooled meta-analysis of eight cohort 
studies found an increased risk of colorectal cancer with alcohol consumption but this 
positive association was again limited to consumption of more than 30 g/day (RR (95% 
CI): 0 g/day vs. 30-45 g/day 1.16 (0.99, 1.36); 0 g/day vs. ≥45 g/day 1.41 (1.16 to 1.72)) 
(82). 
Regarding the associations between colorectal cancer and specific types of alcohol (i.e. 
wine, beer, spirits), findings from observational studies are mainly inconsistent (83). The 
main concept is that different alcoholic beverages contain many other different 
substances apart from alcohol, which might have different effects on colorectal cancer. 
One example is the hypothesis that beer might increase rectal cancer risk due to its high 
content in volatile nitrosamines (83). However, results from various large studies, 
including results from a meta-analysis published in 1990 (84), from the Pooling Project 
(82), from the EPIC study (80) and from the Netherlands Cohort Study (83), did not 
provide strong evidence for a different colorectal cancer risk (overall or site specific) 
according to the type of alcohol. 
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1.5.11 Smoking 
Cigarette smoking has been consistently linked with risk of colorectal adenomatous 
polyps. A recent meta-analysis combining findings from 42 case-control and nested 
case-control studies (15,354 cases and 100,011 controls) reported pooled colorectal 
adenoma ORs of 2.14 (1.86, 2.46) for current vs. never smokers, of 1.47 (1.29, 1.67) for 
former vs. never smokers and of 1.82 (1.65, 2.00) for ever versus never smokers (85). In 
the same meta-analysis the authors found that smoking was also more strongly 
associated with high risk adenomas than with low risk adenomas and therefore they 
concluded that smoking is an important risk factor for both the formation and 
aggressiveness of adenomatous polyps (85). In addition, a systematic review conducted 
in 2001, after reviewing 22 studies on the association between colorectal adenomas and 
smoking, reported that long-term heavy smokers have a 2 to 3 fold increased risk to 
develop colorectal adenomas (86). However, evidence of a causal link between smoking 
and colorectal cancer is still debatable, and it was not considered as an established risk 
factor for colorectal cancer by the IARC (85). Early studies (before the 1970s) reported 
no associations whereas more recent studies reported positive associations between 
cigarette smoking and colorectal cancer (87). A possible explanation of this difference is 
that early studies may not have considered
 
a sufficiently long time lag between smoking 
exposure and time
 
of risk (86). However, inconsistencies in the relationship between 
smoking and colorectal cancer risk have been reported also in more recent studies, with 
some studies reporting statistically significant associations only with rectal cancer (87-
89), other studies reporting statistically significant associations only among men (90;91) 
and some other studies reporting generally no significant associations (92;93).   
1.5.12 Non steroidal anti-inflammatory drugs and aspirin 
The protective short-term effect of NSAIDs and/ or aspirin on colorectal adenomas in 
patients with a history of colorectal adenomas or colorectal cancer has been 
demonstrated in three recent randomised clinical trials (94-96). In addition, results from 
three other randomised control studies showed a 40% reduction in colorectal adenomas 
recurrence with the use of either celecoxib or rofecoxib, which are also cyclo-
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oxygenase-2 enzyme (COX-2) inhibitors (97-99). However, the effect of NSAIDs or 
aspirin on colorectal cancer risk is still not well established, possibly due to the long 
time that colorectal cancer needs to develop (100). Two large randomised trials, the 
Physicians’ Health Study (101) and the Women’s Health Study (102), failed to show a 
protective benefit of low-dose aspirin on risk of colorectal cancer in men and women. 
However, this failure to detect a protective effect of aspirin might be due to either low 
doses or insufficient duration of the treatment and results from a recent secondary 
analysis (103) of data pooled from two other randomised trials (104;105) support this 
argument (pooled HR (95% CI), p-value: 0.74 (0.56, 0.97) 0.02 overall; 0.63 (0.47, 0.85, 
0.002 for 5 years or more). In addition, results from the Health Professional Follow-up 
Study after 18 years of follow up, reported that regular, long-term aspirin use reduces 
risk of colorectal cancer among men, but the benefit of aspirin requires at least 6 years of 
continuous and consistent use (100). Finally, both a systematic review of randomised, 
controlled trials, case-control and cohort studies (106) and a meta-analysis of 
observational studies, including data from 19 case-control and 11 cohort studies (103) 
reported that regular use of aspirin or NSAIDs was consistently associated with a 
reduced risk of colorectal cancer, especially in high doses and after use for more than 10 
years. 
1.5.13 Hormone replacement therapy 
Post menopausal HRT has been found to be inversely associated with colorectal cancer 
in several observational studies (summarised in (107-109)). A meta-analysis of 18 
observational studies, published in 1999 reported a 34% reduction in colorectal cancer 
risk for current versus no HRT (RR (95% CI): 0.66 (0.59, 0.74)) and a 20% reduction in 
risk for ever versus never users of HRT (RR (95% CI): 0.80 (0.74, 0.86)) (107). A 
systematic review and meta-analysis of 15 randomised clinical trials was published in 
2005 from the Cochrane Collaboration and investigated the effects of long term HRT for 
peri-menopausal and post-menopausal women on several chronic diseases including 
colorectal cancer (110). Colorectal cancer outcome was measured in four of these trials 
(111-114), however only the WHI trial data were included in the meta-analysis due to 
the very small size of the remaining three clinical trials.  Therefore, according to the 
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findings of this study, for women taking oestrogen combined with progesterone HRT 
there was no statistically significant difference in the incidence of colorectal cancer 
when compared to women taking placebo after one to four years’ follow-up. However, 
women taking combined continuous HRT for five or more years had a statistically 
significant lower incidence of colon cancer (RR (95% CI): 0.62 (0.43 to 0.89)) (114). 
Furthermore cancers, which were diagnosed in women who were taking combined HRT, 
had greater lymph node involvement and were of a more advanced stage (114). 
However, the statistically significant lower colorectal cancer risk observed in the
 
combined continuous HRT group during the intervention phase of the WHI trial did not 
persist three years
 
after stopping the intervention (HR (95% CI):  1.08 (0.66-1.77)) 
(115). 
1.6 Summary 
Colorectal cancer is a cancer that forms either in the tissues of the colon or the rectum, 
and more than 95% of colorectal cancers are adenocarcinomas, deriving from colorectal 
adenomatous polyps. Approximately 25% of colorectal cancer cases are due to an 
inherited predisposition (5-10% hereditary syndromes, 15-20% familial colorectal 
cancer) with the remaining 75% having no obvious genetic predisposition (sporadic 
colorectal cancer). Sporadic colorectal cancer might therefore occur due to low-
penetrance genetic mutations, due to effects of environmental risk factors or due to 
specific gene-environment interactions.  
Colorectal cancer is the third most common cancer in global incidence and mortality 
rates accounting for 9% of all cancer cases and for 8% of all cancer related deaths 
(2002). However, large geographical variations in incidence rates are observed with the 
lowest rates to be recorded in Africa and the highest in N. America, Europe and 
Australia. Temporal trends in incidence rates of colorectal cancer differ between 
countries, with countries that have recently made a transition to a higher-income 
economy (e.g. eastern and southern European countries, Japan, Singapore) to show a 
rapid increase and countries with traditionally higher colorectal cancer incidence rates to 
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show a slight decrease in the last few years. Survival rates of colorectal cancer though 
have been significantly improved in most countries the last 25 years.  
The established risk factors of colorectal cancer include personal history of previous 
colorectal cancer or adenomatous polyps, family history of colorectal cancer, chronic 
bowel inflammatory disease and presence of any of the hereditary syndromes. In 
addition, due to the fact that the majority of colorectal cancer cases (approximately 90%) 
occur after the age of 50, advanced age is also considered as a risk factor and in many 
countries colorectal cancer screening is recommended for those older than 50 years old. 
Finally, evidence for significant associations between colorectal cancer and other risk 
factors, including diet, body weight, physical activity, smoking, alcohol intake, NSAIDs 
intake and HRT in post-menopausal women, is promising and increasing. 
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2 AIMS AND OBJECTIVES 
2.1 Introduction 
In chapter 1, the fact that colorectal cancer is a common cancer accounting for 9% of all 
cancer cases and for 8% of all cancer related deaths was highlighted. At least 75% of 
colorectal cancer cases occur without a specific genetic background (sporadic colorectal 
cancer) and some established non-genetic risk factors (including age, personal history of 
previous colorectal cancer or adenomatous polyps, chronic bowel inflammatory disease, 
specific dietary aspects, body weight, physical activity, smoking, alcohol intake, 
NSAIDs intake and HRT) are thought to affect colorectal carcinogenesis. In this chapter 
the main aims and objectives of the thesis will be presented. In particular, this thesis had 
two aims, for the investigation of which a population-based case-control study of 
colorectal cancer was used (described in detail in chapter four, on page 141). 
2.2 Aims 
2.2.1 Aim 1: To investigate the association between specific 
nutrients and colorectal cancer 
The first aim of this thesis was to determine whether particular nutrients are associated 
with colorectal cancer in a hypothesis-driven type of analysis. The dietary risk factors 
that were selected for this part of the analysis (part 1) were of two types. The first type 
(hypotheses 1 and 2) included relatively novel dietary risk factors, whose associations 
with colorectal cancer were not widely investigated in observational studies. In 
particular, this group included the following risk factors: 1) the flavonoid subgroups: 
flavonols, flavones, flavan3ols, procyanidins, flavanones and the individual flavonoid 
compounds: quercetin, catechin, epicatechin, naringenin and hesperetin (hypothesis 1); 
and 2) total fatty acids (FAs), the fatty acid subgroups saturated fatty acids (SFAs), 
mono-unsaturated fatty acids (MUFAs), poly-unsaturated fatty acids (PUFAs), omega-3 
PUFAs (ω3PUFAs), omega-6 PUFAs (ω6PUFAs), trans fatty acids (tFAs) and trans 
mono-unsaturated fatty acids (tMUFAs) and the individual fatty acid compounds 
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palmitic acid, stearic acid, oleic acid, linoleic acid, γ-linolenic acid, arachidonic acid, α-
linolenic acid, eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) (hypothesis 2). 
The second type of the dietary risk factors (hypotheses 3 and 4) that were included in the 
hypothesis-driven analysis part (part 1) consisted of dietary risk factors that were more 
widely studied in other observational studies, but their role in colorectal carcinogenesis 
is still not well established. In addition, for hypotheses 3 and 4, associations between 
colorectal cancer and particular genetic factors closely linked to the dietary factors were 
investigated. In particular the risk factors included in hypothesis 3 were the dietary risk 
factors folate, vitamin B2, vitamin B6, vitamin B12 and alcohol, which are involved in 
the one-carbon metabolic pathway (folate metabolic pathway) and the four following 
single nucleotide polymorphisms (SNPs) of three genes also involved in the one-carbon 
metabolic pathway: rs1801133 (MTHFR C677T), rs1801131 (MTHFR A1298C), 
rs1805087 (MTR A2756G) and rs1801394 (MTRR A66G) (genetic risk factors). Finally, 
the risk factors that were included in hypothesis 4 were vitamin D and calcium (dietary 
risk factors) and the four following SNPs of the vitamin D receptor (VDR) gene: 
rs10735810 (FokI), rs1544410 (BsmI), rs11568820 and rs7975232 (ApaI). 
2.2.2 Aim 2: To conduct an overall analysis of the study and 
to identify the risk factors that better explain colorectal cancer 
risk in this population by applying forward and backward 
stepwise regression 
The second aim of this thesis was to investigate the relationship between all the lifestyle 
and dietary risk factors that were collected from the Scottish Colorectal Cancer Study 
and colorectal cancer (overall analysis). In addition, stepwise regression models were 
applied in order to identify the risk factors that explained better colorectal cancer risk. 
The main goal of this part of the thesis (part 2) was to generate new hypotheses for 
future studies and not to draw any specific conclusions about the associations of these 
risk factors with colorectal cancer. 
2.3 Objectives 
The main objectives of this thesis are described below separately for aims 1 and 2. 
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2.3.1 Objectives of aim 1 (Hypotheses 1-4) 
2.3.1.1 Hypotheses 1 and 2 
1) To summarise the dietary intake of the novel dietary risk factors (flavonoid and 
fatty acid subgroups and individual compounds) for all subjects and after case/ 
control status stratification (mean, standard deviation, median, interquartile range 
of the dietary intakes; calculation of the t-test and Wilcoxon rank test). 
2) To investigate the univariable associations between the novel dietary risk factors 
(same as above) and colorectal cancer using a crude conditional logistic 
regression model. 
3) To investigate the multivariable associations between the novel dietary risk 
factors (same as above) and colorectal cancer using four conditional logistic 
regression models adjusted for different potential confounding factors. 
4) To investigate the multivariable associations between the novel dietary risk 
factors (same as above) and colorectal cancer using a conditional logistic 
regression model adjusted for potential confounding factors, after sex, age and 
cancer site stratification. 
2.3.1.2 Hypotheses 3 and 4 
1) To summarise the dietary intake of the additional dietary risk factors (folate, 
vitamin B2, vitamin B6, vitamin B12, alcohol, vitamin D and calcium) for all 
subjects and after case/ control status stratification (mean, standard deviation, 
median, interquartile range of the dietary intakes; calculation of the t-test and 
Wilcoxon rank test). 
2) To investigate the univariable associations between the additional dietary risk 
factors (same as above) and colorectal cancer using a crude unconditional 
logistic regression model. 
3) To investigate the multivariable associations between the additional dietary risk 
factors (same as above) and colorectal cancer using three unconditional logistic 
regression models adjusted for different potential confounding factors. 
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4) To investigate the multivariable associations between the additional dietary risk 
factors (same as above) and colorectal cancer using an unconditional logistic 
regression model adjusted for potential confounding factors, after sex, age and 
cancer site stratification. 
5) To investigate the univariable and multivariable associations between the genetic 
factors and colorectal cancer using a crude and a simply adjusted unconditional 
logistic regression model. 
6) To investigate the multivariable associations between the additional dietary risk 
factors (same as above) and colorectal cancer using an unconditional logistic 
regression model adjusted for potential confounding factors, after stratification 
according to the genetic factors and to investigate the interaction relationships 
between the genetic factors and the dietary risk factors.  
2.3.2 Objectives of aim 2 
1) To summarise all the explanatory variables that were to be included in the 
second part of the analysis by presenting percentages of the categorical 
variables and mean (with standard deviations) and median intakes (with 
interquartile ranges) of the continuous variables (for the whole sample and after 
case/ control status stratification). 
2) To examine the correlation relationships (calculating Spearman rank correlation 
coefficient) between each individual continuous explanatory variable. 
3) To investigate the univariable associations between each explanatory variable 
(quartiles for continuous variables; categories for categorical variables) and 
colorectal cancer using a crude unconditional logistic regression model. (Note: 
food and nutrient variables were adjusted for dietary energy intake by using the 
residual or the standard method of energy adjustment.) 
4) To apply forward and backward stepwise regression to three different sets of 
explanatory variables (quartile form of continuous variables): a) Set 1: 
demographic factors, lifestyle variables and food variables; b) Set 2: 
demographic factors, lifestyle variables and nutrients; c) Set 3: demographic 
factors, lifestyle variables, food variables and nutrients.  
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5) To reapply, forward and backward stepwise regression on all three sets of 
variables (quartile form of continuous variables) separately for males and 
females. 
6) To examine the stability of the built models by selecting 100 bootstrap samples 
and then for each bootstrap sample, applying forward and backward stepwise 
regression to the three different sets of the variables in the whole sample 
(bootstrap method). 
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3 LITERATURE REVIEW OF EXAMINED DIETARY 
RISK FACTORS 
3.1 Introduction 
In chapter 1, epidemiological evidence for the most clearly established dietary factors 
including red and processed meat, dietary fibre and fruit and vegetables was presented. 
In this chapter the dietary risk factors that were examined in the first part of this thesis 
comprising the prior hypotheses (aim 1; see chapter 2, on page 61) are described and 
evidence from observational studies is presented. These factors include: flavonoids, fatty 
acids, nutrients involved in the one-carbon metabolic pathway (folate, vitamin B2, 
vitamin B6, and vitamin B12), vitamin D and calcium. 
Literature searches for each dietary factor examined in this thesis (as part of the prior 
hypothesis) were carried out in the PUBMED (MEDLINE) database limited to humans, 
English language and from years 1990 to 2008. The exact words used for each literature 
search as well as the results of each search are presented in Appendix I.  
The first step of relevant references involved looking at the title of the study in order to 
identify whether the publication was applicable for inclusion. If necessary information 
for inclusion or exclusion were not available in study’s title, the abstract of the study 
was examined (second step). Studies that appeared relevant on first and second step 
were entered into a Reference Manager database. The selected studies were then 
examined at a whole-article level review to see if they met the inclusion/exclusion 
criteria (third step). Those studies that did not meet the inclusion criteria were excluded. 
The inclusion criteria were studies, which were: 1) Observational (prospective or 
retrospective); 2) Having as primary or secondary endpoint colon and/or rectal 
adenocarcinoma; 3) Investigating the associations with a) the dietary nutrient intake 
(using a validated assessment of diet) or b) serum/ plasma concentration of a valid 
metabolite (biomarker) of the nutrient under examination; 4) Providing RRs or ORs and 
95% confidence interval (95% CI) or information allowing us to calculate them. 
Additional studies were identified through published reviews, systematic literature 
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reviews and meta-analyses and/ or citations from the included studies. Summary tables 
are presented in the end of each section.  
3.2 Flavonoids 
3.2.1 Introduction 
One type of plant secondary metabolite is a group of biologically active polyphenolic 
compounds widely distributed in a variety of plants. These compounds are of two types: 
flavonoids (consist of a C15 skeleton based on 1,3-diphenylpropane) and isoflavones 
(consist of a C15 skeleton based on 1,2-diphenylpropan). More than 10,000 plant 
flavonoids have been described, and they have been classified into at least ten chemical 
subgroups according to their structural patterns and their diverse bioactivities (116). 
However, laboratory and epidemiologic studies have focused on isoflavones and six 
flavonoid subgroups: flavonols, flavones, flavan3ols, anthocyanidins, pro- or antho-
cyanidins and flavanones. 
The main dietary sources of these flavonoids differ widely among subgroups (117-120). 
Flavonols (main representatives: quercetin, kaempferol, myricetin) are mainly present in 
leafy vegetables, apples, onions and berries and these are the most abundant flavonoids 
in foods. Flavones (main representatives: apigenin, luteolin) and procyanidins are in low 
quantities in some vegetables and wine respectively. Flavan3ols are found in green tea, 
black tea, grapes, apples, chocolate and red wine. Flavanones, such as naringenin and 
hesperetin known also as citrus flavonoids are found in citrus fruits and their juices 
(121). The last subgroup, isoflavones, can be found in soya beans and together with 
lignans, whose precursors are present in a wide variety of plant foods, form the subgroup 
of phytoestrogens (122).  
Flavonoids have many biological activities including antioxidant effects, inhibiting 
inflammation, antimutagenic and antiproliferative properties and involvement in the cell 
cycle regulation and apoptosis (117). In addition, results from laboratory studies show 
that flavonoids affect both molecular and cellular mechanisms that are involved in 
carcinogenesis (119). For colorectal cancer, in particular, in vitro colon cell lines and in 
vivo animal studies have reported anticarcinogenic properties associated with 
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flavonoids, including free radical scavenging, modifying or inactivating enzymes that 
activate or detoxify carcinogens, inhibiting the induction of transcription factors such as 
activator protein-1 (AP-1) activity and inducing apoptosis (123;124). 
3.2.2 Evidence from observational studies 
A few observational studies, have reported associations between flavonoid intake and 
incidence of different types of cancer (breast, lung, stomach, prostate, urothelial, bladder 
and colorectal) (125-130), but the most consistent findings have been observed for a 
reduced lung cancer risk (131). Regarding colorectal cancer, 13 observational studies 
(nine cohort and four case-control studies) that have examined the association between 
flavonoid and isoflavone intakes and colorectal cancer have been identified and 12 of 
them are presented in Table 4 (cohort studies) and Table 5 (case-control studies) 
(118;125;128;129;131-139). Four of the nine cohort studies were small with less than 
200 cases and thus had very limited power to detect moderate or weak associations 
(118;128;129;134). In addition, the three larger cohort studies did not investigate all 6 
subgroups of flavonoids (125;132;133;139) and only one, the Iowa Women’s Health 
study reported statistically significant associations (125). This explanatory study 
examined associations between flavan3ols and many types of cancer and was restricted 
to postmenopausal women. The authors reported an inverse association with rectal 
cancer but did not correct statistical significance levels to account for the many tests 
performed and concluded that the role of flavonoid intake in colorectal cancer should be 
studied further (125). In a more recent analysis of the Iowa Women’s Health study, the 
association between total flavonoids and the main subgroups (flavonols, flavones, 
flavan3ols, anthocyanidins, procyanidins, flavanones and isoflavones) and incidence of 
several types of cancer (including colorectal) was examined (131). However, no 
statistically significant associations between colorectal cancer and total flavonoid or any 
of the main subgroups was observed and the main finding of this study was a further 
support of an inverse association between flavonoids and lung cancer (not enough data 
to be presented in Table 4) (131).   
All four case-control studies reported statistically significant inverse associations 
between flavonoid subgroups or compounds and colorectal cancer. In the Italian case-
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control study the effect of the main six flavonoid subgroups was examined and the 
authors have reported a statistically significant inverse association for flavonols, 
flavones, anthocyanidins and isoflavones (135). The Canadian and Chinese case-control 
studies examined the associations between colorectal cancer and specific flavonoids and 
reported significant findings for phytoestrogens (and separately for lignans and 
isoflavones) and for specific flavan3ols, respectively (137;138).   
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Table 4 Colorectal cancer risk and flavonoid intake; Results from published cohort studies (1990-2008)* 
Study Country; 
Study; Sample 
Assessment Flavonoid Comparison 
(high vs. low) 
Outcome Cases Adjustments RR (95% CI) p
†
 
















highest vs. lowest 
quartile (mg/d)  
colorectal 55 age, examination 
years, BMI, smoking, 
PA, alcohol, fat, SF and 
energy adjusted intake 
of fibre, vitamin C and 
E 
1.53 (0.72, 3.23) 
0.71 (0.30, 1.65) 
1.37 (0.65, 2.89) 
0.59 (0.24, 1.41) 
0.90 (0.37, 2.20) 















isoflavones M: 59.58 vs. 22.45 mg/d 
F: 59.58 vs. 22.45 mg/d 
colon 111 
102 
energy, age, height, 
alcohol, smoking, BMI, 
PA, coffee, use of HRT 
(women) 
1.47 (0.90, 2.40) 
0.73 (0.44, 1.18) 
0.12 
0.20 




















M >30.5 vs. <10.7 mg/d 













age, BMI, FH, history of 
CR polyps, prior 
sigmoidoscopy 
screening, PA, pack-
years of smoking, red 
meat, alcohol, energy, 
calcium, folate, fibre, 
aspirin, multivitamin 
1.28 (0.89, 1.83) 
1.13 (0.83, 1.52) 
 
1.16 (0.80, 1.68) 
1.01 (0.75, 1.35) 
 
1.09 (0.78, 1.52) 
1.14 (0.85, 1.52) 
 
1.33 (0.93, 1.89) 


























>75.1 vs. <3.6 mg/d 
>24.7 vs. <3.6 mg/d 
 
>24.3 vs. <3.2 mg/d 














age, energy, BMI, 
waist-to-hip ratio, PA, 
pack-years of smoking, 
smoking, number of 
years since quit 
smoking, alcohol,  fruit 
1.10 (0.85, 1.44) 
0.55 (0.32, 0.95) 
 
1.04 (0.71, 1.29) 
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gallates >50.8 vs. <0.4 mg/d 





and vegetable 0.95 (0.72, 1.25) 
0.39 (0.22, 0.71) 
0.44 
0.02 





















M >3.9 vs. <1.5 mg/d 
F >4.7 vs. <1.8 mg/d 
M >0.8 vs. <0.1 mg/d 
F >0.9 vs. <0.1 mg/d 
M >0.1 vs. <0.06 mg/d 
F >0.2 vs. <0.03 mg/d 
M >15.4 vs. 0 mg/d 
F >26.8 vs. <3.2 mg/d 
M >4.7 vs. <4.7 mg/d 
F >7.7 vs. <0.9 mg/d 
M >26.9 vs. <4.3 mg/d 
F >39.5 vs. <8.5 mg/d 
colorectal 90 sex, age, geographic 
area, occupation, 
smoking, BMI 
0.62 (0.33, 1.17) 
 
1.13 (0.60, 2.12) 
 
1.31 (0.71, 2.43) 
 
0.97 (0.50, 1.90) 
 
0.93 (0.48, 1.82) 
 


































43.5 vs. 12.7 mg/d colorectal 603  0.97 (0.71, 1.32) 0.92 
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M >4.8 vs. <2.1 mg/d 
F >5.5 vs. <2.4 mg/d 
colorectal 72 sex, age, geographic 
area, occupation, BMI, 
smoking, energy, 
vitamin C, vitamin E, 
beta carotene, fibre, 
SFAs, MUFAs, 
PUFAs, cholesterol 
0.74 (0.32, 1.68)  
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SFAs: saturated fatty acids; MUFAs: mono-unsaturated fatty acids; PUFAs: poly-unsaturated fatty acids 
† P-value for trend 
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Table 5 Colorectal cancer risk and flavonoid intake; Results from published case-control studies (1990-2008)* 
Study Country; 
Study; Sample 
Assessment Flavonoid Comparison 
(high vs. low) 



















>36.8 vs. <16.0 mg/d 
>1.9 vs. <0.5 mg/d 
>162.1 vs. 42.6 mg/d 
>45.2 vs. <16.7 mg/d 
>40.6 vs. <7.4 mg/d 
>857.6 vs. <402.7 µg/d 
 colorectal 1456 matched on age, sex, 
residence area; 
adjusted for FH; BMI; 
PA; smoking; and 
intakes of energy 
(residual), fibre, 
alcohol and NSAIDs 
0.73 (0.59, 0.91) 
1.11 (0.88, 1.40) 
0.81 (0.65, 1.01) 
0.81 (0.65, 1.00) 
1.13 (0.89, 1.43) 


















>7.82 vs. 0 µmol/g Cr 
>2.00 vs. 0 µmol/g Cr 
colorectal 162 
 
matched on age, date 





number of years), 
alcohol, number of 
alcoholic beverages  
0.76 (0.47, 1.24) 















>0.26 vs. <0.16 mg/d 
>1.10 vs. <0.29 mg/d 
>1.34 vs. <0.53 mg/d 
colorectal 1095 lignans adjusted for: 




adjusted for age, sex, 
and energy 
0.73 (0.56, 0.94) 
0.71 (0.58, 0.86) 












>28.5 vs. <13.2 mg/d 
>0.7 vs. <0.3 mg/d 
>88.5 vs. <20.8 mg/d 
>31.7 vs. <5.3 mg/d 
colorectal 1953 age, sex, study centre, 
FH, education, alcohol, 














total flavonoids  
>67.0 vs. <12.5 mg/d 
>33.9 vs. <14.4 µg/d 







                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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3.3 Fatty acids 
3.3.1 Introduction 
All fats consist of fatty acids (organic (carboxylic) acids), which are classified as either 
saturated or unsaturated, depending on their chemical structure. SFAs have no double 
bonds between the carbon atoms of the fatty acid chain. The most abundant SFAs are 
butyric acid, which is the main product of fibre fermentation in the large bowel, and 
palmitic and stearic acids, which are mainly found in meat products. SFAs are also 
found in butter, lard, coconut oil, cream and cheese. Unsaturated fatty acids have one 
(MUFAs) or more (PUFAs) double bonds in the fatty acid chain. The most common 
MUFAs are palmitoleic acid and oleic acid and they are mainly present in nuts, 
avocados and olive oil. PUFAs are further divided in ω3PUFAs and ω6PUFAs fatty 
acids. The difference is that ω3PUFAs have a double bond, three carbons away from the 
methyl carbon, whereas ω6PUFAs have it six carbons away from the methyl carbon. 
Omega-3 PUFA subgroup consists of α-linolenic acid mainly found in seeds (rapeseed, 
soybeans, walnuts and flaxseed) oils, and EPA and DHA acids mainly found in oily fish 
(herring, salmon, mackerel and halibut) and sea food. Omega-6 PUFAs consist of 
linoleic, γ-linolenic and arachidonic acids and their main sources are sunflower and 
safflower oil. Unlike other fatty acids, linoleic and α-linolenic acids (essential fatty 
acids) cannot be synthesised by the body and therefore intake through the diet is 
required (140). Trans fatty acids are a type of either MUFAs or PUFAs and occur 
naturally in small quantities in meat and dairy products from ruminates. However, most 
tFAs consumed today, are industrially produced through partial hydrogenation of plant 
oils and animal fats (141). 
Animal and cell-line studies have suggested that the effect of fats depends not only on 
their quantity but also on composition of fatty acids, which might explain the differences 
in the observed associations (142). Several hypothesised mechanisms regarding the role 
of specific fatty acids on the development of colon cancer have been described. One 
example is the anticarcinogenic properties of butyric acid, which is mainly produced in 
the large bowel as result of fibre fermentation (142). Furthermore it has been shown that 
MUFAs and tFAs promote human colon growth through increase in fatty acid oxidation 
and disturbance of membrane enzymes (142). In addition, there is increasing interest on 
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the possible protective effects of ω3PUFAs in contrast to the increased risk of 
ω6PUFAs. The different effects of these two series are related to their enzymatic 
competition for their metabolic conversion in eicosanoids, which effect many 
physiological processes, including apoptosis, cell proliferation and immune cell function 
(143;144). 
3.3.2 Evidence from observational studies 
Consumption of fats and oils varies throughout the world, with intake in more developed 
regions of the world (Europe, North America, Australia and New Zealand) being higher 
(approximately 30-40 % of total energy intake) than in less developed countries (Africa, 
Asia and Latin America; approximately 20-30% of total energy intake) (30). Since the 
first study that suggested that dietary fats might affect colorectal carcinogenesis (145) 
many studies have investigated the colorectal cancer effect of fat according to its amount 
(total fat), its type (saturated, mono-unsaturated and poly-unsaturated fat) and its origin 
(animal, vegetable, fish derived fat) (142). Neither case-control nor cohort studies have 
found that high total fat intakes increase risk of colorectal cancer (64). In addition a 
meta-analysis of case-control studies (conducted from 1976 to 1988) concluded that 
there were no energy-independent associations between the three major fat subclasses 
(SFAs, MUFAs or PUFAs) and colorectal cancer (142). Regarding specific fatty acid 
subgroups (SFAs, MUFAs, PUFAs, ω3PUFAs, ω6PUFAs and tFAs), few observational 
studies have studied their associations with colorectal cancer. Regarding the fat origin, 
results from ecological studies indicate that diets particularly high in animal fat to be 
generally associated with increased risk in colorectal cancer, in contrast to diets high in 
vegetable or fish derived fat (146). In addition, according to the AICR/WCRF report 
(2007), the evidence that high intake of animal fat is causally linked to colorectal cancer 
is fairly consistent but limited and a summary relative risk of three prospective studies 
was 1.16 (95% CI 0.92, 1.38) per 20g/day (30). In addition, according to the findings of 
the same report the evidence that high fish intake is inversely associated with colorectal 
cancer is limited (summary RR of seven prospective studies (95% CI): 0.96 (0.92, 1.00)) 
(30). 
We identified nine cohort (Table 6) and six case-control studies (Table 7) that studied 
the association between colorectal cancer and saturated fat (62;63;65;66;141;147-156) 
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and two cohort (Table 6) and nine case-control studies (Table 7) that studied the 
association between colorectal cancer and SFAs (157-167). Only one case-control 
reported a statistically significant positive association between SFAs and colorectal 
cancer (160). Regarding MUFAs, we identified seven cohort (Table 8) and four case-
control studies (Table 9) that examined the association between mono-unsaturated fat 
and colorectal cancer (62;63;66;141;147-150;152;153;155) and three cohort (Table 8) 
and nine case-control studies (Table 9) that examined the association between MUFAs 
and colorectal cancer (157-168). One cohort study reported a statistically significant 
inverse association between MUFAs and colon cancer (168) and one case-control study 
a significant inverse association between MUFAs and colorectal cancer (66). Regarding 
PUFAs, we identified four cohort (Table 10) and four case-control studies (Table 11) 
that examined the association between poly-unsaturated fat and colorectal cancer 
(62;66;147;148;150;152;153;155) and two cohort (Table 10) and seven case-control 
studies (Table 11) that examined the association between PUFAs and colorectal cancer 
(157;160-167). Three case-control studies reported significant inverse associations 
between PUFAs or poly-unsaturated fat and colorectal cancer (66;160;165). 
A few studies have investigated the associations between colorectal cancer and 
ω3PUFAs or ω6PUFAs, separately. We identified six cohort (Table 12) and 10 case-
control studies (Table 13) that tested association between risk of colorectal cancer and 
ω3PUFAs or the individual ω3PUFAs EPA, DHA and/or α-linolenic acid 
(141;147;150;158-164;166;169-173). In total, one cohort and four case-control studies 
reported a statistically significant inverse association between ω3PUFAs and colorectal 
cancer (158;161;164;170;172). Regarding ω6PUFAs, we identified three cohort (Table 
14) and 10 case-control studies (Table 15) that investigated their associations (or the 
associations with linoleic acid) with colorectal cancer (141;150;158-
164;166;169;173;174), with only one case-control study reporting a significant inverse 
association (160). Finally, we identified three cohort (Table 16) and three case-control 
(Table 17) studies that examined the association between tFAs and colorectal cancer 
(141;161;162;164;175;176), with one case-control study reporting significant positive 
association for female colorectal cancer cases (175). 
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Table 6 Colorectal cancer risk and saturated fat or saturated fatty acids; Results from published cohort studies (1990-2008)* 
Study Country; 
 Study; Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 











SF M: 45.8 vs. 28.9 g/d 
F: 36.6 vs. 23.9 g/d 
colon 434 age, sex, BMI, smoking, 
energy, FH of CRC 
0.94 (0.69, 1.27) 0.54 








SF M: 45.8 vs. 28.9 g/d 
F: 36.6 vs. 23.9 g/d 
rectum 160 
 
age, sex, BMI, smoking, 
energy intake, FH of CRC 
0.73 (0.46, 1.17) 0.37 





Study; 37547 F 
FFQ; 
quintiles  
SF 13 vs. 7 % energy colorectal 202 age, random treatment 
assignment, BMI, FH of 
CRC, history of colorectal 





0.92 (0.61, 1.41) 0.44 






Project; 45496 F 
FFQ; 
quintiles 










SFAs M: >86.6 vs. 53.5 g/d 
F: >60.1 vs. <35.6 g/d 
colorectal 109 age, sex, BMI, 
occupation, smoking, 
geographical area, 
energy, vegetables, fruits 
and cereals 







SFAs 65.1 vs. 33.8 g/d colorectal 185 age, supplement group, 
smoking years, BMI, 
0.9 (0.6, 1.4) 0.27 





alcohol, education, PA at 
work, calcium 





Study; 14727 F 
FFQ; 
quartiles 
SF high vs. low quartile colorectal 100 total calorie intake, age, 
place at enrolment, 
highest level of education 
1.05 (0.59, 1.88) 0.51 
Gaard M, 1996 
(63) 





Health; 32215 F 
FFQ;  
quintiles 
SF >31.7 vs. <16.0 g/d colon 212 age, energy, height, 
parity, vitamin E, vitamin 
























SF M: 47 vs. 28 g/d 
F: 27 vs. 23 g/d 
colon 215 age, energy, dietary fibre 1.07 (0.69, 1.66) 0.91 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; SF: saturated fat; SFAs: saturated fatty acids; BMI: body mass index; FH: family history; CRC: colorectal 
cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs  
† P-value for trend 
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Table 7 Colorectal cancer risk and saturated fat or saturated fatty acids; Results from published case-control studies (1990-2008)* 
Study Country; 
Study; Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 











SFAs ≥43.64 vs. <31.72 g/d colorectal 1458 matched on age, sex, 
are of residence, 
adjusted for FH, total 
energy intake 
(residual method), 
fibre intake, alcohol 
intake, use of 
NSAIDs, smoking, 
BMI, PA 
1.27 (1.00, 1.61) 0.08 








SFAs 22.10 vs. 11.39 g/d colorectal 
 
782 energy (residual), 
age, sex, residential 
area, BMI 10 years 
before, parental CRC, 
smoking, alcohol use, 
type of job, leisure-
time PA, dietary 
calcium and fibre 
intake 
1.04 (0.71, 1.51) 0.52 
Kuriki K, 2006 
(160) 





SFAs >52.80 vs. <50.89 mol% colorectal 74 BMI, habitual 
exercise, drinking and 
smoking status, 
green-yellow 
vegetable intake, FH 
8.20 (2.86, 23.52) <0.0001 
Wakai K, 2006 
(166) 
Japan; 2535 FM FFQ; 
quartiles 




energy, sex, age, 
year and season of 
first visit to the 
hospital, reason for 
visit, FH of CRC< 
0.83 (0.57, 1.20) 
0.86 (0.56, 1.33) 
0.35 
0.57 















SFAs M: ≥36.1 vs. <31.9 
weight % of total serum 
lipids 
F: ≥35.4 vs. <31.4 






matched on age and 
participating 
institution; adjusted 
for FH of CRC, BMI, 
education, smoking, 
alcohol, green leafy 
vegetable intake, PA  
1.71 (0.66, 4.47) 
 
 







France; 480 FM diet history; 
quartiles 
SFAs M: >50.8 vs. <8.9 g/d 
F: >44.0 vs. <7.7 g/d 
colorectal 171 age, sex, energy, 
BMI, PA 









SFAs >123.3 vs. 66.14 g/d colorectal 402 
 
energy (residual), 
age, marital status, 
history of colorectal 
cancer in first-degree 
relatives, BMI one 
year prior to 
diagnosis, and PA 
0.97 (0.68, 1.38) 0.53 
Levi F, 2002 
(66) 
Switzerland; 
836 FM  
FFQ; 
tertiles 
SF >312 vs. <205 g/d colorectal 286 age, sex, education, 
PA and residual 
energy 




Italy; 6107 FM FFQ; 
per 100 kcal of 
total energy/day 
SF mean: 230 kcal/day colorectal 1953 age, sex, study 
centre, education, PA 
and alcohol intake 








SFAs M >69.3 vs. <42.0 g/MJ 
F >68.0 vs. 39.2 g/MJ 
colon 1095 
888 
age at diagnosis or 
selection, energy 
intake, dietary fibre, 
cholesterol, calcium, 
BMI, physical activity, 
FH of CRC, NSAIDs 
 
0.88 (0.64, 1.22) 
0.96 (0.67, 1.37) 
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SF M >27 vs. <18 g/d 
F >20 vs. <14 g/d 
colorectal 698 
494 




PA, BMI five years 
ago, and caloric, 




1.2 (0.8, 1.8) 





Canada; 1070 FM FFQ; 
quartiles 
SF high vs. low quartile colon 402 sex, age, marital 
status, history of 
colon carcinoma in 
first-degree relatives, 
energy 
0.71 (0.49, 1.03) 0.09 
De Stefani E, 
1997 (154) 
Uruguay; 846 FM quartiles SF >35.3 vs. ≤25.8 mg/d colorectal 282 age, sex, residence, 
urban/rural status, 
energy, calcium, 
vitamin D, folate 
1.52 (0.84, 2.77) 0.18 
Trichopoulou 
A, 1992 (151) 
Greece; 200 FM FFQ SF continuous colorectal 100 age, gender, energy 1.28 (0.71, 2.30) >0.05 
Zaridze D, 1992 
(165) 
Russia; 434 FM FFQ; 
quartiles 
SFAs M: >80.8 vs. <48.3 g/d  
F: >74.8 vs. <44.5 g/d 
colorectal 217 energy, education 1.56 (0.59, 4.18) 0.40 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; SF: saturated fat; SFAs: saturated fatty acids; BMI: body mass index; FH: family history; CRC: colorectal 
cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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Table 8 Colorectal cancer risk and mono-unsaturated fat or mono-unsaturated fatty acids; Results from published cohort studies (1990-2008)* 
Study Country; Study; 
Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 











MUF M: 42.5 vs. 28.2 g/d 
F: 33.1 vs. 22.4 g/d 
colon 434 age, sex, BMI, smoking, 
energy intake and FH of 
CRC 
0.99 (0.73, 1.34) 0.79 








MUF M: 42.5 vs. 28.2 g/d 
F: 33.0 vs. 22.4 g/d 
rectum 160 
 
age, sex, BMI, smoking, 
energy intake and FH of 
CRC 
0.87 (0.56, 1.37) 0.80 





Study; 37547 F 
FFQ; 
quintiles  
MUF 15 vs. 8 % energy colorectal 202 age, random treatment 
assignment, BMI, FH of 
CRC, history of colorectal 
polyps, PA, smoking, 
alcohol consumption, 
HRT, energy 




Finnish Mobile Clinic 
Health Examination 
Survey; 9959 FM 
diet history; 
quartiles 
MUFAs M: >49.2 vs. 30.5 g/d 
F: >34.0 vs. <20.8  
colorectal 109 age, sex, BMI, 
occupation, smoking, 
geographical area, energy 
intake, vegetables, fruits 
and cereals 











MUFAs 40.7 vs. 28.4 g/d colorectal 185 age, supplement group, 
smoking years, BMI, 
alcohol, education, PA at 
work, calcium 
1.2 (0.8, 1.8) 0.44 
Gaard M, 1996 
(63) 
 
Norway; 50535 FM FFQ MUF  colon 143 energy no association  





(USA); 7945 M 
24 hour diet 
history;quartiles 




age 0.73 (0.53, 1.00) 







Health; 32215 F 
FFQ; 
quintiles 
MUF >33.1 vs. <16.6 g/d colon 212 age, energy (residual), 
height, parity, vitamin E, 
vitamin E x age term, 
vitamin A supplement 



















MUF M: 43 vs. 27 g/d 
F: 27 vs. 23 g/d 
colon 215 age, energy, dietary fibre 1.00 (0.63, 1.57) 0.88 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; MUF: mono-unsaturated fat; MUFAs: mono-unsaturated fatty acids; BMI: body mass index; FH: family 
history; CRC: colorectal cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
Chapter three  Literature review of examined dietary factors 
 85
Table 9 Colorectal cancer risk and mono-unsaturated fat or mono-unsaturated fatty acids; Results from published case-control studies (1990-2008)* 
Study Country; 
Study; Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 











MUFAs ≥36.16 vs. <28.72 g/d colorectal 1458 matched on age, sex, 
are of residence; 
adjusted for FH, total 
energy intake (residual), 
fibre intake, alcohol 
intake, use of NSAIDs, 
smoking, BMI, PA 
1.33 (1.05, 1.68) 0.06 








MUFAs 28.06 vs. 15.29 g/d colorectal 
 
782 Energy (residual), age, 
sex, residential area, 
BMI 10 years before, 
parental CRC, smoking, 
alcohol use, type of job, 
leisure-time PA, dietary 
calcium and fibre intake 
0.88 (0.62, 1.25) 0.44 
Kuriki K, 2006 
(160) 





MUFAs >18.85 vs. <17.56 
mol% 
colorectal 74 BMI, habitual exercise, 
drinking and smoking 
status, green-yellow 
vegetable intake, and FH 
colorectal cancer 
1.93 (0.88, 4.23) 0.15 
Wakai K, 2006 
(166) 
Japan; 2535 FM FFQ; 
quartiles 




energy, sex, age, year 
and season of first visit 
to the hospital, reason 
for visit, FH of CRC< 
BMI, exercise, alcohol, 
smoking, multivitamin 
0.92 (0.62, 1.36) 










MUFAs M: ≥24.7 vs. <20.8 
weight % of total 
colorectal 83 
 
matched on age and 
participating institution; 
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 serum lipids 
F: ≥24.1 vs. <20.4 
weight % of total 
serum lipids  
 
86 
adjusted for FH of CRC, 
BMI, education, smoking, 
alcohol, green leafy 
vegetable intake, PA  
 





France; 480 FM diet history; 
quartiles 
MUFAs M: >44.5 vs. <10.0 g/d 
F: >35.6 vs. <8.1 g/d 
colorectal 171 age, sex, energy, BMI, 
PA 









MUFAs >50.01 vs. 25.99 g/d colorectal 402 
 
energy (residual), age, 
marital status, history of 
colorectal cancer in first-
degree relatives, BMI 
one year prior to 
diagnosis, and PA 
0.99 (0.69, 1.41) 0.96 
Levi F, 2002 
(66) 
Switzerland; 
836 FM  
FFQ; 
tertiles 
MUF >335 vs. <249 g/d colorectal 286 age, sex, education, PA 
and residual energy 







per 100 kcal of 
total energy/day 
MUF mean: 264 kcal/day colorectal 1953 age, sex, study centre, 
education, PA and 
alcohol intake 








MUFAs M >66 vs. <44 g/MJ 
F >63 vs. <39 g/MJ 
colon 1095 
888 
age at diagnosis or 
selection, energy intake, 
dietary fibre, cholesterol, 
calcium, BMI, PA, FH of 
CRC, NSAIDs 
0.89 (0.65, 1.21) 
0.94 (0.66, 1.34) 
 






MUF M >33 vs. <24 g/d 
F >20 vs. <14 g/d 
colorectal 698 
494 
age, FH of CRC, 
alcoholic drinks/week, 
pack-years, 
lifetime recreational PA, 
BMI five years ago, and 
caloric, dietary fibre and 
calcium intakes; residual 
Calorie-adjustment 
1.4 (0.9, 2.1) 
1.4 (0.9, 2.2) 
0.06 
0.1 




Canada; 1070 FM FFQ; 
quartiles 
MUF high vs. low quartile colon 402 sex, age, marital status, 
history of colon 
carcinoma in first-degree 
relatives, energy 
0.89 (0.61, 1.30) 0.63 
Zaridze D, 1992 
(165) 
Russia; 434 FM FFQ; 
quartiles 
MUFAs M: >72.4 vs. <45.9 g/d  
F: >69.4 vs. <42.8 g/d 
colorectal 217 energy, education 0.54 (0.20, 1.51) 0.23 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; MUF: mono-unsaturated fat; MUFAs: mono-unsaturated fatty acids; BMI: body mass index; FH: family 
history; CRC: colorectal cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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Table 10 Colorectal cancer risk and poly-unsaturated fat or poly-unsaturated fatty acids; Results from published cohort studies (1990-2008)* 
Study Country; 
Study; Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 







Study; 120852 FM 
FFQ; 
quartiles 
PUF M: 29.3 vs. 11.6 g/d 
F: 22.5 vs. 8.8 g/d 
colon 434 age, sex, BMI, smoking, 
energy intake and FH of 
CRC 
1.21 (0.89, 1.63) 0.38 




Study; 3346 FM 
FFQ; 
quartiles 
PUF M: 29.1 vs. 11.6 g/d 
F: 22.5 vs. 8.8 g/d 
rectum 160 
 
age, sex, BMI, smoking, 
energy intake and FH of 
CRC 




Finnish Mobile Clinic 
Health Examination 
Survey; 9959 FM 
diet history; 
quartiles 
PUFAs M: >10.3 vs. 5.9 g/d 
F: >7.5 vs. <4.1  
colorectal 109 age, sex, BMI, occupation, 
smoking, geographical 
area, energy intake and 
consumption of 
vegetables, fruits and 
cereals 











PUFAs 19.4 vs. 6.5 g/d colorectal 185 age, supplement group, 
smoking years, BMI, 
alcohol, education, PA at 
work, calcium 





Health; 32,215 F 
FFQ; 
quintiles 
PUF >16.2 vs. <8.0 g/d colon 212 age, energy (residual), 
height, parity, vitamin E, 
vitamin E x age term, 
vitamin A supplement  





Study; 3500 FM 
FFQ; 
quintiles 
PUF M: 31 vs. 11 g/d 
F: 24 vs. 8 g/d 
colon 215 age, energy, dietary fibre 1.38 (0.88, 2.16) 0.19 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; PUF: poly-unsaturated fat; PUFAs: poly-unsaturated fatty acids; BMI: body mass index; FH: family history; 
CRC: colorectal cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 












PUFAs ≥16.75 vs. <12.01 g/d colorectal 1458 matched on age, sex, 
are of residence; 
adjusted for FH, total 
energy intake (residual 
method), fibre intake, 
alcohol intake, use of 
NSAIDs, smoking, BMI, 
PA 










PUFAs >31.09 vs. <28.21 mol% colorectal 74 BMI, habitual exercise, 
drinking and smoking 
status, green-yellow 
vegetable intake, FH 











energy, sex, age, year 
and season of first visit 
to the hospital, reason 
for visit, FH of CRC< 
BMI, exercise, alcohol, 
smoking, multivitamin 
use 
0.90 (0.61, 1.31) 









PUFAs M: >18.8 vs. <2.6 g/d 
F: >14.4 vs. <2.1 g/d 
colorectal 171 age, sex, energy, BMI, 
PA 









PUFAs >21.55 vs. 11.15 g/d colorectal 402 
 
energy (residual), age, 
marital status, FH of 
CRC, BMI one year 
prior to diagnosis, and 
PA 
 
1.04 (0.74, 1.48) 0.69 





836 FM  
FFQ; 
tertiles 
PUF >194 vs. <138 g/d colorectal 286 age, sex, education, PA 
and residual energy 
0.6 (0.4, 0.9) <0.05 




FFQ; per 100 
kcal of energy 
PUF mean: 96 kcal/day colorectal 1953 age, sex, study centre, 
education, PA and 
alcohol  










PUFAs M >34.7 vs. <21.3 g/MJ 
F >8.26 vs. 4.94 g/MJ 
colon 1095 
888 
age at diagnosis or 
selection, energy intake, 
dietary fibre, 
cholesterol, calcium, 
BMI, PA, FH of CRC, 
NSAIDs 
1.07 (0.82, 1.41) 
1.05 (0.77, 1.43) 
 






PUF M >28 vs. <19 g/d 
F >22 vs. <15 g/d 
colorectal 698 
494 
age, FH of CRC, 
alcoholic drinks/week, 
pack-years, 
lifetime recreational PA, 
BMI five years ago, and 




0.7 (0.5, 1.1) 









PUF high vs. low quartile colon 402 sex, age, marital status, 
history of colon 
carcinoma in first-
degree relatives, energy 







PUFAs M: >30.4 vs. <15.1 g/d  
F: >31.2 vs. <17.0 g/d 
colorectal 217 energy, education 0.29 (0.13, 0.64) 0.004 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; PUF: poly-unsaturated fat; PUFAs: poly-unsaturated fatty acids; BMI: body mass index; FH: family history; 
CRC: colorectal cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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Table 12 Colorectal cancer risk and omega-3 poly-unsaturated fatty acids; Results from published cohort studies (1990-2008)* 
Study Country; Study; 
Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 
Outcome Cases Adjustments RR (95% CI) p
†
 











high vs. low quartile colorectal 500 age, smoking, BMI, 
multivitamin use, history 
of diabetes, random 
assignment to aspirin or 
placebo, vigorous 
exercise, alcohol intake, 
red meat intake 
0.76 (0.59, 0.98) 0.02 





Study; 37547 F 
FFQ; 
quintiles  
ω3PUFAs  0.21 vs. 0.03 %energy colorectal 202 
 
age, random treatment 
assignment, BMI, FH of 
CRC, history of colorectal 




and total energy intake 





















F 0.31 vs. 0.06 g/d 
 
M 0.39 vs. 0.07 g/d 
 
F 0.50 vs. 0.11 g/d 
 


















age, area, FH of CRC, 
BMI, PA, smoking, 
alcohol, use of vitamin 
supplements, energy, 
cereal, vegetable and 
meat intake 
1.04 (0.60, 1.80) 
0.57 (0.29, 1.15) 
1.06 (0.71, 1.58) 
1.37 (0.81, 2.32) 
1.08 (0.63, 1.87) 
0.66 (0.33, 1.33) 
0.98 (0.66, 1.46) 





















0.70 vs. 0.45 g/d 
0.09 vs. 0.03 g/d 
0.18 vs. 0.08 g/d 
colorectal 460 age, BMI, education level, 
energy intake, intakes of 
red meat and alcohol, 
dietary fibre, calcium, 
vitamin C, folic acid, 
0.99 (0.75, 1.32) 
0.96 (0.72, 1.28) 
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0.7 vs. 0.2 g/d colorectal 185 age, supplement group, 
smoking years, BMI, 
alcohol, education, PA at 
work, calcium 





Health; 32215 F 
FFQ; quintiles ω3PUFAs >0.18 vs. <0.03 g/d colon 212 age, energy (residual), 
height, parity, vitamin E, 
vitamin E x age term, 
vitamin A supplement 
0.70 (0.45, 1.09) 0.26 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; ω3PUFAs: omega 3 poly-unsaturated fatty acids; SFAs: saturated fatty acids; MUFAs: mono-unsaturated 
fatty acids; PUFAs: poly-unsaturated fatty acids; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; ALA: α-linolenic acid; BMI: body mass index; FH: family history; CRC: 
colorectal cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 
Outcome Cases Adjustments OR (95% CI) p
†
 









ω3PUFAs >6.06 vs. <4.43 %TF colorectal 178 BMI, multivitamin use, 
history of diabetes, 
random assignment to 
aspirin or placebo, 
vigorous exercise, 
alcohol intake, red meat 










ω3PUFAs ≥2.82 vs. <1.85 g/d colorectal 1458 matched on age, sex, 
are of residence; 
adjusted for FH, total 
energy intake (residual), 
fibre intake, alcohol 
intake, use of NSAIDs, 
smoking, BMI, PA 
0.63 (0.50, 0.80) <0.0005 









ω3PUFAs 3.94 vs. 1.99 g/d colorectal 782 Energy (residual), age, 
sex, residential area, 
BMI 10 years before, 
parental CRC, smoking, 
alcohol use, type of job, 
leisure-time PA, dietary 
calcium and fibre intake 
0.74 (0.52, 1.06) 0.05 










ω3PUFAs >9.75 vs. <7.98 mol% colorectal 74 BMI, habitual exercise, 
drinking and smoking 
status, green-yellow 
vegetable intake, and 
FH colorectal cancer 
0.41 (0.15, 1.09) 0.16 
Chapter three  Literature review of examined dietary factors 
 94










energy, sex, age, year 
and season of first visit 
to the hospital, reason 
for visit, FH of CRC< 
BMI, exercise, alcohol, 
smoking, multivitamin 
use 
0.89 (0.61, 1.30) 
0.85 (0.57, 1.27) 
0.72 
0.37 













M ≥12.0 vs. <7.7 weight 
% of total serum lipids 
F ≥11.0 vs. <7.8 weight 







matched on age and 
participating institution; 
adjusted for FH of CRC, 
BMI, education, 
smoking, alcohol, green 
leafy vegetable intake, 
PA 
0.24 (0.08, 0.76) 
 













ω3PUFAs  >1.46 vs. <0.55 g/w 
 
colorectal 2280 age, sex, study centre, 
education, BMI, energy, 
alcohol, smoking, PA 









ω3PUFAs >2.92 vs. <1.46 g/d colorectal 402 
 
energy (residual), age, 
marital status, history of 
colorectal cancer in 
first-degree relatives, 
BMI one year prior to 
diagnosis, and PA 












M >3.36 vs. <2.14 g/MJ 




age at diagnosis or 
selection, energy 
intake, dietary fibre, 
cholesterol, calcium, 
BMI, physical activity, 
FH of CRC, NSAIDs 
 
1.00 (0.76, 1.31) 
0.89 (0.66, 1.22) 
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M >2.6 vs. <1.7 g/d 
F >2.1 vs. <1.3 g/d 
colorectal 698 
494 
age, FH of CRC, 
alcoholic drinks/week, 
pack-years, lifetime 
recreational PA, BMI 
five years ago, and 
caloric, dietary fibre and 
calcium intakes; energy 
(residual) 
0.8 (0.5, 1.1) 
1.4 (0.9, 2.2) 
0.1 
0.4 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; ω3PUFAs: omega 3 poly-unsaturated fatty acids; SFAs: saturated fatty acids; MUFAs: mono-unsaturated 
fatty acids; PUFAs: poly-unsaturated fatty acids; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone replacement therapy; 
NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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Table 14 Colorectal cancer risk and omega-6 poly-unsaturated fatty acids; Results from published cohort studies (1990-2008)* 
Study Country; Study; 
Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 
Outcome Cases Adjustments RR (95% CI) p
†
 





Study; 37547 F 
FFQ; 
quintiles  
ω6PUFAs 7.6 vs. 3.8 % energy colorectal 202 age, random treatment 
assignment, BMI, FH of 
CRC, history of 




and total energy intake 
1.60 (0.98, 2.60) 0.16 
Terry P, 2001 
(173) 
Sweden; 61463 F FFQ; 
quartiles 
linoleic acid 7.4 vs. 3.7 g/d colorectal 460 age, BMI, education 
level, energy intake, 
intakes of red meat and 
alcohol, dietary fibre, 
calcium, vitamin C, folic 
acid, vitamin D, SFAs, 
MUFAs, PUFAs 
1.06 (0.78, 1.45) 0.53 










linoleic acid 16.4 vs. 4.5 g/d colorectal 185 age, supplement group, 
smoking years, BMI, 
alcohol, education, PA at 
work, calcium 
1.3 (0.8, 2.0) 0.20 
                                               
* Abbreviations: F: females; FFQ: food frequency questionnaire; ω6PUFAs: omega 6 poly-unsaturated fatty acids; BMI: body mass index; FH: family history; CRC: colorectal cancer; 
PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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Table 15 Colorectal cancer risk and omega-6 poly-unsaturated fatty acids; Results from published case-control studies (1990-2008)* 
Study Country; 
Study; Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 
Outcome Cases Adjustments OR (95% CI) p
†
 










ω6PUFAs >40.1 vs. <36.1  %TF colorectal 178 BMI, multivitamin use, 
history of diabetes, 
random assignment to 
aspirin or placebo, 
vigorous exercise, 
alcohol intake, red meat 
intake. 










ω6PUFAs ≥13.12 vs. <8.90 g/d colorectal 1458 matched on age, sex, 
are of residence; 
adjusted for FH, total 
energy intake (residual 
method), fibre intake, 
alcohol intake, use of 
NSAIDs, smoking, BMI, 
PA 
1.03 (0.81, 1.30) 0.86 





Study; 1575 FM 
FFQ; 
quintiles 
ω6PUFAs 15.23 vs. 7.98 g/d colorectal 782 Energy (residual), age, 
sex, residential area, 
BMI 10 years before, 
parental CRC, smoking, 
alcohol use, type of job, 
leisure-time PA, dietary 
calcium and fibre intake 
0.77 (0.54, 1.10) 0.17 
Kuriki K, 2006 
(160) 





ω6PUFAs >21.51 vs. <19.74 mol% colorectal 74 BMI, habitual exercise, 
drinking and smoking 
status, green-yellow 
vegetable intake, and FH 
colorectal cancer 
0.24 (0.10, 0.59) <0.005 
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Wakai K, 2006 
(166) 
Japan; 2535 FM FFQ; 
quartiles 




energy, sex, age, year 
and season of first visit 
to the hospital, reason 
for visit, FH of CRC< 
BMI, exercise, alcohol, 
smoking, multivitamin 
0.84 (0.57, 1.24) 
0.97 (0.65, 1.45) 
0.77 
0.78 













M ≥36.1 vs. <28.9 weight 
% of total serum lipids 
F ≥37.5 vs. <31.9  weight 







matched on age and 
participating institution; 
adjusted for FH of CRC, 
BMI, education, smoking, 
alcohol, green leafy 
vegetable intake, PA 
0.69 (0.30, 1.61) 
 















high vs. low quartile colorectal 310 age, year of recruitment, 
gender, dialect, 
education, BMI, smoking, 
alcohol, FH of CRC 




Canada; 1070 FM FFQ; 
quartiles 
 
ω6PUFAs >18.06 vs. 19.05 g/d colorectal 402 
 
energy (residual), age, 
marital status, history of 
colorectal cancer in first-
degree relatives, BMI 
one year prior to 
diagnosis, and PA 











M: >30.9 vs. <18.4 g/MJ 




age at diagnosis or 
selection, energy intake, 
dietary fibre, cholesterol, 
calcium, BMI, physical 
activity, FH of CRC, 
NSAIDs 
1.12 (0.85, 1.47) 
1.07 (0.79, 1.46) 
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* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; ω6PUFAs: omega 6 poly-unsaturated fatty acids; BMI: body mass index; FH: family history; CRC: 
colorectal cancer; PA: physical activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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Table 16 Colorectal cancer risk and trans fatty acids; Results from published cohort studies (1990-2008)* 
Study Country; Study; 
Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 











tFAs >3.28 vs. ≤1.96 g/d colorectal 1229 age, total energy intake 
(residual), body mass index, 
physical activity level, 
oestrogen use, self-reported 
diabetes mellitus, smoking 
status, and intake of total 
fat, red meat, fruits and 
vegetables, calcium, folate, 
vitamin E and alcohol 
1.06 (0.88, 1.28) 0.40 





Study; 37547 F 
FFQ; 
quintiles  
tFAs 1.9 vs. 0.6% energy colorectal 202 age, random treatment 
assignment, BMI, FH of 
CRC, history of colorectal 
polyps, PA, cigarette 
smoking, alcohol 
consumption, 
postmenopausal HRT, and 
total energy intake 
1.30 (0.89, 2.05) 0.18 










tFAs 5.7 vs. 1.8 g/d colorectal 185 age, supplement group, 
smoking years, BMI, 
alcohol, education, PA at 
work, calcium 
1.1 (0.7, 1.6) 0.49 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; tFAs: trans fatty acids; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical 
activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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Table 17 Colorectal cancer risk and trans fatty acids; Results from published case-control studies (1990-2008)* 
Study Country; 
Study; Sample 
Assessment Fatty acid 
subgroup 
Comparison 
(high vs. low) 











tFAs ≥4.24 vs. <2.88 g/d colorectal 1458 matched on age, sex, are of 
residence; adjusted for FH, total 
energy intake (residual method), 
fibre intake, alcohol intake, use 
of NSAIDs, smoking, BMI, PA 




Canada; 1070 FM FFQ; 
quartiles 
 
tFAs >1.60 vs. 0.32 g/d colorectal 402 
 
energy (residual), age, marital 
status, history of colorectal 
cancer in first-degree relatives, 
BMI one year prior to diagnosis, 
and PA 
0.83 (0.58, 1.19) 0.31 
Slattery ML, 
2001 (175) 




tFAs M: >3.34 vs. ≤1.69 
g/1000kcal 





age, BMI, PA, energy, fibre and 
calcium intake, oestrogen status 
(women) 
1.2 (0.9, 1.7) 
 




                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; tFAs: trans fatty acids; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical 
activity; HRT: hormone replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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3.4 Folate, vitamin B2, vitamin B6, vitamin B12 
3.4.1 Introduction 
Folate, vitamin B2 (riboflavin), vitamin B6 and vitamin B12 are water soluble vitamins 
that occur naturally in food. In addition, their synthetic forms can be taken as 
supplements. Their main dietary sources of folate are: broccoli, brussels sprouts, 
asparagus, peas, chickpeas, brown rice and fortified breakfast cereals; of vitamin B2 are: 
milk, eggs, fortified breakfast cereals, rice and mushrooms; of vitamin B6 are: poultry, 
fish, meat, legumes, nuts,
 
potatoes, whole grains and fortified breakfast cereals; and of 
vitamin B12 are: meat, salmon, cod, milk, cheese, eggs, yeast extract, and fortified 
breakfast cereals (Food Standards Agency). The recommended daily intake for adults for 
folate is 0.2mg (0.4mg for pregnant women), for vitamin B2 1.3mg for men and 1.1mg 
for women, for vitamin B6 1.4mg for men and 1.2mg for women and for vitamin B12 
0.0015mg (Food Standards Agency). 
The metabolic pathway of folate, also known as one-carbon metabolism is very 
important for DNA synthesis, repair and methylation and vitamins B2, B6 and B12 act 
as co-enzymes in different steps of the pathway (Figure 30). Briefly, folate or folic acid 
is converted initially to 5,10-methylene thetrahydrofolate (5,10-MTHF; co-enzyme: 
vitamin B6), which is the compound needed for the nucleotide synthesis and DNA 
methylation. 5,10-MTHF is then converted to 5-MTHF by the enzyme MTHF reductase 
(MTHFR) and the co-enzyme vitamin B2. In the next step, 5,10-MTHF gives 
homocysteine and methionine and the enzyme that catalyses the latter reaction is 
methionine synthase (MTR; co-enzyme: vitamin B12) which is activated by the MTR 
reductase (MTRR) (177;178). In the final step homocysteine, through the action of the 
enzyme cystathionine β-synthase (CBS) and the co-enzyme vitamin B6, is catabolised to 
glutathione, a detoxification enzyme that inactivates many carcinogenic compounds and 
protect cells from oxidative stress and DNA damage (177-179) (Figure 30).  
The role of folate in preventing neural tube defects (NTDs) is well established and in 
1998 mandatory folic acid fortification was introduced in the USA and Canada in order 
to reduce the number of children born with that defect (180). Indeed, the rate of NTDs 
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during the full fortification period (2000-2002) was decreased by 46% in Canada when 
compared to the pre-fortification period (1993-1997) (181). In 2007, the Standing 
Advisory Committee on Nutrition of the United Kingdom decided that mandatory folic 
acid fortification (by adding folic acid to either bread or flour) should be introduced also 
in the UK (182). However, a recent temporal study reported a statistically significant 
increase in colorectal cancer absolute rates both in the USA and Canada for the period 
that followed the full folic-acid fortification (180). And since it has been hypothesised 
that folate and in particular folic acid might have some enhancing effects on cancer, 
including colorectal cancer (183), folic acid fortification in the UK has been postponed 
until the release of the results of two clinical trials investigating the relationship between 
folic acid and several types of cancer.  
3.4.2 Evidence from observational studies 
According to the WCRF/AICR second report (2007), there is limited evidence that folate 
is inversely associated with colorectal cancer, and due to the inconsistency of the results 
of the different studies, residual confounding from other nutrients (e.g. fibre) cannot be 
ruled out (30). In addition, a meta-analysis, which was published in 2005 and included 
seven cohort and nine case-control studies, reported that there is some evidence of a 
protective effect of dietary folate (and not supplementary folic acid) on colorectal 
cancer, but due to significant heterogeneity (particularly among case-control studies) this 
effect might be confounded by other dietary nutrients (e.g. fibre) (184). We identified 14 
cohort (Table 18) and 24 case-control studies (Table 19) that investigated the association 
between folate/folic acid and colorectal cancer (166;167;185-220). Four cohort and five 
case-control studies reported a statistically significant inverse association between 
dietary folate (185;190;192;193;199;201;206;218;220) and colorectal cancer, two case-
control studies reported a statistically significant inverse association between serum 
folate levels and colorectal cancer (198;209) and one case-control study reported a 
statistically significant inverse association between supplementary folic acid and colon 
cancer (219). 
A smaller number of observational studies have investigated the associations between 
colorectal cancer and vitamin B2, vitamin B6 and vitamin B12. We identified: one 
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cohort (Table 20) and six case-control studies (Table 21) investigating the association 
between vitamin B2 and colorectal cancer (185;203;206;207;212;221;222), with only 
one case-control study reporting a statistically significant inverse association (221); four 
cohort (Table 22) and 11 case-control (Table 23) investigating the association between 
vitamin B6 and colorectal cancer (167;185;195;196;200;203;206;207;212;213;218;221; 
223-225), with three cohort studies and five case-control studies reporting a statistically 
significant inverse association between colorectal cancer and dietary vitamin B6 
(196;200;213;218;221;223-225) and one cohort study reporting a statistically significant 
positive association between rectal cancer and total vitamin B6 (195); and two cohort 
(Table 24) and nine case-control (Table 25) investigating the association between 
vitamin B12 and colorectal cancer (167;185;195;196;200;203;206;207;209;212;226), 
with one cohort study reporting a significant positive association between dietary 
vitamin B12 and colorectal cancer (196). 
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Figure 30 Simplified diagram of the one-carbon (folate) metabolic pathway. Adapted from Sharp & Little, AJE, 2007 
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Table 18 Colorectal cancer risk and folate; Results from published cohort studies (1990-2008)* 
Study Country;  
Study; Sample 
Assessment Nutrient Comparison 
(high vs. low) 















M: 530 vs. 214 µg/d 
F: 564 vs. 238 µg/d 
colorectal 335 
191 
age, alcohol, smoking, 
BMI,  supplement use, 
PA, calcium, vitamin D, 
meat intake, study area 
1.20 (0.85, 1.71) 
1.33 (0.85, 2.09) 
0.46 
0.14 










M: 279.9 vs. 162.7 µg/d 
F: 248.0 vs. 142.5 µg/d 
colon 213 
186 
age, FH, BMI, iron, fibre, 
energy, riboflavin, 
vitamin B6, vitamin C, 
and methionine 
0.96 (0.61, 1.54) 






1969 & 1978 
Busselton Health 
survey; 1035 FM 
serum and red 
cell; 
quartiles 
folate Serum: <2.99 µg/l vs. 
≥6.00  
Red cell: <199.9  vs. 
≥350.0 µg/l 
(high quartile is the 
reference category) 
colorectal 41 age, sex, smoking, 
alcohol, BMI 
2.15 (0.73, 6.31) 
 













≥614 vs. <259 µg/d (total) 
≥385 vs. <244 µg/d (diet) 



















BMI, FH of CRC, history 
of colon polyps, PA, 
smoking status, red 
meat, alcohol, energy, 
menopausal status, 
HRT, aspirin 
1.16 (0.76, 1.79) 
0.67 (0.43, 1.03) 








Study; 3656 FM 
FFQ; 




M: per 100 µg/d increase 
 









age, BMI, smoking, 
alcohol, fresh meat, 
energy, FH of CRC, 
vitamin C, iron, fibre 
0.87 (0.66, 1.14) 
0.58 (0.36, 0.93) 
0.98 (0.62, 1.56) 
1.85 (1.13, 3.02) 
 
















age, BMI, education, 
energy, intake of red 
meat, SF, calcium, 
vitamin B6, beta-
carotene, cereal fibre 




















age, FH, BMI, PA, beef, 
pork or lamb as a main 
dish, processed meat, 
alcohol, calcium, height, 
pack-years smoking 
before age 30, history of 
endoscopy, sex 
0.82 (0.68, 0.99) 














M: >266 vs. <168 µg/d 
 









age, alcohol intake, 
energy intake, FH of 
CRC, iron intake, vitamin 
C intake, and dietary 
fibre intake 
0.73 (0.46, 1.17) 
0.66 (0.35, 1.21) 
0.68 (0.39, 1.20) 


















Diet: >272 vs. <142 µg/d 
Total: >633 vs. <188 µg/d 
colorectal 490 energy, methionine, and 
alcohol, and for total fat 
(for the analysis of the 
total fat) 
0.86 (0.65, 1.13) 













>367 vs. ≤233 µg/d colorectal 295 age, smoking, BMI, 
hours of vigorous PA, 
education, and intakes of 
total fat and energy 














>634.03 vs. <231.12 µg/d 





age, pack-years of 
cigarettes, BMI, 
oestrogen use, and 
intakes of calcium, 
vitamin E and energy 
1.12 (0.77, 1.63) 
0.89 (0.52, 1.51) 
0.67 
0.44 
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>249.0 vs. <103.3 µg/d colon 219 baseline age, race, 
gender, education level, 
dietary intakes of 
calories, fat, vitamin B6, 
vitamin B12, alcohol  
0.57 (0.34, 0.97) 0.18 
Giovannucci 
E, 1998 (193) 
USA; 
Nurses' Health 






>400 vs. ≤200 µg/d colon 442 energy, smoking, FH of 
CRC; PA, BMI, aspirin 

















No FH of CRC 
>413.49 vs. ≤255.38 µg/d 
FH of CRC 





age, energy, history of 
rectal cancer polyps 
0.7 (0.5, 1.0) 
 




                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
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Table 19 Colorectal cancer risk and folate; Results from published case-control studies (1990-2008)* 
Study Country;  
Study; Sample 
Assessment Nutrient Comparison 
(high vs. low) 
Outcome Cases Adjustments OR (95% CI) p
†
 









≥348.6 vs. ≤263.9 µg/d colorectal 264 sex, age, total energy, PA, 
FH of CRC, NSAIDs, sex ×  
NSAID 
1.37 (0.79, 2.36) 0.40 




controls of Public 
Health Centre-
based prospective 




folate M: ≥8.6 vs. <5.6 ng/m 
F: ≥10.6 vs. <6.6 ng/ml 
colorectal 163 
160 
matched pairs with 
adjustment for pack-years 
of smoking, alcohol, BMI, 
PA, vitamin supplement 
use, and FH of CRC 
0.86 (0.45, 1.60) 









≥370.6 vs. ≤216.5 µg/d colorectal 1229 age, sex, NSAIDs, 
screening colonoscopy, 
doctor visits 2 years before 
index date, alcohol, 
education, calcium 
supplement use, vitamin E 
use, SF, cholesterol, fibre, 
methionine, energy, folate 
containing supplement use 
0.7 (0.4, 1.1) 0.1 
Murtaugh MA, 
2007 (206) 






Diet: >475 vs. ≤323 µg/d 
Total: >743 vs. ≤441 µg/d 
rectal 751 age, sex, BMI, PA, energy, 
fibre, calcium, ibuprofen 
use, and smoking 
0.66 (0.48, 0.92) 




B, 2006 (216) 
Sweden; 
nested case-









folate M: >11.3 vs. <5.1 µmol/l 
F: >13.0 vs. <5.7 µmol/l 
colorectal 226 BMI, current smoking, 
recreational and 
occupational PA, and 
alcohol intake 
1.34 (0.72, 2.50) 0.33 
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>419 vs. <246 µg/d colorectal 715 age, sex, alcohol, BMI, 
energy intake, FH of CRC, 
oral contraceptive pill use, 
cigarette pack-years, 
aspirin use 
1.24 (0.81, 1.89) 
 
 
Wakai K, 2006 
(166) 








energy, sex, age, year and 
season of first visit to the 
hospital, reason for visit, FH 
of CRC< BMI, exercise, 
alcohol, smoking, 
multivitamin use 
0.75 (0.51, 1.11) 
0.81 (0.53, 1.23) 
0.32 
0.20 
Jiang Q, 2005 
(197) 








sex, age, methionine, 
smoking status, drinking 
status, and zinc 
0.91 (0.69, 1.19) 
1.39 (0.56, 3.50) 
0.41 
0.41 
Otani T, 2005 
(207) 




≥485 vs. <343 µg/d colorectal 107 Matched on sex, age, 
residence area; adjusted for 
smoking, alcohol 
consumption, BMI, dietary 
fibre intake 
1.3 (0.49, 3.4) 0.62 
Senesse P, 
2004 (167) 




M: >350.3 vs. <79.8 µg/d 
F: >300.7 vs. <116.8 µg/d 
colorectal 171 age, sex, energy, BMI, PA 1.1 (0.6, 2.0) 0.96 
Satia-Abouta 










Whites :  
741 vs. 196 µg/d 
African/Americans:  




energy, other potential 
confounders examined 
include age, sex, education, 
BMI, smoking, PA, FH of 
CRC, NSAIDs, supplement 
use, fat, dietary fibre, 
calcium, folate, fruits, 
vegetables 
0.8 (0.5, 1.2) 
 










high vs. low tertile colorectal 28 sex, age, BMI, smoking, 
and alcohol intake 
0.09 (0.01, 0.57) 0.01 











La Vecchia C, 
2002 (201) 




>330.8 vs. <197.6 µg/d colorectal 1953 energy, sex, age, study 
centre, education, PA and 
FH 
0.72 (0.60, 0.86) 0.01 
Le Marchand 
L, 2002 (203) 






Diet : >406 vs. ≤252 µg/d 
Total: >2430 vs. ≤297 
µg/d 
colorectal 727 Matched on sex, age, 
ethnicity; adjusted for 
energy (residual method), 
pack-years of cigarette 
smoking, lifetime 
recreational PA, lifetime 
aspirin use, BMI, years of 
schooling, intakes of non-
starch polysaccharides from 
vegetables, calcium from 
foods and supplements 
0.9 (0.6, 1.3) 
0.8 (0.6, 1.1) 
0.43 
0.23 








1144.9 vs. 431.2 µg/d colorectal 223 age, sex, years of 
education, smoking, 
alcohol, BMI, PA, total 
energy and fibre 
intake  
1.54 (0.8, 3.1) >0.05 
















FFQ: ≥626 vs. ≤224 µg/d 
Serum: ≥31.04 vs. ≤12.23 
nmol/l 
colorectal 105 FH of CRC, beer intake, 
prior occult blood testing 
and number of hours spent 
in sport activities in their 
early 30 
0.88 (0.46, 1.69) 
 













only from plant 
foods 
M: ≥210 vs. ≤120 µg/1000 
kcal 
F: ≥230 vs. ≤130 
µg/1000kcal 




age, BMI, lifetime vigorous 
leisure time PA, use of 
aspirin/ NSAIDs, presence 
or absence of a first degree 
relative with CRC, total 
energy intake, calcium 
1.2 (0.8, 1.6) 
 
























FFQ: 388 vs. 268 µg/d 
 










total energy intake, and 
energy-adjusted intakes of 
vitamin A and starch 
(residuals) 
0.51 (0.20, 1.31) 
2.12 (0.43, 2.54) 
0.96 (0.40, 2.30) 












M: >360 vs. <110 µg/d 
F: >320 vs. <185 µg/d 
colorectal 171 - 1.00 (0.5, 2.00) >0.05 
Ferraroni M, 
1994 (190) 




>261.49 vs. <162.63 µg/d colorectal 1326 age, sex, education, FH of 
CRC, BMI, energy 
0.52 (0.40, 0.68) <0.05 
Meyer F, 1993 
(205) 




high vs. low quartile colon 424 age, interviewer, dietary 




Benito E, 1991 
(185) 




>227 vs. <146 µg/d colorectal 286 energy, age, sex, weight 0.61 <0.05 
Freudenheim 
JL, 1991 (192) 






M: >380 vs. <240 µg/d 
>385 vs. <250 µg/d 
F: >340 vs. <210 µg/d 









energy 1.03 (0.56, 1.89) 
0.31 (0.16, 0.59) 
0.69 (0.36, 1.30) 





                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
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Table 20 Colorectal cancer risk and vitamin B2 (riboflavin); Results from published cohort studies (1990-2008)* 
Study Country;  
Study;  
Sample 
Assessment Nutrient Comparison 
(high vs. low) 

















exercise, FH of CRC, 
vitamin supplements 
use and calorie intake 
1.4 (0.9, 2.4) 0.36 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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Table 21 Colorectal cancer risk and vitamin B2 (riboflavin); Results from published case-control studies (1990-2008)* 
Study Country;  
Study; Sample 
Assessment Nutrient Comparison 
(high vs. low) 
Outcome Cases Adjustments OR (95% CI) p
†
 
Sharp L, 2008 
(212) 





≥2.49 vs. ≤1.87 
mg/d 
colorectal 264 sex, age, total energy, 
PA, FH of CRC, NSAIDs, 
sex ×  NSAID 
1.44 (0.83, 2.47) 0.17 
Murtaugh MA, 
2007 (206) 






Diet: >2.68 vs. 
≤1.84 mg/d 
Total: >4.00 vs. 
≤2.49 mg/d 
rectal 751 age, sex, BMI, PA, 
energy, fibre, calcium, 
ibuprofen use, and 
smoking (pack-years) 
1.27 (0.91, 1.77) 
 




Otani T, 2005 
(207) 




≥1.85 vs. <1.49 
mg/d 
colorectal 107 Matched on sex, age, 
residence area; adjusted 
for smoking, alcohol 
consumption, BMI, 
dietary fibre intake 
1.1 (0.52, 2.5) 0.64 
Le Marchand 
L, 2002 (203) 






Total: >13.31 vs. 
≤1.52 mg/d 
colorectal 727 Matched on sex, age, 
ethnicity; adjusted for 
energy (residual 
method), pack-years of 
cigarette smoking, 
lifetime recreational PA, 
lifetime aspirin use, BMI, 
years of schooling, 
intakes of non-starch 
polysaccharides from 
vegetables, calcium from 
foods and supplements 
1.4 (1.0, 1.9) 0.13 
La Vecchia C, 
1997 (221) 










age, centre, sex, 
education, PA, energy, 
fibre 
0.72 (0.6, 0.9) <0.01 
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Benito E, 1991 
(185) 




>1.87 vs. <1.17 
µg/d 
colorectal 286 energy, age, sex, weight 1.41 >0.05 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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Table 22 Colorectal cancer risk and vitamin B6; Results from published cohort studies (1990-2008)* 
Study Country;  
Study; Sample 
Assessment Nutrient Comparison 
(high vs. low) 















M: 1. 91 vs. 1.09 mg/d 
F: 1.80 vs. 1.02 mg/d 
colorectal 335 
191 
age, alcohol, smoking, 
BMI,  supplement use, 
PA, calcium, vitamin D, 
meat intake, study area 
0.69 (0.48, 0.98) 













≥4.00 vs. <1.78 mg/d 
(total) 
≥2.40 vs. <1.69 mg/d 
(diet) 




















BMI, FH of CRC, history 
of colon polyps, PA, 




1.14 (0.77, 1.69) 
 
0.84 (0.56, 1.27) 
 
















≥2.05 vs. <1.53 mg/d colorectal 805 age, BMI, education, 
energy, intake of red 
meat, SF, calcium, 
folate, beta-carotene, 
cereal fibre 

















>4.35 vs. <1.59 mg/d 





age, pack-years of 
cigarettes, BMI, 
oestrogen use, and 
intakes of calcium, 
vitamin E and energy 
0.95 (0.67, 1.36) 
1.97 (1.08, 3.62) 
0.88 
0.03 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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Table 23 Colorectal cancer risk and vitamin B6; Results from published case-control studies (1990-2008)* 
Study Country;  
Study; Sample 
Assessment Nutrient Comparison 
(high vs. low) 
Outcome Cases Adjustments OR (95% CI) p
†
 
Sharp L, 2008 
(212) 





≥3.04 vs. ≤2.29 
mg/d 
colorectal 264 sex, age, total energy, 
PA, FH of CRC, NSAIDs, 
sex ×  NSAID 













Diet: ≥3.26 vs. 
≤2.55 mg/d 
Total: ≥3.39 vs. 
≤2.58 mg/d 
colorectal 2028 energy (residual), age, 
sex, folate, fibre, alcohol, 
smoking, BMI, PA 
NSAIDs, FH of CRC 
0.77 (0.61, 0.98) 
 












Diet: >2.6 vs. ≤1.79 
mg/d 
Total: >4.08 vs. 
≤2.44 mg/d  
rectal 751 age, sex, BMI, PA, 
energy, fibre, calcium, 
ibuprofen use, and 
smoking (pack-years) 
0.92 (0.72, 1.17) 
 




Kune G, 2006 
(200) 




>3.4 vs. <1.7 mg/d colorectal 715 age, sex, alcohol, BMI, 
energy intake, FH of 
CRC, oral contraceptive 
pill use, cigarette pack-
years, aspirin use 
0.52 (0.34, 0.80) 
 
 




















131.2 vs. 23.9 
pmol/ml 





Matched on year of birth, 
month and year of blood 
collection, fasting status; 
adjusted for BMI, PA, 
smoking, menopausal 
status, post menopausal 
HRT, duration of regular 
aspirin use, FH of CRC, 
intake of alcohol and red 
meat, plasma vitamin D, 
history of endoscopy 
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Otani T, 2005 
(207) 




≥1.74 vs. <1.46 
mg/d 
colorectal 107 Matched on sex, age, 
residence area; adjusted 
for smoking, alcohol 
consumption, BMI, 
dietary fibre intake 
0.88 (0.41, 1.9) 0.77 
Senesse P, 
2004 (167) 




M: >2.2 vs. <0.6 
mg/d 
F: >1.7 vs. <0.7 
mg/d 
colorectal 171 age, sex, energy, BMI, 
PA 
1.9 (0.9, 4.0) 0.13 
Le Marchand 
L, 2002 (203) 





>2.46 vs. ≤1.69 
mg/d 
colorectal 727 Matched on sex, age, 
ethnicity; adjusted for 
energy (residual), 
smoking, lifetime 
recreational PA, lifetime 
aspirin use, BMI, years 
of schooling, intakes of 
non-starch 
polysaccharides from 
vegetables, calcium from 
foods and supplements 
1.0 (0.7, 1.4) 0.74 
La Vecchia C, 
1997 (221) 










age, centre, sex, 
education, PA, energy, 
fibre 













M: ≥1.18 vs. ≤0.75 
mg/1000 kcal 
F: ≥1.28 vs. ≤0.82 
mg/1000kcal 




age, BMI, lifetime 
vigorous leisure time PA, 
use of aspirin/ NSAIDs, 
presence or absence of 
a first degree relative 
with CRC, total energy 
intake, calcium 
0.7 (0.6, 1.0) 
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>2.20 vs. <1.40 
mg/d 
colorectal 286 energy, age, sex, weight 0.85 >0.05 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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Table 24 Colorectal cancer risk and vitamin B12; Results from published cohort studies (1990-2008)* 
Study Country;  
Study; Sample 
Assessment Nutrient Comparison 
(high vs. low) 















M: 13.7 vs. 4.2 µg/d 
F: 12.8 vs. 4.0 µg/d 
colorectal 335 
191 
age, alcohol, smoking, 
BMI,  supplement use, 
PA, calcium, vitamin D, 
meat intake, study area 
1.50 (0.96, 2.35) 
















>18.36 vs. <5.12 µg/d 





age, pack-years of 
cigarettes, BMI, 
oestrogen use, and 
intakes of calcium, 
vitamin E and energy 
0.94 (0.69, 1.27) 
1.29 (0.78, 2.14) 
0.86 
0.35 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
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Table 25 Colorectal cancer risk and vitamin B12; Results from published case-control studies (1990-2008)* 
Study Country;  
Study; Sample 
Assessment Nutrient Comparison 
(high vs. low) 















M: ≥351.2 vs. 
<220.2 pmol/L 
F: ≥391.9 vs. 
<232.1 pmol/L 
colorectal 226 BMI, current smoking, 
recreational and 
occupational PA, alcohol, 
and plasma folate and total 
homocysteine  
0.82 (0.46, 1.45) 0.71 
Sharp L, 2008 
(212) 





≥7.98 vs. ≤5.25 
µg/d 
colorectal 264 sex, age, total energy, PA, 
FH of CRC, NSAIDs, sex ×  
NSAID 
0.95 (0.56, 1.62) 0.73 
Murtaugh MA, 
2007 (206) 






Diet: >6.57 vs. 
≤3.92 µg/d 
Total: >11.2 vs. 
≤6.09 µg/ 
rectal 751 age, sex, BMI, PA, energy, 
fibre, calcium, ibuprofen 
use, and smoking (pack-
years) 
1.13 (0.86, 1.51) 
 












>11.1 vs. <4.1 
µg/d 
colorectal 715 age, sex, alcohol, BMI, 
energy intake, FH of CRC, 
oral contraceptive pill use, 
cigarette pack-years, aspirin 
use 
0.49 (0.34, 0.71)  
Otani T, 2005 
(207) 




≥11.2 vs. <7.3 
µg/d 
colorectal 107 Matched on sex, age, 
residence area; adjusted for 
smoking, alcohol, BMI, 
dietary fibre intake 
1.1 (0.55, 2.2) 0.77 
Senesse P, 
2004 (167) 




M: >13.5 vs. <2.0 
µg/d 
F: >9.87 vs. <2.0 
µg/d 
colorectal 171 age, sex, energy, BMI, PA 1.4 (0.8, 2.5) 0.21 
Pufulete M, 
2003 (209) 
UK; 104 FM serum 
measurements; 
tertiles  
vitamin B12 high vs. low 
tertile µg/l 
colorectal 28 sex, age, BMI, smoking, and 
alcohol intake 
0.25 (0.04, 1.72) 0.22 
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Le Marchand 
L, 2002 (203) 





>4.99 vs. ≤2.89 
µg/d 
 
colorectal 727 Matched on sex, age, 
ethnicity; adjusted for 
energy (residual), smoking, 
lifetime recreational PA, 
lifetime aspirin use, BMI, 
years of schooling, non-
starch polysaccharides from 
vegetables, calcium from 
foods and supplements 
1.1 (0.8, 1.6) 0.69 
Benito E, 1991 
(185) 




>22.09 vs. <3.93 
µg/d 
colorectal 286 energy, age, sex, weight 0.61 >0.05 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs 
† P-value for trend 
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3.5 Vitamin D and calcium 
3.5.1 Introduction 
Vitamin D can be ingested or synthesized in the skin from inactive precursors through 
the action of UV sunlight. Its active form, 1α,25(OH)2D3 is produced after two 
hydroxylation steps in the liver and kidneys (227). Foods that are good sources of 
vitamin D include oily fish and eggs, as well as fortified margarine, breakfast cereals 
and powdered milk. The recommended dietary intake of vitamin D is 10µg per day 
(Food Standards Agency). Calcium is mainly found in dairy products including milk and 
cheese. Other calcium sources include green leafy vegetables, soya products with added 
calcium (such as soya beans, tofu, soya drinks), nuts, bread and anything made with 
fortified flour. The recommended daily intake of calcium is currently 700 mg in the UK 
(Food Standards Agency). It has been suggested that prevalence of vitamin D deficiency 
(<75 nmol/l of 25(OH)D) in Scotland is high not only among elderly housebound 
individuals, but also among the middle aged ones, with persons that live in Scotland 
having a double risk of having less than 40
 
nmol/l of 25(OH)D than those who live in 
England or Wales  (228). One of the main reasons is the high latitude of Scotland, with 
skin being unable to make vitamin D effectively during the winter months. Therefore, 
routine vitamin D and calcium supplementation especially for the ones that are 
housebound (>65 years old) is recommended (229). 
Vitamin D regulates the blood concentration and absorption of calcium (227). Several 
biological mechanisms regarding the way that vitamin D and calcium might affect 
colorectal carcinogenesis have been described in laboratory studies. Briefly, some of the 
mechanisms of vitamin D and calcium include binding of long-chain fatty acids and bile 
acids in the small intestine or on the colonic lumen and therefore protecting the colonic 
mucosa from their mutagenic actions (230;231). They may also affect colorectal cancer 
risk via binding to the VDR influencing cell proliferation, differentiation, apoptosis and 
angiogenesis (231;232) or affecting insulin resistance (233).  
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3.5.2 Evidence from observational studies and randomised 
clinical trials 
According to the findings of the second WCRF/AICR report (2007), the evidence that 
vitamin D status is associated with a decreased colorectal cancer risk is limited (30). In 
addition, a randomised clinical trial investigating the effects of daily calcium and 
vitamin D supplementation for seven years showed no effect on colorectal cancer 
incidence among postmenopausal women (234). 
We identified 13 cohort (162;193;220;231;235-243) and 13 case-control studies 
(166;167;185;190;204;221;244-250) that examined the associations between dietary or 
total vitamin D intake and colorectal cancer and their results are inconclusive (Table 26, 
Table 27). Briefly, five cohort and four case-control studies reported a significant 
inverse association between total or dietary calcium intake and colorectal cancer or 
colon cancer (190;220;221;231;237;240;241;246;250). Results from serum/ plasma 
studies (234;251-255) are more consistent, indicating an inverse association with 
colorectal cancer (Table 28). In addition, a pooled meta-analysis of five studies 
examining the association between serum 25(OH)D and colorectal cancer risk, reported 
a significant and dose dependent (p<0.0001) association with the OR and 95% CI of the 
highest versus the lowest quintile being 0.46 (0.32, 0.64) (256).  
Regarding calcium, a pooled meta-analysis of 10 cohort studies reported a statistically 
significant reduced risk of colorectal cancer for the highest versus the lowest calcium 
intake (RR (95% CI): 0.86 (0.78, 0.95)) (257). In addition a meta-analysis of 10 cohort 
studies conducted in the second WCRF/AICR report (2007), reported a RR for 
colorectal cancer of 0.98 (95% CI: 0.95, 1.00) per 200mg increase of calcium intake 
(30). 
We identified 21 cohort (63;65;162;217;220;222;230;231;235-243;258-261) and 24 
case-control studies (126;153;166;167;185;190;204;205;211;219;221;244-249;262-267) 
investigating the association between calcium and colorectal cancer risk (Table 29, 
Table 30). Briefly, ten cohort and ten case-control studies reported a statistically 
significant inverse association between total or dietary calcium and colorectal cancer 
risk (65;153;162;166;211;219-221;230;231;235;241-243;245-247;258;262;267). 
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Table 26 Colorectal cancer risk and vitamin D; Results from published cohort studies (1990-2008)* 
Study Country;  
Study; 
Sample 
Assessment Nutrient Comparison 
(high vs. low) 
















M: ≥276 vs. ≤39 IU/1000kcal/d 
F: ≥276 vs. ≤39 IU/1000kcal/d  
Diet: 
M: ≥96 vs. ≤31 IU/1000kcal/d  
F: ≥96 vs. ≤31 IU/1000kcal/d  
Supplements: 
M: >400 vs. 0 IU/d  
F: >400 vs. 0 IU/d  
Diet no supplement users 
M: ≥96 vs. ≤31 IU/1000kcal/d  













ethnicity, time since 
cohort entry, age, pack-
years of cigarette 
smoking, FH of CRC, 
PA, history of intestinal 
polyps, NSAIDs, BMI, 




0.72 (0.51, 1.00) 
0.89 (0.63, 1.27) 
 
0.91 (0.73, 1.13) 






0.87 (0.66, 1.13) 






















>3.23 vs. <1.72 µg/d 
 
colorectal 172 educational level, 
current smoking status, 
FH of CRC BMI, PA, 
energy, alcohol 









vitamin D;  
Diet + 
Supplements 
≥545 vs. <161 IU/d (total) 
≥333 vs. <125 IU/d (diet) 
>0-400 vs. 0 µg/d (Supplements) 
 
colorectal 223 age, randomised 
treatment assignment, 
BMI, FH of CRC, 
history of colon polyps, 
PA, smoking status, red 





1.34 (0.84, 2.13) 
0.96 (0.60, 1.55) 















>525 vs. <110 IU/d (total) 





age, smoking, BMI, 
education, PA, FH of 
CRC, energy, %SF, 
0.80 (0.62, 1.02) 










M: >240 vs. <90 IU/d (diet) 
(excluding multivitamin users) 
F: >240 vs. <90 IU/d (diet) 







0.74 (0.50, 1.11) 
 














vitamin D ; 
Diet 
≥3.8 vs. <2.6 µg/d colorectal 572 energy, age, BMI, 
education level, red 
meat, alcohol, energy 
adjusted SF, folic acid, 
vitamin C, calcium 















M: ≥4.89 vs. <2.58 µg/d 
F: ≥3.42 vs. <1.82 µg/d 



















8.62 vs. 2.58 µg/d colorectal 185 age, supplement group, 
smoking years, BMI, 
alcohol, education, PA 
at work, calcium 













>475.5 vs. <224.1 IU/d rectal 144 age, smoking status, 
pack-years of smoking, 
HRT, energy 
0.76 (0.50, 1.16) 0.20 
Giovannucci 










high vs. low quartile colon 442 energy, smoking, FH of 
CRC; PA, BMI, aspirin 
use; and intakes of
 
red 
meat, alcohol, fibre, 
folate 
0.86 (0.60, 1.28) >0.20 














No FH of CRC 
>478.2 vs. ≤226.3 IU/d (total) 
high vs. low tertile (diet) 
>400 vs. 0 IU/d (supplement) 
FH of CRC 
>478.2 vs. ≤226.3 IU/d (total) 
high vs. low tertile (diet) 







age, energy, history of 
rectal cancer polyps 
 
0.6 (0.4, 0.9) 
0.7 (0.5, 1.0) 
0.8 (0.5, 1.3) 
 
0.9 (0.5, 1.7) 
0.8 (0.4, 1.7) 




















>477 vs. <92 IU/d (total) 
>477 vs. <92 IU/d (total) (women 
with unchanged milk intake) 
>245 vs. <76 IU/d (diet) 
>245 vs. <76 IU/d (diet) (women 







age, BMI, PA, FH of 
CRC, aspirin, cigarette 
smoking, red-meat 
intake, and alcohol  
0.88 (0.66, 1.16) 
0.67 (0.47, 0.95) 
 
0.84 (0.63, 1.13)  


















≥613 vs. <161 IU/d (total) 
≥358 vs. <134 IU/d (dietary) 
≥448 vs. <4.0 IU/d (supplements) 
colon 203 age, total calories, FH 
of CRC, previous 
polyps screening, past 
history of smoking, 
alcohol, aspirin, PA, 
BMI, red meat, SF, 
dietary fibre 
0.66 (0.42, 1.05) 
0.88 (0.54, 1.42) 

















>618 vs. <159 IU/d (total) 
>373 vs. <127 IU/d (diet) 
>400 vs. 0 IU/d (Supplements) 
 
colon 212 age,  energy, height, 
parity, low fat meat 
intake, vitamin E, a 
vitamin E x age 
interaction term 
0.73 (0.45, 1.18) 
0.98 (0.61, 1.58) 




                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
Chapter three  Literature review of examined dietary factors 
 128
Table 27 Colorectal cancer risk and vitamin D; Results from published case-control studies (1990-2008)* 
Study Country;  
Study; 
Sample 
Assessment Nutrient Comparison 
(high vs. low) 
















Diet: ≥6.00 vs. ≤2.51 µg/d 
Total: ≥8.31 vs. ≤2.76 µg/d 
colorectal 2070 energy (residual 
method), energy 
(included as a 
covariate), age, sex, 
deprivation score, fibre, 
FH of CRC, BMI, 
smoking, NSAIDs, PA 
0.77 (0.63, 0.94) 















energy, sex, age, year 
and season of first visit 
to the hospital, reason 
for visit, FH of CRC< 
BMI, exercise, alcohol, 
smoking, multivitamin 
use 
1.04 (0.72, 1.51) 












M: >10.2 vs. <4.2 µg/d 





age, PA, energy, fibre, 
BMI, NSAIDs 
 
1.08 (0.73, 1.60) 










M: >5.3 vs. <0.6 µg/d 
F: >4.3 vs. <0.7 µg/d 
colorectal 171 age, sex, energy, BMI, 
PA 
1.1 (0.6, 2.0) 0.66 








2.6 vs. 1.2 µg/d colorectal 223 age, sex, years of 
education, smoking, 
alcohol drinking, BMI, 
PA, energy, fibre 










M: >11.2 vs. <3.6 µg/d 
F: >8.6 vs. <2.6 µg/d 
colon 1086 
880 
age, BMI, FH, aspirin 
and./ or NSAIDs, 
energy, long-term 
vigorous activity, fibre, 
calcium 
1.40 (1.00, 2.20) 
1.10 (0.70, 1.70) 
 











≥557 vs. <148 IU/d (total) 
≥336 vs. <122 IU/d (diet) 
≥400 vs. 0 IU/d (Supplement) 
≥557 vs. <148 IU/d (total) 
≥336 vs. <122 IU/d (diet) 










age, energy, fibre 0.70 (0.40, 1.10) 
0.80 (0.50, 1.30) 
0.80 (0.60, 1.10) 
0.80 (0.50, 1.50) 
0.90 (0.40, 1.60) 















≥4.28 vs. <2.02 µg/d colorectal 1953 
 
age, area of residence, 
sex, education, PA, 
energy, fibre  















age, sex, energy, 
protein 
0.60 (0.40, 1.00) 











M: >5.7 vs. <2.5 µg/d 
F: >4.7 vs. <2.1 µg/d 
colorectal 171 age, sex and caloric 
intake 









>1.97 vs. <0.79 µg/d colorectal 1326 
 
age, sex, education, FH 
of CRC, BMI, energy  










per 108 IU increase/day colon 746 fat, protein, 
carbohydrates, alcohol, 
calcium, FH, weight, PA, 
pregnancies (females) 









>1.66 vs. <0.32 µg/d colorectal 286 energy, age, sex, weight 0.74 >0.05 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 
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Table 28 Colorectal cancer risk and serum/ plasma vitamin D metabolites; Results from published nested case-control studies (1990-2008)* 
Study Country;  
Study; 
Sample 
Assessment Metabolite Comparison 
(high vs. low) 
Outcome Cases Adjustments OR (95% CI) p
†
 


















FH, aspirin use, PA, 
folate, calcium, retinol, 
pack-years of smoking, 
alcohol, meat intake 
(total red and 
processed meat) 















25(OH)D M: >32.1 vs. <22.9 ng/ml 
 










matched on sex, age, 
study area, date of 
blood draw, fasting 
time; adjusted for pack-
years of smoking, 
alcohol, BMI, PA, 
vitamin supplement 
use, FH of CRC 
0.73 (0.35, 1.5) 
 















25(OH)D ≥23 vs. <12 ng/mL  colorectal 306 matched on age, 
centre, race or ethnic 
group, date of blood
 
sampling 












39.9 vs. 16.2 ng/mL 





matched on year of 
birth, month of blood 
draw; adjusted for BMI, 
PA, pack-years of 
smoking, menopausal 
status, HRT, aspirin, FH 
of CRC, calcium, folate, 
methionine, retinol, red 
meat, alcohol 
0.53 (0.27, 1.04) 
1.77 (0.93, 3.36) 
0.02 
0.51 
















>19.3 vs. ≤9.8 ng/l 






matched on age, date 
of baseline blood draw, 
study clinic 
0.6 (0.3, 1.1) 











>30.1 vs. <17.2 ng/mL 
>41.3 vs. <26.6 pg/ml 
colon 57 matched on age, race, 
sex, date of blood draw 
0.40 (0.1, 1.4) 
1.1 (0.4, 3.2) 
0.57 
0.88 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
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Table 29 Colorectal cancer risk and calcium; Results from published cohort studies (1990-2008)* 
Study Country;  
Study; 
Sample 
Assessment Nutrient Comparison 
(high vs. low) 
















M: ≥611 vs. ≤288 mg/1000kcal/d  
F: ≥611 vs. ≤288 mg/1000kcal/d 
Diet: 
M: ≥466 vs. ≤260 mg/1000kcal/d  
F: ≥466 vs. ≤260 mg/1000kcal/d 
Supplements 
M: ≥200 vs. 0 mg/d 
F: ≥200 vs. 0 mg/d 
Diet excluding supplement users: 
M: ≥466 vs. ≤260 mg/1000kcal/d 













ethnicity, time since 
cohort entry, age, pack-
years of cigarette 
smoking, FH of CRC, 
PA, history of intestinal 
polyps, NSAIDs, BMI, 




0.70 (0.52, 0.93) 
0.64 (0.50, 0.83) 
 
0.76 (0.59, 0.96) 
0.91 (0.72, 1.17) 
 
0.74 (0.60, 0.90) 
0.82 (0.69, 0.98) 
 
0.73 (0.54, 1.00) 
























>610.8 vs. ≤291.9 mg/d colorectal 
 




FH of CRC, vitamin 
supplements use and 
calorie intake 













≥1445 vs. <956 mg/d colorectal 449 age, education, FH of 
CRC, BMI, exercise, 
history of diabetes, 
smoking, aspirin, 
multivitamin use, energy, 
SF, total vitamin D, 
alcohol, fruit, vegetables, 
red meat 
0.68 (0.51, 0.91) 0.01 











total Ca: >1201.8 vs. <766.2 mg/d 
dairy Ca: >736.0 vs. <359.2 mg/d 
 
colorectal 172 educational level, current 
smoking status, FH of 
CRC BMI, PA, energy, 
alcohol 
0.72 (0.47, 1.10) 














≥1357 vs. <614 mg/d (total) 
≥1083 vs. <480 mg/d (diet) 
≥500 vs. 0 ug/d (Supplements) 
 
colorectal 223 age, randomised 
treatment assignment, 
BMI, FH of CRC, history 
of colon polyps, PA, 
smoking status, red 
meat, alcohol, total 
energy, SF, multivitamin 
use, menopausal status, 
HRT 
1.20 (0.79, 1.85) 
0.90 (0.53, 1.54) 

















>1270 vs. <472 mg/d (total) 
>830 vs. <412 mg/d (diet) 
>800 vs. 0 ug/d (Supplements) 
 
colorectal 482 energy, age 0.74 (0.55, 0.99) 
0.74 (0.56, 0.98) 























age, FH, BMI, PA, beef, 
pork or lamb as a main 
dish, processed meat, 
alcohol, calcium, height, 
pack-years smoking 
before age 30, history of 
endoscopy, sex 
0.88 (0.73, 1.07) 















>988 vs. <504 mg/d (diet) 
>500 vs. 0 mg/d (Supplements) 





age, smoking, BMI, 
education, PA, FH of 
CRC, energy, %SF, fruit, 
vegetables, 
0.92 (0.72, 1.17) 
0.69 (0.49, 0.96) 

























categories: 7 for 
total Ca; 6 for 
dietary Ca; 6 for 





M: >1250 vs. ≤500 mg/d (total) 
F: >1250 vs. ≤500 mg/d (total) 
M: >1000 vs. ≤500 mg/d (diet) 
F: >1000 vs. ≤500 mg/d (diet) 
M: >800 vs. ≤200 mg/d (dairy) 
F: >800 vs. ≤200 mg/d (dairy) 
M: >350 vs. ≤250 mg/d (non-dairy) 
F: >350 vs. ≤250 mg/d (non-dairy) 
colon 399 
626 
age, FH, BMI, PA, pack-
years of smoking before 
age of 30, aspirin, red 
meat, alcohol; for 
women: HRT, 
menopausal status 
0.64 (0.43, 0.95) 
0.94 (0.66, 1.33) 
0.67 (0.46, 0.96) 
0.97 (0.68, 1.38) 
0.78 (0.53, 1.16) 
0.78 (0.50, 1.21) 
1.02 (0.73, 1.43) 





















914 vs. 486 mg/d colorectal 572 energy, age, BMI, 
education level, red 
meat, alcohol, energy 
adjusted SF, folic acid, 
vitamin C, calcium 














M: ≥1953.3 vs. <1178.2 mg/d 
F: ≥1416.7 vs. <862.5 mg/d 





















1789 vs. 856 mg/d colorectal 185 age, supplement group, 
smoking years, BMI, 
alcohol, education, PA at 
work, calcium 
0.6 (0.4, 0.9) 0.04 














>1278.7 vs. <800.8 mg/d rectal 144 age, smoking status, 
pack-years of smoking, 
HRT, energy 














No FH of CRC 
>1296.6 vs. ≤820.7 mg/d (total) 
>964.7 vs. ≤615 mg/d (diet) 
>500 vs. 0 IU/d (supplement) 
FH of CRC 
>1296.6 vs. ≤820.7 mg/d (total) 
>964.7 vs. ≤615 mg/d (diet) 







age, energy, history of 
rectal cancer polyps 
 
0.5 (0.3, 0.7) 
0.7 (0.4, 1.0) 
0.6 (0.4, 0.9) 
 
1.2 (0.6, 2.2) 
0.8 (0.4, 1.7) 


















calcium high vs. low quartiles (total) 
high vs. low quartiles (from 
fish/shellfish) 
high vs. low quartiles (from dairy) 
 
colorectal 100 total calorie intake, age, 
place at enrolment, 
highest level of 
education 
0.71 (0.39, 1.28) 
0.41 (0.22, 0.74) 




















>957 vs. <475 mg/d (diet) 
>957 vs. <475 mg/d (diet) (women 




age, BMI, PA, FH of 
CRC, aspirin, cigarette 
smoking, red-meat 
intake, and alcohol  
0.80 (0.60, 1.07) 















≥1213 vs. <631 mg/d (total) 
≥1051 vs. <605 mg/d (dietary) 
≥620 vs. <137 mg/d (dairy) 
≥864 vs. <119 mg/d (non-dairy) 
colon 203 age, total calories, FH of 
CRC, previous polyps 
screening, past history of 
smoking, alcohol, aspirin, 
PA, BMI, red meat, SF, 
dietary fibre 
0.75 (0.48, 1.15) 
0.81 (0.52, 1.28) 
0.68 (0.42, 1.09) 













1288 vs. 596 mg/d (diet) 
417 vs. 238 mg/d (non-dairy) 
colorectal 478 age, gender, FH of CRC, 
energy, energy-adjusted 
0.92 (0.64, 1.34) 
1.77 (1.08, 2.90) 
0.89 
0.01 





 634 vs. 64 mg/d (fermented dairy) 
540 vs. 45 mg/d (unfermented 
dairy) 
intake of fat and dietary 
fibre, BMI, history of 
gallbladder surgery 
1.14 (0.77, 1.68) 
















>1547 vs. <629 mg/d (total) 
>1186 vs. <496 IU/d (diet) 
>500 vs. 0 mg/d (Supplements) 
 
colon 212 age,  energy, height, 
parity, low fat meat 
intake, vitamin E, a 
vitamin E x age 
interaction term 
0.52 (0.33, 0.82) 
0.73 (0.48, 1.13) 















low vs. high (total) 
low vs. high (dairy) 
low vs. high (non-dairy) 
colon 189 age 1.3 (0.9, 1.8) 
1.2 (0.9, 1.8) 




                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
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Table 30 Colorectal cancer risk and calcium; Results from published case-control studies (1990-2008)* 
Study Country;  
Study; 
Sample 
Assessment Nutrient Comparison 
(high vs. low) 
















Diet: ≥1.32 vs. ≤0.89 g/d 
Total: ≥1.34 vs. ≤0.89 g/d 
colorectal 2070 energy (residual 
method), energy 
(included as a covariate), 
age, sex, deprivation 
score, fibre, FH of CRC, 
BMI, smoking, NSAIDs, 
PA 
0.96 (0.78, 1.17) 















energy, sex, age, year 
and season of first visit 
to the hospital, reason 
for visit, FH of CRC< 
BMI, exercise, alcohol, 
smoking, multivitamin 
use 
0.67 (0.46, 1.00) 












M: >1543 vs. <743 mg/d 





age, PA, energy, fibre, 
BMI, NSAIDs 
 
1.02 (0.66, 1.56) 










M: >1241.3 vs. <321.1 mg/d 
F: >1168.6 vs. <365.6 mg/d 
colorectal 171 age, sex, energy, BMI, 
PA 
1.4 (0.8, 2.6) 0.38 
Satia-Abouta 













Whites :  
1691 vs. 456 mg/d 
African/Americans:  




energy, other potential 
confounders examined 
include age, sex, 
education, BMI, smoking, 
PA, FH of CRC, NSAIDs, 
supplement use, fat, 
dietary fibre, calcium, 
folate, fruits, vegetables 
0.4 (0.3, 0.6) 
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≥340 vs. ≤132 mg/d (dairy) 
≥291 vs. ≤42 mg/d (milk) 
 
colorectal 193 age, smoking, BMI, 
alcohol, multivitamin use, 
aspirin, exercise, molar 
ratio of IGF-I to IGFBP-3 
0.62 (0.38, 1.02) 
0.66 (0.40, 1.09) 
0.09 
0.06 








1144.9 vs. 431.2 mg/d colorectal 223 age, sex, years of 
education, smoking, 
alcohol drinking, BMI, 
PA, energy, fibre 










M: >1701 vs. <681 mg/d  
F: >1330 vs. <546 mg/d  
colon 1086 
880 
age, BMI, FH, aspirin 
and./ or NSAIDs, energy, 
long-term vigorous 
activity, fibre 
0.7 (0.5, 0.9) 











≥1396 vs. <532 mg/d (total) 
≥1121 vs. <466 mg/d (diet) 
≥800 vs. 0 mg/d (Supplement) 
≥1396 vs. <532 mg/d (total) 
≥1121 vs. <466 mg/d (diet) 










age, energy, fibre, SF, 
animal fat,  
0.6 (0.4, 1.0) 
0.8 (0.5, 1.4) 
1.0 (0.7, 1.6) 
0.6 (0.3, 1.1) 
0.7 (0.3, 1.3) 















≥1495 vs. <799 ug/d colorectal 1953 
 
age, area of residence, 
sex, education, PA, 
energy, fibre  



















high vs. low quartile colon 402 sex, age, marital status, 
history of colon 
carcinoma in first-degree 
relatives, energy 
0.69 (0.47, 1.00) 0.04 






>951.9 vs. ≤554.3 mg/d colorectal 282 age, sex, residence, 
urban/rural status, 
0.41 (0.24, 0.69) 0.001 
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age, sex, energy, protein 1.2 (0.7, 2.1) 











high vs. low quintile (diet) 
high vs. low quintile (non-dairy) 
high vs. low quintile (dairy) 
colorectal 171 age, sex and caloric 
intake 
1.7 (0.8, 2.3) 
1.6 (0.8, 3.0) 












>1029.7 vs. <468.1 mg/d colorectal 1326 
 
age, sex, education, FH 
of CRC, BMI, energy  









M: >1401.7 vs. ≤641.2 mg/d 
F: >1141.0 vs. ≤592.5 mg/d 
 colon 324 age, BMI, energy, fibre 0.3 (0.1, 0.8) 








diet history calcium; Diet Diet 
>1480 vs. ≤1010 mg/d 
From fermented dairy 
>683 vs. ≤333 mg/d 
From unfermented dairy 
>530 vs. ≤170 mg/d 
From non-dairy 
>402 vs. ≤296 mg/d 
colon 232 age, gender, 
urbanization level, 
energy, FH of CRC, 
cholecystectomy and 
energy-adjusted intake of 
total fat, dietary fibre, 
vitamin C and alcohol 
 
1.81 (1.05, 3.12) 
 
1.26 (0.74, 2.16) 
 
1.10 (0.63, 1.91) 
 

















high vs. low quartile colon 424 age, interviewer, dietary 












continuous colon 746 FH, weight, PA, 
pregnancies (females) 









above vs. below the median 
intake 





















M: high vs. low quartile 
F: high vs. low quartile 
rectal 277 
145 
 1.51 (0.94, 2.44) 
1.63 (0.91, 2.91) 
>0.05 
>0.05 
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age, sex, education, area 
of residence, and 
consumption of selected 
indicator foods 
1.1 (0.8, 1.6) 
1.2 (0.8, 1.9) 
>0.05 
>0.05 
                                               
* Abbreviations: F: females; M: males; FFQ: food frequency questionnaire; BMI: body mass index; FH: family history; CRC: colorectal cancer; PA: physical activity; HRT: hormone 
replacement therapy; NSAIDs: Non-steroidal anti-inflammatory drugs; SF: saturated fat 
† P-value for trend 
‡ Results that are part of the current thesis and will be presented in detail in the following chapters 




In this chapter the overall methodology of the thesis is described. In the first part, the 
population-based case-control study that the analysis was based on is presented. In the 
second part of the chapter the specific elements of data collection and process (prior to 
analysis) are described. Finally, in part three of the chapter the overall statistical 
methodology is outlined.  
4.2 Scottish Colorectal Cancer Study  
4.2.1 Study design 
This thesis was based on a population-based case-control study of colorectal cancer 
(Scottish Colorectal Cancer Study; SOCCS) in relation to genetic susceptibility, lifestyle 
and dietary risk factors. The recruitment for this study commenced in February 1999 and 
ended in December 2006. It was funded by the Cancer Research UK (CR-UK), the 
Medical Research Council (MRC) and the Chief Scientist Office of the Scottish 
Executive (CSO) and was headed by Professors Malcolm G Dunlop, Harry Campbell 
and Mary E Porteous. The main aims of the study were to identify genetic factors that 
influence colorectal carcinogenesis but also to investigate what are the effects of diet and 
general lifestyle on colorectal cancer.  
4.2.2 Ethical approval and consultant consent 
Ethical approval for the SOCCS study was obtained from the MultiCentre Research 
Ethics committee for Scotland (MREC; approval number MREC/ 01/0/0), 18 Local 
Research Ethics committees, 18 Caldicott guardians and 16 NHS Trust management 
committees (Appendix II). The principles and procedures detailed in the MRC document 
“Human tissue and biological samples for use in research”, November 1999 were 
followed and the model consent form proposed by MRC was used. Individual informed 
consent was received on the basis that the DNA sample and other data about the 
individual could be stored by the research team at Edinburgh University for uses in 
future research and may be shared with other medical research groups (with appropriate 
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ethical approvals first being obtained where necessary). This consent includes 
interactions with researchers working for commercial companies (Appendix II). 
Consultant surgeons in all Scottish hospitals were asked permission for their eligible 
patients to receive information on the SOCCS studies. More than 100 surgeons allowed 
and only two surgeons refused to allow their patients to be informed. 
4.2.3 Case recruitment 
4.2.3.1 Eligibility for the study 
All cases between 16 and 79 years old with colorectal adenocarcinoma diagnosed after 
February of 1999 and permanently resident in Scotland were eligible to take part in the 
study. In each case the diagnosis was confirmed histologically and with reference to the 
pathological report. 
Cases that 1) were not normally resident in Scotland, 2) were recurrent colorectal cancer 
cases or 3) had a) squamous cell carcinoma of the anus, b) melanoma of the rectum or c) 
carcinoid tumours of the colon, were not eligible to be included in the study. In addition 
cases that could not give informed consent, because they 1) were too ill, 2) had mental 
health problems, 3) had learning difficulties or 4) had dementia, were excluded from the 
study.  
4.2.3.2 Recruitment 
Eight research nurses were trained by the principal investigators, the project co-ordinator 
and the research nurse co-ordinator (3-day training session) and appointed to eight 
geographical areas. Study awareness in 41 NHS and private funded Scottish hospitals 
was ensured by several presentations to the medical and nursing staff delivered by the 
research nurse co-ordinator. Following this presentation a recruitment strategy to 
ascertain eligible patients and to provide them with the study’s information pack was 
developed. For eligible cases that did not wish to participate (non-participants) or did not 
respond within two months of initial approach (non-responders) a non-participant form 
was completed, recording sex, age of diagnosis, consultant, health board (where treated), 
reason of non-participation (if given) and type of surgery (if applicable; curative or 
palliative). 
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The initial recruitment plan for the study was that each research nurse would visit and 
recruit patients in the last few days of their hospital stay. However, because of a new 
discharge policy, which was implemented soon after recruitment commenced, eligible 
cases were recruited in their homes after having been discharged from the hospital. 
4.2.3.3 Recruitment protocol 
According to the recruitment protocol, each patient received an information pack 
containing a patient invitation letter, a patient information sheet, a sample consent form, 
a patient detail sheet and a prepaid envelope, 24 hours prior to the recruitment visit 
(Appendix II). The main steps of the patient recruitment were: 
• Discussion with the patient about the main aims and elements of the study;  
• Check that all necessary details on the patient details sheet were completed and 
legible; 
• Permission to take a family history and drawing of it on sheet provided; 
• Assessment of family history risk (moderate and high risk patients were offered 
genetic testing or were referred to a cancer genetic clinic); 
• Recording of any previous cancer(s) (including year and hospital of diagnosis); 
• Completion of study’s consent form; 
• If patient wished for his/ her blood sample to be taken, also the DNA storage consent 
form was completed; 
• Completion of next of kin sheet (in case the patient did not wish his/ her blood 
sample to be taken); 
• Completion of the treatment questionnaire; 
• Patient was asked to complete the lifestyle (Appendix III) and food frequency 
questionnaires (Appendix IV) to the best of his/her ability and return in pre-paid 
envelope (this step was included for cases recruited after 01 September 2001). 
4.2.4 Control recruitment 
4.2.4.1 Selection procedure 
Controls eligible for the study were randomly identified through the Community Health 
Index (CHI), which is a NHS population-based register. CHI is a national register of all 
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individuals who are registered with a general practitioner (GP) in Scotland. The 
completeness of the CHI has been estimated to be greater than 95% and it thus 
represents an excellent sampling frame for the selection of population-based controls 
(268). The controls were drawn following a matching protocol applied to the CHI and 
they were recruited through clinics set up in over 40 locations across Scotland. Access to 
the CHI for research purposes has recently been restricted following implementation of 
the Data Protection Act 1998 on 1 March 2000.  However, the study received MREC 
(Scotland) approval to collaborate with the guardians of the CHI to use it as a sampling 
frame but without knowing the identity of individuals until they agreed to participate. 
Controls were selected at random according to the study’s instructions, by the 
Practitioner Services Division (PSD) of the  Information and Statistics Division (ISD) of 
the NHS in Scotland (Step 1) and invitations passed on to these individuals via their GPs 
(Step 2). In particular, the GPs’ information pack sent by post contained information and 
forms 1) for the GPs (covering letter, reply form, explanatory letter) and 2) for the 
controls (information sheet, reply form (Appendix II), lifestyle and food frequency 
questionnaires (Appendix III, IV). In case of no reply from the GP (within a 4 week 
period), a second information pack was sent repeating Step 2. If the GP refused to 
inform the eligible control, the type of response (NO) was recorded in the control 
recruitment recording form, the next eligible control for a particular case was 
approached and steps 1 and 2 were repeated (Step 3). If the GP agreed to inform the 
eligible control, the type of response (YES) was recorded in the control recruitment 
recording form and the study office waited for 3 weeks for the control to reply via ISD 
(Step 3). In case of no reply (within a 3 week period) a reminder letter was sent directly 
to the control (Step 4). If the control refused to take part, the type of response (NO) was 
recorded in the control recruitment recording form, the next eligible control for a 
particular case was approached and steps 1 and 2 were repeated (Step 5). If the control 
agreed to participate, the type of response was recorded (YES) in the control recruitment 
recording form and the details were passed to the research nurse responsible for the 
recruitment visit (Step 6) (Figure 31). 




Figure 31 Selection procedure of controls 
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4.2.4.2 Recruitment protocol 
According to the recruitment protocol, each control received the lifestyle and food 
frequency questionnaires prior to the recruitment meeting and controls were responsible 
to bring them to the recruitment meeting. The main steps of the control recruitment 
were: 
• Discussion with the control about the main aims and elements of the study; 
• Check that all necessary details were completed and legible on the control details 
sheet; 
• Permission to take a family history and drawing of it on sheet provided; 
• Assessment of family history risk (moderate and high risk patients were offered 
genetic testing or were referred to a cancer genetic clinic); 
• Recording of any previous cancer(s) (including year and hospital of diagnosis); 
• Completion of study’s consent form; 
• If control wished for his/ her blood sample to be taken, also the DNA storage 
consent form was completed.  
• Completion of next of kin sheet (in case the control did not wish his/ her blood 
sample to be taken); 
• Control was asked whether he/ she had brought along the lifestyle (Appendix III) 
and food frequency questionnaires (Appendix IV). If: 
o Yes; Questionnaires were quickly checked through and any necessary help 
was given. 
o No (forgot to bring along); A prepaid reply envelope was provided. 
o No (did not receive questionnaires); Blank questionnaires and a prepaid reply 
envelope were provided. 
o No (refused to complete); this answer was recorded in the controls detail 
form.
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4.2.5 Subject data processing and management 
4.2.5.1 Assignment of ID numbers 
Subjects were assigned to unique identification (ID) numbers (Study ID). The Study ID 
consisted of four ID parts: a) “Case” ID (4 digits); b) “Status” ID (1 digit); c) “Relevant 
number” ID (2 digits); d) “Nurse number” ID (2 digits). For cases, “Case” ID numbers 
were assigned consecutively according to the order in which they were identified from 
the hospital files. Control subjects were assigned a “Case” ID identical to the “Case” ID 
of the case subjects that they were matched to. “Status” ID was used to separate cases 
from control subjects by having the value 0 for cases and the value 2 or 4 for the 
controls. “Relevant number” ID was used when multiple controls were recruited for one 
case. Therefore, it always had the value 00 for cases and from 00 up to 06 for the 
controls. Finally each research nurse had each own code number (“Nurse number” ID). 
For storing, elaborating and analysis of the collected data this ID system was used in 
order to protect the subjects’ identity.  
4.2.5.2 Main database 
Recruitment and subject details were entered in an Access database (Main database). 
Details for non-participants and participants were held in separate tables. The main 
information contained in the non-participant and participant tables are listed separately 
for cases and controls in Table 31 and Table 32. 
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Table 31 List of details included in the Main database: Cases 
Title Data 
Participants  
Study ID Unique ID number 
CHI number National unique identification number assigned from the Community 
Health Index 
Recruitment Date Date of recruitment 
Name 3 columns for case’s title, forename and surname 
Address 6 columns for case’s address: Address line 1, address line 2, post code, 
post code area, health board area, post code area for calculation of 
deprivation score 
Deprivation score Deprivation score 
Date of birth Case’s date of birth 
Sex Sex 
MRC consent Study participation consent (Yes/ No) 
C note consent Case medical records consent (Yes/ No) 
GP details 7 columns for case’s GP details: Name, surgery, address (2 columns), 
town, postcode, telephone number 
Hospital Name of hospital that the case was treated and recruited 
Blood sample details 9 columns for blood sample receipt 
Questionnaire Whether lifestyle and food frequency questionnaires were given and 
returned 
Risk CRC family history risk (low, moderate, high, unclear, not applicable, 
missing) 
Withdrawn 3 columns: Case withdrawn (yes/no), date of withdrawn, reason of 
withdrawn 
Non-participants  
ID number Unique ID number 
Sex Sex 
Age Age (at time of approach for recruitment) 
Under 55 Whether the case was under 55 years old 
Hospital Name of the hospital the case was treated 
Consultant 2 columns for the consultant and the associated consultant that treated 
the case 
Date of invite Date that the case was invited to take part 
Health board Health board of residence 
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Reason Reason of no participation 
Surgery Whether the case had colorectal cancer surgery or not (yes/no) 
Curative/ Palliative Whether the surgery was curative, palliative or not recorded 
Additional Info Additional information regarding the reason of no participation 
  
Table 32 List of details included in the Main database: Controls 
Title Data 
Participants  
Study ID Unique ID number 




 Date Date that control’s details received from PSD 
Name 3 columns for control’s title, forename and surname 
Address 6 columns for control’s address: Address line 1, address line 2, post code, 
post code area, health board area, post code area for calculation of 
deprivation score 
Deprivation score Deprivation score 
Date of birth Control’s date of birth 
Sex Sex 
GP details 7 columns for control’s GP: Name, surgery, address (2 columns), town, 
postcode, telephone number 
Appointment date Date of appointment of control with research nurse 
MRC consent Study participation consent (Yes/ No) 
Blood sample details 9 columns for blood sample receipt 
Questionnaire Whether lifestyle and food frequency exposure questionnaires were given 
and returned 
Risk CRC family history risk (low, moderate, high, unclear, not applicable, 
missing) 
Withdrawn 3 columns: Control withdrawn (yes/no), date of withdrawn, reason of 
withdrawn 
Non-participants  
ID number Unique ID number 
Case ID ID of the case that controls was approached for 
Sex Sex 
PSD* Centre PSD centre 
For each control The following variables were completed for all the approached controls 
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approached: 
PSD* PSD sector 
Control Start recruiting control (yes/no) 
Control accept Control accepted to be recruited to the study (yes/no) 
Post code area Post code area for calculation of deprivation score 
For a subset of the 
approached controls: 
The following variables were completed for a subset of the controls 
approached for recruitment. (Up to 15 controls for each case could have 
been approached) 
PSD* PSD sector 
Control Start recruiting control (yes/no) 
GP write 1 Write to the GP for the first time regarding control (yes/no) 
GP re-write Write to the GP for a second time regarding control (yes/no) 
GP reply GP replied regarding control (yes/no) 
GP accept GP accepted to send study information package to control (yes/no) 
Control re-write Write for a second time to control (yes/no) 
Control reply Reply from the control (yes/no) 
Control accept Control accepted to be recruited to the study (yes/no) 
Post code area Post code area for calculation of deprivation score 
Deprivation score Deprivation score 
Reason Reason why the GP or control has not agreed to participate (if applicable) 
Other notes Additional information regarding control recruitment status 
                                               
* PSD: Practitioner Services Division 
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4.2.6 Subject participation analysis 
In total, 6,678 eligible cases were identified, of which 3,471 cases agreed to participate 
(overall participation rate: 52.0%). Of the 3,471 recruited cases 54 withdrew from the 
study and 3,417 cases were finally included in the study (98.4% of the recruited cases). 
The main reasons of cases withdrawn were: 1) 43 cases did not fulfil the inclusion 
criteria, 2) five cases withdrew their consent, 3) five cases were duplicates and 4) one 
case was never recruited. 
Regarding controls, 10,593 population-based controls were identified, of which 4,134 
agreed to participate (overall participation rate: 39.0%). Of the 4,134 recruited controls, 
737 withdrew from the study and 3,396 controls were finally included in the study 
(82.2% of the recruited controls). The main reasons of controls withdrawn were: 1) 364 
controls withdrew their consent, 2) 185 controls were never recruited, 3) 105 controls 
could not be contacted or moved house, 4) 40 controls did not give blood or their DNA 
yield was insufficient, 5) 10 controls did not attend the appointments, 6) 10 controls 
developed colorectal cancer, 7) 23 controls for other reasons.  
Distribution of cases was examined across sex, age, and health board area of residence 
for participants, non-participants and withdrawn subjects (Table 33). Among the non-
participants, reason of no response was also examined (Table 34). Distribution of 
controls was examined across sex, age, health board area of residence, and deprivation 
score for participants, non-participants and withdrawn subjects (Table 35). For 
deprivation score information see chapter 4.4.1. 
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Table 33 Distribution of cases across sex, age, and health board area of residence for participants, 














P vs. NP 
p-value 
P vs. W 
Sex      
Men 1958 (57.3%) 1858 (57.9%) 31 (57.4%)   
Women 1459 (42.7%) 1342 (41.8%) 23 (42.6%)   
Not recorded 0 (0.0%) 7 (0.2%) 0 (0.0%) 0.02 0.99 
Age      









     
Argyll & Clyde 249 (7.3%) 199 (6.2%) 2 (3.7%)   
Ayrshire & Arran 228(6.7%) 239 (7.5%) 3 (5.6%)   
Borders 97 (2.8%) 81 (2.5%) 1 (1.8%)   
Dumfries & 
Galloway 
102 (3.0%) 106 (3.3%) 0 (0.0%)   
Fife 220 (6.4%) 180 (5.6%) 5 (9.3%)   
Forth Valley 187 (5.5%) 154 (4.8%) 4 (7.4%)   
Grampian 497 (14.5%) 282 (8.8%) 13 (24.1%)   
Greater Glasgow 520 (15.2%) 746 (23.3%) 7 (13.0%)   
Highland 165 (4.8%) 116 (3.6%) 3 (5.6%)   
Lanarkshire 315 (9.2%) 350 (10.9%) 2 (3.7%)   
Lothian 533 (15.6%) 447 (13.9%) 7 (13.0%)   
Orkney 11 (0.3%) 4 (0.1%) 0 (0.0%)   
Shetland 16 (0.5%) 9 (0.3%) 0 (0.0%)   
Tayside 263 (7.7%) 281 (8.8%) 2 (3.7%)   
Western Isles 12 (0.3%) 8 (0.3%) 1 (1.8%)   
Not recorded 2 (0.1%)
**
 5 (0.2%) 4 (7.4%) <0.0005 <0.0005 
                                               
* Agreed to participate 
† Did not agree to participate 
‡ Missing data for 56 non-participants 
§ Missing data for 3 withdrawn participants 
** Move to England 
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Table 34 Reason of no response for non-participants 
Type of “no” response Cases (non-participants: n=3207) 
Unable to take part
*
 1276 (39.8%) 
Did not want to take part 1877 (58.5%) 
Not recorded 54 (1.7%) 
                                               
* Reasons for being unable to take part: deceased (n=377), exact reason not recorded (n=289), patient too ill to 
participate (n=276), advanced disease (n=52), unaware of diagnosis (n=33), dementia (n=29), learning difficulties 
(n=28), not appropriate (n=26), limited understanding (n=18), consultant not agreed for patient to be approached 
(n=18), patient confused (n=18), mental health problems (n=17), not approached (n=8), unable to give informed 
consent (n=7), communication problems (n=7), Alzheimer’s disease/ Parkinson’s disease/ Schizophrenia (n=7), 
unconfirmed diagnosis (n=6), patient too anxious (n=6), memory problems (n=5), patient did not speak English (n=5), 
patient depressed (n=3), patient did not live in Scotland (n=3), other reason (n=38). 
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Table 35 Distribution of controls across sex, age, health board area of residence and Carstairs 














P vs. NP 
p-value 
P vs. W 
Sex
‡
      
Men 1908 (56.2%) 4194 (57.52%) 410 (55.63%)   
Women 1488 (43.8%) 3088 (42.35%) 327 (44.37%)   
Not recorded 0 (0.0%) 9 (0.12%) 0 (%) 0.05
§
 0.78 
Age‡      













     
Argyll & Clyde 224 (6.6%) 615 (8.4%) 57 (7.7%)   
Ayrshire & Arran 233 (6.9%) 616 (8.4%) 37 (5.0%)   
Borders 111 (3.3%) 177 (2.4%) 23 (3.1%)   
Dumfries & 
Galloway 
132 (3.9%) 245 (3.4%) 28 (3.8%)   
Fife 236 (6.9%) 354 (4.8%) 52 (7.1%)   
Forth Valley 187 (5.5%) 373 (5.1%) 59 (8.0%)   
Grampian 540 (15.9%) 780 (10.7%) 111 (15.1%)   
Greater Glasgow 416 (12.2%) 1496 (20.1%) 92 (12.5%)   
Highland 195 (5.7%) 257 (3.5%) 34 (4.6%)   
Lanarkshire 255 (7.5%) 829 (11.4%) 59 (8.0%)   
Lothian 568 (16.7%) 956 (13.1%) 84 (11.4%)   
Orkney 14 (0.4%) 17 (0.2%) 4 (0.5%)   
Shetland 13 (0.4%) 21 (0.3%) 8 (1.1%)   
Tayside 264 (7.8%) 537 (7.4%) 79 (10.7%)   
Western Isles 8 (0.2%) 36 (0.5%) 10 (10.7%)   





     
1 318 (9.4%) 270 (3.7%) 52 (7.1%)   
2 686 (20.2%) 675 (9.3%) 128 (17.4%)   
3 923 (27.2%) 1086 (14.9%) 186 (25.2%)   
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4 794 (23.4%) 1310 (18.0%) 183 (24.8%)   
5 365 (10.7%) 714 (9.8%) 99 (13.4%)   
6 218 (6.4%) 547 (7.5%) 61 (8.3%)   
7 92 (2.7%) 341 (4.7%) 28 (3.8%)   
Not recorded 0 (0.0%) 2348 (32.2%) 0 (0.0%) <0.0005
***
 0.01 
                                               
* Agreed to participate 
† Did not agree to participate 
‡ Sex, age and Health Board information for non-participants population controls was obtained from the cases the non-
participant population controls were matched to. 
§ The chi-square test p-value was 0.17, when we compared men and women distributions (participants versus non-
participants) ignoring the 9 subjects, whose sex was not recorded.  
** For 17 participants, age was calculated based on the date that the PSD report was returned to the study office and 
for 4 participants age could not be calculated. 
†† Age is missing for 9 non-participants population controls. 
‡‡  For 467 withdrawn population controls, age was calculated based on the date that the PSD report was returned to 
the study office and for 4 withdrawn population controls age could not be calculated. 
§§ The chi-square test p-value was <0.0005, when we compared Health Board distributions (participants versus non-
participants) ignoring the 9 subjects, whose health board information was not recorded. 
*** The chi-square p-value was <0.0005 when we compared Carstairs Deprivation Index distributions (participants 
versus non-participants) ignoring the 2348 subjects, whose post code sector information was either not recorded or 
inadequate. 
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4.2.7 Biological materials 
Materials collected from case and control subjects comprised blood, from which DNA, 
peripheral blood lymphocytes and plasma were prepared and stored in a custom made 
facility. In addition, tumour material and matched tumour/ normal material were 
collected from cases under 55 years old. Tumour material was also collected from older 
cases (>55 years old), but the rate of success was lower than for those >55 years old. 
4.2.7.1 DNA preparation, storage and quality assurance 
Blood samples were transferred to the academic campus at the Western General Hospital 
within 72 hours of sampling. Three aliquots of 10ml of blood were collected from each 
subject in two sodium Ethylene Diamine Tetraacetic Acid (EDTA) tubes and one Acid 
Citrate Dextrose (ACD) tube. Samples were received centrally, logged and bar-coded in 
the Wellcome Trust Millennial Clinical Research Facility (WT-CRF). DNA extraction 
was carried out using Nucleon kits. Samples were bar coded for sample tracking and 
management. Standard operating procedures appropriate for CPA accreditation were 
followed by the laboratory. One EDTA sample was directly extracted to DNA, the other 
was stored frozen as a white blood cell pallet in case of extraction failure. Median DNA 
yield on samples was 327µg (maximum yield 1197µg). The minimum yield was 50 µg 
of DNA since patients were asked to give a further blood sample in event of lower 
yields. Quality control procedures included spectrophotometric readings of every sample 
(either A260/280 or PicoGreen™), agarose gel electrophoresis of uncut and restriction 
enzyme cut DNA from 2% of samples and a control PCR on 1% of samples. Stock DNA 
concentration is currently stored at a target concentration of 1 mg/ml. 
4.2.7.2 Peripheral Blood Lymphocytes 
Peripheral blood lymphocytes processing and cryopreservation was carried out in the 
Cytogenetics Service of the South East Scotland Clinical Genetic Service, which is 
aligned with the WT-CRF. 10ml of blood in ACD anticoagulant tubes were bar coded. 
Peripheral blood lymphocytes were separated from whole blood by centrifugation over 
Ficoll-Hypaque. After centrifugation, mononuclear cells were isolated from the interface 
of the buffer, washed in media and preserved in FCS/DMSO. After controlled cooling, 
Chapter four  Methods 
 157 
the cells were stored in liquid nitrogen in two aliquots, if sufficient blood in good 
condition was received. If fewer lymphocytes were obtained they were stored in one 
aliquot. The mean cell count of project samples was 4.4 x 10
6
 cells (maximum cell count 
has been 80 x 10
6
 cells). 
4.2.7.3  Plasma 
Plasma was prepared by gentle centrifugation of sodium EDTA tubes prior to DNA 
extraction. 1500 µl of plasma was stored for each case and control for future proteomic 
studies.  Plasma samples were all bar-coded and stored at -80ºC. 
4.2.7.4 Tumour material 
Formalin-fixed, paraffin-embedded tumour and normal material from all colorectal 
cancer patients aged <55yrs at diagnosis was collected.  In addition, matched tumour/ 
normal material was stored for cases aged <55yrs.  
4.2.8 Phenotype data collected 
4.2.8.1 Tumour related parameters, clinical data and treatment 
details 
Tumour related parameters, clinical data and treatment details were extracted from 
medical records by medical students or research nurses trained by the research nurse co-
ordinator. In particular, information on tumour site, histological type, degree of 
differentiation, presence of synchronous or metachronous polyps, co-existent 
inflammatory bowel disease, Charlson co-morbidity index and types of symptoms before 
diagnosis were gained from pathology reports and medical records. In addition details on 
surgery procedure, adjuvant chemotherapy, radiotherapy and/ or palliative treatment 
were extracted from medical records.  
To extract tumour stage details, a Specialist Registrar looked at all the pathology reports. 
However pathology reports of some subjects lacked information regarding metastasis 
status. For those cases, the Specialist Registrar looked at their Computerised 
Tomography (CT) scans (Health boards of: Lothian, Fife) and/ or wrote to the cases 
consultant (hospital) doctors and/ or to the cases GP doctors to get the necessary 
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information. Two systems were used to describe the extent of colorectal cancer in the 
patient bodies:  the Dukes’ and AJCC systems.  
4.2.8.2 Personal, demographic and family history data  
Ethnicity and ancestry data were recorded for all study participants. Demographic data 
were derived directly from participants and NHS clinical notes. Data were also collected 
from central NHS data and held by the Information and Statistics Division of the NHS in 
Scotland.  
In addition, if participants agreed, a three-generation family history was constructed by a 
trained research nurse at recruitment time. Each family history then was assessed 
according to the risk levels published in the Scottish Executive cancer guidelines for 
colorectal cancer.  
4.2.9 Self-administered lifestyle and food frequency 
questionnaires 
Two standard questionnaires (the Lifestyle and Cancer Questionnaire - LCQ and the 
Scottish Collaborative Group Food Frequency Questionnaire - SCG-FFQ) were 
administered gathering data on use of aspirin/ NSAIDs, reproductive history/ hormonal 
factors, occupation, inflammatory bowel disease and on lifestyle characteristics such as 
diet, physical activity, tobacco smoking and alcohol intake. These questionnaires 
consisted of validated instruments used in other studies (i.e. the physical activity section 
was based on a modified version of the standard EPIC questionnaire, the women’s 
reproduction section was based on the Million Women Study questionnaire and for 
measuring dietary intakes the SCG-FFQ was used, which was validated in Scottish 
populations). The reference (exposure) period for both questionnaires was one year prior 
recruitment for controls or one year prior to diagnosis for cases. 
4.2.9.1 Lifestyle and Cancer Questionnaire  
The LCQ was used in order to gather information about the general lifestyle of the 
subjects and the questions were referred in a time period of one year before diagnosis 
(cases) or recruitment (controls). It consisted of 69 questions grouped in 8 categories 
(Medical history, Lifestyle, Physical activity, Height and weight, Medicines, About you, 
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Employment, Women’s health questions) (Table 36: a summarised presentation of the 
LCQ; Appendix III; the LCQ). There was an information sheet enclosed with 
instructions of how to complete the questionnaire and in the last page of it there was 
space to add any comments or concerns. 
4.2.9.2 Scottish Collaborative Group Food Frequency 
Questionnaire 
The FFQ used in this study was the validated SCG-FFQ, Version 6.41, which has been 
based on an FFQ extensively used in Scottish populations (269). It has been validated 
against 4-day weighed diet records (270;271) and against serum phytoestrogen 
concentrations (272). The SCG-FFQ consisted of a list of 150 foods, divided into 20 
food groups (Table 37: a summarised presentation of the FFQ; Appendix IV; the SCG-
FFQ). Subjects were asked to describe the amount and frequency of each food on the list 
they have eaten a year prior to recruitment. Regarding frequency, subjects were asked to 
circle “R” (stands for rarely/ never) for those foods that were eaten either never or less 
than once a month. For foods that were eaten once a month or more, subjects were asked 
to report the amount of food eaten (counted in measures: 1 up to 5+ measures) and the 
number of days per week the food was usually eaten (once a month up to 7 days per 
week). In addition the FFQ included a field that the subjects could use to add other foods 
that were not listed in the FFQ and that they ate regularly (once a month or more often). 
Subjects were also asked to report the type and amount of vitamins, minerals and food 
supplements if taken, recent dietary changes and special diets or dietary restrictions. The 
last part of the FFQ consisted of general questions about the diet of the subjects 
including the amount of meals per day, the times per usual week that had fried or grilled 
meat and how well cooked they normally had their fried or grilled meat (lightly, medium 
or well browned). An FFQ information sheet that included a colour picture showing 
examples of the size of measures was enclosed with the FFQ. 
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Table 36 Lifestyle and Cancer Questionnaire sections and questions  
Group Subgroup LCQ Questions 
Medical History -  1 – 6 
Lifestyle Cigarette smoking 7 – 15 
 Cigar smoking 16 – 20 
 Pipe smoking 21 – 25 
Physical Activity Occupational Physical Activity 26 – 27 
 Leisure Physical Activity 28 – 30 
Height and Weight -  31 – 32 
Medicines Aspirin / Painkillers 33, 35 
 Stomach medicines/tablets 34, 35 
About you Education 36 
 Ethnic Origin 37 
 Ancestry 38 – 44 
Employment - 45 – 54 
Women’s Health Questions Menstrual Periods 55 – 57 
 Hormone Replacement Therapy 58 – 62 
 Reproductive History 63 – 65 
 Hormonal forms of Contraception 66 – 69 
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Table 37 FFQ food groups and other sections 
FFQ Section Food group / Other questions 
1. a – e Breads 
2. a – f Breakfast cereals 
3. a – e Milk 
4. a – e Cream and yoghurt 
5. a – e  Cheese 
6. a – c  Eggs 
7. a – l  Meats 
8. a – l Fish 
9. a – j Potatoes, rice and pasta 
10. a – s  Savoury foods, soups and sauces 
11. a – q  Vegetables 
12. a – j Fruit 
13. a – h Puddings and desserts 
14. a – i  Chocolates, sweets, nuts and crisps 
15. a – g Biscuits 
16. a – e Cakes 
17. a – g Spreads 
18. a – m Beverages and soft drinks 
19. a – h Alcoholic drinks 
20. a – d Other foods and drinks 
21. a – d Vitamin, mineral and food supplements 
22. a – i Dietary restrictions and special diets 
23. a – j Other information 
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4.3 Collection and process of lifestyle and dietary 
data 
This thesis was based on the analysis of the data collected from the self-administered 
environmental exposure questionnaires. In this part of the chapter details about the 
collection, storing and process of the lifestyle and dietary data are presented. 
Of the 3,417 cases that were enrolled in the study: 291 cases were not asked to complete 
the lifestyle and food frequency questionnaires (participants recruited before September 
of 2001; 8.5%), 508 cases refused to complete the questionnaires (14.9%), 2,244 cases 
returned both questionnaires (65.7%), 64 cases returned just one questionnaire (1.9%; 52 
cases returned only the LCQ and 12 cases returned only the FFQ) and 310 cases did not 
return any of the questionnaires (9.1%) (Table 38). 
Of the 3,396 controls that were enrolled in the study: 26 controls were not asked to 
complete the lifestyle and food frequency questionnaires (0.8%), 33 controls refused to 
complete the questionnaires (1.0%), 2,850 controls returned both questionnaires 
(83.9%), 124 controls returned just one questionnaire (3.6%; 105 controls returned only 
the LCQ and 19 controls returned only the FFQ) and 363 controls did not return any of 
the questionnaires (10.7%) (Table 39). Distribution of cases and controls across sex, age, 
health board area of residence and deprivation score was examined according to the 
questionnaire status (not asked, refused, not returned, returned both, returned one) 
(Table 38, Table 39). 
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Table 38 Distribution of cases across sex, age, health board area of residence and deprivation examined according to the questionnaire status 















(one or both) 
p-value 
(returned  
vs. all other) 
Number 291 508 310 2244 64 1109 2308  
Sex         
Males 169 (58.1%)  312 (61.4%) 162 (52.3%) 1277 (56.9%) 38 (59.4%) 643 (58.0%) 1315 (57.0%)  
Females 122 (41.9%) 196 (38.6%) 148 (47.7%) 967 (43.1%) 26 (40.6%) 466 (42.0%) 993 (43.0%) 0.58 





        
Argyll & Clyde 23 (7.9%) 36 (7.1%) 30 (9.7%) 154 (6.9%) 6 (9.4%) 89 (8.0%) 160 (6.9%)  
Ayrshire & Arran 20 (6.9%) 29 (5.7%) 23 (7.4%) 155 (6.9%) 1 (1.6%) 72 (6.5%) 156 (6.8%)  
Borders 2 (0.7%) 6 (1.2%) 6 (1.9%) 81 (3.6%) 2 (3.1%) 14 (1.3%) 83 (3.6%)  
Dumfries & 
Galloway 
9 (3.1%) 12 (2.4%) 6 (1.9%) 72 (3.2%) 3 (4.7%) 27 (2.4%) 75 (3.2%)  
Fife 17 (5.8%) 27 (5.3%) 29 (9.3%) 142 (6.3%) 5 (7.8%) 73 (6.6%) 147 (6.4%)  
Forth Valley 13 (4.5%) 33 (6.5%) 11 (3.5%) 128 (5.7%) 2 (3.1%) 57 (5.1%) 130 (5.6%)  
Grampian 34 (11.7%) 60 (11.8%) 40 (12.9%) 351 (15.6%) 12 (18.7%) 134 (12.1%) 363 (15.7%)  
Greater Glasgow 47 (16.1%) 121 (23.8%) 33 (10.6%) 311 (13.9%) 8 (12.5%) 201 (18.1%) 319 (13.8%)  
Highland 17 (5.8%) 29 (5.7%) 13 (4.2%) 100 (4.5%) 6 (9.4%) 59 (5.3%) 106 (4.6%)  
Lanarkshire 29 (10.0%) 72 (14.2%) 31 (10.0%) 179 (8.0%) 4 (6.2%) 132 (11.9%) 183 (7.9%)  
Lothian 47 (16.1%) 63 (12.4%) 60 (19.3%) 354 (15.8%) 9 (14.1%) 170 (15.3%) 363 (15.7%)  
Orkney 1 (0.3%) 1 (0.2%) 1 (0.3%) 8 (0.4%) 0 (0.0%) 3 (0.3%) 8 (0.3%)  
Shetland 6 (2.1%) 0 (0.0%) 2 (0.6%) 7 (0.3%) 1 (1.6%) 8 (0.7%) 8 (0.3%)  
Tayside 23 (7.9%) 17 (3.3%) 22 (7.1%) 196 (8.7%) 5 (7.8%) 62 (5.6%) 201 (8.7%)  
Western Isles 1 (0.3%) 2 (0.4%) 3 (1.0%) 6 (0.3%) 0 (0.0%) 6 (0.5%) 6 (0.3%)  
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Not recorded 2 (0.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.2%) 0 (0.0%) <0.0005 
Deprivation 
score 
        
1 27 (9.3%) 30 (5.9%) 22 (7.1%) 206 (9.2%) 2 (3.1%) 79 (7.1%) 208 (9.0%)  
2 32 (11.0%) 84 (16.5%) 65 (21.0%) 463 (20.6%) 13 (20.3%) 181 (16.3%) 476 (20.6%)  
3 73 (25.1%) 105 (20.7%) 85 (27.4%) 578 (25.8%) 19 (29.7%) 263 (23.7%) 597 (25.9%)  
4 72 (24.7%) 141 (27.7%) 81 (26.1%) 523 (23.3%) 11 (17.2%) 294 (26.5%) 534 (23.1%)  
5 33 (11.3%) 61 (12.0%) 34 (11.0%) 247 (11.0%) 14 (21.9%) 128 (11.5%) 261 (11.3%)  
6 30 (10.3%) 52 (10.2%) 11 (3.5%) 159 (7.1%) 3 (4.7%) 93 (8.4%) 162 (7.0%)  
7 22 (7.6%) 35 (6.9%) 12 (3.9%) 66 (2.9%) 2 (3.1%) 69 (6.2%) 68 (2.9%)  
Not recorded 2 (0.7%) 0 (0.0%) 0 (0.0%) 2 (0.1%) 0 (0.0%) 2 (0.2%) 2 (0.1%) <0.0005 
 
Table 39 Distribution of controls across sex, age, health board area of residence and deprivation examined according to the questionnaire status 
Controls Not asked 
 











(one or both) 
p-value  
returned 
vs. all other) 
Number 26 33 363 2850 124 422 2974  
Sex         
Males 17 (65.4%) 20 (60.6%) 186 (51.2%) 1617 (56.7%) 68 (54.8%) 223 (52.8%) 1685 (56.7%)  
Females 9 (34.6%) 13 (39.4%) 177 (48.8%) 1233 (43.3%) 56 (45.2%) 199 (47.2%) 1289 (43.3%) 0.14 





        
Argyll & Clyde 2 (7.7%) 1 (3.0%) 31 (8.5%) 182 (6.4%) 8 (6.4%) 34 (8.1%) 190 (6.4%)  
Ayrshire & Arran 5 (19.2%) 1 (3.0%) 25 (6.9%) 197 (6.9%) 5 (4.0%) 31 (7.3%) 202 (6.8%)  
Borders 1 (3.8%) 1 (3.0%) 11 (3.0%) 93 (3.3%) 5 (4.0%) 13 (3.1%) 98 (3.3%)  




2 (7.7%) 0 (0.0%) 9 (2.5%) 114 (4.0%) 7 (5.6%) 11 (2.6%) 121 (4.1%)  
Fife 3 (11.5%) 5 (15.1%) 33 (9.1%) 181 (6.3%) 14 (11.3%) 41 (9.7%) 195 (6.6%)  
Forth Valley 0 (0.0%) 0 (0.0%) 10 (2.7%) 171 (6.0%) 6 (4.8%) 10 (2.4%) 177 (5.9%)  
Grampian 2 (7.7%) 9 (27.3%) 51 (14.0%) 458 (16.1%) 20 (16.1%) 62 (14.7%) 478 (16.1%)  
Greater 
Glasgow 
2 (7.7%) 3 (9.1%) 39 (10.7%) 362 (12.7%) 10 (8.1%) 44 (10.4%) 372 (12.5%)  
Highland 1 (3.8%) 2 (6.1%) 26 (7.2%) 159 (5.6%) 7 (5.6%) 29 (6.9%) 166 (5.6%)  
Lanarkshire 2 (7.7%) 3 (9.1%) 23 (6.3%) 219 (7.7%) 8 (6.4%) 28 (6.6%) 227 (7.6%)  
Lothian 2 (7.7%) 6 (18.2%) 70 (19.3%) 469 (16.5%) 21 (16.9%) 78 (14.5%) 490 (16.5%)  
Orkney 0 (0.0%) 1 (3.0%) 0 (0.0%) 13 (0.5%) 0 (0.0%) 1 (0.2%) 13 (0.4%)  
Shetland 0 (0.0%) 0 (0.0%) 1 (0.3%) 11 (0.4%) 1 (0.8%) 1 (0.2%) 12 (0.4%)  
Tayside 4 (15.4%) 1 (3.0%) 33 (9.1%) 215 (7.5%) 11 (8.9%) 38 (9.0%) 226 (7.6%)  
Western Isles 0 (0.0%) 0 (0.0%) 1 (0.3%) 6 (0.2%) 1 (0.8%) 1 (0.2%) 7 (0.2%)  
Not recorded 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.05 
Deprivation 
score 
        
1 3 (11.5%) 2 (6.1%) 38 (10.5%) 263 (9.2%) 12 (9.7%) 43 (10.2%) 275 (9.2%)  
2 4 (15.4%) 5 (15.1%) 70 (19.3%) 577 (20.2%) 30 (24.2%) 79 (18.7%) 607 (20.4%)  
3 5 (19.2%) 10 (30.3%) 94 (25.9%) 782 (27.4%) 32 (25.8%) 109 (25.8%) 814 (27.4%)  
4 8 (30.8%) 9 (27.3%) 82 (22.6%) 666 (23.4%) 29 (23.4%) 99 (23.5%) 695 (23.4%)  
5 3 (11.5%) 2 (6.1%) 47 (12.9%) 300 (10.5%) 13 (10.5%) 52 (12.3%) 313 (10.5%)  
6 3 (11.5%) 2 (6.1%) 25 (6.9%) 182 (6.4%) 6 (4.8%) 30 (7.1%) 188 (6.3%)  
7 0 (0.0%) 3 (9.1%) 7 (1.9%) 80 (2.8%) 2 (1.6%) 10 (2.4%) 82 (2.8%) 0.83 
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4.3.1 Pre-entering (LCQ) or pre-scan (FFQ) review process 
A protocol was set up to review the returned questionnaires. In the main database of the 
study a field was set up to record the status of the questionnaires (returned: no/ yes). 
When the questionnaires returned to the study office, it was recorded in the main 
database (returned: yes), the sex of the subject was written at the top of the LCQ and 
they were passed to the project co-ordinator (from 01/02/1999 to 15/01/2005) or to the 
author (from 16/01/2005 to 31/12/2006) for checking for any blanks, missed questions 
or mistakes. If only one questionnaire was returned (either the LCQ or the FFQ) this was 
noted on the top of the returned questionnaire and it was recorded in the field of the 
main database (returned: yes).  
4.3.1.1 Lifestyle and Cancer Questionnaire 
If there were any blanks, missed questions or mistakes in the LCQ, then it was sent back 
to the subject for corrections and the new corrected version was used. If the 
questionnaire sent for corrections was not back within three months then the uncorrected 
version was used. The pre-enter review checklist is presented in Box 1. After the pre-
enter review the original or corrected LCQs were entered manually in the Lifestyle and 
Cancer database and the hard-copies were stored in filing cabinets according to their 
status (cases or population controls) and in numerical order. 
4.3.1.2 Food frequency questionnaire  
The FFQs pre-scan review was done using the FFQ review checklist (Box 2) to ensure 
that the FFQ was complete and ready to be scanned. For any queries regarding the 
“Spreads” and “Other Foods” sections the FFQ queries database was developed. In this 
database any queries on other foods and odd spreads or fats were stored. With the 
guidance of Dr Geraldine McNeill (University of Aberdeen) the “Extra Fats” guidelines 
and the “Other Foods” guidelines were developed and the latter queries were answered. 
After the pre-scan review the original or corrected FFQs were scanned using a multi-
page scanner and the software scanning package TELEForm. Once the FFQs had been 
scanned, the scanning procedure was verified using the TELEForm Verifier. In 
particular, it was checked whether the FFQ data had been correctly scanned and read, 
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that open answer questions were correctly identified and that the chosen values for 
multiple response answers were correctly recognised. The FFQ data were then 
automatically exported and saved to an SPSS file and the hard-copies were stored in 
filing cabinets according to their status (cases or controls) and in numerical order.   
 
Box 1: LCQ pre-enter review checklist 
Data checks • The whole questionnaire was checked to see if blank. 
• If there were any questions, where there were major parts not filled in or two or 
more conflicting options had been reported the questionnaire was sent back. 
• If there was a need to decide on conflicting answers, the first part was taken as the 
correct one. 
• If there was more than one dates entered the earliest one was used. 
• Physical activity section (Q28):  
- The items of this question form a score so if there were any missing parts, the 
questionnaire was sent back to the subject. 
- If a range instead of an absolute value was given, the average was taken. 
•  Height and weight (Q31 and Q32a): If a range instead of an absolute value was 
given, the average was taken. 
• Waist measurement: If no waist measurement was given the clothing size was 
asked and the waist measurement was calculated from a clothing guide. 
• Medicine section (Q33-Q35): 
- If Q33a was YES and nothing ticked at Q33b it meant that participants did not 
take any medicines for at least 4 days a week for at least a month. 
- Any medicines ticked at Q33b and Q34b were checked that they were listed at 
Q35. 
- Number of months taken for a medicine was calculated if participants were no 
longer taking the medicine and it was left blank if they were still taking it. 
• Employment section (Q45-54): 
- If this section was completely blank the questionnaire was sent back for 
clarification. 
- Often self-employed people with no employees said that 0 people worked at their 
work, which was corrected to 1-9 employees. 
• Female section (Q55-Q69): 
- The female part of the LCQ was checked to see whether it was blank for male 
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subjects and completed for female subjects.   
- If the whole section was blank (and the questionnaire was filled in by a female 
subject) the questionnaire was sent back to the subject 
- It was checked that for each birth given in Q64 a record was entered in Q65 
Filling of LCQs • After manually entering, the LCQs were stored in filing cabinets according to their 
status (cases or population controls) and in numerical order. 
 
Box 2: FFQ pre-scan review checklist  
Data checks • The whole questionnaire was checked to see if it was blank. 
• For the questions 1 to 18 the following checks were done:  
- Number of blank lines: For up to 10 blank lines (both “measures per day” and 
“number of days per week” were blank) the questionnaire was not returned for 
completion. 
- Number of missing “measures per day”: For up to 10 missing “measures per day” 
the questionnaire was not returned for completion. 
- Number of missing “days per week”: For up to 10 missing “days per week” the 
questionnaire was not returned for completion. 
- If M (monthly) was circled together with a number of days per week then: if it was 
M and 1, 2 or 3 the number was just crossed out. If it was M and 4, 5, 6 or 7 the M 
and the number were crossed out and 1 for once a week was circled. 
- If R (rarely) was circled together with a number for the “measure per day”, the 
number was crossed out leaving the R alone. 
- If the subject had circled M plus days or R plus measures all the way through, then 
the questionnaire was sent back for clarification. 
• In the dietary restrictions section we checked if anything not eaten did not 
correspond with the questions 1 to 18 and that all the fields were answered. 
Coding • Questions 17.e and 17.g were open-ended questions relating to the spreads, fats 
and oil consumed. Codes were entered onto the FFQ according to the type of 
spread/ fat/ oil. Queries were entered in the FFQ queries database and were 
checked with Dr G McNeill.  
Other foods • Section 20 allowed subjects to record foods and drinks that were not included in 
the FFQ and that they regularly ate. If the subject had reported any other food we 
did as follows: 
- We checked if the food could be easily entered in the FFQ and if so we did that by 
consulting the Other Food guidance and the FFQ queries database. 
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- Some foods could be ignored (e.g. if less than once a week) and in that case we 
just scored out the food. 
- If guidance had a code listed for that particular food, then we wrote the details of 
this questionnaire (ID, food type, portion, “measures per day “and” days per week) 
in the FFQ other food database. 
- Finally, if the food was not listed and we didn’t know how to deal with it, we 
added its details to the FFQ queries database and it was sent to Dr G McNeill for 
clarification. 
ID number • ID was written in the top right hand corner of each FFQ page. 
Filling of FFQs • After scanning and verifying, the FFQs were stored in filing cabinets according to 
their status (cases or controls) and in numerical order. 
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4.3.2 Quality checking of data entry 
A quality checking protocol and quality checking databases were developed for all data 
entry of the environmental questionnaires and it was applied on a regular basis by the 
project co-ordinator (from 01/02/1999 to 15/01/2005) or by the author (from 16/01/2005 
to 31/12/2006). This generally involved looking at 1 in 20 questionnaires and checking 
that they had been entered correctly. The quality checking procedure was recorded on a 
separate sheet for each database, noting the number of errors. Any errors found were 
corrected on the original databases.  
4.3.3 Coding of the LCQ variables 
2,296 and 2,955 LCQs were received from cases and controls respectively. Six cases 
(0.3%) and nine controls (0.3%) sent blank LCQs and could not be used in the analysis. 
In addition 13 controls (0.4%) were removed. These controls were given the same IDs 
with 13 withdrawn controls. However, it was not possible to distinguish whether the 
questionnaires were from the newly recruited or from the withdrawn controls and 
therefore they were not included in the analysis. The final number of LCQs that could be 
analysed was 2,290 for the cases and 2,933 for the controls. After the entering procedure 
of the data and the quality checking of it, the LCQ data were processed to form the 
variables used in the analysis (Table 40).  
 
Table 40 List of variables coded from the LCQ 
Category Variables 
Smoking Smoking Status; Level of smoking; Duration of smoking; Pack-years of 
smoking (see Table 41) 
Physical Activity Occupational Physical Activity; Leisure time Physical Activity 
(recreational, household and stair climbing variables); Total Physical 
Activity index (see Table 45); Cambridge Physical Activity index (see 
Table 46); Limited Physical Activity (see Table 47) 
Medicines Mini-aspirin intake; Non steroidal anti-inflammatory drugs intake; 
Painkillers intake; Stomach tablets intake; Dose of intake (for mini 
aspirin); Duration of intake (see Table 48) 
Women’s Health  Hormone replacement intake; Hormonal forms of contraceptives (see 
Table 49)
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4.3.3.1 Smoking variables 
The smoking variables were coded using information from the lifestyle section of the 
LCQ (questions 7 to 25). Smoking status variable was coded using information from 
questions 7, 9, 16, 18, 21 and 23. Subjects that had never smoked regularly cigarettes (at 
least one per day), cigars (at least one per month) or a pipe were considered as “never 
smokers”. Subjects that had used to smoke regularly cigarettes, cigars or a pipe, but 
quitted at least one year prior to recruitment were considered as “former smokers”. 
Subjects that smoked regularly cigarettes, cigars or a pipe were considered as “current 
smokers” (Table 41).    
The other three smoking variables (level, duration and pack-years of smoking) were 
based only on the smoking cigarettes questions (questions 7 to 15) and they were 
available for “current” and “former” smokers (Table 41). “Level of smoking” variable 
was about the quantity of cigarettes smoked per day and “Duration of smoking” variable 
was about the total years of smoking. “Pack-years of smoking” variable was coded 
combining information for both the quantity and duration of smoking using the 
following formula:    
 Pack-years of smoking = (n x y) / 20,  
Where n was the number of cigarettes smoked per day and y was the number of years of 
smoking (Table 41). 
 
Table 41 Smoking variables 
Smoking variables   
All subjects Cases (n=2290) Controls (n=2933) 
Smoking Status   
 Never 965 (42.1%) 1261 (43.0%) 
 Former 884 (38.6%) 1110 (37.8%) 
 Current 394 (17.1%) 537 (18.3%) 
 Missing 47 (2.0%) 25 (0.8%) 
Current smokers Cases (n=342) Controls (n=467) 
Level of smoking    
 0-10 43 (12.6%) 78 (16.7%) 
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 10-20 127 (37.1%) 182 (39.0%) 
 ≥ 20 163 (47.7%) 203 (43.5%) 
 missing 9 (2.6%) 4 (0.9%) 
Duration of smoking   
 0-15 7 (2.0%) 6 (1.3%) 
 15-30 42 (12.3%) 57 (12.2%) 
 ≥ 30 291 (85.1%) 404 (86.5%) 
 missing 2 (0.6%) 0 (0.0%) 
Pack-years of smoking   
 0-10 25 (7.3%) 39 (8.3%) 
 10-20 46 (13.4%) 77 (16.5%) 
 ≥ 20 261 (76.3%) 347 (74.3%) 
 missing 10 (2.9%) 4 (0.9%) 
Former smokers Cases (n=900) Controls (n=1127) 
Level of smoking   
 0-10 116 (12.9%) 165 (14.6%) 
 10-20 308 (34.2%) 385 (34.2%) 
 ≥ 20 458 (50.9%) 563 (50.0%) 
 missing 18 (2.0%) 14 (1.2%) 
Duration of smoking   
 0-15 184 (20.4%) 294 (26.1%) 
 15-30 339 (37.7%) 400 (35.5%) 
 ≥ 30 350 (38.9%) 411 (36.5%) 
 missing 27 (3.0%) 22 (36.5%) 
Pack-years of smoking   
 0-10 221 (24.6%) 315 (27.9%) 
 10-20 180 (20.0%) 260 (23.1%) 
 ≥ 20 465 (51.7%) 523 (46.4%) 
 missing 33 (3.7%) 29 (2.6%) 
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4.3.3.2 Physical activity variables 
The physical activity part of the LCQ was the short version of the EPIC core physical 
activity questionnaire and we used their protocol for coding the variables. The four EPIC 
physical activity questions referred to activity for the year prior to diagnosis or 
recruitment. The first question was about the occupational physical activity and it had 
two parts:  1) a binary part asking for the occupation status a year prior to the 
recruitment (q26) and 2) a four-points, mutually-exclusive, ordered part concerning the 
intensity of the physical activity at work (q27). The way that the questionnaire was 
designed only the participants that were currently working, were asked about the type of 
their job. Therefore, participants that were either unemployed or retired (for at least one 
year prior to recruitment) did not report their physical activity at work. 
The second question (recreational physical activities) asked about the amount of time 
spent (in hours per week) in each of the following activities: walking (separately for 
summer and winter), cycling (separately for summer and winter), gardening (separately 
for summer and winter), do-it-yourself activities, physical exercise (separately for 
summer and winter) and housework (q28). The third question asked whether any of the 
activities in question 28 were engaged in such that it caused sweating or faster heartbeat 
and if so, for how many hours during a typical week (q29). Finally, the fourth question 
asked about the amount of flights of stairs climbed per day (q30). 
To be able to assess the impact of the physical activity as a whole, it was necessary to 
combine occupational data with the recreational, household, vigorous activity and flights 
of stair climbing data. We did that by using two different indexes; the Total Physical 
Activity index (developed by the EPIC study group) and the Cambridge Physical 
Activity index (developed by the Cambridge group of the EPIC study). The first index is 
a cross tabulation table of the occupational physical activity and a summary variable of 
the household, recreational and stair climbing physical activities. The second index 
combines the occupational physical activity with two measurements of the recreational 
physical activity: cycling and physical exercise. In addition, we applied a limited 
physical activity measurement taking into account only two recreational physical 
activities. 




Occupational physical activity 
To assess the physical activity at work a six-level categorical variable was created 
(“Occupational physical activity”): 1) sedentary occupation, 2) standing occupation, 3) 
manual work, 4) heavy manual work, 5) unemployed (included participants that reported 
not to have done any type of work a year prior to recruitment), 6) missing (Table 42). A 
limitation of the occupational part of the physical activity questionnaire was that the 
retired participants were misclassified as unemployed and their occupational physical 
activity was not reported. Therefore 48% of the cases and 47% of the controls were 
classified as unemployed (Table 42).  
Leisure time physical activity 
Regarding the leisure time physical activity 12 variables were available: 1) Walking in 
summer (hours/week), 2) walking in winter (hours/week), 3) cycling in summer 
(hours/week), 4) cycling in winter (hours/week), 5) gardening in summer (hours/week), 
6) gardening in winter (hours/week), 7) doing sports in summer (hours/week), 8) doing 
sports in winter (hours/week), 9) housework (hours/week), 10) Do-It-Yourself (DIY) 
activities (hours/week), 11) engaging in vigorous activities (hours/week) and 12) number 
of flights of stairs climbed per day. Reasonable maximum gender-specific cut-off points 
were set for each activity and values above those maxima were deleted (Table 43). 
To estimate the intensity of the leisure time physical activity, the hours per week of each 
activity were multiplied with a specific metabolic equivalent (MET) value. A MET is 
defined as the ratio of the metabolic rate for a specific activity compared to the resting 
metabolic rate. The MET values used were abstracted from the Compendium of Physical 
Activities (273) and were: 3.0 for walking, 6.0 for cycling, 4.0 for gardening, 6.0 for 
sports, 4.5 for DIY activities, 3.0 for housework and 9.0 for vigorous activities. To 
convert the flights of stairs into a MET-hour/week variable we used the following 
formula (taken from the EPIC protocol): 
20 steps/flight * 1min/72 steps * 1hr/60min * #flights/day * 8 METS * 7 days/week  
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Means for all those variables that had been reported separately for summer and winter 
were created and finally by adding all the METS-hours/week variables of the leisure 
time, the summary variable “Leisure time physical activity” was created (Table 44). 
Total Physical Activity index was the sum of “Occupational activity” and “Leisure time 
physical activity” (Table 45). Cambridge Physical Activity index was the sum of 
“Occupational activity” and two recreational physical activities (cycling and doing 
sports) (Table 46). Finally, for the third measurement of the physical activity only the 
“cycling” and “doing sports” recreational physical activities were used and the 
“Occupational activity” was not included. In Table 47 the distribution of the study 
participants according to the three different physical activity measurements is presented. 
 
Table 42 Occupational physical activity 
Occupational physical activity Cases (n=2290) Controls (n=2933) 
Sedentary occupation 454 (19.8%) 625 (21.3%)  
Standing occupation 350 (15.3%) 462 (15.7%) 
Manual work 266 (11.6%) 351 (12.0%) 
Heavy manual work 83 (3.6%) 72 (2.4%) 
Unemployed (including retired) 1103 (48.2%) 1389 (47.4%) 
Missing 34 (1.5%) 34 (1.2%) 
 




(hours per week) 
Men   Women  Subjects 
with missing 
data (%) 
Subjects  with 
values above 









Cases (n=2290)       
Walking- summer 9 (4-16) 55 10 (5-15) 55 49 (2.1%) 38 (1.7%) 
Walking- winter 7 (3-12) 50 7 (4-12) 50 56 (2.4%) 28 (1.2%) 
Cycling- summer 0 (0-0) 20 0 (0-0) 20 146 (6.4%) 0 (0.0%) 
Cycling- winter 0 (0-0) 15 0 (0-0) 15 157 (6.8%) 1 (0.0%) 
Gardening- summer 4 (1-8) 35 3 (0-7) 30 58 (2.5%) 18 (0.8%) 
Gardening- winter 0 (0-2) 30 0 (0-1) 25 97 (4.2%) 3 (0.1%) 
Doing sports- summer 0 (0-2) 30 0 (0-2) 30 100 (4.4%) 2 (0.1%) 
Doing sports- winter 0 (0-2) 25 0 (0-2) 25 108 (4.7%) 2 (0.1%) 
Housework 3 (0-7) 30 15 (10-25) 70 65 (2.8%) 23 (1.0%) 
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DIY activities 2 (0-4) 30 0 (0-1) 30 120 (5.2%) 10 (0.4%) 
Flights of stairs 6 (2-10) 50 5 (1-10) 50 66 (2.9%) 22 (1.0%) 
Vigorous activities 4 (2-10) 40 4 (2-8) 40 50 (2.2%) 11 (0.5%) 
Controls (n=2933)       
Walking- summer 10 (5-15) 55 8 (4-14) 55 41 (1.4%) 33 (1.1%) 
Walking- winter 7 (3-12) 50 6 (3-12) 50 48 (1.6%) 24 (0.8%) 
Cycling- summer 0 (0-0) 20 0 (0-0) 20 60 (2.0%) 2 (0.1%) 
Cycling- winter 0 (0-0) 15 0 (0-0) 15 80 (2.7%) 0 (0.0%) 
Gardening- summer 3 (1-8) 35 3 (0-7) 30 15 (0.5%) 23 (0. 8%) 
Gardening- winter 0 (0-2) 30 0 (0-1) 25 48 (1.6%) 3 (0.1%) 
Doing sports- summer 0 (0-2) 30 0 (0-3) 30 42 (1.4%) 5 (0.2%) 
Doing sports- winter 0 (0-2) 25 0 (0-2) 25 58 (2.0%) 11 (0.4%) 
Housework 3 (1-8) 30 15 (8-25) 70 37 (1.3%) 39 (1.3%) 
DIY activities 2 (0-4) 30 0 (0-1) 30 58 (2.0%)  18 (0.6%) 
Flights of stairs 6 (1-10) 50 5 (1-10) 50 49 (1.7%) 44 (1.5%) 
Vigorous activities 4 (2-8) 40 4 (2-7) 40 58 (2.0%) 12 (0.4%) 
 
Table 44 Leisure time physical activity 
Leisure time physical activity 
(Met-hours/week) 
Cases (n=2290) Controls (n=2933) 
≤61.30 498 (21.7%) 617 (21.0%)  
61.30 to 101.59 460 (20.1%) 656 (22.4%) 
101.59 to 159.89 474 (20.7%) 636 (21.7%) 
>159.89 477 (20.8%) 636 (21.7%) 
Missing 381 (16.6%) 388 (13.2%) 
 
Table 45 Total Physical Activity Index (according to the reported occupational, recreational, 
household vigorous and stair climbing activities) 
Occupational 
activity  





(61.30 to 101.57) 
High 
(101.57 to 159.89) 
Very high 
(>159.89) 
Sedentary Inactive Inactive Moderately inactive Moderately active 
Standing Moderately inactive Moderately inactive Moderately active Active 
Manual Moderately active Moderately active Active Active 
Heavy manual Moderately active Moderately active Active Active 
Unemployed Moderately inactive Moderately inactive Moderately active Moderately active 
Unknown/ Missing Inactive Moderately inactive Moderately inactive Moderately active 
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Table 46 Cambridge Physical Activity Index (according to the reported occupational physical 
activity and two recreational physical activities: cycling and doing sports) 
Occupational 
activity  
Cycling and doing sports (hours/week) 
 Low (0) Medium (0 to 3.5) High (3.5 to 7) Very high (≥7) 
Sedentary Inactive Moderately inactive Moderately active Active 
Standing Moderately inactive Moderately active Active Active 
Manual Moderately active Active Active Active 
Heavy manual Active Active Active Active 
 
Table 47 Distribution of study participants according to the Total Physical Activity Index, the 
Cambridge Physical Activity Index and the limited physical activity measurement 
Physical activity Cases (n=2290) Controls (n=2933) 
Total Physical Activity Index   
Inactive 267 (11.7%) 344 (11.7%)  
Moderately inactive 696 (30.4%) 928 (31.6%) 
Moderately active 695 (30.3%) 963 (32.8%) 
Active 251 (11.0%) 310 (10.6%) 
Missing 381 (16.6%) 388 (13.2%) 
Cambridge Physical Activity Index   
Inactive 220 (9.6%)  259 (8.8%) 
Moderately inactive 295 (12.9%) 436 (14.9%) 
Moderately active 295 (12.9%) 419 (14.3%) 
Active 287 (12.5%) 348 (11.9%) 
Missing 1193 (52.1%) 1471 (50.1%) 
Limited physical activity measurement 
(hours/ week of cycling and sports) 
  
0 hours/week 1233 (53.8%) 1540 (52.5%) 
0-3.5 hours/week 518 (22.6%) 727 (24.8%) 
3.5-7 hours/week 216 (9.4%) 356 (12.1%) 
>7 hours/week 145 (6.3%) 198 (6.7%) 
missing 178 (7.8%) 112 (3.8%) 
Chapter four  Methods 
 178 
4.3.3.3 Consumption of analgesics (including aspirin and NSAIDs) 
Information on the use of mini aspirin, NSAIDs and painkillers was ascertained by
 
asking participants the following questions: "Up until a year ago, had you ever taken 
aspirin or other painkillers?" (q33a) and “Up until a year ago, had you ever taken any of 
the following medicines or tablets for at least 4 days per week for at least one month?” 
(q33b). In particular, subjects were asked to give information for the following 
medicines or tablets: mini-dose aspirin (75mg), normal-dose aspirin (325mg), 
aceclofenac, diclofenac sodium, diclofenac sodium with misoprostol, etodolac, 
ibuprofen, ibuprofen + codeine phosphate, indomethacin, mefenamic acid, meloxicam, 
nabumetone, naproxen, piroxicam, rofecoxib and any other NSAIDs or painkillers that 
were not included in the list. Individuals who reported regular drug use (for at least 4 
days per week for at least one month) were asked to give further information regarding 
the started taking date, the total number of months taken and the number of days per 
week taken (q35). Medicine information was available for 2,279 cases (99.5%) and 
2,911 (99.2%) controls and was entered in a separate Access database (Drugs database). 
In Table 48 the distribution of study participants according to their medicine intake is 
shown.  
 
Table 48 Distribution of study participants according to intake of medicines 
Categories Cases (n=2290) Controls (n=2933) 
No
*
 1602 (70.0%) 1854 (63.2%) 
Mini aspirin
†
 354 (15.5%) 527 (18.0%) 
Normal aspirin
‡
 16 (0.7%) 19 (0.6%) 
NSAIDs
§
 241 (10.5%) 385 (13.1%) 
NSAIDs and mini aspirin
**
 53 (2.3%) 115 (3.9%) 
NSAIDs and normal aspirin
††
 13 (0.6%) 11 (0.4%) 
Missing 11 (0.5%) 22 (0.7%) 
                                               
* Subjects with no intake of mini aspirin, normal aspirin and other NSAID drugs 
† Subjects that only take mini aspirin (excluding subjects that additionally take any other NSAIDs) 
‡ Subjects that only take normal aspirin (excluding subjects that additionally take any other NSAIDs) 
§ Subjects that only take NSAIDs (excluding subjects that additionally take mini aspirin) 
** Subjects that take both mini aspirin and other NSAIDs  
†† Subjects that take both normal aspirin and other NSAIDs 
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4.3.3.4 Women’s health variables 
Female information was ascertained from the women’s health part of the LCQ 
(questions 55 to 69). 2,259 female participants completed a LCQ and 2,255 of them 
completed the female section of it (99.8%). We mainly used information regarding the 
menstrual, hormonal replacement therapy (HRT) and oral contraception intake status. 
The distribution of female cases and controls for these variables is shown in Table 49. 
 
Table 49 Distribution of female study participants along the women’s health part questions 
Women’s health part Cases (n=987) Controls (n=1272) 
Menstrual status   
 Post-menopausal 751 (76.10%) 961 (75.5%) 
 Pre- / peri-menopausal 224 (22.7%) 292 (23.0%) 
 Missing 12 (1.2%) 19 (1.5%) 
Hormonal replacement therapy   
 Ever had 240 (24.3%) 421 (33.1%) 
 Never had 731 (74.1%) 840 (66.0%) 
 Missing 16 (1.6%) 11 (0.9%) 
Hormonal replacement therapy (for the subjects 
that reported to have had HRT) 
  
 Were on a year prior to recruitment 108 190 
 Were not on a year prior to recruitment 128 230 
 Missing 4 1 
Oral contraception   
 Ever used 404 (40.9%) 586 (46.1%) 
 Never used 556 (56.3%) 659 (51.8%) 
 Don’t remember 4 (0.4%) 3 (0.2%) 
 Missing 23 (2.3%) 24 (1.9%) 
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4.3.3.5 Body Mass Index  
Body Mass Index (BMI) was calculated using information from questions 31 and 32 and 
by applying the following formula: 
BMI = weight (in kilograms) / height
2 
(in metres) 
Height information was available for 2,272 cases (99.2%) and 2,918 controls (99.5%). 
Weight information was available for 2,265 cases (98.9%) and 2,899 controls (98.8%). 
Two cases and one control were further removed due to reporting extreme values of 
either height (3.39 and 0.58 metres) or weight (886.2 kilos). In addition subjects that had 
either missing height or missing weight data could not be included in the BMI 
calculation. Finally, BMI was calculated for 2,257 cases (98.6%) and 2,894 controls 
(98.7%). BMI categories were selected according to WHO recommendations: under-
weight (<18.5), average (18.5 – 24.99), over-weight (25-30), and obese (≥ 30) and the 
distributions of cases and controls are shown in Table 50.  
 
Table 50 Distribution of study participants in BMI categories 
BMI (kg/m
2
) Cases (n=2290) Controls (n=2933) 
Mean (SD) 26.7 (4.4) 26.7 (4.6) 
BMI categories   
18.5 – 24.99 (normal weight) 856 (37.4%) 1056 (36.0%) 
<18.5 (under-weight) 24 (1.0%) 42 (1.4%) 
25-30 (over-weight) 949 (41.4%) 1240 (42.3%) 
≥ 30 (obese) 428 (18.7%) 556 (19.0%) 
Missing 33 (1.4%) 39 (1.3%) 
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4.3.4 Coding of the FFQ variables 
2,256 and 2,851 FFQs were received from cases and controls respectively. 
Questionnaires that had blank values and/or blank lines were processed as described in 
the missing values protocol (Box 3). 241 questionnaires did not fulfil the missing values 
criteria (183 from cases (8.1%) and 58 from controls (2.0%)) and therefore 2,073 cases 
and 2,793 controls had valid FFQs for further analysis. After elaborating the FFQ data, 
two types of results were obtained: 1) nutrient and mineral intakes and 2) food item and 
food group intakes.  
4.3.4.1 Nutrient intake calculations 
Intakes of dietary energy, macro- and micro-nutrients were calculated using UK 
National Nutrient Databank, based on “McCance and Widdowson’s, The Composition 
of Foods (5
th
 edition)” and related supplements. Flavonoid data for the subgroups of 
flavones, flavonols, flavan3ols, procyanidins and flavanones and also for the individual 
flavonoid compounds quercetin, kaempferol, myricetin, apigenin, luteolin, catechin, 
epicatechin, epigallocatechin, epicatechin-3 gallate, epigallocatechin-3 gallate, 
gallocatechin, naringenin and hesperetin were obtained from a nutrient database for 
flavonoids developed by Kyle & Duthie (274). Phytoestrogen values were derived from 
a database developed by Ritchie (275). Finally, specific fatty acid data (including total 
FAs, SFAs, MUFAs, PUFAs, ω6PUFAs, ω3PUFAs, tFAs and tMUFAs, palmitic acid, 
stearic acid, oleic acid, linoleic acid, γ-linolenic acid, arachidonic acid, α-linolenic acid, 
EPA and DHA) were obtained from both the UK food composition tables (McCance and 
Widdowson’s The Composition of Foods, 6th summary edition) and the FOODBASE 
database (London, Institute of Brain Chemistry), a nutrient database for fatty acids. 
Although FOODBASE database contained some errors, all values were manually 
checked and corrected from the team of the University of Aberdeen.  
Fixed ascii files (DAT files) were created from the saved SPSS scanned FFQs and sent 
to the University of Aberdeen for nutrient calculation. In University of Aberdeen, data 
were stored in an SQL Server database and then a programme written in MS Access 
(2000) was used to access and prepare the data. The nutrient analysis was performed 
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using the software Visual Basic for Applications (VBA). The nutrient intakes were 
calculated in three different levels (nutrients per day, nutrients per food group per day, 
nutrients per food per day), except for the specific fatty acid intakes, which were 
calculated in two levels (nutrients per day, nutrients per food group per day). Nutrient 
calculations were performed as described in Box 3. When data were received back from 
University of Aberdeen, they were saved in four different Access databases (intakes of 
dietary energy, macro- and micro-nutrients, intakes of flavonoids and phytoestrogens, 
intakes of fatty acid subgroups and intakes of specific fatty acids). The lists of calculated 
nutrients are presented in Table 51, Table 52 and Table 53. 
 
 Box 3: Protocol for handling missing data for nutrient and food group daily intake calculations 
Less than 10 blanks: 
- When the variable “measures per day” was blank, but the variable “number of days 
per week” had a value (either M or a number), a default value of 1 was assigned to 
substitute the missing value. 
- When the variable “number of days per week” was blank but the variable “measures 
per day” had a value, a default value of 1 was assigned to substitute the missing 
value. 
- When a whole line was blank (both the “measures per day” and the “number of days 
per week”) then the intake of this particular food from this individual was assumed 
to be either null or rare and therefore, the value R was assigned to the variable 
“number of days per week”.  
More than 10 blanks: 
- When a questionnaire that was sent back to the subject because it had more than 10 
blanks (“measures per day”, or “number of days per week”, or lines) was returned 
with no changes/ additions then it was rejected and not used for the nutrient 
calculation.  
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Table 51 List of macro- and micro-nutrient intakes from the SCG-FFQ 
Nutrient Units 
Water g/day 
Dietary energy intake kcal/day 




Saturated fat g/day 
Monounsaturated fat g/day 
Polyunsaturated fat g/day 
Cholesterol mg/day 
















Carotene equivalent µg/day 
Vitamin D µg/day 
Vitamin E mg/day 
Thiamine mg/day 
Vitamin B2 mg/day 
Niacin mg/day 
Potential niacin (from tryptophan) mg/day 
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Vitamin B6 mg/day 
vitamin B12 µg/day 
Folic acid µg/day 
Pantothenic acid mg/day 
Biotin µg/day 
Vitamin C mg/day 
Alcohol g/day 
 
Table 52 List of flavonoids and phytoestrogens estimated from the SCG-FFQ 
Nutrient Units 
Flavonols mg/day 
 Quercetin mg/day 
 Kaempferol mg/day 
 Myricetin mg/day 
Flavones  mg/day 
 Apigenin mg/day 
 Luteolin mg/day 
Flavan3ols  mg/day 
 Epigallocatechin mg/day 
 Catechin mg/day 
 Epicatechin mg/day 
 Epigallocatechin-3 gallate mg/day 
 Epicatechin-3 gallate mg/day 
 GC mg/day 
Procyanidins mg/day 
Flavanones mg/day 
 Naringenin mg/day 
 Hesperetin mg/day 
Phytoestrogens µg/day 
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Table 53 List of total and specific fatty acid categories estimated from the SCG-FFQ 
Nutrient Units 
Total fatty acids g/day 
Total saturated fatty acids g/day 
 Palmitic acid g/day 
 Stearic acid g/day 
Total monounsaturated fatty acids g/day 
Total poly-unsaturated fatty acids g/day 
 Oleic acid g/day 
Total ω6 poly-saturated fatty acids g/day 
 Linoleic acid g/day 
 γ-Linolenic acid mg/day 
 Arachidonic acid mg/day 
Total ω3 poly-saturated fatty acids g/day 
 α-Linolenic acid mg/day 
 Eicosapentaenoic acid (EPA) mg/day 
 Docosahexaenoic acid (DHA)  mg/day 
Total trans fatty acids g/day 
Total trans mono-unsaturated fatty acids g/day 
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4.3.4.2 Food group variables 
In addition to the nutrients, the FFQ food items were used to calculate food group intake 
data (Table 54), using a procedure that followed the same protocol as the one used in the 
nutrient calculations and questionnaires that had blank values and/or blank lines were 
processed as described in the Missing values protocol (Box 3). 
In particular, the daily consumption of each individual food item (e.g. daily consumption 
of carrots) and of each food group (e.g. vegetables) was computed using the following 
formulas: 
- Daily consumption of food items: 
- When the day response was one to seven days per week: 
Food item intake per day = (number of measures)*(number of days)/7 
- When the day response was “monthly” an alternative formula was used: 
Food item intake per day = (number of measures)* 1.5 measures/ 28 days 
- When the day response “Rarely” was recorded then a default value of 0 for the 
daily food item intake was used. 
- Daily consumption of food groups: 
Food group intake = sum of food item intakes within the food group 
In addition to the food items and groups consumption the grilled meat score was 
calculated. It combined the number of times that a subject ate grilled or fried meat with 
the doneness of the meat using the following formula:  
Grilled meat score = [Number of times of grilled or fried meat per week]*[meat 
doneness] 
Note: Meat doneness: 1 = lightly browned, 2 = medium browned or 3 = well browned. 
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Table 54 List of food group variables and other food-associated variables 
Food group FFQ food items (FFQ question number) 
Total: Bread/Cereal products 
    Bread products 
    Cereal products 
Breads (qu.1), Breakfast Cereals (qu.2) 
Breads (qu.1) 
Breakfast Cereals (qu.2) 
Total: Fruit & Vegetables 
    Fruit 
    Vegetables 
Fruit (qu.12), Vegetables (qu.11) 
Fruit (qu.12) 
Vegetables (qu.12) 
Total: Meat products 
    Meat products 
    Red meat 
    Processed meat 
Meats (qu.7), Fish (qu.8) 
Meats (qu.7) 
Meats (qu.7: a-e, g-i) 
Meats (qu.7: b, c, i-l) 
Total: Fish 
    White fish 
    Oily fish 
Fish (qu.8) 
Fish (qu.8: a-d) 
Fish (qu.8: e-g, i) 
Total: Dairy products 
 
    Milk products 
    Cream & yoghurts 
    Cheese 
    Eggs 
Milk (qu.3), Cream and Yoghurt (qu.4), 
Cheese (qu.5), Eggs (qu.6) 
Milk (qu.3) 
Cream and Yoghurt (qu.4) 
Cheese (qu.5) 
Eggs (qu.6) 
Total: Alcohol intake 
    Beer & Lager 
    Wine 
    Spirits 
Alcoholic drinks (qu.19) – as units 
Alcoholic drinks (qu.19: a-c) 
Alcoholic drinks (qu.19: d, e) 
Alcoholic drinks (qu.19: f-h) 
Total: Beverages and Soft drinks 
    Beverages 
        Caffeine beverages 
        Non-caffeine beverages  
    Soft drinks 
        Fruit/vegetable juices 
        Fizzy drinks 
Beverages and Soft drinks (qu.18) 
Beverages and Soft drinks (qu.18: a-e) 
Beverages and Soft drinks (qu.18: a, c, e) 
Beverages and Soft drinks (qu.18: b, d) 
Beverages and Soft drinks (qu.18: f-l) 
Beverages and Soft drinks (qu.18: f-i) 
Beverages and Soft drinks (qu.18: j, k) 
Frequency of eating: Total number 
of meals and snacks per day 
    Number of main meals per day 
    Number of snack meals per day 
    Number of snack foods per day 
    Number of sweet drinks per day 
Other information (qu23: a-d) 
 
Other information (qu23: a) 
Other information (qu23: b) 
Other information (qu23: c) 
Other information (qu23: d) 
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4.3.4.3 Computation of energy-adjusted nutrient and food group 
variables 
To adjust for the potential effect of dietary energy intake on the associations between the 
nutrient or food intakes and colorectal cancer we used the residual method, as 
determined by Willet and Stampfer (276). This method estimates individual dietary 
intake when the energy intake remains constant (Box 4). However, to apply this method 
the distribution of the particular nutrient or food should be normal. Therefore, in case 
that a particular nutrient or food was not normally distributed (even after logarithmic or 
square-root transformation) then the standard method of energy adjustment was used, 
where dietary energy intake was added as a covariable in the logistic regression model 
that was used to estimate the association between the nutrient or food and colorectal 
cancer (Box 4). 
 
 Box 4 Procedure followed to control for the possible confounding effect of dietary energy intake 
(residual or standard method of energy adjustment) 
For each dietary intake variable we did as follows: 
1. Check the distribution of dietary energy intake 
The distribution of dietary energy intake was checked and any outliers were identified. 
2. Check the distribution of nutrient/food intake 
The distribution of each nutrient/ food was checked. If it was normal we went to step 5. The nutrients or 
foods that were not normally distributed were transformed (logarithmic or square root transformation). 
3. Check the distribution of transformed nutrient/food intake 
The distribution of the transformed nutrient/ food was checked. If it was normal, we went to step 5. If it 
was not normally distributed, we went to step 4. 
4. Standard energy adjustment 
The confounding effect of energy was controlled by adding energy as a covariable in the logistic 
regression model with colorectal cancer as the response variable and nutrient intake as an explanatory 
variable. 
5. Residual energy adjustment: Simple linear regression 
Simple linear regression with dietary intake variable as response (Y variable) and energy intake as x 
variable was performed: Y = a + bx; a is the intercept and b is the slope 
6. Residual energy adjustment: Record the residuals 
Residuals from step 5, the intercept a and the slope b were saved. 
Chapter four  Methods 
 189 
7. Residual energy adjustment: Calculate the mean energy intake 
The mean energy intake (χ) i.e. mean of x was calculated. 
8. Residual energy adjustment: Calculate the expected nutrient intake, when energy intake is 
constant (i.e. equal to its mean) 
The expected nutrient intake (y variable) was calculated using the formula: y = a + (b* χ) 
Where values for a and b were from step 5 and χ is the mean of the energy intake, from step 7. The value 
for y for each dietary intake variable was calculated.  
9. Residual energy adjustment: Calculate the energy adjusted dietary intake variable 
To obtain the energy adjusted dietary intake value, y was added to the residuals recorded in step 5 and 
saved in step 6. 
10. Residual energy adjustment: For previously transformed variables 
If the dietary intakes in step 2 have been transformed, these were reversed in this step. For example if the 
log transformation of a dietary intake variable had been used then the values obtained in step 9 were to be 
exponentiated. 
11. Residual energy adjustment: Analyse the energy adjusted variables 
We looked at the mean, standard deviation, minimum and maximum of the energy adjusted variable. We 
compared the mean of the energy adjusted variable to that of the original variable. The means should have 
been similar, but the standard deviation should have been lower for the energy adjusted variable. There 
should have been no negative values in the energy adjusted variable. If negative values were present we 
went back to step 1 and step 2 and checked for outliers and ensured that the skewness of the data was 
between –1 and 1.  
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4.3.4.4 Supplements 
Regular intake of dietary supplements (within the reference period) was recorded in 
section 21 of the FFQ and nutrient intake from these supplements was added to the daily 
nutrient intake from the FFQ. The supplement information (which included the brand 
name of the supplement, the type of the supplement, the dosage, the measures per day 
and the days per week) was entered in a database different to the FFQ database 
(Supplement database). The total number of subjects that took any kind of supplements 
was 1,772 (706 cases and 1,066 controls).  
A database containing the vitamin, mineral and herb dosages of the products recorded by 
the subjects was established (Supplement reference look-up database). The necessary 
information regarding the composition of the supplements was collected by the 
manufacturer’s product information, by contacting the company directly or by the 
internet. 
The combination of the Supplement database and Supplement reference look-up 
database gave all the necessary information to calculate the daily nutrient intake from 
the supplements which was null for subjects that had not been taking any supplements. 
This combination was made on a supplement code that was attached on each specific 
supplement. This code was unique for each brand-type-dosage supplement and was 
entered in both tables. For example the supplement Cod Liver Oil (525 mg each capsule) 
that was made by the brand Seven Seas had the code SS CLO 525. 
The daily intake from the supplements was added to the nutrient output from foods after 
the energy adjustment. The reason for this was that we were not willing to energy-adjust 
for the supplement intake. It is possible that the participants might have overestimated 
their supplement intake since they may have forgotten to take them some time or even 
stopped for a period. However, this overestimation probably would not be related to any 
overestimation of their total dietary energy intake. Therefore on balance and having 
consulted Dr G McNeill (University of Aberdeen), we felt it would be more accurate to 
adjust the nutrients from foods for total dietary energy intake and then add the estimated 
daily nutrient intakes from supplements to the adjusted values. 
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4.4 Collection and process of additional data 
4.4.1 Deprivation category data 
The Carstairs deprivation index (deprivation score), which was based on the 2001 
Census data, was assigned to each subject at the postcode sector level. The index 
contained seven categories ranging from very low deprivation (deprivation score 1) to 
very high deprivation (deprivation score 7). The criteria that are included in the Carstairs 
deprivation index are presented in Table 55. In Table 56 the distribution of cases and 
controls along the Carstairs deprivation index categories is presented. 
 
Table 55 Carstairs Deprivation Index criteria 
Criterion Description  
Overcrowding: Persons in private household living at a density 
of >1 person per room of all persons in private 
households 
Male unemployment: Proportion of economically active males who are 
seeking work 
Low social class: Proportion of all persons in private households 
with head of household in social class 4 or 5 
No car: Proportion of all persons in private households 
with no car 
 
Table 56 Distribution of cases and controls along the categories of Carstairs deprivation index 




1 287 (8.4%) 318 (9.4%) 
2 657 (19.2%) 686 (20.2%) 
3 860 (25.2%) 923 (27.2%) 
4 828 (24.2%) 794 (23.4%) 
5 389 (11.4%) 365 (10.7%) 
6 255 (7.5%) 218 (6.4%) 
7 137 (4.0%) 92 (2.7%) 
Missing 4 (0.1%) 0 (0.0%) 
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4.4.2 Family history risk 
Family history risk was assigned according to the Scottish guidelines (see Introduction, 
chapter 1.5.4). The distribution of cases and controls along the family history categories 
are presented in Table 57. 
4.4.3 Tumour related parameters 
4.4.3.1 Site of cancer 
Information about the site of tumour was extracted from the medical history records and 
from the treatment questionnaires. Distribution of the cases according to the tumour 
location is presented in Table 58. 
4.4.3.2 Stage of cancer 
During the recruitment period Duke’s stage was recorded to describe the extent of the 
cancer in the body. In addition, by using Duke’s stage information we formed the AJCC 
stage for each case. However, for 2,719 cases metastasis information was missing and 
data were requested from the Scottish regional cancer networks (SCAN, WoSCAN and 
NoSCAN). These data were also incomplete and therefore CT scans for all patients from 
the Lothian region were requested (n= 578) and individually checked for evidence of 
metastasis. For the WoSCAN and NoSCAN regions, the consultants of individual 
patients were contacted by letter requesting the staging information for their patients. 
Following this first round of letter to consultant surgeons, it became clear that there were 
inconsistencies between the staging provided by the regional databases and the death 
status (e.g. patients noted to have metastasis in the databases were alive several years 
later). A second round of letters was then sent to consultant surgeons requesting 
clarification of metastases status of their patients. For the remaining cases with 
outstanding metastasis status, individual GPs were contacted by letter. This process led 
to only 126 cases left without staging. The distribution of the cases according to the 
Duke’s and AJCC staging systems is presented in Table 59. 
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Table 57 Distribution of cases and controls of assigned family history 




Low 2503 (73.7%) 3084 (90.8%) 
Medium 613 (18.0%) 33 (1.0%) 
High 74 (2.2%) 1 (0.0%) 
Unknown 135 (4.0%) 20 (0.6%) 
Not given 92 (2.7%) 258 (7.6%) 
 Refused  61  28  
 Adopted  1  8  
 Other reason  0  1  
 No reason given  30  221 
 
Table 58 Distribution of cases according to tumour location 
Site of cancer Cases 
(n=3417) 
Colon cancer 2006 (58.7%) 
 Proximal 947 
 Distal 782 
 2 proximal tumours 23 
 2 distal tumours 8 
 1 proximal, 1 distal 10 
 Unspecified 236 
Rectal cancer 1355 (39.6%) 
Colon and rectal cancer 18 (0.5%) 
Other (including cancer of 
the appendix and anus, 
polyps only or unknown) 
30 (0.9%) 









Table 59 Distribution of the cases along the categories of the Duke’s and AJCC stage systems 
Stage of cancer Cases (n=3417) 
Duke’s staging  
 A 609 (17.8%) 
 B 1203 (35.2%) 
 C 1371 (40.1%) 
 D 31 (0.9%) 
 Missing 203 (5.9%) 
Metastasis  
 No 2819 (82.5%) 
 Yes 520 (15.2%) 
 Missing 78 (2.3%) 
AJCC  
 1 619 (18.1%) 
 2A 871 (25.5%) 
 2B 241 (7.0%) 
 2 (unspecified) 8 (0.2%) 
 3A 110 (3.2%) 
 3B 591 (17.3%) 
 3C 344 (10.1%) 
 4 507 (14.8%) 
 Missing 126 (3.7%) 
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4.4.4 Genetic data of specific variants 
In this thesis a limited amount of genetic variants were considered for investigation. In 
particular the genes, which were associated with colorectal cancer were investigated, 
were the following: rs1801133 (MTHFR C677T), rs1801131 (MTHFR A1298C), 
rs1805087 (MTR A2756G) and rs1801394 (MTRR A66G) (hypothesis 3), and four VDR 
SNPs: rs10735810 (FokI), rs1544410 (BsmI), rs11568820 and rs7975232 (ApaI) 
(hypothesis 4).  
Genotyping for MTHFR, MTR and MTRR SNPs was undertaken as part of an array-
based candidate gene approach. Genotyping of patients aged less than 55 years old along 
with matched controls was undertaken together using the Illumina Infinium I Custom 
array platform and performed by Illumina in San Diego. DNA samples were accurately 
quantified by Pico-Green
TM
 and quality controlled prior to dispatch to San Diego. To 
avoid potential systematic batch-to-batch variation or bias, samples were anonymised as 
to disease status and were randomly distributed within plates. Data were subject to 
Illumina quality control procedures and genotypes were discarded if call rates were less 
than 99.5%. Genotype data for the MTHFR, MTR and MTRR SNPs were available for a 
subsample of 1001 cases and 1010 controls. 
Genotyping for the four VDR SNPs was undertaken in two phases as part of an array-
based candidate gene approach, using the Illumina Infinium I Custom array platform and 
performed by Illumina (San Diego). In phase I, two VDR gene variants (rs10735810 and 
rs1544410) of 1,012 cases and 1,012 controls (<55 years old) were genotyped, whereas 
in phase II, four VDR gene variants (rs10735810, rs1544410, rs11568820, rs7975232) 
of 2,013 patients and 2,071 controls (21 to 83 years old) were genotyped. DNA samples 
were accurately quantified by Pico-Green
TM
 and quality controlled prior to dispatch to 
San Diego. Case and control DNA samples were stored, genotyped and analysed in the 
same way. In addition to avoid potential systematic batch-to-batch variation or bias, 
samples were anonymised as to disease status and were randomly distributed within 
plates. Data were subject to Illumina quality control procedures and genotypes were 
discarded if call rates were less than 99.5%. 
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4.5 Data analysis of part 1 (Hypothesis driven 
analyses) 
4.5.1 Introduction 
In the first part of this thesis particular dietary factors were investigated in order to 
assess their associations with colorectal cancer in a hypothesis-driven type of analysis. 
In particular, four different hypotheses were tested comprising the investigation of the 
associations between colorectal cancer and: 1) flavonoid variables (hypothesis 1), 2) 
fatty acid variables (hypothesis 2), 3) nutrients involved in the one-carbon metabolic 
pathway (including folate, vitamin B2, vitamin B6, vitamin B12 and alcohol; hypothesis 
3) and 4) vitamin D and calcium (hypothesis 4). Results of the first two hypotheses are 
presented in chapter 6 and results of the last two hypotheses are presented in chapter 7. 
 In this section the datasets that were used to investigate the aforementioned hypotheses 
including detailed list of the included variables will be presented. Finally, the overall 
descriptive statistical analysis of part 1 and the particular statistical methods that were 
employed will be described. All statistical analyses were conducted using the statistical 
package STATA IC (version 10.0, TEXAS, USA). 
4.5.2 Matched and unmatched dataset 
2,062 cases and 2,776 controls had complete and valid FFQ and LCQ data and were 
included in the analysis. Analysis was applied in two different datasets: a finely matched 
(1:1) dataset including 1,489 cases and 1,489 controls (used for investigation of 
hypotheses 1 and 2) and an unmatched dataset including 2,062 cases and 2,776 controls 
(used for investigation of hypotheses 3 and 4). The characteristics of both the matched 
and unmatched dataset are presented in the first section of chapter 6 and chapter 7, 
respectively. For the genetic analysis of hypothesis 3 (analysis of the following SNPs: 
rs1801133, rs1801131, rs1805087 and rs1801394) an unmatched dataset including 1,001 
cases and 1,010 controls (aged ≤55 years old) was used. In addition, for the joined 
analysis of the genetic and dietary factors of hypothesis 3, an unmatched dataset of 468 
cases and 761 controls younger than 55 years old was used. Regarding the genetic 
analysis of the hypothesis 4, an unmatched dataset of 2,013 cases and 2,071 controls was 
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used (for SNPs rs11568820, rs7975232), whereas an unmatched dataset of 3,025 cases 
and 3,083 controls was used (for SNPs rs10735810 and rs1544410). Finally, for the 
joined analysis of rs7975232, rs11568820 and the dietary factors of hypothesis 4 a 
dataset of 1,392 cases and 1,817 controls was used, whereas for the joined analysis of 
rs10735810, rs1544410 and the dietary factors of hypothesis 4 a dataset of 1,859 cases 
and 2,578 controls was used.  
4.5.3 List of variables 
The variables that were included in hypothesis 1 (association between flavonoids and 
colorectal cancer) were: 1) the flavonoid subgroups: flavonols, flavones, flavan3ols, 
procyanidins, flavanones and phytoestrogens and 2) the individual flavonoid 
compounds: quercetin, catechin, epicatechin, naringenin and hesperetin. The variables 
that were included in hypothesis 2 (association between fatty acids and colorectal 
cancer) were: 1) total FAs, 2) the fatty acid subgroups: SFAs, MUFAs, PUFAs, 
ω6PUFAs, ω3PUFAs, tFAs and tMUFAs and 3) the individual fatty acid compounds: 
palmitic acid, stearic acid, oleic acid, linoleic acid, γ-linolenic acid, arachidonic acid, α-
linolenic acid, EPA and DHA. The variables that were included in hypothesis 3 
(association between nutrients involved in one-carbon metabolic pathway and colorectal 
cancer) were: folate, vitamin B2, vitamin B6, vitamin B12 and alcohol and the SNPs 
rs1801133, rs1801131, rs1805087 and rs1801394. Finally, the variables that were 
included in hypothesis 4 were: vitamin D and calcium and the SNPs rs10735810, 
rs1544410, rs11568820 and rs7975232. The variables and potential confounding factors 
that were included in this part of the analysis are listed in Table 60. 
Chapter four  Methods 
 198 
Table 60 List of the variables included in the first part of the analysis (four hypotheses) and list of 
the potential confounding factors 
Variables Confounders 
Matched analysis Unmatched analysis  
Hypothesis 1   Hypothesis 2 Hypothesis 3 Hypothesis 4 All hypotheses 
Flavonols Total FAs Folate Vitamin D Age 
Flavones SFAs Vitamin B2 Calcium Sex 
Flavan3ols MUFAs Vitamin B12 rs10735810 Deprivation index 
Procyanidins PUFAs Vitamin B6 rs1544410 Family history 
Flavanones ω6PUFAs Alcohol rs11568820 Body mass index 
Phytoestrogens ω3PUFAs rs1801133 rs7975232 Physical activity 
Quercetin tFAs rs1801131  Smoking 
Catechin tMUFAs rs1805087  Dietary energy 
Epicatechin Palmitic acid rs1801394  Dietary fibre 
Naringenin Stearic acid   Alcohol  
Hesperetin Oleic acid   NSAIDs
*
  
 Linoleic acid    
 γ-Linolenic acid    
 Arachidonic acid    
 α-Linolenic acid    
 EPA     
 DHA     
                                               
* NSAIDs: Non Steroidal Anti-inflammatory Drugs 
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4.5.4 Statistical analysis of part 1 
4.5.4.1 Descriptive analysis 
The distribution of each dietary and potential confounding variable was examined. Any 
extreme values and outliers were noted with the view of omitting them from subsequent 
analysis using continuous data. Any variable that showed a skewed distribution was 
normalised by using appropriate transformation methods (logarithmic or square root 
transformation). In addition, a correlation analysis, using spearman’s rank correlation 
was performed on the dietary variables to examine any association between these 
variables.  
The distribution of each environmental variable and confounding factor was examined 
by cases versus controls. Differences in dietary intakes and confounding variables 
between cases and controls were tested for significance by using t-test (continuous 
variables) and Pearson χ
2
 test (categorical variables). Finally, the Wilcoxon rank-sum 
test was used to test for differences in median dietary intakes. 
4.5.4.2 Data categorisation 
Dietary and non-dietary variables that were measured on a continuous scale were 
initially used as continuous variables in the statistical models. In addition they were 
grouped into four categories using quartiles as the cut-off points (based on the combined 
distribution of cases and controls).  
4.5.4.3 Logistic regression analysis 
The association of case/ control status with each dietary, non-dietary and confounding 
variable of the four hypotheses was examined by using logistic regression models. In 
general, logistic regression analysis is used to model dichotomous outcomes (log odds of 
an outcome) defined by the values of covariables in the model. For the analysis of the 
unmatched dataset (unconditional) logistic regression was used. For the analysis of the 
matched dataset, conditional logistic regression analysis was used, which is a 
modification of the (unconditional) logistic regression where the likelihood takes into 
account the fine matching.  
Chapter 4  Methods 
 200 
Odds ratios and 95% CIs were obtained by comparing quartiles of each dietary variable 
using the lowest quarter as reference. In addition linear trend of the ORs that represents 
a dose-response association was examined by calculating a p-value for trend. Uni- and 
multi-variable conditional or unconditional logistic regression models were used to 
study the associations between colorectal cancer and each dietary and confounding 
factor. 
Three main logistic regression models (conditional or unconditional) were applied: 
Model I was not adjusted for any confounding factors (crude analysis); Model II was 
corrected for dietary energy intake by using either the residual method, as determined by 
Willet and Stampfer (for the normal distributed variables) or the standard method 
including the dietary energy variable as a covariate in the regression model (for the non-
normal distributed variables); Model III was corrected for family history of cancer (low, 
medium/high risk), BMI (kg/m
2
, continuously), physical activity (hours/week of cycling 
and any other sport activities, 4 categories), smoking (yes vs. no), dietary energy intake 
(residual or standard method of adjustment), fibre intake (grams/day, energy adjusted, 
continuously), alcohol intake (grams/day, energy adjusted, continuously) and regular 
NSAIDs intake (yes vs. no) and additionally for age (continuous), sex and deprivation 
score for the unmatched analysis. 
Two additional models were applied in hypothesis 1 (associations between colorectal 
cancer and intakes of flavonoids): Model IV, which was corrected for the confounding 
factors of model III and additionally for fruit and vegetable intake (measures/day, 
continuously, energy adjusted); and model V, which was corrected for the confounding 
factors of model III and further adjusted mutually between flavonoid categories. Two 
additional models were applied in hypothesis 2 (associations between colorectal cancer 
and intakes of fatty acids), as well: Model IV, which was corrected for the confounding 
factors of model III and in addition to the residual energy adjustment dietary energy 
intake was included as a covariate; and model V, which was corrected for the 
confounding factors of model III and further adjusted for total fatty acid intake. Finally, 
one additional model was applied in hypothesis 4 (associations between colorectal 
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cancer and intakes of vitamin D and calcium): Model IV, which was corrected for the 
confounding factors of model III and further adjusted for intake of ω3PUFAs. 
In addition to the whole sample analysis, ORs and 95% CIs were calculated in stratified 
groups according to sex, age (≤55 years old and >55 years old) and cancer site (colon 
and rectal cancer) by applying model III for all four hypotheses.  
4.5.4.4 Analysis of genetic data and gene-environment interactions 
(for hypotheses 3 and 4) 
The association of case/ control status with each SNP (hypotheses 3 and 4) was 
examined by using logistic regression models. Each genotype (heterozygous and 
homozygous for the variant allele) was compared with the reference category 
(homozygous for the wild type allele) in order to obtain ORs and 95% CIs. Two 
unconditional logistic regression models were used to study the associations between 
colorectal cancer and each SNP: one univariable model and one simply adjusted for age, 
sex and deprivation score. In addition, multivariable associations between the dietary 
risk factors that were included in hypotheses 3 and 4, and colorectal cancer were 
investigated after stratification of the study sample according to the genetic factors by 
applying model III. In addition, interaction associations were examined by investigating 
the combined effects of the genotypes and nutrient intakes. Interaction was tested by 
examining the deviance of two different nested models; an interactive model and its 
nested multiplicative one. The referent category used was homozygotes of the wild type 
allele and being at the lower quartile of the dietary nutrient intake. 
4.5.4.5 Multiple testing 
For each hypothesis we corrected the observed p-values according to the number of tests 
that were performed in order to control for multiple testing. Correction for multiple 
testing was conducted in three different ways. 
First, the p-values were corrected using the Bonferroni correction for the number of 
independent tests performed as follows: hypothesis 1 (flavonoids) was corrected for six 
independent tests; hypothesis 2 (fatty acids) for 14 independent tests (eight for the fatty 
acids making a subtotal of 14 tests including hypothesis 1); hypothesis 3 (folate, vitamin 
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B2, vitamin B6, vitamin B12 and alcohol) was corrected for 19 independent tests (five 
for the current hypothesis making a subtotal of 19 tests including hypotheses 1 and 2); 
and hypothesis 4 (vitamin D and calcium) was corrected for 21 independent tests (two 
for the current hypothesis making a subtotal of 21 tests including hypotheses 1, 2 and 3). 
For an original significance level (α) of 0.05, the adjusted significance level for 
hypothesis 1 was 0.008 (0.05 divided by 6), for hypothesis 2 was 0.004 (0.05 divided by 
14), for hypothesis 3 was 0.003 (0.05 divided by 19) and for hypothesis 4 was 0.002 
(0.05 divided by 21). 
The second way was to account for the number of tests separately for each hypothesis 
but to consider each single test by including the number of models as follows: 
hypothesis 1 was corrected for 30 tests for the flavonoid subgroups (6 flavonoid 
subgroups multiplied by 5 models = 30 tests) and for 25 tests for the individual 
flavonoids (5 individual flavonoids multiplied by 5 models = 25 tests); hypothesis 2 was 
corrected for 39 tests for the fatty acid subgroups (total fatty acids multiplied by 4 
models = 4 tests plus 7 fatty acid subgroups multiplied by 5 models = 35 tests) and for 
45 tests for the individual fatty acids (9 individual fatty acids multiplied by 5 models = 
45 tests); hypothesis 3 was corrected for 15 tests (5 nutrients multiplied by 3 models = 
15 tests); and hypothesis 4 was corrected for eight tests (2 nutrients multiplied by 4 
models = 8 tests). Both the Bonferroni correction method and the less conservative False 
Discovery Rate (FDR) method were applied. 
Third, the significance level was corrected for the toal number of tests performed in all 4 
hypotheses, by applying both the Bonferroni and the FDR method. In the subgroup 
level, we corrected for 69 independent tests (30 in hypothesis 1 and 40 in hypothesis 2), 
whereas in the individual nutrient level we corrected for 93 tests (25 in hypothesis 1, 45 
in hypothesis 2, 15 in hypothesis 3 and 8 in hypothesis 4). 
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4.6 Data analysis of part 2 (Overall and stepwise 
regression analysis) 
4.6.1 Introduction 
In the second part of the thesis, an overall univariable analysis of all the collected risk 
factors (including demographic factors, lifestyle variables, food variables and nutrients) 
was conducted. In addition, stepwise regression models were applied to three different 
sets of variables to develop models that explain colorectal cancer risk. Results of the 
second part of the thesis are presented in chapter 8. 
This section includes a description of the datasets used and the statistical methods. All 
statistical analyses were conducted using the statistical package STATA IC (version 
10.0, TEXAS, USA). 
4.6.2 Dataset 
The dataset that was used for part 2 of the analysis was the unmatched one consisting of 
2,062 cases and 2,776. Its main characteristics are presented in the first section of 
chapter 7 (on page 260). 
4.6.3 List of variables 
The variables, which were tested for an association with colorectal cancer were: 1) the 
demographic risk factors: age, sex, family history and deprivation score; 2) the lifestyle 
variables: smoking, alcohol intake, BMI, physical activity, dietary energy intake, 
NSAIDs intake and HRT intake (females only); 3) the food variables: breads, cereals, 
milk, cream, cheese, eggs, poultry, red meat, processed meat, white fish, oily fish, 




, tea, coffee, fruit/ vegetable 
juice, fizzy drinks; and 4) the nutrients: quercetin, catechin, epicatechin, flavones, 
procyanidins, flavanones, phytoestrogens, SFAs, MUFAs, ω6PUFAs, ω3PUFAs, tFAs, 
tMUFAs, sodium, potassium, calcium, magnesium, phosphorus, iron, copper, zinc, 
manganese, selenium, iodine, chloride, vitamin A, carotenes, vitamin D, vitamin E, 
                                               
1 Summary variable of savoury foods, soups and sauces 
2 Summary variable of puddings and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
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vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folate, pantothenic acid, 
potential niacin, biotin and vitamin C. 
Stepwise regression was applied in three different sets of variables that are presented in 
Table 61. Briefly, set 1 consisted of demographic risk factors, lifestyle variables and 
food variables; set 2 consisted of demographic risk factors, lifestyle variables and 
nutrients; and set 3 consisted of demographic risk factors, lifestyle variables, food 
variables and nutrients. All food and nutrient variables were adjusted for dietary energy 
(by the residual method), except for tea and coffee (sets 1 and 3) and flavones (sets 2 
and 3). 
 
Table 61 List of the variables included in the three datasets of the second part of the analysis. All 
food and nutrient variables were residually adjusted for dietary energy, except for the food 
variables: tea and coffee and the nutrients: flavones and flavan-3-ols. 
Set 1 Set 2 Set 3 
Demographic risk factors Demographic risk factors Demographic risk factors 
Age, sex, family history, 
deprivation score 
Age, sex, family history, 
deprivation score 
Age, sex, family history, 
deprivation score 
Lifestyle variables Lifestyle variables Lifestyle variables 
Smoking, alcohol intake, BMI, 
physical activity, dietary 
energy intake, NSAIDs, HRT 
(females only) 
Smoking, alcohol intake, 
BMI, physical activity, 
dietary energy intake, 
NSAIDs, HRT (females only) 
Smoking, alcohol intake, 
BMI, physical activity, 
dietary energy intake, 
NSAIDs, HRT (females only) 
Food variables Flavonoid variables Food variables 
Breads, cereals, milk, cream, 
cheese, eggs, poultry, red 
meat, processed meat, white 
fish, oily fish, potatoes/ pasta/ 





, tea (crude 
intakes), coffee (crude 
intakes), fruit/ vegetable juice, 
fizzy drinks 
Quercetin, catechin, 
epicatechin, flavones (crude 
intake), procyanidins, 
flavanones, phytoestrogens 
Breads, cereals, milk, 
cream, cheese, eggs, 
poultry, red meat, processed 
meat, white fish, oily fish, 
potatoes/ pasta/ rice, fruit, 
vegetables, savoury, 
sweets, tea (crude intakes), 
coffee (crude intakes), fruit/ 
vegetable juice, fizzy drinks 
 Fatty acid variables Flavonoid variables 
 SFAs, MUFAs, ω6PUFAs, 
ω3PUFAs, tFAs, tMUFAs 
Quercetin, catechin, 
epicatechin, flavones (crude 




 Macronutrients Fatty acid variables 
 Protein, cholesterol, sugars, 
starch, fibre 
SFAs, MUFAs, ω6PUFAs, 
ω3PUFAs, tFAs, tMUFAs 
 Minerals Macronutrients 
 Sodium, potassium, calcium, 
magnesium, phosphorus, 
iron, copper, zinc, 
manganese, selenium, 
iodine  
Protein, cholesterol, sugars, 
starch, fibre 
 Vitamins Minerals 
 Vitamin A, carotenes, 
vitamin D, vitamin E, vitamin 
B1, vitamin B2, niacin, 
vitamin B6, vitamin B12, 
folate, pantothenic acid, 
biotin, vitamin C 
Sodium, potassium, calcium, 
magnesium, phosphorus, 
iron, copper, zinc, 
manganese, selenium, 
iodine 
  Vitamins 
  Vitamin A, carotenes, 
vitamin D, vitamin E, vitamin 
B1, vitamin B2, niacin, 
vitamin B6, vitamin B12, 
folate, pantothenic acid, 
biotin, vitamin C 
                                               
* Summary variable of savoury foods, soups and sauces 
† Summary variable of puddings and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
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4.6.4 Statistical analysis of part 2 
4.6.4.1 Descriptive analysis 
The distribution of each demographic, lifestyle, food and nutrient variable was 
examined. Any extreme values and outliers were investigated with the view of omitting 
them from subsequent analysis using continuous data. Any variable that showed a 
skewed distribution was normalised by using appropriate transformation methods 
(logarithmic or square root transformation).  
The distribution of each variable was examined by cases versus controls and the 
distributions were tested for significance by using t-test (continuous variables) and 
Pearson χ
2
 test (categorical variables). In addition, the Wilcoxon rank-sum test was used 
to test the median of the continuous variables. Finally, a correlation analysis, using 
spearman’s rank correlation was performed on all continuous variables to examine any 
association between these variables. All food and nutrient variables were residually 
energy adjusted (except for tea, coffee and flavones).  
4.6.4.2 Data categorisation 
Dietary and non-dietary variables that were measured on a continuous scale were 
initially used as continuous variables in the statistical models. In addition they were 
standardised and changes per standard deviation were reported. Finally, they were 
grouped into four categories using quartiles as the cut-off points (based on the combined 
distribution of cases and controls).  
4.6.4.3 Overall univariable logistic regression 
Univariable logistic regression models were fitted for each demographic, lifestyle, 
dietary, food and nutrient variable. For the regression of food and nutrient variables, 
their residual energy adjusted form was included (except for the food groups tea and 
coffee and the nutrient: flavones).  
4.6.4.4 Stepwise regression 
Stepwise regression (both forward and backward) was applied to the three different set 
of variables. The p-value threshold for a variable to enter the model (forward stepwise 
regression) or to remain in the model (backward stepwise regression) was 0.10. In each 
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set of variables the quartile form of the continuous variables was included. Finally, 
forward and backward stepwise regression was reapplied separately for males and 
females for all three sets of variables using the quartile form of the continuous variables. 
4.6.4.5 Bootstrap method 
 In order to examine the stability of the built models the bootstrap method was applied. 
A bootstrap sample is a sample of the same size as the original sample but where 
subjects have been replaced. A given subject of the original sample may occur in a 
specific bootstrap sample many times, only once, or not at all. 100 bootstrap samples 
were selected. Once a bootstrap sample was selected by the computer programme, for 
each set of variables forward and backward stepwise regression models were applied (in 
the whole sample). The p-value threshold for a variable to enter the model (forward 
stepwise regression) or to remain in the model (backward stepwise regression) was again 
0.10. Therefore, for a given bootstrap sample and for each set of variables, two final 
models were obtained (1 after applying forward and 1 after applying backward stepwise 
regression). 
For each obtained model, the selected variables were noted, results across the variable 
selection models were compared and this procedure was repeated for all 100 bootstrap 
samples. For each variable, the number of times that it was included in a regression 
model was calculated. In addition, the agreement between the type and number of 
variables included in the models after applying forward and backward stepwise 
regression was determined. 
4.6.4.6 Multiple testing 
The purpose of the overall and stepwise analysis was not to draw any certain 
conclusions about the strength of the associations between the risk factors and colorectal 
cancer. Instead, the purpose was to identify risk factors and to generate new hypotheses, 
which would then be tested in other prospective or retrospective studies. Therefore, no 
correction was made for multiple testing.  
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5 RESULTS: Description of the results 
presentation 
This chapter describes the layout of the results and discussion sections of the thesis. In 
chapters 6 and 7, the analyses of the four “a priori” hypotheses will be described (aim 1). 
Chapter 6 includes the results of the matched analysis of the novel dietary risk factors 
(flavonoid and fatty acid subgroups and individual compounds), whereas chapter 7 
includes the unmatched analysis of the additional dietary risk factors (folate, vitamin B2, 
vitamin B6, vitamin B12, alcohol, vitamin D and calcium). Chapter 8 (aim 2) includes 
the results of the univariable overall analysis of all the explanatory variables and of the 
stepwise regression models.   
In the first part of each chapter the study population that was included in the analysis is 
presented, including descriptive analysis of the main confounding factors and logistic 
regression analysis to investigate the association relationships between the confounding 
factors and colorectal cancer risk. Since the study sample that was used in chapters 7 and 
8 was the same, description of its main characteristics will be presented only once, in 
chapter 7. In the second part of each chapter descriptive analysis of the dietary variables 
(chapters 6 and 7) or of all the explanatory variables (chapter 8) are presented including 
distribution analysis (whole sample and by case/ control status) and correlation analysis. 
In addition, the association relationships between colorectal cancer and each variable are 
investigated by applying different logistic regression models. Finally, the last part of 
chapter 8 includes the stepwise regression stepwise models for three different sets of 
explanatory variables. In the end of each chapter, a brief summary is included 
highlighting the main findings of each analysis, whereas further discussion of the 
important findings will be presented in chapter 9 (Discussion). Tables and figures of the 
analyses are presented at the end of each section of each chapter, as indicated in the text. 
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6 RESULTS: Associations between colorectal 
cancer and intakes of flavonoids and fatty acids 
(matched dataset) 
6.1 Introduction 
In this chapter the results of the matched analysis of the novel dietary risk factors that 
comprise the first two hypotheses, are presented. In particular the dietary risk factors that 
were analysed using the matched dataset included: 1) flavonoids (subgroups, individual 
compounds) and 2) fatty acids (total, subgroups, individual compounds). 
In the first part, the study population included in the matched analysis is described, 
including descriptive analysis of the main confounding factors and logistic regression 
analysis to investigate their association relationships with colorectal cancer risk. 
In the second part of the chapter descriptive analysis of the flavonoid and fatty acid 
variables are presented including distribution analysis (whole sample and by case/ 
control status) and correlation analysis. In addition, the association relationships 
between colorectal cancer and each flavonoid and fatty acid variable are investigated by 
applying three main and two additional conditional logistic regression models. All tables 
and figures are presented at the end of each section or in the Appendix, as indicated in 
the text. 
6.2 The study sample 
This section describes the characteristics of the cases and controls that were included in 
the matched dataset. In total 2,980 cases and controls were matched (1:1). One case had 
unrealistically high dietary energy and nutrient intakes and was removed from further 
analysis, together with its matched control.  
6.2.1 Descriptive analysis of the confounding factors 
The distribution of the continuous confounding factors was examined by looking at their 
histograms. In addition, their summary statistics are presented in Table 62 for the whole 
sample and also separately for cases and controls. The t-test was used to test differences 
between cases and controls in mean age, BMI, dietary energy intake, fibre intake (crude 
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and residually energy adjusted) and alcohol intake (crude and residually energy 
adjusted). The Pearson χ
2
 test was used to test the differences in terms of sex, 
deprivation score, family history of cancer, physical activity (hours/ week of cycling and 
sport activities), smoking status and NSAIDs intake (Table 62).  
6.2.2 Associations between confounding factors and 
colorectal cancer risk 
The association relationship between each confounding factor and colorectal cancer risk 
was tested by applying univariable conditional logistic regression models (Table 63). 
Statistically significant associations were observed for the majority of the confounding 
factors, including: 




- Physical activity (>7 hours/week vs. 0 hours/week: OR (95% CI), p-value for trend: 
0.77 (0.56, 1.04), 0.009); 
- Dietary energy intake (highest vs. lowest quartile: OR (95% CI), p-value for trend: 
1.34 (1.09, 1.65), 0.001); 
- Residually energy adjusted fibre intake (highest vs. lowest quartile: OR (95% CI) p-
value for trend) 0.67 (0.54, 0.83), 0.0001); 
- Residually energy adjusted alcohol intake (highest vs. lowest quartile: OR (95% CI), 
p-value for trend: 0.81 (0.65, 1.00), 0.04); 
- NSAIDs intake (yes vs. no: OR (95% CI) p-value: 0.74 (0.63, 0.86), 0.0001). 
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Age (years) 64.0 (9.7) 63.6 (9.7) 64.4 (9.7) 0.03 
Age (years)     
 ≤55 years 596 (20.0%) 318 (21.4%) 278 (18.7%)  
 >55 years 2382 (80.0%) 1171 (78.6%) 1211 (81.3%) 0.07 
Sex     
 Men 1734 (58.2%) 867(58.2%) 867(58.2%)  
 Women 1244 (41.8%) 622 (41.8%) 622 (41.8%) 1.00 
Deprivation score
‡
     
 1 311 (10.4%) 140 (9.4%) 171 (11.5%)  
 2 650 (21.8%) 327 (22.0%) 323 (21.7%)  
 3 769 (25.8%) 402 (27.0%) 367 (24.7%)  
 4 713 (23.9%) 356 (23.9%) 357 (24.0%)  
 5 305 (10.2%) 152 (10.2%) 153 (10.3%)  
 6 162 (5.4%) 77 (5.2%) 85 (5.7%)  
 7 68 (2.3%) 35 (2.4%) 33 (2.2%) 0.52 
Family history risk of 
cancer 
    
 Low 2664 (89.4%) 1215 (81.6%) 1449 (97.3%)   
 Medium 186 (6.2%) 170 (11.4%) 16 (1.1%)  
 High 22 (0.7%) 21 (1.4%) 1 (0.1%)  
 Unknown 71 (2.4%) 62 (4.2%) 9 (0.6%) <0.0005 





 23.6 (4.4) 26.6 (4.3) 26.7 (4.6) 0.45 
Physical activity 
(hours/day) 
(cycling and other 
sport activities) 
    
 0  1646 (55.3%) 846 (56.8%)  800 (53.7%)   
 0-3.5  692 (23.2%) 337 (22.6%) 355 (23.8%)  
 3.5-7  322 (10.8%) 144 (9.7%) 178 (11.9%)  
 >7  198 (6.6%) 89 (6.0%) 109 (7.3%) 0.07 
 Missing 120 (4.0%) 73 (4.9%) 47 (3.1%)  
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Smoking     
 No 1242 (41.7%) 606 (40.7%)  636 (42.7%)  
 Yes
**
 1701(57.1%) 862 (57.9%) 839 (56.3%) 0.32 





10.9 (4.1%) 11.2 (4.2%) 10.6 (3.9%) 0.0002 
Fibre intake (g/day)
‡‡
 22.4 (9.6) 22.3 (9.5) 22.4 (9.8) 0.90 
Energy-adjusted 
fibre intake (g/day) 











12.9 (15.0) 12.8 (15.5) 13.0 (14.4) 0.36 
NSAIDs intake
†††
     
No 1939 (65.1%) 1019 (68.4%) 920 (61.8%)  
Yes 1038 (34.8%) 469 (31.5%) 569 (38.2%) <0.0005 
Missing 1 (0.0%) 1 (0.1%) 0 (0.0%)  
                                               
* Mean values and in parentheses standard deviations for quantitative variables; number of subjects and in parenthesis 
percentages for categorical variables. 
† P-values from the Pearson χ2 for categorical variables; from t-test for continuous variables 
‡ Locally based deprivation index (Carstairs deprivation index) based on the 2001 Census data; 7 categories ranging 
from very low deprivation (deprivation score 1) to very high deprivation (deprivation score 7) 
§ Missing data for 15 cases and 19 controls; T-test was applied after logarithmic transformation 
** Smokers were defined as individuals who have smoked at least one cigarette per day and/ or one cigar per month 
and/ or pipe.  
†† T-test was applied after logarithmic transformation 
‡‡ T-test was applied after logarithmic transformation 
§§ T-test was applied after square-root transformation 
*** T-test was applied after square-root transformation 
††† Frequent use was defined as an intake of at least 4 days per week for at least one month. 
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Table 63 Association between the confounding factors and colorectal cancer risk (univariable 
conditional logistic regression analysis) 
Confounding 
variables 
Categories Frequency Univariable analysis 
  cases controls OR 95% CI p-value 
Family history 
risk of cancer 
Low 1215 1449 1.00   





) continuous 1474 1470 0.99 0.98, 1.01 0.38 
BMI (kg/m
2
) 18.5-25 573 531 1.00   
 <18.5 13 18 0.67 0.33, 1.38 0.28 
 25-30  629 644 0.90 0.77, 1.06 0.23 
 ≥ 30  259 277 0.87 0.71, 1.07 0.18 
    p-value for trend 0.14  
Physical activity 
(hours/week) 
0  1646 846  1.00   
0-3.5  692  337  0.90 0.75, 1.08 0.25 
3.5-7  322 144  0.75 0.59, 0.97 0.03 
>7  198 89 0.77 0.56, 1.04 0.09 
    p-value for trend 0.009  
Smoking No 606 636 1.00   
Former 616 586 1.11 0.94, 1.31 0.22 
Current 246 253 1.02 0.83, 1.25 0.88 
    p-value for trend 0.51  
Dietary energy 
intake (MJ/day) 
continuous 1489 1489 1.03 1.01, 1.05 0.0005 
Dietary energy 
intake (MJ/day) 
0- 8.28 352 393 1.00   
8.28-10.17 345 399 0.98 0.80, 1.20 0.82 
10.17- 12.73 389 356 1.25 1.02, 1.55 0.04 
>12.73 403 341 1.34 1.09, 1.65 0.006 
    p-value for trend 0.001  
Fibre intake 
(g/day) 
continuous 1489 1489 1.00 0.99, 1.01 0.83 
Fibre intake 
(g/day) 
0- 16.10 382 381 1.00   
16.10- 20.70 371 368 1.01 0.82, 1.23 0.95 
20.70- 26.80 380 364 1.04 0.85, 1.28 0.68 
>26.80 356 376 0.94 0.77, 1.16 0.58 
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0- 17.45 392 353 1.00   
17.45- 20.89 392 352 1.00 0.81, 1.22 0.97 
20.89- 24.85 384 361 0.95 0.77, 1.17 0.61 
>25.85 321 423 0.67 0.54, 0.83 3.6x10
-5 
    p-value for trend 0.0001  
Alcohol intake 
(g/day) 
continuous 1489 1489 1.00 0.99, 1.01 0.81 
Alcohol intake 
(g/day) 
0-1.60 376 369 1.00   
 1.60-8.10 392 366 1.05 0.86, 1.28 0.63 
 8.10-18.80 362 369 0.95 0.78, 1.17 0.64 
 >18.80 359 385 0.89 0.72, 1.11 0.31 








0-1.61 384 361 1.00   
1.61-8.12 387 357 1.02 0.83, 1.25 0.87 
8.12-18.85 368 377 0.91 0.74, 1.12 0.37 
>18.85 350 394 0.81 0.65, 1.00 0.05 
    p-value for trend 0.04  
NSAIDs intake No 1939 1019 1.00   
 Yes 1038 469 0.74 0.63, 0.86 0.0001 
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6.3 Flavonoids 
This analysis describes the distribution and correlation among subgroups of the 
flavonoid variables. In addition, the differences in crude and energy-adjusted flavonoid 
intakes between cases and controls and the unadjusted and adjusted associations between 
flavonoid intakes and colorectal cancer are presented. 
6.3.1 Descriptive analysis 
6.3.1.1 Distribution of flavonoid variables 
After careful examination of the distribution of the flavonoid variables (subgroups and 
individual compounds) by looking at their histograms (original and transformed 
variables if skewed) I excluded kaempferol, myricetin, apigenin, luteolin and the 
gallates: epigallocatechin, epicatechin-3 gallate, epigallocatechin-3 gallate, gallocatechin 
from further analysis because of their extreme patterns of distribution (perhaps due to 
limited compositional information). Therefore, the subclasses that were investigated 
were: flavonols (summary measurement of quercetin, kaempferol and myricetin), 
flavones (summary measurement of apigenin and luteolin), flavan3ols (summary 
measurement of catechin, epicatechin and gallates), procyanidins (summary 
measurement of procyanidin type BI - IV), flavanones (summary measurement of 
naringenin and hesperetin), and phytoestrogens (summary measurement of isoflavones 
and lignans) and the individual compounds: quercetin, catechin, epicatechin, naringenin 
and hesperetin (Table 64). The skewed flavonoid variables were normalised either with 
square root or with logarithmic transformation prior to applying parametric tests. If the 
distributions were not normalised after transformation (flavones, flavan3ols), only non-
parametric tests were applied (Table 64). 
6.3.1.2 Distribution of flavonoid variables by case control status 
Evaluation of the flavonoid composition of the diet of our study population showed that 
the most abundant flavonoids (individual compounds) were epicatechin, quercetin and 
hesperetin accounting for the 11.9% and 9.0% and 7.8% of the total dietary intake of 
flavonoids (excluding phytoestrogens), respectively. No statistically significant 
differences were observed between cases and controls for crude mean and median 
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flavonoid intakes (Table 65). After energy adjustment (residual energy adjustment for 
normal distributed flavonoid variables) cases reported a lower mean intake for flavonols 
(p=0.02), flavanones (p=0.04), quercetin (p=0.004), catechin (p=0.003), naringenin 
(p=0.04), and hesperetin (p=0.04). In addition cases reported a lower median intake for 
flavonols (p=0.02), quercetin (p=0.004) and catechin (p=0.002) (Table 65). 
6.3.1.3 Correlations between the flavonoid variables 
Overall the flavonoid variables were highly correlated. The highest correlations were 
observed between flavonols, flavan3ols, procyanidins, quercetin, catechin and 
epicatechin, with r>0.7. In addition, flavanones, naringenin and hesperetin were highly 
correlated with r>0.7. Phytoestrogens were not correlated with any of the flavonoid 
subgroups or individual compounds (r≤0.15) (Table 66). 
6.3.1.4 Main sources of flavonoid variables 
The three main food sources (at individual food item level) of the flavonoid subgroups 
were: 1) for flavonols: regular tea (64.3%), onions (9.1%), and soups- home made 
(6.3%); 2) for flavones:  soups- home made (78.2%), other salad vegetables (10.9%), 
and meat or chicken pies, pasties, sausage roll (4.3%); 3) for flavan3ols: regular tea 
(89.3%), apples (3.1%), and red wine (2.1%); 4) for procyanidins: regular tea (74.2%), 
apples (11.2%), and red wine (8.4%); 5) for flavanones: oranges, satsumas or grapefruits 
(69.3%), pure fruit juice (29.1%) and red wine (1.2%); and 6) for phytoestrogens: soya 
milk (26.3%), wholemeal bread (including toast and sandwiches) (18.0%), soya beans, 
TVP, Tofu or soya meat substitute (13.4%) (Table 67). 
In addition the three main food sources of the flavonoid individual compounds were: 1) 
for quercetin: regular tea (50.6%), red wine (13.3%) and soups- home made (9.0%); 2) 
for catechin: regular tea (45.1%), red wine (16.2%) and other fruits (9.8%); 3) for 
epicatechin: regular tea (67.5%), apples (11.7%), chocolate (6.1%); 4) for naringenin: 
oranges, satsumas or grapefruits (70.5%), pure fruit juice (26.7%), red wine (2.1%); and 
5) for hesperetin: oranges, satsumas or grapefruits (67.8%), pure fruit juice (31.5%) and 
red wine (0.6%) (Table 67). 
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6.3.2 Associations between flavonoid variables and 
colorectal cancer risk 
6.3.2.1 Main conditional logistic regression models 
None of the flavonoid variables were significantly associated with colorectal cancer in 
the crude model (Model I) (Table 68). In Model II, flavonols, procyanidins, quercetin, 
catechin and epicatechin were significantly associated with a decreased colorectal cancer 
risk (high vs. low quartile OR (95%): 0.77 (0.63-0.94), 0.80 (0.65-0.98), 0.71 (0.58-
0.88), 0.68 (0.55-0.83), 0.77 (0.63-0.94); respectively), and these associations were also 
dose-dependant (p-value for trend: 0.02, 0.04, 0.002, 0.0001, 0.04; respectively) (Table 
68). Quercetin and catechin showed also and inverse and dose-dependent association 
with colorectal cancer risk in Model III (p-value for trend: 0.04 and 0.02; respectively) 
with approximately a 25% reduction in risk for those of high versus those of low intake 
(OR (95% CI): 0.77 (0.60-0.99), 0.75 (0.58-0.97); respectively) (Table 68). In distinct 
contrast, there were no associations between flavones, flavanones and phytoestrogens 
and colorectal cancer risk (p-value for trend 0.28, 0.39 and 0.87 respectively in model 
III) (Table 68). 
6.3.2.2 Additional conditional logistic regression models 
Since these associations could be confounded by other compounds present in fruit and 
vegetables or by the intake of other flavonoids we explored these relationships further in 
two additional models (Model IV and V; Table 69). Model IV was corrected for the 
confounding factors of model III and for fruit and vegetable intake (measures/day, 
continuously, energy adjusted). The observed association with catechin remained 
significant (high vs. low quartile OR (95% CI): 0.79 (0.61-1.03); p-value for trend 0.05) 
(Table 69). The associations with flavonols, quercetin and epicatechin had the same 
direction, but were marginally not statistically significant (high vs. low quartile OR 
(95% CI): 0.81 (0.63-1.01), 0.82 (0.63-1.06), 0.78 (0.61-1.00), respectively) (Table 69). 
In model V association were corrected for the confounding factors of model III and 
further adjusted mutually between flavonoid categories. The observed associations 
between flavonols, catechin, epicatechin and colorectal cancer became stronger and 
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remained statistically significant (high vs. low quartile OR (95% CI), p-value for trend: 
0.29 (0.16-0.54), 0.0001; 0.56 (0.37-0.86), 0.007; 0.46 (0.23-0.92), 0.03; respectively) 
(Table 69). 
6.3.2.3 Multiple testing corrections 
Bonferroni correction for multiple testing 
In model II, the inverse association with catechin (p-value 0.0001) remained significant 
under every level of correction and the inverse association with quercetin (p-value 
0.002) remained significant in the first two levels, but not after having considered all the 
tests conducted in all 4 hypotheses (Table 68). In model V, the inverse association with 
flavonols (p-value 0.0001) remained significant under every level of correction, whereas 
the inverse association with catechin (p-value 0.007) remained significant only in the 
first level of correction (Table 69). 
FDR correction for multiple testing 
After correcting for multiple testing using the FDR method the inverse associations that 
remained significant were: with catechin (p=0.0001) and quercetin (p=0.002) in model II 
(Table 68) and with flavonols (p=0.0001) and catechin (p=0.007) in model V (Table 69). 
6.3.2.4  Associations between colorectal cancer and the main food 
sources of flavonols, procyanidins, quercetin, catechin and 
epicatechin 
Intakes of the following food items were tested: regular tea, onions, apples and red wine. 
Results from model III, showed that comparison of highest versus lowest quartile intakes 
of these foods (tertiles for red wine intakes) showed ORs for colorectal cancer risk of 
0.82 (95% CI 0.63, 1.06; p-value for trend 0.27) for regular tea; 0.92 (95% CI 0.72, 1.17; 
p-value for trend 0.44) for onions; 0.97 (95% CI 0.75, 1.25; p-value for trend 0.77) for 
apples; and 0.87 (95% CI 0.68, 1.11; p-value for trend 0.33) for red wine (Table 70). 
6.3.2.5 Associations between the flavonoid variables and colorectal 
cancer after sex, age and cancer site stratification 
Associations between each flavonoid variable and colorectal cancer risk were tested 
after sex, age and cancer site stratification by applying model III (data not shown). Sex-
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specific associations were similar for almost all flavonoid subgroups and individual 
compounds. However, high intake of phytoestrogens was associated with a non 
statistically significant decrease in colorectal cancer risk for men (high vs. low intake 
OR (95% CI), p-value for trend: 0.80 (0.58, 1.10), 0.14), but with a not statistically 
significant increase in colorectal cancer risk for women (high vs. low intake OR (95% 
CI), p-value for trend: 1.55 (1.02, 2.36), 0.06) (data not shown). Intakes of flavonols, 
procyanidins, quercetin, catechin and epicatechin were significantly and dose-
dependently associated with a decreased risk of colorectal cancer for the individuals 
older than 55 years old (data not shown). However, associations were not as clear for the 
individuals younger than 55 years old, with none of them reaching the 0.05 significance 
level (data not shown). Finally, after cancer site stratification, flavonols, procyanidins, 
quercetin, catechin and epicatechin were found to be inversely though not significantly 
associated with both colon and rectal cancer (data not shown). 
6.3.3 Summary of results 
Moderately strong inverse associations which showed dose response relationships were 
found: 1) in model II: between colorectal cancer risk and intakes of flavonols (p=0.02), 
procyanidins (p=0.04), quercetin (p=0.002), catechin (p=0.0001) and epicatechin 
(p=0.04) (Table 68); 2) in model III: between colorectal cancer and intakes of quercetin 
(p=0.04) and catechin (p=0.02) (Table 68); 3) in model IV between colorectal cancer 
and catechin (p=0.05) (Table 69); 4) in model V between colorectal cancer and intakes 
of flavonols (p=0.0001), catechin (p=0.007) and epicatechin (p=0.03) (Table 69). In 
marked contrast we showed no associations between intakes of the other four of the six 
flavonoid subgroups studied (flavones, flavan3ols, flavanones and phytoestrogens) and 
colorectal cancer risk (Table 68, Table 69).  
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Table 64 Flavonoid variables (subgroups and individual compounds) that were elected to be 
included in the analysis 
Flavonoid variables  
included in the analysis 
Transformation 
Subgroups  
Flavonols Square root 
Flavones n/a 
Flavan3ols n/a 
Procyanidins Square root 
Flavanones Square root 
Phytoestrogens Logarithmic 
Individual compounds  
Quercetin Square root 
Catechin Square root 
Epicatechin Square root 
Naringenin Square root 
Hesperetin Square root 
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Table 65 Descriptive report of crude and energy-adjusted flavonoid intakes 







T-test  Wilcoxon 











Median (IQR) p-value p-value 
Subgroups         


























(16.1, 37.0)  
0.02 0.02 
Flavones (mg/day) 1.3 (1.2) 1.0  
(0.5, 1.9) 
1.4 (1.3) 1.1 
(0.5, 1.9) 
1.3 (1.1) 1 
(0.5, 1.8) 
n/a 0.14 
Flavones- energy adjusted 
(mg/day) 
n/a n/a n/a n/a n/a n/a n/a n/a 















n/a n/a n/a n/a n/a n/a n/a n/a 


























































Phytoestrogens (µg/day) 1075.2 596.0 981.6 593.1 1168 599.3 0.73 0.84 
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Table 66 Spearman rank correlation coefficients between flavonoid variables (n=2978, all p-values<5x10-5) 
Flavonoids Flavonols Flavones Flavan3ols Procyanidins Flavanones Phytoestr. Quercetin Catechin Epicatechin Naringenin Hesperetin 
Flavonols 1.00                     
Flavones 0.26 1.00          
Flavan3ols 0.94 0.08 1.00         
Procyanidins 0.92 0.09 0.95 1.00        
Flavanones 0.08 0.16 0.02 0.07 1.00       
Phytoestrogens 0.13 0.12 0.08 0.09 0.11 1.00      
Quercetin 0.98 0.35 0.86 0.87 0.15 0.15 1.00     
Catechin 0.71 0.15 0.72 0.81 0.11 0.11 0.70 1.00    
Epicatechin 0.93 0.10 0.96 0.96 0.11 0.11 0.88 0.79 1.00   
Naringenin 0.08 0.16 0.02 0.07 1.00 0.11 0.15 0.23 0.11 1.00  
Hesperetin 0.08 0.16 0.02 0.06 1.00 0.10 0.15 0.21 0.11 1.00 1.00 
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Table 67 Three main dietary (food) sources of flavonoids in our population 
Flavonoids Main sources 
Flavonols Regular tea (62.3%) 
Onions (8.8%) 
Soups- home made (6.1%) 
Flavones Soups- home made (77.8%) 
Other salad vegetables (11.5%) 
Meat or chicken pies, pasties, sausage roll (4.1%)
*
 
Flavan3ols Regular tea (88.6%) 
Apples (3.0%) 
Red wine (2.0%) 
Procyanidins Regular tea (72.9%) 
Apples (12.7%) 
Red wine (8.4%) 
Flavanones Oranges, satsumas or grapefruits (69.1%) 
Pure fruit juice (29.1%) 
Red wine (1.3%) 
Phytoestrogens Soya milk (24.6%) 
Wholemeal bread (including toast and sandwiches) (18.0%) 
Soya beans, TVP, Tofu or soya meat substitute (12.5%) 
Quercetin Regular tea (50.6%) 
Onions (13.3%) 
Soups- home made (9.0%) 
Catechin Regular tea (45.1%) 
Red wine (16.2%) 
Other fruits (9.8%) 
Epicatechin Tea (67.5%) 
Apples (11.7%) 
Chocolate (6.1%) 
Naringenin Oranges, satsumas or grapefruits (70.5%) 
Pure fruit juice (26.7%) 
Red wine (2.1%) 
Hesperetin Oranges, satsumas or grapefruits (67.8%) 
Pure fruit juice (31.5%) 
Red wine (0.6%) 
                                               
* Flavones probably come from suede or parsley that are usual ingredients of these foods 
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Table 68 Association between the flavonoid variables and colorectal cancer risk in the whole sample (3 main conditional logistic regression 
models; Cases and controls matched on age, gender and area of residence) 
Flavonoids Quartiles
*
 Frequency Model I
†
 Model II
‡ Model III§ 
  cases controls OR 95% CI OR 95% CI OR 95% CI 
Flavonols 
(mg/day) 
0 - 15.59 392 353 1.00  1.00  1.00  
15.59 - 27.09 373 371 0.90 0.73, 1.11 0.90 0.74, 1.11 0.88 0.69, 1.13 
 
27.09 - 36.34 381 364 0.95 0.77, 1.16 0.94 0.76, 1.15 0.92 0.72, 1.17 
 > 36.75 343 401 0.87 0.71, 1.07 0.77 0.63, 0.94 0.78 0.60, 0.99 
 p-value for trend (quartiles)  0.27  0.02  0.08 
 p-value for trend (continuous)  0.27  0.02  0.16 
Flavones 
(mg/day) 
0-0.5 424 427 1.00  1.00  1.00  
0.5-1.0 317 332 0.96 0.78, 1.18 0.93 0.76, 1.14 0.91 0.71, 1.16 
 1.0-1.9 380 403 0.95 0.78, 1.16 0.90 0.74, 1.10 1.04 0.82, 1.31 
 >1.9 368 327 1.13 0.93, 1.38 0.99 0.80, 1.23 1.14 0.87, 1.48 
 p-value for trend (quartiles)  0.32  0.78  0.28 




0-42 374 372 1.00  1.00  1.00  
42-114.95 366 377 0.97 0.79, 1.20 0.97 0.78, 1.19 0.95 0.74, 1.22 
 114.95-161.3 393 352 1.12 0.91, 1.38 1.11 0.90, 1.37 1.09 0.85, 1.40 
 >161.3 356 388 0.92 0.75, 1.12 0.86 0.70, 1.05 0.81 0.63, 1.04 
 p-value for trend (quartiles)  0.68  0.32  0.22 
 p-value for trend (continuous)  0.74  0.34  0.30 
Procyanidins 
(mg/day) 
0-16.40 384 361 1.00  1.00  1.00  
16.40-32.34 380 364 0.97 0.79, 1.19 0.97 0.79, 1.20 0.94 0.74, 1.21 
 32.34-45.01 384 361 1.01 0.83, 1.24 1.00 0.82, 1.22 1.00 0.79, 1.27 
 >45.01 341 403 0.89 0.73, 1.10 0.80 0.65, 0.98 0.82 0.64, 1.05 
 p-value for trend (quartiles)  0.37  0.04  0.19 
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 p-value for trend (continuous)  0.31  0.09  0.31 
Flavanones 
(mg/day) 
0-7.69 353 392 1.00  1.00  1.00  
7.69-20.51 404 340 1.36 1.11, 1.67 1.33 1.08, 1.63 1.52 1.19, 1.95 
 20.51-40.86 388 357 1.26 1.03, 1.54 1.21 0.98, 1.49 1.46 1.13, 1.88 
 >40.86 344 400 0.98 0.80, 1.20 0.95 0.77, 1.17 1.15 0.88, 1.51 
 p-value for trend (quartiles)  0.78  0.48  0.39 
 p-value for trend (continuous)  0.09  0.04  0.67 
Phytoestrogens 
(µg/day) 
0-401.33 368 377 1.00  1.00  1.00  
401.33-581.70 403 341 1.29 1.05, 1.59 1.22 0.99, 1.50 1.18 0.92, 1.50 
 581.70-856.39 372 373 1.17 0.95, 1.43 1.02 0.83, 1.26 1.12 0.87, 1.42 
 >856.39 346 398 1.04 0.84, 1.28 0.90 0.73, 1.10 1.04 0.81, 1.34 
 p-value for trend (quartiles)  0.97  0.11  0.87 
 p-value for trend (continuous)  0.15  0.06  0.51 
Quercetin 
(mg/day) 
0-11.53 392 353 1.00  1.00  1.00  
11.53-17.63 387 357 0.96 0.78, .18 0.98 0.80, 1.20 0.97 0.76, 1.24 
 17.63-22.80 379 366 0.91 0.74, 1.11 0.93 0.76, 1.15 0.90 0.70, 1.14 
 >22.80 331 413 0.93 0.75, 1.14 0.71 0.58, 0.88 0.77 0.60, 0.99 
 p-value for trend (quartiles)  0.37  0.002  0.04 
 p-value for trend (continuous)  0.20  0.004  0.12 
Catechin 
(mg/day) 
0-4.84 405 340 1.00  1.00  1.00  
4.84-7.21 385 359 0.90 0.73, 1.10 0.89 0.73, 1.10 0.87 0.68, 1.11 
 7.21-9.40 367 378 0.96 0.78, 1.17 0.82 0.67, 1.01 0.79 0.62, 1.00 
 >9.40 332 412 0.82 0.67, 1.00 0.68 0.55, 0.83 0.75 0.58, 0.97 
 p-value for trend (quartiles)  0.11  0.0001  0.02 
 p-value for trend (continuous)  0.08  0.004  0.19 
Epicatechin 
(mg/day) 
0-12.90 385 360 1.00  1.00  1.00  
12.90-24.05 374 370 0.91 0.74, 1.12 0.95 0.77, 1.17 0.95 0.74, 1.21 
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 24.05-32.47 396 349 1.02 0.83, 1.25 1.08 0.87, 1.33 1.10 0.86, 1.42 
 >32.47 334 410 0.88 0.71, 1.07 0.77 0.63, 0.94 0.77 0.61, 0.99 
 p-value for trend (quartiles)  0.40  0.04  0.12 




0-3.79 356 389 1.00  1.00  1.00  
3.79-9.89 400 344 1.34 1.09, 1.64 1.28 1.04, 1.57 1.43 1.12, 1.83 
 9.89-19.72 392 353 1.33 1.08, 1.63 1.22 0.99, 1.50 1.42 1.10, 1.84 
 >19.72 341 403 0.96 0.78, 1.18 0.92 0.75, 1.13 1.11 0.85, 1.45 
 p-value for trend (quartiles)  0.80  0.38  0.46 
 p-value for trend (continuous)  0.08  0.04  0.66 
Hesperetin 
(mg/day) 
0-3.92 354 391 1.00  1.00  1.00  
3.92-10.60 405 339 1.30 1.06, 1.60 1.32 1.08, 1.62 1.53 1.20, 1.97 
 10.60-21.10 381 364 1.22 1.00, 1.50 1.16 0.94, 1.42 1.10 1.09, 1.80 
 
>21.10 349 395 0.97 0.79, 1.19 0.97 0.79, 1.20 1.18 0.90, 1.55 
 p-value for trend (quartiles)  0.70  0.52  0.36 
 p-value for trend (continuous)  0.09  0.04  0.68 
                                               
*Based on the distribution of the energy adjusted variable, except for the flavonoid subgroups flavones and flavan3ols, which quartiles are based on the distribution of the 
crude variables 
†Model I: Crude analysis 
‡Model II: Adjusted for total energy intake (residual method except for the flavonoid variables flavones and flavan3ols, for which the standard energy adjustment method 
was used) 
§Model III: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake, fibre intake (energy adjusted), alcohol intake (energy adjusted), 
NSAIDs intake 
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Table 69 Association between the flavonoid variables and colorectal cancer risk in the whole sample 
(2 additional conditional logistic regression models; Cases and controls matched on age, gender and 
area of residence) 
Flavonoids Quartiles
*




  cases controls OR 95% CI OR 95% CI 
Flavonols 
(mg/day) 
0 - 15.59 392 353 1.00  1.00  
15.59 - 27.09 373 371 0.90 0.71, 1.15 0.63 0.45, 0.87 
 
27.09 - 36.34 381 364 0.94 0.74, 1.20 0.46 0.29, 0.74 
 > 36.75 343 401 0.81 0.63, 1.01 0.29 0.16, 0.54 
 p-value for trend (quartiles)  0.15  0.0001 




0-0.5 424 427 1.00  1.00  
0.5-1.0 317 332 0.93 0.73, 1.19 0.93 0.73, 1.19 
 1.0-1.9 380 403 1.05 0.83, 1.33 1.12 0.88, 1.44 
 >1.9 368 327 1.14 0.88, 1.49 1.31 0.98, 1.75 
 p-value for trend (quartiles)  0.28  0.05 




0-42 374 372 1.00  1.00  
42-114.95 366 377 0.95 0.74, 1.23 1.11 0.79, 1.56 
 114.95-161.3 393 352 1.09 0.85, 1.41 1.51 0.90, 2.52 
 >161.3 356 388 0.81 0.63, 1.04 1.26 0.63, 2.50 
 p-value for trend (quartiles)  0.22  0.51 
 p-value for trend (continuous)  0.32  0.03 
Procyanidins 
(mg/day) 
0-16.40 384 361 1.00  1.00  
16.40-32.34 380 364 0.95 0.74, 1.22 0.91 0.64, 1.28 
 32.34-45.01 384 361 1.01 0.80, 1.29 0.93 0.56, 1.52 
 >45.01 341 403 0.84 0.65, 1.07 0.74 0.39, 1.43 
 p-value for trend (quartiles)  0.24  0.37 
 p-value for trend (continuous)  0.40  0.97 
Flavanones 
(mg/day) 
0-7.69 353 392 1.00  1.00  
7.69-20.51 404 340 1.53 1.20, 1.97 1.52 1.18, 1.95 
 20.51-40.86 388 357 1.48 1.15, 1.91 1.52 1.10, 1.84 
 >40.86 344 400 1.21 0.92, 1.59 1.14 0.87, 1.50 
 p-value for trend (quartiles)  0.21  0.44 
 p-value for trend (continuous)  0.82  0.68 
Phytoestrogens 
(µg/day) 
0-401.33 368 377 1.00  1.00  
401.33-581.70 403 341 1.14 0.89, 1.46 1.16 0.91, 1.49 
 581.70-856.39 372 373 1.03 0.81, 1.33 1.10 0.85, 1.41 
 >856.39 346 398 0.93 0.72, 1.21 1.04 0.80, 1.34 
 p-value for trend (quartiles)  0.46  0.92 
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 p-value for trend (continuous)  0.39  0.48 
Quercetin 
(mg/day) 
0-11.53 392 353 1.00  1.00  
11.53-17.63 387 357 1.00 0.78, 1.27 0.89 0.63, 1.26 
 17.63-22.80 379 366 0.92 0.72, 1.18 0.72 0.43, 1.20 
 >22.80 331 413 0.82 0.63, 1.06 0.57 0.28, 1.17 
 p-value for trend (quartiles)  0.10  0.10 
 p-value for trend (continuous)  0.32  0.43 
Catechin 
(mg/day) 
0-4.84 405 340 1.00  1.00  
4.84-7.21 385 359 0.88 0.69, 1.13 0.77 0.58, 1.03 
 7.21-9.40 367 378 0.80 0.62, 1.02 0.65 0.45, 0.92 
 >9.40 332 412 0.79 0.61, 1.03 0.56 0.37, 0.86 
 p-value for trend (quartiles)  0.05  0.007 
 p-value for trend (continuous)  0.41  0.14 
Epicatechin 
(mg/day) 
0-12.90 385 360 1.00  1.00  
12.90-24.05 374 370 0.96 0.75, 1.23 0.77 0.54, 1.09 
 24.05-32.47 396 349 1.13 0.88, 1.45 0.77 0.46, 1.30 
 >32.47 334 410 0.78 0.61, 1.00 0.46 0.23, 0.92 
 p-value for trend (quartiles)  0.15  0.03 




0-3.79 356 389 1.00  1.00  
3.79-9.89 400 344 1.44 1.12, 1.85 1.44 1.11, 1.87 
 9.89-19.72 392 353 1.45 1.12, 1.87 1.42 1.06, 1.89 
 >19.72 341 403 1.17 0.89, 1.54 1.15 0.74, 1.79 
 p-value for trend (quartiles)  0.25  0.14 
 p-value for trend (continuous)  0.82  0.99 
Hesperetin 
(mg/day) 
0-3.92 354 391 1.00  1.00  
3.92-10.60 405 339 1.54 1.20, 1.98 1.56 1.20, 2.02 
 10.60-21.10 381 364 1.42 1.10, 1.84 1.43 1.07, 1.91 
 
>21.10 349 395 1.25 0.95, 1.64 1.32 0.85, 2.06 
 p-value for trend (quartiles)  0.19  0.08 
 p-value for trend (continuous)  0.82  0.99 
                                               
* Based on the distribution of the energy adjusted variable, except for the flavonoid subgroups flavones and 
flavan3ols, which quartiles are based on the distribution of the crude variables 
† Model IV: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake, fibre intake 
(energy adjusted), alcohol intake (energy adjusted), NSAIDs intake and fruit and vegetable intake (energy adjusted) 
‡ Model V: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake, fibre intake 
(energy adjusted), alcohol intake (energy adjusted), NSAIDs intake and mutually adjusted for other flavonoid 
subgroups. 
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Table 70 Association between intakes of tea, onions, apples and red wine and colorectal cancer risk in the whole sample (3 main conditional logistic regression 
models; Cases and controls matched on age, gender and area of residence) 
Food items Quartiles
*
 Frequency Model I
†
 Model II
‡ Model III§ 
  cases controls OR 95% CI OR 95% CI OR 95% CI 
Regular tea 
(m/day**) 
0-0.85 376 373 1.00  1.00  1.00  
0.85-3 553 557 0.99 0.82, 1.20 0.99 0.82, 1.20 0.93 0.74, 1.17 
 
3-4 265 243 1.09 0.86, 1.37 1.05 0.83, 1.33 1.09 0.82, 1.44 
 >4 295 316 0.93 0.75, 1.15 0.89 0.72, 1.10 0.82 0.63, 1.06 
 p-value for trend (quartiles)  0.70  0.40  0.27 
 p-value for trend (continuous)  0.90  0.58  0.36 
Onions 
(m/day) 
0-0.14 553 552 1.00  1.00  1.00  
0.14-0.28 266 260 1.02 0.83, 1.26 1.00 0.81, 1.24 1.01 0.78, 1.29 
 0.28-0.57 325 322 1.01 0.83, 1.22 0.97 0.80, 1.18 0.94 0.74, 1.19 
 >0.57 345 355  0.97 0.80, 1.17 0.87 0.72, 1.07 0.92 0.72, 1.17 
 p-value for trend (quartiles)  0.78  0.21  0.44 
 p-value for trend (continuous)  0.02  0.0002  0.03 
Apples 
(m/day) 
0-0.05 494 501 1.00  1.00  1.00  
0.05-0.28 423 377 1.14 0.94, 1.37 1.13 0.93, 1.36 1.16 0.92, 1.45 
 0.28-0.57 267 262 1.04 0.84, 1.28 1.01 0.82, 1.25 1.07 0.83, 1.40 
 >0.57 305 349 0.89 0.73, 1.08 0.84 0.69, 1.03 0.97 0.75, 1.25 
 p-value for trend (quartiles)  0.23  0.09  0.77 
 p-value for trend (continuous)  0.12  0.02  0.32 
Red wine 
(m/day) 
0 939 877 1.00  1.00  1.00  
0-1.5 238 246 0.90 0.73, 1.10 0.89 0.73, 1.09 0.99 0.77, 1.25 
 >1.5 312 366 0.79 0.66, 0.95 0.78 0.65, 0.93 0.87 0.68, 1.11 
 p-value for trend (quartiles)  0.01  0.007  0.33 
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 p-value for trend (continuous)  0.15  0.10  0.45 
                                               
*Based on the distribution of the crude variables 
†Model I: Crude analysis 
‡Model II: Adjusted for total energy intake (standard method) 
§Model III: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake, fibre intake (energy adjusted), alcohol intake (energy adjusted), NSAIDs intake 
** m/day: measures per day 
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6.4 Fatty acids 
This analysis describes the distribution and correlation of the fatty acid variables. In 
addition, the differences in crude and energy-adjusted fatty acid intakes between 
cases and controls and the unadjusted and adjusted associations between fatty acid 
intakes and colorectal cancer are presented. 
6.4.1 Descriptive analysis 
6.4.1.1 Distribution of fatty acid variables 
After careful examination of the distribution of the fatty acid variables (total, 
subgroups and individual compounds) by looking at their histograms (original and 
transformed variables if skewed) we elected to study the following variables: total 
FAs; seven fatty acid subgroups: SFAs, MUFAs, PUFAs, ω6PUFAs, ω3PUFAs, 
tFAs and tMUFAs; and nine individual fatty acid compounds: palmitic and stearic 
acids (SFAs), oleic acid (MUFAs), linoleic, γ-linolenic and arachidonic acids 
(ω6PUFAs) and α-linolenic, EPA and DHA (ω3PUFAs) ( 
Table 71). For total FAs, the subgroups ω6 and ω3PUFAs and the individual 
compounds EPA and DHA, dietary and total (diet and supplements) intakes were 
available. 
6.4.1.2 Distribution of fatty acid variables by case control status 
Evaluation of the fatty acid composition of the diet of our study population showed 
that the most abundant fatty acids (individual compounds) were oleic, palmitic and 
stearic acids, accounting for the 29.4%, 22.0% and 10.2% of the total dietary intake 
of fatty acids respectively. For crude fatty acid intakes, cases reported a higher mean 
intake for total FAs (p<5x10-5), the subgroups: SFAs (p<5x10-5), MUFAs (p<5x10-
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), linoleic (p=0.001), γ-linolenic (p=0.007), arachidonic (p=0.0008) and α-linolenic 
(p=0.02) (Table 72). In addition, cases reported a higher median intake for total FAs 
(p<5x10-5), the subgroups: SFAs (p<5x10-5), MUFAs (p<5x10-5), PUFAs (p=0.009), 
ω6PUFAs (p=0.004), tFAs (p<5x10-5), tMUFAs (p<5x10-5) and the individual fatty 








), linoleic (p=0.0045), 
γ-linolenic (p=0.01), arachidonic (p=0.0025), α-linolenic (p=0.03) and  a lower 
median intake for the individual fatty acid of EPA (p=0.05) (Table 72). 
After energy adjustment (residual) cases reported a higher mean intake for total FAs 
(p=0.0018), the subgroups: SFAs (p=0.0001), MUFAs (p=0.03), tFAs (=0.0026), 
tMUFAs (p=0.0003) and the individual fatty acids: palmitic (p=0.0003), stearic 
(p=0.0001), oleic (p=0.0062) and a lower mean intake for the subgroup of ω3PUFAs 
(p<5x10-5) and the individual fatty acids of EPA (p<5x10-5) and DHA (p<5x10-5) 
(Table 72). In addition cases reported a higher median intake for total FAs 
(p=0.0005), the subgroups: SFAs (p=0.0001), MUFAs (p=0.01), tFAs (=0.001), 
tMUFAs (p<5x10
-5
) and the individual fatty acids: palmitic (p=0.0002), stearic 
(p=0.0001), oleic (p=0.002) and a lower median intake for the subgroup of 
ω3PUFAs (p<5x10-5) and the individual fatty acids of EPA (p<5x10-5) and DHA 
(p<5x10-5) (Table 72). 
6.4.1.3 Correlations between the fatty acid variables 
Overall they were highly correlated. The highest correlations were observed between 
total FAs, SFAs, MUFAs, PUFAs, tFAs, tMUFAs, palmitic acid, stearic acid, oleic 
acid with r>0.7. In addition, EPA, DHA and ω3PUFAs were highly correlated with 
r>0.8 (Table 73).  
6.4.1.4 Main sources of fatty acid variables 
For fatty acid variables food sources data were not available for individual food 
items. The three main food sources (at food group level) of total FAs were: meat and 
meat products (18.0%), spreads
1
 and cooking oils (13.4%) and confectionery and 
savoury snacks (8.3%). The three main food sources of the fatty acid subgroups 
were: 1) for SFAs: meat and meat products (17.5%), spreads and cooking oils 
(13.1%) and cheese (10.3%); 2) for MUFAs: meat and meat products (19.7%), 
spreads and cooking oils (13.7%), fish and fish dishes (8.5%); 3) for PUFAs: meat 
and meat products (15.3%), spreads and cooking oils (13.5%), confectionery and 
savoury snacks (11.4%); 4) for ω6PUFAs: spreads and cooking oils (15.2%), meat 
and meat products (14.8%), confectionery and savoury snacks (10.2%); 5) for 
                                               
1 Including butter, margarine, jam, honey, marmalade, yeast or meat extract, peanut butter, and chocolate spread 
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ω3PUFAs: fish and fish dishes (30.3%), meat and meat products (16.2%) and 
vegetables (13.1%); 6) for tFAs: spreads and cooking oils (20.7%), confectionery 
and savoury snacks (15.7%) and meat and meat products (15.4%); and 7) for 
tMUFAs: spreads and cooking oils (25.2%), meat and meat products (14.6%) and 
cheese (11.9%) (Table 74). 
Finally, the three main food sources of the fatty acid individual compounds were: 1) 
for palmitic acid: meat and meat products (19.8%), spreads and cooking oils (12.8%) 
and cheese (8.5%); 2) for stearic acid: meat and meat products (24.8%), spreads and 
cooking oils (11.9%) and biscuits (8.7%); 3) for oleic acid:  meat and meat products 
(20.6%), spreads and cooking oils (14.0%) and confectionery and savoury snacks 
(9.0%); 4) for linoleic acid: meat and meat products (15.9%), spreads and cooking 
oils (12.8%) and confectionery and savoury snacks (10.6%); 5) for γ-linolenic acid: 
meat and meat products (69.8%), potatoes, rice and pasta (8.6%) and fish and fish 
dishes (8.5%); 6) for arachidonic acid meat and meat products (62.4%), eggs (11.1%) 
and savoury foods, soups and sauces (10.2%); 7) for α-linolenic acid: vegetables 
(22.3%),  spreads and cooking oils (13.0%) and savoury foods, soups and sauces 
(10.6%); 8) for EPA: fish and fish dishes (69.0%), meat and meat products (23.3%) 
and savoury foods, soups and sauces (5.7%); and 9) for DHA: fish and fish dishes 
(67.8%), meat and meat products (23.6%) and eggs (3.3%) (Table 74). 
One thousand fifty four participants reported consumption of supplement products 
and 740 of them reported consumption of supplements that contributed to the fatty 
acid daily intake (for total FAs; the subgroups of: PUFAs, ω6PUFAs and ω3PUFAs; 
and the individual fatty acids of: linoleic, γ-linolenic, α-linolenic, EPA and DHA). In 
particular supplements that contributed to the fatty acid daily intakes included: cod or 
halibut liver oil (35.6% of total number of supplements taken), evening primrose oil 
(5.8%) and fish oils (2.5%). We identified the exact nutrient composition of these 
dietary supplements and added the supplement nutrients to the dietary ones. 
6.4.2 Associations between fatty acid variables and 
colorectal cancer risk 
6.4.2.1 Main conditional logistic regression models 
In model I, dietary intakes of total FAs, SFAs, MUFAs, PUFAs, ω6PUFAs, tFAs and  
tMUFAs as well as of the individual fatty acids palmitic, stearic, oleic, linoleic, γ-
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linolenic, arachidonic, EPA and DHA acid showed a dose-dependent association 
with colorectal cancer risk (p-value for trend fatty acid subgroups: 5.6x10-6, 4.8x10-6, 







, 0.005, 0.03, 0.001, 0.05, 0.04; respectively) (Table 75). 
Associations between total intakes (from diet and supplements) of fatty acids and 
colorectal cancer were not examined in model I, since intake from supplements was 
added to the energy-adjusted nutrients. 
In model II, a dose-dependent increase in risk was observed for dietary intake of total 
FAs, SFAs, MUFAs, tFAs and tMUFAs and for the individual fatty acids palmitic, 
stearic and oleic (high vs. low intake: OR (95% CI): 1.30 (1.06, 1.59), 1.42 (1.15, 
1.75), 1.29 (1.05, 1.58), 1.38 (1.12, 1.70), 1.47 (1.19, 1.80), 1.43 (1.16, 1.75), 1.64 
(1.32, 2.02), 1.38 (1.12, 1.69); respectively) (Table 75). In addition, intake of dietary 
ω3PUFAs, EPA and DHA was inversely and dose dependently associated with 
colorectal cancer (p-value for trend: 9.3x10-6, 0.0001, 0.0002, respectively) with 
approximately a 35% reduction in risk for those of high versus low intake (OR (95% 
CI): 0.65 (0.53, 0.79), 0.66 (0.54, 0.81), 0.68 (0.56, 0.84); respectively) (Table 75). 
Regarding total intakes, total FAs were associated with an increased and dose 
dependent colorectal cancer risk, whereas total intakes of ω3PUFAs, EPA and DHA 
were associated with a decreased and dose dependent colorectal cancer risk (p-value 
for trend: 0.001, 1.1x10-5, 3.4x10-6, 1.2x10-5; respectively) (Table 75). 
In model III, only the association between colorectal cancer and stearic acid and the 
inverse associations between colorectal cancer and ω3PUFAs, EPA and DHA 
remained statistically significant (high vs. low intake: OR (95% CI), p-value: 1.46 
(1.11, 1.91), 0.01; 0.75 (0.59, 0.97), 0.01; 0.74 (0.58, 0.95), 0.02; 0.74 (0.58, 0.95), 
0.02; respectively) (Table 75). In addition, ω3PUFA, EPA and DHA total intakes 
were inversely and dose-dependently associated with colorectal cancer risk (p-value 
for trend: 0.008, 0.003, 0.003; respectively) (Table 75).  
6.4.2.2 Additional conditional logistic regression models 
The associations between fatty acid variables and colorectal cancer were tested in 
two additional models (Model IV and V): Model IV was corrected for the 
confounding factors of model III and in addition to the residual energy adjustment 
dietary energy intake was included as a covariate (suggested by Willet to reduce the 
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random error).  In model V associations were corrected for the confounding factors 
of model III and further adjusted for intake of total FAs (Table 76). For the 
subgroups of PUFAs, ω6PUFAs and ω3PUFAs and the individual fatty acids 
linoleic, γ-linolenic, α-linolenic, EPA and DHA additional analyses were conducted 
for their total intake (intake from diet and supplements). 
For both models IV and V positive statistically significant associations were 
observed for stearic acid (Model IV: high vs. low intake OR (95% CI), p-value: 1.38 
(1.05, 1.83), 0.03; Model V: high vs. low intake OR (95% CI), p-value: 1.76 (1.18, 
2.63), 0.01) and inverse significant associations were observed for ω3PUFAs, EPA 
and DHA (Model IV: high vs. low intake OR (95% CI), p-value: 0.75 (0.58, 0.96), 
0.008; 0.74 (0.58, 0.95), 0.02; 0.73 (0.57, 0.94), 0.02; Model IV: high vs. low intake 
OR (95% CI), p-value: 0.69 (0.53, 0.90), 0.002; 0.72 (0.56, 0.93), 0.01; 0.71 (0.55, 
0.92), 0.01; respectively) (Table 76). In addition, total intake of ω3PUFAs, EPA and 
DHA were inversely and dose-dependently associated with colorectal cancer risk 
after applying both models IV and V (p-value for trend: Model IV: 0.006, 0.003, 
0.001; Model V: 0.002, 0.002, 0.001; respectively) (Table 76). 
6.4.2.3 Multiple testing corrections 
Bonferroni correction for multiple testing 
In model I the associations between colorectal cancer and total FAs (p=5.6x10-6), the 
subgroups SFAs (p=4.8x10-6), MUFAs (p=2.0x10-5), tFAs (p=3.1x10-6), tMUFAs 
(p=3.0x10-7), and the individual fatty acids palmitic (p=1.5x10-7), stearic (p=5.9x10-
7
) and oleic (p=3.1x10
-6
) remained significant under every level of correction, 
whereas association with ω6PUFAs (p=0.002) and arachidonic acid (p=0.001) 
remained significant at the first and second level of significance, respectively (Table 
75). In model II, the associations with the subgroups ω3PUFAs (p=9.3x10-6), 
tMUFAs (p=0.0003) and the individual compounds stearic (p=7.9x10-6), EPA 
(p=0.0001) and DHA (p=0.0002) remained significant under every level of 
correction, the associations with total FAs (p=0.001), the subgroup SFAs (p=0.001) 
and the individual compounds palmitic (p=0.001) and oleic (p=0.001) remained 
significant in the first two levels, and finally the association between colorectal 
cancer and tFAs remained significant only at the first level of correction (Table 75). 
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Finally, in model V, the association between ω3PUFAs (p=0.002) and colorectal 
cancer remained significant in the first level of correction (Table 76). 
FDR correction for multiple testing 
After correcting for multiple testing using the FDR method all the associations 
between the dietary intakes and colorectal cancer that their observed p-values were 
≤0.01 remained significant (Table 75, Table 76).  
6.4.2.4 Associations between colorectal cancer and main food 
sources of total fatty acids, SFAs, MUFAs, ω3PUFAs, tFAs, 
tMUFAs, palmitic acid, stearic acid, oleic acid, EPA and DHA  
Intakes of the following food groups were tested: meat and meat products, 
confectionery and savoury snacks (including chocolates, sweets, nuts and crisps) and 
fish and fish dishes. Results from model III, showed that comparison of highest 
versus lowest quartile intakes of these foods showed ORs for colorectal cancer risk 
of 0.93 (95% CI 0.72, 1.21; p-value for trend 0.33) for meat and meat products; 1.47 
(95% CI 0.72, 1.17; p-value for trend 0.002) for confectionery and savoury snacks; 
and 0.77 (95% CI 0.60, 0.99; p-value for trend 0.07) for fish and fish dishes (Table 
77).  
6.4.2.5 Associations between the fatty acid variables and 
colorectal cancer after sex, age and cancer site stratification 
Associations between each fatty acid variable and colorectal cancer risk were tested 
after sex, age and cancer site stratification by applying model III (data not shown). 
Briefly, both dietary and total intakes of ω3PUFAs, EPA and DHA were inversely 
associated with colorectal cancer for both men and women; however associations 
were stronger and statistically significant for men (associations for dietary intakes for 
men: OR (95% CI), p-value for trend: 0.68 (0.49, 0.95), 0.02; 0.70 (0.50, 0.96), 0.02; 
0.69 (0.50, 0.95), 0.02; respectively) (data not shown). In addition, dietary and total 
intake of total FAs, the fatty acid subgroups MUFAs, tFAs and tMUFAs and dietary 
intake of the individual compound oleic acid, were positively and significantly 
associated with colorectal cancer for women but not for men (women (dietary 
intakes): OR (95% CI), p-value for trend: 1.40 (0.92, 2.13), 0.03; 1.67 (1.10, 2.53), 
0.008; 1.38 (0.91, 2.10), 0.05; 2.00 (1.31, 3.06), 0.002; 1.67 (1.10, 2.53), 0.007, 
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respectively) (data not shown). After age stratification, dietary and total intakes of 
ω3PUFAs, EPA and DHA were inversely associated with colorectal cancer mainly 
for the older study participants; with the associations for the individuals younger than 
55 years old not being statistically significant (associations for dietary intakes for 
individuals ≥55 years old: OR (95% CI), p-value for trend: 0.75 (0.56, 0.99), 0.01; 
0.70 (0.53, 0.92), 0.02; 0.71 (0.54, 0.93), 0.02; respectively) (data not shown). In 
addition, dietary intakes of SFAs, MUFAs, tFAs, tMUFAs and palmitic acid were 
positively though not significantly associated with colorectal cancer only for the 
individuals younger than 55 years old (data not shown). Finally, both dietary and 
total intakes of ω3PUFAs, EPA and DHA were inversely associated with both colon 
and rectal cancer (with associations with colon cancer being statistically significant) 
(data not shown). Dietary intakes of MUFAs, tFAs, tMUFAs and oleic acid were 
inversely associated only with rectal cancer, though only the positive association 
with tMUFAs was statistically significant (high vs. low intake of tMUFAs for rectal 
cancer: OR (95% CI), p-value for trend: 1.55 (1.06, 2.28), 0.02) (data not shown). 
6.4.3 Summary of results 
Moderately strong associations which showed dose response relationships were 
found: 1) in model I: between colorectal cancer and dietary intakes of total FAs 
(p=5.6x10-6), SFAs (p=4.8x10-6), MUFAs (p=2.0x10-5), PUFAs (p=0.01), ω6PUFAs 
(p=0.002), tFAs (p=3.1x10-6) and  tMUFAs (p=3.0x10-7), palmitic acid (p=1.5x10-7), 
stearic acid (p=5.9x10-7), oleic acid (p=3.1x10-6), linoleic acid (p=0.005), γ-linolenic 
acid (p=0.03) and arachidonic acid (p=0.001) (high intakes increased risk) (Table 75) 
and between colorectal cancer and dietary intakes of EPA (p=0.05) and DHA 
(p=0.04) (high intakes decreased risk) (Table 75); 2) in model II: between colorectal 
cancer and the dietary intakes of ω3PUFAs (p=9.3x10-6), EPA (p=0.0001), DHA 
(p=0.0002) (high intakes decreased risk) (Table 75) and between colorectal cancer 
and dietary intakes of total FAs (p=0.001), SFAs (p=0.001), MUFAs (p=0.01) tFAs 
(p=0.002), tMUFAs (p=0.0003), palmitic acid (p=0.001), stearic acid (p=7.9x10
-6
) 
and oleic acid (p=0.001) (high intakes increased risk) (Table 75); 3) in model III, 
between colorectal cancer and dietary intakes of ω3PUFAs (p=0.01), EPA (p=0.02) 
and DHA (p=0.02) (high intakes decreased risk) and between colorectal cancer and 
stearic acid (p=0.01) (high intakes increased risk) (Table 75); 4) in model IV and V: 
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between colorectal cancer and stearic acid (p= 0.03 and 0.01, respectively) (high 
intakes increased risk) and between colorectal cancer and ω3PUFAs (p= 0.008 and 
0.002, respectively), EPA (p= 0.02 and 0.01, respectively) and DHA (p= 0.02 and 
0.01, respectively) (Table 76). 
 
Table 71 Fatty acid variables (total FAs, subgroups and individual compounds) that were 
elected to be included in the analysis 
Flavonoid variables 
included in the analysis 
Transformation 
Total FAs  









Individual compounds  
Palmitic acid logarithmic 
Stearic acid logarithmic 
Oleic acid logarithmic 
Linoleic acid logarithmic 
γ-Linolenic acid square root 
Arachidonic acid square root 
α-Linolenic acid logarithmic 
EPA logarithmic 
DHA logarithmic 
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Table 72 Descriptive report of crude and energy-adjusted fatty acid intakes 







T-test  Wilcoxon 
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ω6PUFAs- 
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Oleic acid- 25.0 25.2 25.3 25.5 24.8 24.9 0.006 0.002 
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energy adjusted (g/day) (4.9) (22.1, 28.1) (4.6) (22.4, 28.2) (5.1) (21.7, 27.9) 
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Table 73 Spearman rank correlation coefficients between fatty acid variables (all p-values<5x10-5) 
Fatty  acids FAs SFAs MUFAs PUFAs ω6PUFAs ω3PUFAs tFAs tMUFAs PA SA OA LA γLA AA αLA EPA DHA 
FAs 1.00                                 
SFAs 0.96 1.00                
MUFAs 0.98 0.91 1.00               
PUFAs 0.84 0.67 0.85 1.00              
ω6PUFAs 0.79 0.62 0.80 0.98 1.00             
ω3PUFAs 0.71 0.57 0.76 0.76 0.67 1.00            
tFAs 0.89 0.89 0.85 0.68 0.62 0.52 1.00           
tMUFAs 0.87 0.87 0.85 0.65 0.62 0.55 0.93 1.00          
Palmitic acid (PA) 0.97 0.99 0.93 0.71 0.66 0.61 0.88 0.86 1.00         
Stearic acid (SA) 0.96 0.98 0.91 0.72 0.67 0.56 0.90 0.86 0.97 1.00        
Oleic acid (OA) 0.97 0.89 0.99 0.86 0.82 0.71 0.84 0.83 0.93 0.91 1.00       
Linoleic acid (LA) 0.78 0.61 0.79 0.98 1.00 0.66 0.61 0.61 0.65 0.65 0.81 1.00      
γ-Linolenic acid (γLA) 0.64 0.58 0.67 0.57 0.53 0.58 0.50 0.51 0.62 0.63 0.67 0.51 1.00     
Arachidonic acid (AA) 0.70 0.64 0.72 0.62 0.58 0.63 0.58 0.60 0.68 0.69 0.71 0.55 0.81 1.00    
α-Linolenic acid (αLA) 0.79 0.66 0.82 0.85 0.81 0.82 0.66 0.68 0.70 0.66 0.82 0.80 0.56 0.56 1.00   
EPA 0.40 0.32 0.45 0.43 0.33 0.82 0.24 0.28 0.33 0.30 0.37 0.32 0.40 0.50 0.40 1.00  
DHA  0.42 0.32 0.46 0.45 0.35 0.83 0.24 0.27 0.35 0.30 0.39 0.34 0.42 0.50 0.42 0.99 1.00 
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Table 74 Three main dietary (food) sources of fatty acids in our population 
Fatty acids subgroups Main sources (% of total intake) 
Total fatty acids 
 
Meat & meat products (18.0%) 
Spreads
*
 & cooking oils (13.4%) 
Confectionery & savoury snacks (8.3%) 
Saturated fatty acids 
 
Meat & meat products (17.5%) 
Spreads
*






Meat & meat products (19.7%) 
Spreads* & cooking oils (13.7%) 
Fish & fish dishes (8.5%) 
Poly-unsaturated fatty acids 
 
 
Meat & meat products (15.3%) 
Spreads
* 
& cooking oils (13.5%) 
Confectionery & savoury snacks (11.4%) 






& cooking oils (15.2%) 
Meat & meat products (14.8%) 
Confectionery & savoury snacks (10.2%) 




Fish & fish dishes (30.3%) 
Meat & meat products (16.2%) 
Vegetables (13.1%) 





& cooking oils (20.7%) 
Confectionery & savoury snacks (15.7%) 







 & cooking oils (25.2%) 
Meat & meat products (14.6%) 
Cheese (11.9%) 
Palmitic acid  Meat & meat products (19.8%) 
Spreads
‡
 & cooking oils (12.8%) 
Cheese (8.5%) 
Stearic acid  Meat & meat products (24.8%) 
Spreads* & cooking oils (11.9%) 
Biscuits (8.7%)  
Oleic acid  Meat & meat products (20.6%) 
Spreads
*
 & cooking oils (14.0%) 
Confectionery & savoury snacks (9.0%) 
Linoleic acid  Meat & meat products (15.9%) 
Spreads
*
 & cooking oils (12.8%) 
Confectionery & savoury snacks (10.6%) 
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γ-Linolenic acid Meat & meat products (69.8%) 
Potatoes, rice and Pasta (8.6%) 
Fish & fish dishes (8.5%) 
Arachidonic acid  Meat & meat products (62.4%) 
Eggs (11.1%) 
Savoury foods, soups and sauces (10.2%) 
α-Linolenic acid  Vegetables (22.3%) 
Spreads
*
 & cooking oils (13.0%) 
Savoury foods, soups and sauces (10.6%) 
EPA Fish & fish dishes (69.0%) 
Meat & meat products (23.3%) 
Savoury foods, soups and sauces (5.7%) 
DHA  Fish & fish dishes (67.8%) 
Meat & meat products (23.6%) 
Eggs (3.3%) 
                                               
* Including butter, margarine, jam, honey, marmalade, yeast or meat extract, peanut butter, and chocolate spread 
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Table 75 Association between the fatty acid variables and colorectal cancer risk in the whole sample (3 main conditional logistic regression models; Cases and 
controls matched on age, gender and area of residence) 
Fatty acids Quartiles
*







  cases controls OR 95% CI OR 95% CI OR 95% CI 
Total FAs 
(g/day) 
0-75.93 339 399 1.00  1.00  1.00  
75.93-86.21 345 392 1.09 0.89, 1.35 1.03 0.84, 1.26 0.99 0.78, 1.27 
 86.21-94.91 404 334 1.37 1.11, 1.68 1.43 1.17, 1.76 1.25 0.98, 1.61 
 >94.91 387 350 1.55 1.25, 1.92 1.30 1.06, 1.59 1.05 0.81, 1.36 
 p-value for trend (quartiles)  5.6x10
-6 
 0.001  0.36 
 p-value for trend (continuous)  3.9x10
-5 
 0.002  0.27 
Total FAs 
(total) (g/day) 
0-75.98 338 400   1.00  1.00  
75.98-86.34 346 391   1.04 0.85, 1.28 1.01 0.79, 1.29 
 86.34-94.95 404 334   1.44 1.17, 1.77 1.27 0.99, 1.34 
 >95.94 387 350   1.31 1.07, 1.60 1.06 0.82, 1.37 
 p-value for trend (quartiles)    0.001  0.33 
 p-value for trend (continuous)    0.002  0.28 
SFAs 
(g/day) 
0-31.72 336 402 1.00  1.00  1.00  
31.72-37.18 365 372 1.03 0.83, 1.28 1.18 0.96, 1.45 1.13 0.88, 1.45 
 37.18-43.55 375 363 1.22 0.99, 1.50 1.24 1.01, 1.52 1.01 0.79, 1.30 
 >43.55 399 338 1.58 1.28, 1.95 1.42 1.15, 1.75 1.19 0.91, 1.55 
 p-value for trend (quartiles)  4.8x10
-6 
 0.001  0.34 
 p-value for trend (continuous)  4.1x10
-6 
 0.0001  0.13 
MUFAs 
(g/day) 
0-28.62 333 405 1.00  1.00  1.00  
28.62-32.54 377 360 1.10 0.89, 1.35 1.27 1.04, 1.56 1.27 0.99, 1.63 
 32.54-36.04 385 353 1.38 1.12, 1.69 1.33 1.08, 1.64 1.23 0.96, 1.59 
 >36.04 380 357 1.50 1.22, 1.86 1.29 1.05, 1.58 1.13 0.88, 1.46 
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 p-value for trend (quartiles)  2.0x10
-5
  0.01  0.45 
 p-value for trend (continuous)  0.0003  0.03  0.42 
PUFAs  
(g/day) 
0-11.94 380 358 1.00  1.00  1.00  
11.94-14.03 370 367 1.01 0.82, 1.24 0.95 0.77, 1.17 1.11 0.87, 1.42 
 14.03-16.58 348 390 0.96 0.78, 1.18 0.84 0.68, 1.03 0.94 0.74, 1.20 
 >16.58 377 360 1.35 1.09, 1.66 0.98 0.80, 1.20 0.98 0.76, 1.25 
 p-value for trend (quartiles)  0.01  0.62  0.54 
 p-value for trend (continuous)  0.004  0.96  0.66 
PUFAs 
(total) (g/day) 
0-11.99 383 355   1.00  1.00  
11.99-14.08 365 372   0.91 0.74, 1.12 1.04 0.82, 1.33 
 14.08-16.67 350 388   0.83 0.68, 1.02 0.91 0.71, 1.17 
 >16.67 377 360   0.97 0.79, 1.18 0.97 0.76, 1.24 
 p-value for trend (quartiles)    0.60  0.56 
 p-value for trend (continuous)    0.82  0.58 
ω6PUFAs 
(g/day) 
0-8.87 365 373 1.00  1.00  1.00  
8.87-10.61 380 357 1.03 0.84, 1.26 1.09 0.89, 1.34 1.14 0.89, 1.45 
 10.61-13.04 361 377 1.00 0.81, 1.23 0.98 0.79, 1.20 1.07 0.83, 1.37 
 >13.04 369 368 1.42 1.15, 1.75 1.02 0.84, 1.26 1.02 0.80, 1.31 
 p-value for trend (quartiles)  0.002  0.92  0.97 
 p-value for trend (continuous)  0.001  0.42  0.77 
ω6PUFAs 
(total) (g/day) 
0-8.89 365 373   1.00  1.00  
8.89-10.62 381 356   1.09 0.89, 1.34 1.15 0.90, 1.47 
 10.62-13.06 360 378   0.97 0.79, 1.19 1.07 0.83, 1.37 
 >13.06 369 368   1.02 0.84, 1.26 1.02 0.80, 1.31 
 p-value for trend (quartiles)    0.89  0.94 
 p-value for trend (continuous)    0.45  0.80 




0-1.82 416 322 1.00  1.00  1.00  
1.82-2.22 377 360 1.12 0.91, 1.38 0.82 0.66, 1.00 0.95 0.74, 1.22 
 2.22-2.73 348 390 1.05 0.86, 1.28 0.70 0.57, 0.86 0.80 0.63, 1.02 
 >2.73 334 403 1.07 0.87, 1.32 0.65 0.53, 0.79 0.75 0.59, 0.97 
 p-value for trend (quartiles)  0.67  9.3x10
-6 
 0.01 





0-1.84 409 329   1.00  1.00  
1.84-2.26 381 356   0.86 0.70, 1.06 0.95 0.74, 1.22 
 2.26-2.79 360 378   0.77 0.63, 0.95 0.89 0.70, 1.13 
 >2.79 325 412   0.64 0.52, 0.78 0.71 0.55, 0.92 
 p-value for trend (quartiles)    1.1x10-5  0.008 





0-2.87 325 413 1.00  1.00  1.00  
2.87-3.54 379 358 1.08 0.88, 1.32 1.34 1.09, 1.64 1.24 0.97, 1.58 
 3.54-4.22 386 352 1.19 0.97, 1.47 1.38 1.13, 1.69 1.31 1.03, 1.66 
 >4.22 385 352 1.63 1.32, 2.00 1.38 1.12, 1.70 1.13 0.88, 1.46 
 p-value for trend (quartiles)  3.1x10
-6 
 0.002  0.28 
 p-value for trend (continuous)  1.1x10-5  0.003  0.41 
tMUFAs 
(g/day) 
0-2.20 318 420 1.00  1.00  1.00  
2.20-2.71 378 359 1.08 0.88, 1.32 1.40 1.14, 1.73 1.39 1.08, 1.78 
 2.71-3.23 390 348 1.34 1.09, 1.65 1.47 1.20, 1.80 1.35 1.05, 1.72 
 >3.23 389 348 1.65 1.34, 2.02 1.47 1.19, 1.80 1.28 1.00, 1.65 
 p-value for trend (quartiles)  3.0x10
-7 
 0.0003  0.09 
 p-value for trend (continuous)  3.1x10
-6 
 0.0004  0.15 
Palmitic acid 
(g/day) 
0-16.13 329 409 1.00  1.00  1.00  
16.13-18.72 369 368 1.16 0.94, 1.44 1.25 1.02, 1.53 1.16 0.91, 1.49 
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 18.72-21.36 384 354 1.38 1.12, 1.70 1.35 1.10, 1.66 1.22 0.95, 1.57 
 >21.36 393 344 1.72 1.39, 2.12 1.43 1.16, 1.75 1.13 0.86, 1.47 
 p-value for trend (quartiles)  1.5x10
-7
  0.001  0.36 
 p-value for trend (continuous)  9.5x10
-6 
 0.0003  0.21 
Stearic acid 
(g/day) 
0-7.37 322 416 1.00  1.00  1.00  
7.37-8.71 368 369 0.95 0.77, 1.18 1.31 1.06, 1.61 1.29 1.00, 1.66 
 8.71-10.03 377 361 1.27 1.03, 1.57 1.37 1.12, 1.69 1.32 1.02, 1.70 
 >10.03 408 329 1.61 1.30, 1.99 1.64 1.32, 2.02 1.46 1.11, 1.91 




  0.01 
 p-value for trend (continuous)  8.4x10-7  6.6x10
-5
  0.08 
Oleic acid 
(g/day) 
0-22.06 334 404 1.00  1.00  1.00  
22.06-25.22 365 372 1.13 0.91, 1.39 1.19 0.97, 1.46 1.14 0.89, 1.46 
 25.22-28.06 385 353 1.50 1.21, 1.85 1.32 1.08, 1.62 1.24 0.97, 1.59 
 >28.06 391 346 1.56 1.25, 1.93 1.38 1.12, 1.69 1.23 0.95, 1.59 
 p-value for trend (quartiles)  3.1x10
-6 
 0.001  0.10 
 p-value for trend (continuous)  6.9x10
-5 
 0.006  0.15 
Linoleic acid 
(g/day) 
0-8.41 367 371 1.00  1.00  1.00  
8.41-10.14 377 360 1.02 0.83, 1.25 1.06 0.86, 1.29 1.08 0.84, 1.38 
 10.14-12.56 360 378 0.98 0.79, 1.21 0.96 0.78, 1.18 1.04 0.81, 1.34 
 >12.56 371 366 1.38 1.12, 1.69 1.02 0.83, 1.25 1.00 0.78, 1.28 
 p-value for trend (quartiles)  0.005  0.95  0.92 




0-8.42 368 370   1.00  1.00  
8.42-10.15 378 359   1.06 0.86, 1.29 1.09 0.85, 1.39 
 10.15-12.57 359 380   0.95 0.77, 1.17 1.02 0.80, 1.31 
 >12.57 370 366   1.01 0.83, 1.24 0.99 0.78, 1.28 
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 p-value for trend (quartiles)    0.86  0.82 
 p-value for trend (continuous)    0.46  0.80 
γ-Linolenic acid 
(mg/day) 
0-5.86 368 370 1.00  1.00  1.00  
5.86-8.43 387 350 1.00 0.82, 1.21 1.10 0.90, 1.35 1.09 0.86, 1.38 
 8.43-11.29 352 386 1.15 0.94, 1.40 0.91 0.74, 1.12 0.82 0.64, 1.05 
 
>11.29 368 369 1.24 1.00, 1.54 1.00 0.81, 1.23 0.98 0.76, 1.26 
 p-value for trend (quartiles)  0.03  0.57  0.37 
 p-value for trend (continuous)  0.01  0.74  0.99 
γ-Linolenic acid 
(total) (mg/day) 
0-6.06 369 369   1.00  1.00  
6.06-8.69 390 347   1.11 0.91, 1.36 1.14 0.90, 1.44 
8.69-11.79 342 396   0.86 0.70, 1.06 0.79 0.61, 1.01 
 >11.79 374 363   1.03 0.83, 1.26 1.05 0.82, 1.35 
 p-value for trend (quartiles)    0.59  0.58 
 p-value for trend (continuous)    0.23  0.58 
Arachidonic acid 
(mg/day) 
0-238.75 347 391 1.00  1.00  1.00  
238.75-295.30 374 363 1.19 0.97, 1.46 1.17 0.95, 1.44 1.24 0.97, 1.59 
 
295.30-358.60 394 344 1.26 1.02, 1.55 1.29 1.05, 1.58 1.17 0.92, 1.50 
 >358.60 360 377 1.42 1.15, 1.75 1.07 0.87, 1.31 1.04 0.81, 1.33 
 p-value for trend (quartiles)  0.001  0.32  0.86 
 p-value for trend (continuous)  0.001  0.36  0.81 
α-Linolenic acid 
(mg/day) 
0-1123.4 361 377 1.00  1.00  1.00  
1123.4-1315.8 381 356 1.03 0.84, 1.26 1.12 0.91, 1.38 1.22 0.95, 1.57 
 1315.8-1537.6 393 345 1.24 1.00, 1.52 1.19 0.97, 1.46 1.42 1.10, 1.80 
 >1537.6 340 397 1.13 0.91, 1.39 0.90 0.73, 1.10 1.01 0.78, 1.30 
 p-value for trend (quartiles)  0.11  0.41  0.75 
 p-value for trend (continuous)  0.09  0.10  0.53 




0-1123.6 361 377   1.00  1.00  
1123.6-1316.1 380 357   1.11 0.91, 1.37 1.21 0.95, 1.56 
 1316.1-1538.3 394 344   1.20 0.97, 1.47 1.42 1.10, 1.83 
 >1538.3 340 397   0.90 0.73, 1.10 1.01 0.78, 1.31 
 p-value for trend (quartiles)    0.43  0.71 




0-155.16 409 329 1.00  1.00  1.00  
155.16-248.39 371 366 0.95 0.78, 1.17 0.82 0.67, 1.01 0.92 0.72, 1.18 
 248.39-407.67 363 375 0.89 0.73, 1.09 0.78 0.64, 0.96 0.87 0.68, 1.11 
 >407.67 332 405 0.82 0.67, 1.01 0.66 0.54, 0.81 0.74 0.58, 0.95 
 p-value for trend (quartiles)  0.05  0.0001  0.02 





0-166.66 417 321   1.00  1.00  
166.66-268.42 368 369   0.77 0.63, 0.95 0.86 0.67, 1.10 
 268.42-434.83 369 369   0.77 0.63, 0.95 0.85 0.67, 1.09 
 >434.83 321 416   0.60 0.49, 0.73 0.67 0.52, 0.86 
 p-value for trend (quartiles)    3.4x10
-6 
 0.003 
 p-value for trend (continuous)    3.3x106  0.001 
DHA 
(mg/day) 
0-220.06 411 327 1.00  1.00  1.00  
220.06-346.49 370 367 0.95 0.77, 1.16 0.81 0.66, 0.99 0.85 0.67, 1.09 
 346.49-551.44 355 383 0.87 0.71, 1.06 0.74 0.60, 0.91 0.84 0.66, 1.07 
 >551.44 339 398 0.82 0.67, 1.01 0.68 0.56, 0.84 0.74 0.58, 0.95 
 p-value for trend (quartiles)  0.04  0.0002  0.02 





0-233.35 413 325   1.00  1.00  
233.35-362.65 375 362   0.83 0.67, 1.02 0.93 0.72, 1.19 
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 362.65-577.16 358 380   0.74 0.61, 0.91 0.83 0.65, 1.06 
 >577.16 329 408   0.64 0.52, 0.78 0.70 0.54, 0.90 
 p-value for trend (quartiles)    1.2x10
-5 
 0.003 
 p-value for trend (continuous)    5.4x10
-6 
 0.001 
                                               
*Based on the distribution of the energy adjusted variable 
†Model I: Crude analysis 
‡Model II: Adjusted for total energy intake (residual method) 
§Model III: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake (residual method), fibre intake (energy adjusted), alcohol intake (energy adjusted), 
NSAIDs intake 
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Table 76 Association between the fatty acid variables and colorectal cancer risk in the whole 
sample (2 additional conditional logistic regression models; Cases and controls matched on age, 
gender and area of residence) 
Fatty acids Quartiles
*




  cases controls OR 95% CI OR 95% CI 
Total FAs 
(g/day) 
0-75.93 339 399 1.00  n/a  
75.93-86.21 345 392 0.97 0.76, 1.24   
 86.21-94.91 404 334 1.22 0.95, 1.58   
 >94.91 387 350 1.00 0.77, 1.29   
 p-value for trend (quartiles)  0.61   
 p-value for trend (continuous)  0.39   
Total FAs 
(total) (g/day) 
0-75.98 338 400 1.00  n/a  
75.98-86.34 346 391 0.99 0.77, 1.27   
 86.34-94.95 404 334 1.24 0.97, 1.60   
 >95.94 387 350 1.00 0.77, 1.30   
 p-value for trend (quartiles)  0.57   
 p-value for trend (continuous)  0.41   
SFAs 
(g/day) 
0-31.72 336 402 1.00  1.00  
31.72-37.18 365 372 1.12 0.87, 1.44 1.09 0.82, 1.46 
 37.18-43.55 375 363 0.98 0.76, 1.27 0.97 0.70, 1.34 
 >43.55 399 338 1.13 0.86, 1.47 1.11 0.74, 1.66 
 p-value for trend (quartiles)  0.60  0.86 
 p-value for trend (continuous)  0.24  0.27 
MUFAs 
(g/day) 
0-28.62 333 405 1.00  1.00  
28.62-32.54 377 360 1.27 0.99, 1.64 1.21 0.90, 1.64 
 32.54-36.04 385 353 1.23 0.95, 1.59 1.15 0.80, 1.65 
 >36.04 380 357 1.10 0.85, 1.42 1.02 0.65, 1.60 
 p-value for trend (quartiles)  0.60  0.78 
 p-value for trend (continuous)  0.50  0.58 
PUFAs  
(g/day) 
0-11.94 380 358 1.00  1.00  
11.94-14.03 370 367 1.11 0.86, 1.42 1.06 0.82, 1.37 
 14.03-16.58 348 390 0.92 0.72, 1.18 0.88 0.68, 1.14 
 >16.58 377 360 0.97 0.76, 1.24 0.89 0.67, 1.17 
 p-value for trend (quartiles)  0.48  0.20 
 p-value for trend (continuous)  0.70  0.25 
PUFAs 
(total) (g/day) 
0-11.99 383 355 1.00  1.00  
11.99-14.08 365 372 1.04 0.81, 1.33 1.00 0.77, 1.28 
 14.08-16.67 350 388 0.90 0.70, 1.15 0.85 0.65, 1.10 
 >16.67 377 360 0.96 0.75, 1.23 0.88 0.66, 1.16 
 p-value for trend (quartiles)  0.51  0.21 
 p-value for trend (continuous)  0.61  0.20 
ω6PUFAs 0-8.87 365 373 1.00  1.00  
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(g/day) 8.87-10.61 380 357 1.14 0.89, 1.47 1.10 0.86, 1.42 
 10.61-13.04 361 377 1.06 0.83, 1.36 1.03 0.79, 1.33 
 >13.04 369 368 1.03 0.80, 1.32 0.97 0.74, 1.26 
 p-value for trend (quartiles)  0.96  0.63 
 p-value for trend (continuous)  0.71  0.85 
ω6PUFAs 
(total) (g/day) 
0-8.89 365 373 1.00  1.00  
8.89-10.62 381 356 1.16 0.90, 1.49 1.11 0.87, 1.43 
 10.62-13.06 360 378 1.06 0.82, 1.36 1.02 0.79, 1.33 
 >13.06 369 368 1.03 0.80, 1.32 0.96 0.74, 1.26 
 p-value for trend (quartiles)  0.91  0.59 
 p-value for trend (continuous)  0.74  0.81 
ω3PUFAs 
(g/day) 
0-1.82 416 322 1.00  1.00  
1.82-2.22 377 360 0.97 0.75, 1.25 0.92 0.72, 1.19 
 2.22-2.73 348 390 0.80 0.63, 1.03 0.76 0.59, 0.97 
 >2.73 334 403 0.75 0.58, 0.96 0.69 0.53, 0.90 
 p-value for trend (quartiles)  0.008  0.002 
 p-value for trend (continuous)  0.004  0.001 
ω3PUFAs 
(total) (g/day) 
0-1.84 409 329 1.00  1.00  
1.84-2.26 381 356 0.96 0.74, 1.23 0.91 0.71, 1.18 
 2.26-2.79 360 378 0.89 0.69, 1.13 0.84 0.65, 1.07 
 >2.79 325 412 0.71 0.55, 0.91 0.66 0.50, 0.86 
 p-value for trend (quartiles)  0.006  0.002 
 p-value for trend (continuous)  0.001  0.0002 
tFAs 
(g/day) 
0-2.87 325 413 1.00  1.00  
2.87-3.54 379 358 1.22 0.96, 1.56 1.22 0.94, 1.57 
 3.54-4.22 386 352 1.27 0.99, 1.62 1.27 0.96,  1.66 
 >4.22 385 352 1.10 0.85, 1.43 1.08 0.79, 1.48 
 p-value for trend (quartiles)  0.41  0.61 
 p-value for trend (continuous)  0.54  0.90 
tMUFAs 
(g/day) 
0-2.20 318 420 1.00  1.00  
2.20-2.71 378 359 1.38 1.07, 1.77 1.38 1.07, 1.79 
 2.71-3.23 390 348 1.33 1.04, 1.71 1.34 1.02, 1.77 
 >3.23 389 348 1.23 0.96, 1.59 1.28 0.94, 1.74 
 p-value for trend (quartiles)  0.18  0.21 
 p-value for trend (continuous)  0.23  0.34 
Palmitic acid 
(g/day) 
0-16.13 329 409 1.00  1.00  
16.13-18.72 369 368 1.14 0.88, 1.46 1.12 0.84, 1.49 
 18.72-21.36 384 354 1.18 0.91, 1.52 1.15 0.82, 1.61 
 >21.36 393 344 1.08 0.82, 1.41 1.04 0.68, 1.59 
 p-value for trend (quartiles)  0.58  0.93 
 p-value for trend (continuous)  0.33  0.55 
Stearic acid 
(g/day) 
0-7.37 322 416 1.00  1.00  
7.37-8.71 368 369 1.24 0.96, 1.60 1.41 1.06, 1.87 
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 8.71-10.03 377 361 1.29 0.99, 1.67 1.50 1.08, 2.09 
 >10.03 408 329 1.38 1.05, 1.83 1.76 1.18, 2.63 
 p-value for trend (quartiles)  0.03  0.01 
 p-value for trend (continuous)  0.13  0.12 
Oleic acid 
(g/day) 
0-22.06 334 404 1.00  1.00  
22.06-25.22 365 372 1.15 0.90, 1.48 1.17 0.88, 1.56 
 25.22-28.06 385 353 1.24 0.96, 1.59 1.29 0.93, 1.79 
 >28.06 391 346 1.22 0.94, 1.58 1.30 0.87, 1.94 
 p-value for trend (quartiles)  0.12  0.21 




0-8.41 367 371 1.00  1.00  
8.41-10.14 377 360 1.09 0.85, 1.39 1.05 0.82, 1.34 
 10.14-12.56 360 378 1.03 0.80, 1.33 1.00 0.77, 1.30 
 >12.56 371 366 1.01 0.79, 1.29 0.95 0.72, 1.23 
 p-value for trend (quartiles)  0.91  0.58 




0-8.42 368 370 1.00  1.00  
8.42-10.15 378 359 1.10 0.86, 1.40 1.06 0.82, 1.36 
 10.15-12.57 359 380 1.02 0.79, 1.30 0.98 0.76, 1.27 
 >12.57 370 366 1.00 0.78, 1.28 0.94 0.72, 1.22 
 p-value for trend (quartiles)  0.80  0.49 
 p-value for trend (continuous)  0.74  0.83 
γ-Linolenic acid 
(mg/day) 
0-5.86 368 370 1.00  1.00  
5.86-8.43 387 350 1.12 0.88, 1.42 1.08 0.85, 1.36 
 8.43-11.29 352 386 0.85 0.66, 1.09 0.80 0.62, 1.02 
 
>11.29 368 369 0.99 0.77, 1.28 0.94 0.72, 1.22 
 p-value for trend (quartiles)  0.44  0.23 
 p-value for trend (continuous)  0.86  0.78 
γ-Linolenic acid 
(total) (mg/day) 
0-6.06 369 369 1.00  1.00  
6.06-8.69 390 347 1.16 0.91, 1.47 1.12 0.88, 1.42 
 8.69-11.79 342 396 0.81 0.63, 1.04 0.78 0.61, 1.00 
 >11.79 374 363 1.06 0.82, 1.36 1.02 0.79, 1.32 
 p-value for trend (quartiles)  0.61  0.42 
 p-value for trend (continuous)  0.52  0.57 
Arachidonic acid 
(mg/day) 
0-238.75 347 391 1.00  1.00  
238.75-295.30 374 363 1.29 1.01, 1.66 1.24 0.97, 1.58 
 
295.30-358.60 394 344 1.20 0.94, 1.54 1.15 0.90, 1.47 
 >358.60 360 377 1.04 0.81, 1.34 1.02 0.79, 1.31 
 p-value for trend (quartiles)  0.88  0.99 
 p-value for trend (continuous)  0.81  0.97 
α-Linolenic acid 
(mg/day) 
0-1123.4 361 377 1.00  1.00  
1123.4-1315.8 381 356 1.24 0.97, 1.60 1.19 0.92, 1.54 
 1315.8-1537.6 393 345 1.40 1.08, 1.80 1.37 1.05, 1.79 
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 >1537.6 340 397 1.00 0.77, 1.30 0.96 0.73, 1.27 
 p-value for trend (quartiles)  0.82  0.90 
 p-value for trend (continuous)  0.51  0.22 
α-Linolenic acid 
(total) (mg/day) 
0-1123.6 361 377 1.00  1.00  
1123.6-1316.1 380 357 1.24 0.96, 1.59 1.19 0.92, 1.53 
 1316.1-1538.3 394 344 1.40 1.09, 1.81 1.37 1.05, 1.79 
 >1538.3 340 397 1.01 0.78, 1.31 0.97 0.73, 1.28 
 p-value for trend (quartiles)  0.78  0.94 




0-155.16 409 329 1.00  1.00  
155.16-248.39 371 366 0.93 0.72, 1.18 0.92 0.72, 1.17 
 248.39-407.67 363 375 0.88 0.69, 1.13 0.86 0.68, 1.10 
 >407.67 332 405 0.74 0.58, 0.95 0.72 0.56, 0.93 
 p-value for trend (quartiles)  0.02  0.01 
 p-value for trend (continuous)  0.003  0.001 
EPA 
(total) (mg/day) 
0-166.66 417 321 1.00  1.00  
166.66-268.42 368 369 0.86 0.67, 1.11 0.86 0.67, 1.10 
 268.42-434.83 369 369 0.86 0.67, 1.10 0.84 0.66, 1.07 
 >434.83 321 416 0.67 0.52, 0.86 0.66 0.51, 0.84 
 p-value for trend (quartiles)  0.003  0.001 
 p-value for trend (continuous)  0.001  0.0004 
DHA 
(mg/day) 
0-220.06 411 327 1.00  1.00  
220.06-346.49 370 367 0.85 0.67, 1.09 0.85 0.66, 1.08 
 346.49-551.44 355 383 0.84 0.66, 1.08 0.83 0.65, 1.06 
 >551.44 339 398 0.73 0.57, 0.94 0.71 0.55, 0.92 
 p-value for trend (quartiles)  0.02  0.01 
 p-value for trend (continuous)  0.002  0.001 
DHA 
(total) (mg/day) 
0-233.35 413 325 1.00  1.00  
233.35-362.65 375 362 0.94 0.73, 1.21 0.92 0.72, 1.18 
 362.65-577.16 358 380 0.83 0.65, 1.07 0.81 0.64, 1.04 
 >577.16 329 408 0.70 0.55, 0.90 0.67 0.52, 0.87 
 p-value for trend (quartiles)  0.004  0.002 
 p-value for trend (continuous)  0.001  0.0003 
                                               
*Based on the distribution of the energy adjusted variable 
†Model IV: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake (residual 
method), fibre intake (energy adjusted), alcohol intake (energy adjusted), NSAIDs intake and for total energy 
intake (included as a covariate) 
‡Model V: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake (residual 
method), fibre intake (energy adjusted), alcohol intake (energy adjusted), NSAIDs intake and for total fatty acids 
intake (energy-adjusted) 
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Table 77 Association between meat and meat products, confectionery and savoury snacks, fish and fish dishes and colorectal cancer risk in the whole sample (3 
main conditional logistic regression models; Cases and controls matched on age, gender and area of residence) 
Food groups Quartiles
*
 Frequency Model I
†
 Model II
‡ Model III§ 
  cases controls OR 95% CI OR 95% CI OR 95% CI 
Meat and meat products 
(m/day**) 
0-1.71 363 375 1.00  1.00  1.00  
1.71-2.31 380 357 1.14 0.94, 1.40 1.10 0.90, 1.35 1.03 0.81, 1.32 
 
2.31-3.05 360 378 1.08 0.88, 1.34 0.98 0.80, 1.20 0.85 0.66, 1.08 
 >3.05 372 365 1.35 1.09, 1.68 1.05 0.85, 1.30 0.93 0.72, 1.21 
 p-value for trend (quartiles)  0.02  0.89  0.33 
 p-value for trend (continuous)  0.005  0.40  0.89 
Confectionery & savoury 
snacks (m/day) 
0-0.42 339 399 1.00  1.00  1.00  
0.42-0.93 342 395 1.08 0.88, 1.32 1.02 0.83, 1.25 1.08 0.85, 1.37 
 0.93-1.75 380 358 1.29 1.05, 1.59 1.27 1.04, 1.56 1.26 0.99, 1.60 
 >1.75 414 323 1.57 1.28, 1.93 1.55 1.25, 1.91 1.47 1.14, 1.90 




  0.002 
 p-value for trend (continuous)  9.0x10
-5 
 0.002  0.02 
Fish and fish dishes 
(m/day) 
0-0.42 391 347 1.00  1.00  1.00  
0.42-0.73 373 364 1.07 0.87, 1.31 0.91 0.74, 1.11 0.93 0.73, 1.18 
 0.73-1.17 378 360 0.96 0.78, 1.19 0.94 0.76, 1.15 0.96 0.75, 1.21 
 >1.17 333 404 0.92 0.76, 1.14 0.73 0.60, 0.90 0.77 0.60, 0.99 
 p-value for trend (quartiles)  0.30  0.006  0.07 
 p-value for trend (continuous)  0.09  0.002  0.05 
                                               
*Based on the distribution of the energy adjusted variable 
†Model I: Crude analysis 
‡Model II: Adjusted for total energy intake (residual method) 
§Model III: Adjusted for family history of cancer, BMI, physical activity, smoking, total energy intake, fibre intake (energy adjusted), alcohol intake (energy adjusted), NSAIDs intake 
** m/d: measures per day 
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6.5  Summary of results of chapter 6 
In this chapter the results of the matched analysis of the novel dietary risk factors 
(flavonoid and fatty acid subgroups and individual compounds) that comprised the first 
two hypotheses, were presented. In particular, one crude and four multivariable 
conditional logistic regression models were applied in the whole sample, whereas one 
conditional multivariable model adjusted for the main potential confounding factors was 
applied after sex, age and cancer site stratification. 
6.5.1 Flavonoids 
Moderately strong inverse associations which showed dose response relationships were 
found in the energy-adjusted conditional logistic regression model (model II) between 
colorectal cancer risk and the intake of the subgroups flavonols (p=0.02) and 
procyanidins (p=0.04) and the individual flavonoid compounds quercetin (p=0.002), 
catechin (p=0.0001) and epicatechin (p=0.04) (Table 68). After adjusting for the main 
potential confounding factors (model III), only the inverse associations between 
colorectal cancer, quercetin (p=0.04) and catechin (p=0.02) remained statistically 
significant (Table 68). Results from model IV, which was corrected for the confounding 
factors of model III and for fruit and vegetable intake showed an inverse association 
between catechin and colorectal cancer (p=0.05) (Table 69). Finally, results in model V, 
which was corrected for the confounding factors of model III and further adjusted 
mutually between flavonoid categories, showed inverse associations between colorectal 
cancer and flavonols (p=0.0001), catechin (p=0.007) and epicatechin (p=0.03). In 
marked contrast we showed no associations between intakes of the other four of the six 
flavonoid subgroups studied (flavones, flavan3ols, flavanones and phytoestrogens) and 
colorectal cancer risk (Table 68, Table 69). In addition, results of the analysis of the 
main food sources (regular tea, onions, apples and red wine) of the flavonoid variables 
that were found to be significantly associated with colorectal cancer, suggest that there is 
some evidence in favour of an inverse association but this is less well defined than in the 
analysis of the association of flavonol, procyanidin, quercetin, catechin or epicatechin 
intakes and colorectal cancer risk (Table 70). 
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6.5.2 Fatty acids 
After residual energy-adjustment (model II) significant inverse dose-dependent 
associations were observed between colorectal cancer and the dietary intakes of the fatty 
acid subgroup ω3PUFAs (p=9.3x10
-6
) and the individual compounds EPA (p=0.0001) 
and DHA (p=0.0002) (Table 75). In contrast, a dose-dependent increase in risk was 
observed for intake of dietary total FAs (p=0.001), SFAs (p=0.001), MUFAs (p=0.01) 
tFAs (p=0.002) and tMUFAs (p=0.0003) and for the individual fatty acids palmitic 
(p=0.001), stearic (p=7.9x10
-6
) and oleic (p=0.001) (Table 75). In model III, only the 
positive association between colorectal cancer and stearic acid (p=0.01) and the inverse 
associations between colorectal cancer and dietary ω3PUFAs (p=0.01), EPA (p=0.02) 
and DHA (p=0.02) remained statistically significant (Table 75). For both model IV 
(further adjusted for total fatty acid intake) and model V (further adjusted for energy, in 
addition to the residual energy adjustment) positive significant associations were 
observed for stearic acid (p= 0.03 and 0.01, respectively) and inverse significant 
associations were observed for ω3PUFAs, EPA and DHA (model IV: p=0.008, p=0.02 
and p=0.02; model IV: p=0.002, p=0.01, p=0.01; respectively) (Table 76). In marked 
contrast, the subgroups of PUFAs, ω6PUFAs and the individual fatty acids linoleic, γ-
linolenic, arachidonic and α-linolenic were not associated with colorectal cancer risk in 
any of the adjusted logistic regression models (Table 75). Finally, results of the analysis 
of the main food sources (meat and meat products, confectionery and savoury snacks 
and fish and fish dishes) of the fatty acids that were found to be significantly associated 
with colorectal cancer, suggest that there is some evidence in favour of a statistically 
significant association (Table 77). 
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7 RESULTS: Associations between colorectal 
cancer and intakes of folate, vitamin B2, vitamin B6, 
vitamin B12, alcohol, vitamin D and calcium (unmatched 
dataset) 
7.1 Introduction 
In this chapter the results of the unmatched analysis of the additional dietary risk factors 
that comprise the last two hypotheses are presented. Specifically, the dietary risk factors 
that were analysed using the unmatched dataset included: a) folate, vitamin B2, vitamin 
B6, vitamin B12, alcohol and b) vitamin D and calcium. 
In the first part of this chapter, the study population used in the unmatched analysis is 
presented, including descriptive analysis of the main confounding factors and logistic 
regression analysis to investigate their association relationships with colorectal cancer 
risk. In the second part of the chapter descriptive analysis of the dietary risk factors are 
presented including distribution analysis (whole sample and by case/ control status) and 
correlation analysis. In addition, the association relationships between colorectal cancer 
and each nutrient are investigated by applying three main unconditional logistic 
regression models and one additional unconditional logistic regression model (for the 
analysis of vitamin D and calcium). All tables and figures are presented at the end of 
each section or in the Appendix, as indicated in the text. 
7.2 The study sample 
This analysis describes the characteristics of the cases and controls that were included in 
the unmatched dataset. In total 2,062 cases and 2,776 controls were included. One case 
reported very high dietary energy and nutrient intakes and therefore it was removed from 
the analysis.  
7.2.1 Descriptive analysis of the confounding factors 
The distribution of the continuous confounding factors was examined by looking at their 
histograms. In addition, their summary statistics are presented in Table 78 for the whole 
sample and also separately for cases and controls. The t-test was used to test differences 
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between cases and controls in mean age, BMI, dietary energy, fibre intake (crude and 
residually energy adjusted) and alcohol intake (crude and residually energy adjusted). 
The Pearson χ
2
 test was used to test the differences in terms of sex, deprivation score, 
family history of cancer, physical activity (hours/ week of cycling and sport activities), 
smoking status and NSAIDs intake.  
7.2.2 Associations between confounding factors and 
colorectal cancer risk 
The association relationship between each confounding factor and colorectal cancer risk 
was tested by applying univariable logistic regression models (Table 79). Statistically 
significant associations were observed for the majority of the confounding factors, 
including: 
- Age (>55 years old vs. ≤55 years old: OR (95%CI), p-value: 0.85 (0.75, 0.97), 0.01); 




- Dietary energy intake (highest vs. lowest quartile: OR (95% CI), p-value for trend: 
1.37 (1.17, 1.61), 2.2x10
-5
); 
- Residually energy adjusted fibre intake (highest vs. lowest quartile: OR (95% CI), p-
value for trend: 0.71 (0.60, 0.84), 3.3x10
-5
); 
- NSAIDs intake (yes vs. no: OR (95% CI), p-value: 0.73 (0.65, 0.83), 7.3x10-7). 
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Age (years) 62.2 (10.6) 62.0 (10.8) 62.4 (10.5) 0.14 
Age (years)     
 ≤55 years 1392 (28.8%) 632 (30.7%) 760 (27.4%)  
 >55 years 3443 (71.2%) 1429 (69.3%) 2014 (72.6%) 0.01 
Sex     
 Men 2762 (57.1%) 1180 (57.2%) 1582 (57.0%)  
 Women 2075 (42.9%) 881 (42.8%) 1194 (43.0%) 0.85 
Deprivation score
‡
     
 1 452 (9.3%) 194 (9.4%) 258 (9.3%)  
 2 1002 (20.7%) 434 (21.1%) 568 (20.5%)  
 3 1290 (26.7%) 532 (25.8%) 758 (27.3%)  
 4 1133 (23.4%) 488 (23.7%) 645 (23.2%)  
 5 511 (10.6%) 218 (10.6%) 293 (10.6%)  
 6 318 (6.6%) 140 (6.8%) 178 (6.4%)  
 7 130 (2.7%) 54 (2.6%) 76 (2.7%) 0.95 
Family history risk of 
cancer 
    
 Low 4305 (89.0%) 1610 (78.1%) 2695 (97.1%)  
 Medium 328 (6.8%) 299 (14.5%) 29 (1.0%)  
 High 35 (0.72%) 34 (1.6%) 1 (0.0%)  
 Unknown 108 (2.2%) 91 (4.4%) 17 (0.61%) <0.0005 





 26.7 (4.5) 26.6 (4.4) 26.7 (4.6) 0.41 
Physical activity 
(hours/day) 
(cycling and other 
sport activities) 
    
 0  2595 (53.6%) 1139 (55.3%) 1456 (52.4%)  
 0-3.5  1189 (24.6%) 486 (23.6%) 703 (25.3%)  
 3.5-7  544 (11.2%) 205 (9.9%) 339 (12.2%)  
 >7  318 (6.6%) 133 (6.5%) 185 (6.7%) 0.04 
 Missing 191 (3.9%) 98 (4.8%) 93 (3.4%)  
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Smoking     
 No 2074 (42.9%) 874 (42.4%) 1200 (43.2%)  
 Yes
**
 2719 (56.2%) 1161 (56.3%) 1558 (56.1%) 0.70 
 Missing 44 (0.9%) 26 (1.3%) 18 (0.65%)  
Dietary energy 
intake (MJ/day) 
10.91 (4.1) 11.26 (4.4) 10.66 (3.95) <5x10
-5
 
Fibre intake (g/day) 22.4 (9.8) 22.5 (9.8) 22.3 (9.9) 0.64 
Energy-adjusted 
fibre intake (g/day) 









13.0 (15.1) 12.8 (15.3) 13.2 (15.0) 0.44 
NSAIDs intake
††
     
No 3206 (66.3%) 1449 (70.3%) 1757 (63.3%)  
Yes 1605 (33.2%) 605 (29.4%) 1000 (36.0%) <0.0005 
Missing 26 (0.5%) 7 (0.3%) 19 (0.7%)  
                                               
* Mean values and in parentheses standard deviations for quantitative variables; number of subjects and in parenthesis 
percentages for categorical variables. 
† P-values from the Pearson χ2 for categorical variables; from t-test for continuous variables 
‡ Locally based deprivation index (Carstairs deprivation index) based on the 2001 Census data; 7 categories ranging 
from very low deprivation (deprivation score 1) to very high deprivation (deprivation score 7). Missing data for one 
case 
§ Missing data for 21 cases and 34 controls 
** Smokers were defined as individuals who have smoked at least one cigarette per day and/ or one cigar per month 
and/ or pipe.  
†† Frequent use was defined as an intake of at least 4 days per week for at least one month. 
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Table 79 Association between the confounding factors and colorectal cancer risk (univariable 
logistic regression analysis) 
Confounding 
variables 
Categories Frequency Univariable analysis p-value 
  cases controls OR 95% CI  
Age (years)  2061 2774 0.99 0.99, 1.00 0.14 
Age (years) ≤55 years 632 760 1.00   
 >55 years 1429 2014 0.85 0.75, 0.97 0.01 
Sex Men 1180 1582 1.00   
 Women 881 1194 0.99 0.88, 1.11 0.85 
Deprivation 
score 
1 194 258 1.00   
2 434 568 1.02 0.81, 1.27 0.89 
 3 532 758 0.96 0.75, 1.16 0.53 
 4 488 645 1.01 0.81, 1.25 0.96 
 5 218 293 0.99 0.77, 1.28 0.94 
 6 140 178 1.05 0.78, 1.40 0.76 
 7 54 76 0.94 0.64, 1.40 0.78 
    p-value for trend 0.94  
Family history 
risk of cancer 
Low 1610 2695 1.00   




) Continuous 2040 2742 0.99 0.98, 1.01 0.42 
BMI (kg/m
2
) 18.5-25 778 1000 1.00   
 <18.5 21 38 0.71 0.41, 1.22 0.22 
 25-30  862 1173 0.94 0.83, 1.07 0.38 
 ≥ 30  379 531 0.92 0.78, 1.08 0.30 
    p-value for trend 0.27  
Physical activity 
(hours/week) 
0  1139 1456 1.00   
0-3.5  486 703 0.88 0.77, 1.02 0.08 
3.5-7  205 339 0.77 0.64, 0.93 0.008 
>7  133 185 0.92 0.73, 1.16 0.48 
    p-value for trend 0.02  
Smoking No 874 1200 1.00   
Former 818 1049 1.07 0.94, 1.21 0.29 
 Current 343 509 0.93 0.79, 1.09 0.35 
    p-value for trend 0.63  








0- 8.25 478 733 1.00   
8.25-10.17 483 725 1.02 0.87, 1.20 0.80 
10.17- 12.73 529 680 1.19 1.01, 1.40 0.03 
>12.73 571 638 1.37 1.17, 1.61 0.0001 





continuous 2061 2776 1.00 0.99, 1.01 0.64 
Fibre intake 
(g/day) 
0- 15.90 508 712 1.00   
15.90- 20.70 527 690 1.07 0.91, 1.26 0.41 
20.70- 26.90 510 685 1.04 0.89, 1.23 0.61 
>26.90 516 689 1.05 0.89, 1.23 0.56 









0- 17.34 549 661 1.00   
17.34-20.97 542 667 0.98 0.83, 1.15 0.79 
20.97-24.94 521 688 0.91 0.78, 1.01 0.26 
>24.94 449 760 0.71 0.60, 0.84 4.0x10
-5 





continuous 2061 2776 1.00 0.99, 1.00 0.98 
Alcohol intake 
(g/day) 
0-1.70 526 696 1.00   
1.70-8.10 534 692 1.02 0.87, 1.20 0.80 
8.10-19.2 501 681 0.97 0.83, 1.14 0.74 
>19.20 500 707 0.94 0.80, 1.10 0.42 








0-1.84 526 684 1.00   
1.84- 8.07 539 670 1.05 0.89, 1.23 0.58 
8.07-18.99 509 700 0.95 0.80, 1.11 0.50 
>18.99 487 722 0.88 0.75, 1.03 0.11 
    p-value for trend 0.06  
NSAIDs intake No 1449 1757 1.00   
 Yes 605 1000 0.73 0.65, 0.83 7.3x10
-7
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7.3 Folate, vitamin B2, vitamin B6, vitamin B12 
and alcohol 
This analysis describes the distribution and correlation of the nutrients involved in 
one-carbon metabolic pathway. In addition, differences in crude and energy-adjusted 
nutrient intakes between cases and controls and the unadjusted and adjusted 
associations between nutrient intakes and colorectal cancer are presented. 
7.3.1 Descriptive analysis 
7.3.1.1 Distribution of nutrients 
Distribution of the nutrients (folate, vitamin B2, vitamin B6, vitamin B12 and 
alcohol) was examined by looking at their histograms (original and transformed 
variables if skewed). The distributions of the nutrients under study were skewed and 
they were normalised either with square root or with logarithmic transformation 
(Table 80).  
7.3.1.2 Distribution of nutrients by case control status 
Cases reported higher mean crude intakes for folate (p=0.05), vitamin B2 (p=0.0018) 
and vitamin B6 (p=0.03). In addition cases reported higher median crude intakes for 
vitamin B2 (p=0.005) (Table 81). After energy adjustment (residual energy 
adjustment) cases reported lower mean intakes for folate (p=0.0002), vitamin B6 
(<5x10-5) and vitamin B12 (0.0047). In addition cases reported lower median intakes 
for folate (p=0.0003), vitamin B6 (<5x10-5) and vitamin B12 (0.02) (Table 81). 
7.3.1.3 Correlations between the nutrients 
The highest correlations were observed between folate, vitamin B2 and vitamin B6 
with r>0.7. Vitamin B12 was moderately correlated with folate (r=0.56), vitamin B2 
(r=0.69) and vitamin B6 (r=0.62). Alcohol was not correlated with any of the 
nutrients (r<0.15) (Table 82).  
7.3.1.4 Main sources of folate, vitamin B2, vitamin B6, vitamin 
B12 and alcohol 
The three main food sources (at individual food item level) were: 1) for folate: boiled 
or baked potatoes (10.0%), bran flakes and sultana bran and All Bran (4.9%) and 
regular tea (3.7%); 2) for vitamin B2: semi-skimmed milk (14.0%), full fat milk 
(4.5%) and corn flakes, Special K and Rice Krispies (4.1%); 3) for vitamin B6: 
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boiled or baked potatoes (14.4%), bananas (4.9%) and mixed vegetable dishes 
(4.3%); 4) for vitamin B12: fried oily fish (12.9%), liver, liver sausage or liver pate 
(8.4%) and semi-skimmed milk (8.3%). The three alcoholic drinks that were the 
main sourced of the total grams of consumed alcohol were: spirits or liqueurs 
(28.2%), red wine (23.7%) and white wine (17.3%) (Table 83). 
One thousand six hundred and sixty participants reported consumption of supplement 
products and 461 of them reported consumption of supplements that contributed to 
the daily intake of the nutrients involved in the one-carbon metabolic pathway (433 
reported intakes of supplements that contributed in the folate dietary intake, 429 in 
the B2 dietary intake, 445 in the B6 dietary intake and 411 in the B12 intake). We 
identified the exact nutrient composition of these dietary supplements and added the 
supplement nutrients to the dietary ones. 
7.3.2 Associations between folate, vitamin B2, vitamin B6, 
vitamin B12, alcohol and colorectal cancer risk 
7.3.2.1 Main logistic regression models 
In model I, dietary intake of vitamin B2 was positively associated with colorectal 
cancer (high vs. low intake: OR (95% CI), p-value: 1.21 (1.03, 1.42), 0.02) (Table 
84). Associations between total intakes (from diet and supplements) of the nutrients 
and colorectal cancer were not examined in model I, since intake from supplements 
was added to the energy-adjusted nutrients. After energy adjustment (Model II), both 
dietary and total intakes of folate, vitamin B6 and vitamin B12 were significantly and 
inversely associated with colorectal cancer (high vs. low dietary intake: OR (95% 
CI), p-value: 0.80 (0.68, 0.94), 0.003; 0.71 (0.60, 0.83), 7.1x10
-6
; 0.80 (0.68, 0.95), 
0.02; respectively) (Table 84). In model III dietary and total vitamin B12 was 
inversely associated with colorectal cancer risk (high vs. low dietary intake: OR 
(95% CI), p-value: 0.80 (0.67, 0.96), 0.04). In addition, an inverse marginally non-
significant association between dietary vitamin B6 and colorectal cancer was 
observed (high vs. low intake: OR (95% CI), p-value: 0.85 (0.69, 1.04), 0.09) (Table 
84). Regarding alcohol intake, when divided in quartiles, a significant inverse and 
dose-dependent association was observed when applying model III (high vs. low 
intake: OR (95% CI), p-value: 0.83 (0.68, 1.00), 0.03) (Table 84). However, when 
alcohol was divided into categories according to the level of intake, individuals with 
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an intake of more than 60g/day were associated with a non dose-dependent increased 
colorectal cancer risk, which was statistically significant only when applying model I 
(high vs. low dietary intake: OR (95% CI), p-value for trend: 1.70 (1.11, 2.60), 0.28) 
(Table 84). 
7.3.2.2 Multiple testing corrections 
Bonferroni correction for multiple testing 
The adjusted level of significance after having controlled for multiple testing was: a) 
0.003 using the Bonferroni correction for 19 independent tests, b) 0.003 using the 
Bonferroni correction for 15 tests conducted in hypothesis 3 and c) 0.0005 for the 
individual compound analysis after having corrected for 93 tests conducted in all 4 
hypotheses. Here we report only associations between dietary intakes and colorectal 
cancer. In model II the associations between colorectal cancer and vitamin B6 
(p=7.1x10
-6
) remained significant at all three levels of correction, whereas 
associations with folate (p=0.001) remained significant at the second level of 
significance (Table 84). 
FDR correction for multiple testing 
After correcting for multiple testing using the FDR method by taking into account 
the number of tests that were conducted in hypothesis 3 (15 tests) or the number of 
tests that were conducted in all 4 hypotheses (93 tests in the individual compound 
analysis), model II associations between dietary intakes of vitamin B6 (p=7.1x10-6) 
and folate (p=0.001) and colorectal cancer remained significant (Table 84). 
7.3.2.3 Associations between colorectal cancer and main food 
sources of folate, vitamin B6 and vitamin B12  
Intakes of the following food groups were tested: boiled or baked potatoes, bran 
flakes, bananas, fried oily fish and liver, liver sausage or liver pate. Results from 
model III, showed that comparison of highest versus lowest quartile (tertile) intakes 
of these foods showed ORs for colorectal cancer risk of 1.13 (95% CI 0.93, 1.37; p-
value for trend 0.38) for boiled or baked potatoes; 1.15 (95% CI 0.98, 1.35; p-value 
for trend 0.17) for bran flakes; 0.82 (95% CI 0.67, 0.99; p-value for trend 0.06) for 
bananas; 0.74 (95% CI 0.61, 0.91; p-value for trend 0.20) for fried oily fish; and 0.98 
(95% CI 0.81, 1.18; p-value for trend 0.86) for liver, liver sausage or liver pate 
(Table 85). 
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7.3.2.4 Associations between folate, vitamin B2, vitamin B6, 
vitamin B12, alcohol and colorectal cancer after sex, age and 
cancer site stratification 
Associations between each nutrient and colorectal cancer risk were tested after sex, 
age and cancer site stratification by applying model III (data not shown) for both 
dietary and total intakes. Sex-specific associations were similar for almost all 
nutrients and for alcohol. However, high intakes of both dietary and total vitamin B6 
and B12 were associated with a stronger decrease in colorectal cancer risk for 
women (high vs. low dietary intake OR (95% CI), p-value for trend: 0.75 (0.53, 
1.05), 0.08; 0.75 (0.56, 0.99), 0.04, respectively), than for men (data not shown). 
Regarding age-specific differences, high intakes of vitamin B6 (dietary and total) and 
alcohol (when divided in quartiles) was significantly and dose-dependently 
associated with a decreased risk of colorectal cancer for the individuals younger than 
55 years old (high vs. low dietary intake: OR (95% CI), p-value for trend: 0.59 (0.39, 
0.89), 0.005; 0.63 (0.43, .93), 0.006; respectively), whereas high intake of both 
dietary and total vitamin B12 was associated with a significant and dose-dependent 
decreased risk of colorectal cancer for the individuals older than 55 years old (high 
vs. low dietary intake: OR (95% CI), p-value for trend: 0.80 (0.64, 0.98), 0.05) (data 
not shown). Finally, after cancer site stratification, the relationships of all the 
nutrients with colon and rectal cancer were similar. Regarding alcohol, intake when 
divided into quartiles, it was inversely associated with colon cancer (high vs. low 
intake: OR (95% CI), p-value: 0.72 (0.57, 0.91), 0.003) but not with rectal cancer. In 
contrast, when divided into categories according to the level of intake, high intake of 
alcohol (>60 g/day) was positively associated only with rectal cancer (OR (95% CI): 
1.81 (0.99, 3.29)) (data not shown). 
7.3.2.5 Interaction relationships with variants of genes involved 
in the one-carbon metabolic pathway 
The genotypic effects of 3 polymorphic genes involved in the one-carbon metabolic 
pathway on colorectal cancer risk were examined. In particular the genetic variants 
that were examined were rs1801133 (MTHFR C677T), rs1801131 (MTHFR 
A1298C), rs1805087 (MTR A2756G) and rs1801394 (MTRR A66G). The variant 
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allele frequencies of the four polymorphisms in the control sample were under 
Hardy-Weinberg equilibrium (rs1801133 11.6%, rs1801131, 10.0%, rs1805087 
19.6%, rs1801394 3.0%). 
The associations between colorectal cancer risk and each of the four SNPs were 
tested by applying one unadjusted and one simply adjusted (for age, sex and 
deprivation score) logistic regression model (data not shown). In addition, ORs and 
95% CI for dietary intakes of the nutrients were calculated in stratified groups 
according to the rs1801133, rs1801131, rs1805087 and rs1801394 genotypes by 
applying the multivariable model III adjusted for age, sex, deprivation score, family 
history of cancer, BMI, physical activity, smoking, dietary energy intake (residual 
method), fibre intake (energy adjusted), alcohol intake (energy adjusted), NSAIDs 
intake (data not shown). Finally, interaction associations were examined by 
investigating the combined effects of the genotypes and nutrient intakes. Interaction 
was tested by examining the deviance of two different nested models; an interactive 
model and its nested multiplicative one. The referent category used was 
homozygotes of the wild type allele and of the lowest dietary nutrient intake quartile 
(data not shown). 
None of the four examined SNPs was significantly associated with colorectal cancer 
risk (data not shown). However, a not statistically significant increased risk was 
observed for the GG genotype of the rs1805087 (crude model: OR (95% CI), p-value 
for trend: 1.30 (0.79, 2.12), 0.19) (data not shown). In addition, there was no clear 
trend for the associations between colorectal cancer and folate, vitamin B2, vitamin 
B6, vitamin B12 and alcohol after stratification according to the genotypes of 
rs1801133, rs1801131, rs1805087 or rs1801394 (data not shown). Finally, our data 
did not support the hypothesis that folate or any of the vitamins B2, B6, B12 interacts 
with the rs1801133 (MTHFR 677TT) variant or with any of the rs1801131 (MTHFR 
A1298G), rs1805087 (MTR A2756G) or rs1801339 (MTRR A66G) variants (data not 
shown). 
7.3.3 Summary of results 
Inverse associations which showed dose response relationships were found: 1) in 
model II: between colorectal cancer risk and the dietary intakes of folate (p=0.003), 
vitamin B6 (p=7.1x10-6) and vitamin B12 (p=0.02) (Table 84); 2) in model III: 
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between colorectal cancer and vitamin B12 (p=0.05) and alcohol (p=0.03) (Table 
84). When alcohol intakes were divided in six categories (instead of quartiles), no 
association was observed for an intake of less than 60 g/day, whereas a positive non-
significant association was observed for an alcohol intake of more than 60 g/day 
(Table 84). Regarding the analysis of the main food sources of folate, vitamin B6 and 
vitamin B12, results suggest that there is some evidence in favour of a significant 
inverse association between colorectal cancer and intakes of bananas (dietary source 
of vitamin B6) and fried oily fish (dietary source of vitamin B12) (Table 85). Finally, 
regarding the genetic analysis, none of the four examined SNPs was significantly 
associated with colorectal cancer risk. Furthermore, there was no clear trend for the 
associations between colorectal cancer and folate, vitamin B2, vitamin B6, vitamin 
B12 and alcohol after stratification according to the genotypes of the aforementioned 
variants (data not shown). 
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Table 80 Nutrients involved in the one-carbon metabolic pathway that were elected to be included in the analysis 
Nutrients included in the analysis Transformation 
Individual compounds  
Folate logarithmic 
Vitamin B2 logarithmic 
Vitamin B6 logarithmic 
Vitamin B12 logarithmic 
Alcohol square root 
 
Table 81 Descriptive report of crude and energy-adjusted nutrients involved in the one-carbon metabolic pathway 
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Energy-adjusted 
















































































                                               
* Logarithmic transformed values were used for calculating the t-test due to skewed distribution 
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Table 82 Spearman rank correlation coefficients between nutrients involved in the one-carbon 
metabolic pathway (all p-values<5x10-5) 
Nutrients folate B2 B6 B12 alcohol 
folate 1.00     
vitamin B2 0.82 1.00    
vitamin B6 0.92 0.79 1.00   
vitamin B12 0.56 0.69 0.62 1.00  
alcohol 0.14 0.08 0.16 0.15 1.00 
 
Table 83 Three main dietary (food) sources of nutrients involved in the one-carbon metabolic 
pathway in our population 
Nutrients Main sources 
Folate Boiled or baked potatoes (10.0%) 
Bran flakes, Sultana Bran and All Bran (4.9%) 
Tea (3.7%) 
Vitamin B2 Semi-skimmed milk (14.0%) 
Full fat milk (4.5%) 
Corn Flakes, Special K and Rice Krispies (4.1%) 
Vitamin B6 Boiled or baked potatoes (14.4%) 
Bananas (4.9%) 
Mixed vegetable dishes (4.3%) 
Vitamin B12 Fried oily fish (12.9%) 
Liver, liver sausage or liver pate (8.4%) 
Semi-skimmed milk (8.3%) 
Alcohol Spirits or liqueurs (28.2%) 
Red wine (23.7%) 
White wine (17.3%) 
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Table 84 Association between the nutrients involved in the one-carbon metabolic pathway and colorectal cancer risk in the whole sample (3 main 
unconditional logistic regression models) 
Nutrients Quartiles
*







  cases controls OR 95% CI OR 95% CI OR 95% CI 
Folate 
(µg/day) 
0-282.65 533 677 1.00  1.00  1.00  
282.65-325.89 546 663 1.17 0.99, 1.37 1.05 0.89, 1.23 1.22 1.01, 1.46 
 325.89-370.81 515 694 1.13 0.96, 1.33 0.94 0.80, 1.11 1.14 0.94, 1.39 
 ≥370.81 467 742 1.15 0.98, 1.35 0.80 0.68, 0.94 1.03 0.82, 1.29 
 p-value for trend (quartiles)  0.14  0.003  0.92 
 p-value for trend (continuous)  0.19  0.0002  0.73 
Folate 
(total) (µg/day) 
0-286.24 532 678   1.00  1.00  
286.24-332.60 566 643   1.12 0.96, 1.32 1.31 1.09, 1.58 
 332.60-386.03 488 721   0.86 0.73, 1.01 1.07 0.88, 1.30 
 ≥386.03 475 734   0.82 0.70, 0.97 1.06 0.85, 1.31 
 p-value for trend (quartiles)     0.001  0.84 
 p-value for trend (continuous)    0.42  0.36 
Vitamin B2 
(mg/day) 
0-1.80 522 688 1.00  1.00  1.00  
1.80-2.10 537 672 1.03 0.88, 1.22 1.05 0.90, 1.24 1.06 0.88, 1.26 
 2.10-2.42 511 698 1.11 0.94, 1.30 0.96 0.82, 1.13 1.00 0.83, 1.20 
 ≥2.42 491 718 1.21 1.03, 1.42 0.90 0.77, 1.06 0.87 0.72, 1.05 
 p-value for trend (quartiles)  0.02  0.13  0.12 




0-1.83 519 691   1.00  1.00  
1.83-2.15 536 673   1.06 0.90, 1.24 1.04 0.87, 1.24 
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 2.15-2.53 510 699   0.97 0.83, 1.14 0.97 0.81, 1.17 
 ≥2.53 496 713   0.93 0.79, 1.09 0.93 0.77, 1.17 
 p-value for trend (quartiles)    0.22  0.35 
 p-value for trend (continuous)    0.63  0.81 
Vitamin B6 
(mg/day) 
0-2.47 547 663 1.00  1.00  1.00  
2.47-2.83 555 654 1.17 1.00, 1.38 1.03 0.88, 1.21 1.14 0.95, 1.37 
 2.83-3.21 514 695 1.05 0.89, 1.24 0.90 0.76, 1.05 1.04 0.86, 1.26 
 
≥3.21 445 764 1.12 0.95, 1.31 0.71 0.60, 0.83 0.85 0.69, 1.04 
 p-value for trend (quartiles)  0.38  7.1x10
-6 
 0.09 





0-2.51 555 655   1.00  1.00  
2.51-2.90 541 668   0.96 0.81, 1.12 1.08 0.90, 1.30 
 2.90-3.32 494 715   0.81 0.69, 0.96 1.00 0.82, 1.21 
 ≥3.32 471 738   0.75 0.64, 0.89 0.91 0.74, 1.11 
 p-value for trend (quartiles)    0.0001  0.25 
 p-value for trend (continuous)    0.10  0.43 
Vitamin B12 
(µg/day) 
0-5.27 538 672 1.00  1.00  1.00  
5.27-6.96 516 693 1.05 0.89, 1.23 0.93 0.79, 1.09 0.95 0.79, 1.14 
 6.96-9.21 533 676 1.20 1.02, 1.41 0.98 0.84, 1.16 1.00 0.84, 1.20 
 ≥9.21 474 735 1.12 0.95, 1.31 0.80 0.68, 0.95 0.80 0.67, 0.97 
 p-value for trend (quartiles)  0.06  0.02  0.05 
 p-value for trend (continuous)  0.73  0.005  0.003 
Vitamin B12 
(total) (µg/day) 
0-5.35 543 667   1.00  1.00  
5.35-7.09 515 694   0.91 0.78, 1.07 0.90 0.75, 1.08 
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 7.09-9.41 527 682   0.95 0.81, 1.11 0.95 0.80, 1.14 
 ≥9.41 476 733   0.80 0.68, 0.94 0.80 0.67, 0.96 
 p-value for trend (quartiles)    0.01  0.04 




0-1.70 526 696 1.00  1.00  1.00  
1.70-8.10 534 692 1.02 0.87, 1.20 1.05 0.89, 1.22 1.07 0.89, 1.28 
 8.10-19.2 501 681 0.97 0.83, 1.14 0.95 0.80, 1.11 0.94 0.78, 1.13 
 >19.20 500 707 0.94 0.80, 1.10 0.88 0.75, 1.03 0.83 0.68, 1.00 
 p-value for trend (quartiles)  0.34  0.06  0.03 




0 291 427 1.00  1.00  1.00  
0-15 1125 1473 1.12 0.95, 1.33 1.09 0.92, 1.29 1.10 0.91, 1.33 
 15-30 393 548 1.05 0.86, 1.28 1.00 0.82, 1.23 1.02 0.81, 1.29 
 30-45 139 202 1.01 0.78, 1.31 0.94 0.72, 1.22 0.97 0.72, 1.32 
 45-60 61 81 1.11 0.77, 1.59 1.00 0.69, 1.44 0.97 0.65, 1.46 
 >60 52 45 1.70 1.11, 2.60 1.47 0.96, 2.27 1.37 0.84, 2.22 
 p-value for trend  0.28  0.89  0.91 
                                               
*Based on the distribution of the energy adjusted variable 
†Model I: Crude analysis 
‡Model II: Adjusted for total energy intake (residual method) 
§Model III: Adjusted for age, sex, deprivation score, family history of cancer, BMI, physical activity, smoking, total energy intake (residual method), fibre intake (energy adjusted), 
alcohol intake (energy adjusted), NSAIDs intake 
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Table 85 Association between boiled or baked potatoes, bran flakes, bananas, fried oily fish, liver sausage or liver pate and colorectal cancer risk in the whole 
sample (3 main unconditional logistic regression models) 
Food sources Quartiles
*







  cases controls OR 95% CI OR 95% CI OR 95% CI 




0-0.42 583 888 1.00  1.00  1.00  
0.42-0.85 702 845 1.27 1.09, 1.46 1.21 1.05, 1.40 1.22 1.04, 1.44 
 0.85-1.28 197 427 1.06 0.88, 1.27 1.00 0.83, 1.20 1.08 0.88, 1.32 
 >1.28 479 616 1.18 101, 1.39 1.06 0.90, 1.25 1.13 0.93, 1.37 
 p-value for trend (quartiles)  0.14  0.93  0.38 
 p-value for trend (continuous)  0.53  0.31  0.82 
Bran flakes (m/day) 0 1533 2079 1.00  1.00  1.00  
 0-0.05 54 97 0.75 0.54, 1.06 0.75 0.54, 1.06 0.72 0.49, 1.07 
 >0.05 474 600 1.07 0.93, 1.23 1.06 0.93, 1.22 1.15 0.98, 1.35 
 p-value for trend (quartiles)  0.51  0.56  0.17 
 p-value for trend (continuous)  0.47  0.65  0.31 
Bananas (m/day) 0-0.14 645 845 1.00  1.00  1.00  
 0.14-0.42 621 735 1.11 0.95, 1.28 1.09 0.94, 1.26 1.13 0.96, 1.33 
 0.42-0.71 400 511 1.02 0.87, 1.21 0.99 0.83, 1.17 1.07 0.89, 1.30 
 >0.71 395 685 0.75 0.64, 0.89 0.70 0.60, 0.83 0.82 0.67, 0.99 
 p-value for trend (quartiles)  0.001  3.6x10
-5
  0.06 
 p-value for trend (continuous)  0.0003  2.5x10
-6
  0.02 
Fried oily fish (m/day) 0 1148 1524 1.00  1.00  1.00  
 0-0.14 659 832 1.05 0.92, 1.19 1.05 0.92, 1.19 1.09 0.94, 1.26 
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 >0.14 254 420 0.80 0.67, 0.95 0.73 0.61, 0.87 0.74 0.61, 0.91 
 p-value for trend (quartiles)  0.20  0.05  0.20 
 p-value for trend (continuous)  0.02  0.001  0.001 
Liver, liver sausage 
or liver pate (m/day) 
0 1450 1990 1.00  1.00  1.00  
0-0.05 299 417 0.98 0.84, 1.16 0.98 0.83, 1.15 1.00 0.83, 1.20 
 >0.05 312 369 1.16 0.98, 1.37 1.07 0.91, 1.27 0.98 0.81, 1.18 
 p-value for trend (quartiles)  0.18  0.58  0.86 
 p-value for trend (continuous)  0.33  0.92  0.29 
                                               
*Based on the distribution of the crude variable 
†Model I: Crude analysis 
‡Model II: Adjusted for total energy intake (standard method) 
§Model III: Adjusted for age, sex, deprivation score, family history of cancer, BMI, physical activity, smoking, total energy intake (residual method), fibre intake (energy adjusted), 
alcohol intake (energy adjusted), NSAIDs intake 
**
 m/day: measures per day 
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7.4 Vitamin D and calcium 
This analysis describes the distribution and correlation of vitamin D and calcium. In 
addition, the differences in crude and energy-adjusted nutrient intakes between cases 
and controls and the unadjusted and adjusted association between nutrient intakes 
and colorectal cancer are presented. 
7.4.1 Descriptive analysis 
7.4.1.1 Distribution of vitamin D and calcium intakes 
Distributions of vitamin D and calcium were examined by looking at their 
histograms (original and transformed variables if skewed). The distributions of the 
nutrients under study were skewed and they were normalised either with square root 
or with logarithmic transformation (Table 86). 
7.4.1.2 Distribution of vitamin D and calcium intakes by case 
control status 
For crude nutrient intakes, cases reported statistically significant higher mean and 
median intakes of calcium (p-values: 0.0002 and 0.0005, respectively) than controls. 
After residual energy adjustment cases reported lower mean and median vitamin D 
intakes (p-values: 0.001 and 0.001 respectively) than controls (Table 87).  
7.4.1.3 Correlations between vitamin D and calcium 
The Spearman rank correlation coefficient (r) was used to test the correlation 
between vitamin D and calcium (Table 88) and they were found to be moderately 
correlated (r<0.50). 
7.4.1.4 Main sources of vitamin D and calcium  
The three main food sources (at individual food item level) were: 1) for vitamin D 
fried oily fish (22.9%), smoked oily fish (10.0%) and grilled, poached, baked or 
pickled oily fish (6.7%); and 2) for calcium: semi-skimmed milk (17.8%), full fat 
hard cheese (8.7%) and full fat milk (5.9%) (Table 89). 
One thousand six hundred and sixty participants reported consumption of supplement 
products and 1,255 of them reported consumption of supplements that contributed to 
the daily intake of vitamin D (1,212 participants) and calcium (260 participants). The 
exact nutrient composition of these dietary supplements was identified and added to 
the dietary ones. 
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7.4.2 Associations between vitamin D, calcium and 
colorectal cancer risk 
7.4.2.1 Main logistic regression models 
In model I, intakes of calcium were positively associated with colorectal cancer (high 
vs. low intake: OR (95% CI), p-value: 1.33 (1.13, 1.57), 0.001) (Table 90). 
Associations between total intakes (from diet and supplements) of vitamin D and 
calcium and colorectal cancer were not examined in model I, since intake from 
supplements was added to the energy-adjusted nutrients. After energy adjustment 
(Model II), both dietary and total vitamin D intakes were significantly and inversely 
associated with colorectal cancer (high vs. low dietary intake: OR (95% CI), p-value 
for trend: 0.83 (0.70, 0.97), 0.01; high vs. low total intake: OR (95% CI), p-value for 
trend: 0.80 (0.68, 0.95), 0.003) (Table 90). Finally, in model III an inverse 
statistically significant association between dietary vitamin D and colorectal cancer 
(high vs. low dietary intake: OR (95% CI), p-value for trend: 0.83 (0.69, 0.99), 0.03) 
was observed, whereas association with total vitamin D and colorectal cancer was 
marginally not statistically significant (high vs. low total intake: OR (95% CI), p-
value for trend: 0.88 (0.73, 1.06), 0.14) (Table 90).  
7.4.2.2 Additional logistic regression models 
The associations between vitamin D, calcium and colorectal cancer were tested in 
one additional model (Model IV). Model IV was corrected for the confounding 
factors of model III and further adjusted ω3PUFAs intake, since ω3PUFAs share the 
same main food source with vitamin D (Table 91). The inverse association between 
vitamin D intakes (dietary and total) and colorectal cancer was diluted and was no 
longer statistically significant after adjusting for ω3PUFAs intake (p- value for trend: 
0.51 and 0.41 respectively) (Table 91). 
7.4.2.3 Multiple testing corrections 
Bonferroni correction for multiple testing 
The adjusted level of significance after having controlled for multiple testing was: 1) 
0.002 using the Bonferroni correction for 21 independent tests, 2) 0.006 using the 
Bonferroni correction for 8 tests conducted in hypothesis 4 and 3) 0.0005 for the 
individual compound analysis after having corrected for 93 tests conducted in all 4 
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hypotheses. Here we report only associations between dietary intakes and colorectal 
cancer. In model I, the association between colorectal cancer and calcium (p=0.001) 
remained significant at the first and second level of significance (Table 90). 
FDR correction for multiple testing 
After correcting for multiple testing using the FDR method by taking into account 
the number of tests that were conducted in hypothesis 4 (8 tests) or the number of 
tests that were conducted in all 4 hypotheses (93 tests in the individual compound 
analysis), associations between dietary intakes of calcium (p= 0.001; model I) and 
vitamin D (p=0.01; model II) remained statistically significant (Table 90). 
7.4.2.4 Associations between colorectal cancer and main food 
sources of vitamin D and calcium 
Intakes of the following food groups were tested: fried oily fish, smoked oily fish, 
semi-skimmed milk and full fat hard cheese. Results from model III, showed that 
comparison of highest versus lowest tertile intakes of these foods showed ORs for 
colorectal cancer risk of 0.74 (95% CI 0.61, 0.91; p-value for trend 0.20) for fried 
oily fish; 0.85 (95% CI 0.73, 1.00; p-value for trend 0.07) for smoked oily fish; 0.93 
(95% CI 0.76, 1.14, p-value for trend 0.48); and 1.23 (95% CI 1.01, 1.49, p-value for 
trend 0.009) for full fat hard cheese (Table 92). 
7.4.2.5 Associations between vitamin D, calcium and colorectal 
cancer after sex, age and cancer site stratification 
Associations between vitamin D, calcium and colorectal cancer risk were tested after 
sex, age and cancer site stratification by applying model III (data not shown). Sex-
specific associations were similar for dietary vitamin D intake and dietary and total 
calcium intakes, with dietary vitamin D being inversely, but not significantly 
associated with both male and female colorectal cancer (data not shown). In addition, 
total vitamin D intake was associated with a decreased colorectal cancer risk 
(marginally not statistically significant) for men, but not for women (data not 
shown). Regarding age-specific differences, high intake of dietary and total vitamin 
D was significantly and dose-dependently associated with a decreased risk of 
colorectal cancer for the individuals older than 55 years old (high vs. low dietary 
intake: OR (95% CI), p-value for trend: 0.80 (0.65, 0.99), 0.05), but not for the ones 
younger than 55 years old (data not shown). Finally, after cancer site stratification, 
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both colon and rectal cancer were similarly associated with vitamin D (dietary and 
total). Regarding calcium, high intakes of both dietary and total calcium were 
inversely but not statistically significantly associated only with rectal cancer (high 
vs. low intake: OR (95% CI), p-value: 0.83 (0.65, 1.07), 0.21) (data not shown). 
7.4.2.6 Interaction relationships with variants of vitamin D 
receptor gene 
The genotypic effect of four SNPs of VDR (FokI (rs10735810), BsmI (rs1544410), 
rs11568820 and ApaI (rs7975232)) on colorectal cancer risk was examined (data not 
shown). The variant allele frequencies in the control sample of three of the four SNPs 
(FokI (rs10735810), ApaI (rs7975232) and rs11568820) were under Hardy-Weinberg 
equilibrium (p>0.05), but BsmI (rs1544410) was not (p= 0.01). 
The associations between colorectal cancer risk and each of the four SNPs were 
tested by applying one unadjusted and one simply adjusted (for age, sex and 
deprivation score) logistic regression model (data not shown). ORs and 95% CI for 
vitamin D and calcium dietary intakes were calculated in stratified groups according 
to the rs10735810, rs1544410, rs11568820 and rs7975232 genotypes by applying the 
multivariable adjusted model III (adjusted for age, sex, deprivation score, family 
history of cancer, BMI, physical activity, smoking, dietary energy intake (residual 
method), fibre intake (energy adjusted), alcohol intake (energy adjusted), NSAIDs 
intake) (data not shown). In addition, interaction associations were examined by 
investigating the combined effects of the genotypes and nutrient intakes. Interaction 
was tested by examining the deviance of two different nested models; an interactive 
model and its nested multiplicative one. The referent category used was 
homozygotes of the wild type allele being at greatest risk (low dietary nutrient 
intake). 
None of the four examined SNPs was associated with colorectal cancer (data not 
shown). The inverse association between vitamin D and colorectal cancer was more 
profound for individuals of the rs10735810 CC genotype than for individuals of the 
CT or TT genotypes (data not shown). Furthermore, calcium intake was inversely 
though not significantly associated with colorectal cancer for the rs10735810 CC 
individuals, whereas it was positively associated for the TT individuals (data not 
shown). Finally, there was some evidence that rs10735810 interacts with dietary 
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vitamin D (p for interaction 0.06) and calcium intakes (p for interaction 0.13) (data 
not shown). 
7.4.3 Summary of results 
Significant dose-dependent associations were observed: 1) in model I: between 
colorectal cancer and dietary calcium (p=0.001); 2) in model II: between colorectal 
cancer and dietary vitamin D (p=0.01); 3) in model III: between colorectal cancer 
and dietary vitamin D (p=0.03) (Table 90). Regarding the analysis of the main food 
sources of vitamin D and calcium, there is some evidence in favour of a significant 
inverse association between colorectal cancer and intakes of fried and smoked oily 
fish and a positive association between colorectal cancer and intakes of full fat hard 
cheese (Table 92). In addition, none of the four examined SNPs was associated with 
colorectal cancer (data not shown). Finally, there was some evidence that 
rs10735810 interacts with vitamin D (p for interaction 0.06) and calcium dietary 
intakes (p for interaction 0.13) (data not shown). 
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Table 86 Vitamin D and calcium transformation 
Nutrients included in the analysis Transformation 
Individual compounds  
Vitamin D logarithmic 
Calcium logarithmic 
 
Table 87 Descriptive report of crude and energy-adjusted intakes of vitamin D and calcium 
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Table 88 Spearman rank correlation coefficients between nutrients (p-values<5x10-5) 
Nutrients vitamin D calcium 
vitamin D 1.00  
calcium 0.45 1.00 
 
Table 89 Three main dietary (food) sources of vitamin D and calcium in our population 
Nutrients Main sources 
Vitamin D Fried oily fish (22.9%) 
Smoked oily fish (10.0%) 
Grilled, poached, baked or pickled oily fish (6.7%)  
Calcium Semi-skimmed milk (17.8%) 
Full fat hard cheese (8.7%) 
Full fat milk (5.9%) 
                                               
* Logarithmic transformed values were used for calculating the t-test due to skewed distribution 
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Table 90 Association between vitamin D, calcium and colorectal cancer risk in the whole sample (3 main unconditional logistic regression models) 
Nutrients Quartiles
*
 Frequency Model I
†
 Model II
‡ Model III§ 
  cases controls OR 95% CI OR 95% CI OR 95% CI 
Vitamin D 
(µg/day) 
0-2.74 538 672 1.00  1.00  1.00  
2.74-3.86 535 674 0.94 0.80, 1.11 0.99 0.84, 1.16 1.00 0.83, 1.20 
 3.86-5.47 506 703 1.04 0.89, 1.23 0.90 0.77, 1.06 0.93 0.77, 1.11 
 ≥5.47 482 727 0.98 0.84, 1.16 0.83 0.70, 0.97 0.83 0.69, 0.99 
 p-value for trend (quartiles)  0.83  0.01  0.03 
 p-value for trend (continuous)  0.58  0.001  0.002 
Vitamin D 
(total) (µg/day) 
0-3.03 528 682   1.00  1.00  
3.03-4.64 554 655   1.09 0.93, 1.28 1.06 0.88, 1.27 
 4.64-7.48 515 694   0.96 0.82, 1.13 1.00 0.84, 1.20 
 ≥7.48 464 745   0.80 0.68, 0.95 0.88 0.73, 1.06 
 p-value for trend (quartiles)    0.003  0.14 





0-924.53 511 699 1.00  1.00  1.00  
924.53-1091.09 519 690 1.16 0.99, 1.36 1.03 0.88, 1.21 0.93 0.78, 1.12 
 1091.09-1269.60 520 689 1.12 0.95, 1.32 1.03 0.88, 1.21 0.97 0.81, 1.17 
 ≥1269.60 511 698 1.33 1.13, 1.57 1.00 0.85, 1.18 0.96 0.80, 1.15 
 p-value for trend (quartiles)  0.001  0.98  0.76 
 p-value for trend (continuous)  0.001  0.53  0.53 
Calcium 
(total) (mg/day) 
0-931.59 511 699   1.00  1.00  
931.59-1100.64 521 688   1.04 0.88, 1.22 0.94 0.78, 1.13 
 1100.64-1284.65 530 679   1.07 0.91, 1.25 1.00 0.83, 1.20 
 ≥1284.65 499 710   0.96 0.82, 1.13 0.93 0.77, 1.12 
 p-value for trend (quartiles)    0.74  0.59 
 p-value for trend (continuous)    0.32  0.46 
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*Based on the distribution of the energy adjusted variable 
†Model I: Crude analysis 
‡Model I: Adjusted for total energy intake  
§Model III: Adjusted for age, sex, deprivation score, family history of cancer, BMI, physical activity, smoking, total energy intake (residual method), fibre intake (energy 
adjusted), alcohol intake (energy adjusted), NSAIDs intake 
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Table 91 Association between vitamin D, calcium and colorectal cancer risk in the whole sample 
(additional unconditional logistic regression models) 
Nutrients Quartiles
*
 Frequency Model IV
†
 
  cases controls OR 95% CI 
Vitamin D 
(µg/day) 
0-2.74 538 672 1.00  
2.74-3.86 535 674 1.05 0.87, 1.26 
 3.86-5.47 506 703 1.04 0.86, 1.26 
 ≥5.47 482 727 1.10 0.86, 1.41 
 p-value for trend (quartiles)  0.51 
 p-value for trend (continuous)  0.71 
Vitamin D 
(total) (µg/day) 
0-3.03 528 682 1.00  
3.03-4.64 554 655 1.13 0.94, 1.36 
 4.64-7.48 515 694 1.14 0.94, 1.38 
 ≥7.48 464 745 1.09 0.88, 1.36 
 p-value for trend (quartiles)  0.41 
 p-value for trend (continuous)  0.66 
Calcium 
(mg/day) 
0-924.53 511 699 1.00  
924.53-1091.09 519 690 0.95 0.79, 1.13 
 1091.09-1269.60 520 689 1.00 0.84, 1.20 
 ≥1269.60 511 698 0.96 0.80, 1.16 
 p-value for trend (quartiles)  0.87 
 p-value for trend (continuous)  0.60 
Calcium 
(total) (mg/day) 
0-931.59 511 699 1.00  
931.59-1100.64 521 688 0.95 0.80, 1.14 
 1100.64-1284.65 530 679 1.03 0.86, 1.23 
 ≥1284.65 499 710 0.94 0.78, 1.13 
 p-value for trend (quartiles)  0.70 
 p-value for trend (continuous)  0.55 
                                               
* Based on the distribution of the energy adjusted variable 
† Model IV: Adjusted for age, sex, deprivation score, family history of cancer, BMI, physical activity, smoking, 
total energy intake (residual method), fibre intake (energy adjusted), alcohol intake (energy adjusted), NSAIDs 
intake, ω3PUFAs (energy adjusted) 
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Table 92 Association between fried oily fish, smoked oily fish, semi-skimmed milk and full fat hard cheese and colorectal cancer risk in the whole sample (3 
main unconditional logistic regression models) 
Food sources Quartiles
*







  cases controls OR 95% CI OR 95% CI OR 95% CI 




0 1148 1524 1.00  1.00  1.00  
0-0.14 659 832 1.05 0.92, 1.19 1.05 0.92, 1.19 1.09 0.94, 1.26 
 >0.14 254 420 0.80 0.67, 0.95 0.73 0.61, 0.87 0.74 0.61, 0.91 
 p-value for trend (quartiles)  0.20  0.05  0.20 
 p-value for trend (continuous)  0.02  0.001  0.001 
Smoked oily 
fish (m/day) 
0 1258 1628 1.00  1.00  1.00  
0-0.05 324 446 0.94 0.80, 1.10 0.95 0.81, 1.11 0.97 0.81, 1.16 
 >0.05 479 702 0.88 0.77, 1.01 0.82 0.72, 0.95 0.85 0.73, 1.00 
 p-value for trend (quartiles)  0.07  0.01  0.07 





0 687 905 1.00  1.00  1.00  
0-1 555 800 0.91 0.79, 1.06 0.94 0.81, 1.09 0.91 0.77, 1.08 
 1-2 509 670 1.00 0.86, 1.16 1.00 0.86, 1.16 0.95 0.80, 1.12 
 >2 310 401 1.02 0.85, 1.22 0.96 0.81, 1.15 0.93 0.76, 1.14 
 p-value for trend (quartiles)  0.74  0.84  0.48 
 p-value for trend (continuous)  0.78  0.71  0.30 
Full fat hard 
cheese (m/day) 
0-0.05 462 754 1.00  1.00  1.00  
0.05-0.28 533 769 1.13 0.97, 1.33 1.13 0.96, 1.32 1.11 0.93, 1.33 
 0.28-0.71 550 646 1.39 1.18, 1.63 1.34 1.14, 1.58 1.31 1.09, 1.57 
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 >0.71 516 607 1.39 1.18, 1.64 1.26 1.07, 1.50 1.23 1.01, 1.49 
 p-value for trend (quartiles)  6.2x10
-6
  0.001  0.009 
 p-value for trend (continuous)  0.04  0.68  0.85 
                                               
*Based on the distribution of the energy adjusted variable 
†Model I: Crude analysis 
‡Model II: Adjusted for total energy intake, standard method  
§Model III: Adjusted for age, sex, deprivation score, family history of cancer, BMI, physical activity, smoking, total energy intake (residual method), fibre intake (energy adjusted), 
alcohol intake (energy adjusted), NSAIDs intake 
** m/d: measure per day 
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7.5 Summary of results of chapter 7 
In this chapter the results of the unmatched analysis of the additional dietary risk factors 
(folate, vitamin B2, vitamin B6, vitamin B12, alcohol, vitamin D and calcium) that 
comprised the last two hypotheses, were presented. In particular, one crude and three 
multivariable unconditional logistic regression models were applied in the whole 
sample, whereas one unconditional multivariable model adjusted for the main potential 
confounding factors was applied after sex, age and cancer site stratification. 
7.5.1 Folate, vitamin B2, vitamin B6, vitamin B12 and alcohol 
Inverse associations, which showed dose response relationships, were found in the 
energy-adjusted conditional logistic regression model (model II) between colorectal 
cancer risk and the dietary intakes of folate (p=0.003), vitamin B6 (p=7.1x10
-6
) and 
vitamin B12 (p=0.02) (Table 84). After adjusting for the main potential confounding 
factors (model III), only the inverse associations between colorectal cancer and vitamin 
B12 (p=0.05) remained statistically significant (Table 84). Alcohol intake when divided 
in quartiles was associated with a decreased colorectal cancer risk, and the association 
was statistically significant in model III (p=0.03) (Table 84). However, when divided 
into categories, no association was observed for an intake of less than 60 g/day, whereas 
a positive not statistically significant association was observed for an alcohol intake of 
more than 60 g/day (Table 84). Regarding the analysis of the main food sources of 
folate, vitamin B6 and vitamin B12, results suggest that there is some evidence in favour 
of a significant inverse association between colorectal cancer and intakes of bananas 
(dietary source of vitamin B6) and fried oily fish (dietary source of vitamin B12) (Table 
85). Finally, regarding the genetic analysis, none of the four examined SNPs was 
significantly associated with colorectal cancer risk (data not shown). Furthermore, there 
was no clear trend for the associations between colorectal cancer and folate, vitamin B2, 
vitamin B6, vitamin B12 and alcohol after stratification according to the aforementioned 
genotypes (data not shown). 
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7.5.2 Vitamin D and calcium 
Regarding vitamin D, significant inverse dose-dependent associations were observed 
between colorectal cancer and dietary vitamin D in both models II (p=0.01) and III 
(p=0.03) (Table 90). In marked contrast, dietary and total calcium intakes were not 
associated with colorectal cancer risk in any of the adjusted models, whereas high 
dietary calcium intake was associated with a significant increased colorectal cancer risk 
(p=0.001) in model I (Table 90). Regarding the analysis of the main food sources of 
vitamin D and calcium, there is some evidence in favour of a significant inverse 
association between colorectal cancer and intakes of fried and smoked oily fish and a 
positive association between colorectal cancer and intakes of full fat hard cheese (Table 
92). None of the four examined SNPs was associated with colorectal cancer (data not 
shown), but there was some evidence that rs10735810 interacts with vitamin D (p for 
interaction 0.06) and calcium dietary intakes (p for interaction 0.13) (data not shown). 
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8 RESULTS: Overall and stepwise regression 
analysis 
8.1 Introduction 
This analysis describes the overall analysis as well as the application of forward and 
backward stepwise regression. The study sample included in this analysis is the same 
as the sample that was included in the unmatched analysis of the additional dietary 
factors. Therefore, the presentation of the study sample will be omitted, since it has 
been described in detail in the first part of Chapter 7 (on page 260). 
 The explanatory variables that were included in the overall and stepwise regression 
models consist of demographic factors, lifestyle variables, foods and nutrients. In the 
first part of the chapter, distributions and correlations of all the explanatory variables, 
as well as univariable logistic regression of colorectal cancer on each explanatory 
variable are presented (overall analysis). In the second part of the chapter, results of 
the forward and backward stepwise regression applied in three different sets of 
explanatory variables are presented for the whole sample and separately for males 
and females.   
8.2 Overall analysis 
8.2.1 Distribution of explanatory variables by case control 
status 
Numbers and percentages of all categorical explanatory variables as well as mean 
(with standard deviations) and median intakes (with interquartile ranges) of all 
continuous explanatory variables are presented in Table 93 and Table 94. The tests 
chi-square (categorical variables), t-test (continuous variables) and the Wilcoxon 
rank-sum (continuous variables) were used to test for differences between cases and 
controls.  
Regarding the categorical explanatory variables, significant differences were 
observed for family history of colorectal cancer (p<0.0005), physical activity 
(p=0.04), NSAIDs intake (p<0.0005) and HRT intake (p<0.0005) (Table 93). 
Regarding the continuous explanatory variables, cases when compared to controls 
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(p=0.0001), fruit/ vegetable juice (p<5x10-5), SFAs (p<5x10-5), MUFAs (p=0.04), 
tFAs (p=0.002), tMUFAs (p=0.0004), cholesterol (p=0.0001), starch (p=0.04) and 
vitamin A (p=0.0001) (Table 94). In addition cases reported higher median intakes of 
dietary energy (p<5x10
-5









), MUFAs (p=0.01), tFAs (p=0.0004), 
tMUFAs (p<5x10-5), cholesterol (p<5x10-5), starch (p=0.05) and vitamin A 
(p=0.0001) (Table 94). 
On the other hand, cases when compared to controls reported lower mean intakes of 
oily fish (p<5x10
-5





(p=0.02), coffee (p=0.001), ω3PUFAs (p<5x10
-5
), quercetin (p=0.0006), catechin 





(p<5x10-5), phosphorus (p=0.0002), iron (p=0.0004), copper (p<5x10-5), zinc 
(0.003), manganese (p<5x10-5), selenium (p=0.0002), carotenes (p=0.0007), vitamin 





), folate (0.0002), biotin (p<5x10
-5
), vitamin C (p=0.001) 
(Table 94). 
In addition cases reported lower median intakes of oily fish (p=0.0003), fruits 
(p=0.004), vegetables (p<5x10-5), savoury foods (p=0.01), coffee (p=0.001), 
ω3PUFAs (p<5x10-5), quercetin (p=0.001), catechin (p=0.008), phytoestrogens 














), selenium (p=0.005), carotenes (p<5x10
-5
), vitamin 
D (p=0.001), vitamin B1 (p=0.01), potential niacin (p=0.0006), niacin (p<5x10
-5
), 
vitamin B6 (p<5x10-5), vitamin B12 (p=0.02), folate (0.0003), pantothenic acid 
(p=0.006), biotin (p=0.0001), vitamin C (p=0.0001) (Table 94). 
                                               
1 Sweets: Summary variable of puddings and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
2 Savoury foods: Summary variable of savoury foods, soups and sauces 
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Table 93 Descriptive report of all explanatory variables (categorical variables) 
 All subjects (n=4837) Cases (n=2061) Controls (n=2776) χ
2
-test 
Demographic factors Number % Number % Number % p-value 
Sex        
 Males 2762  57.1% 1180 57.2% 1582  57.0%  
 Females 2075  42.9% 881 42.8% 1194  43.0% 0.85 
Family history
*
        
 Low 4305 92.2% 1610 82.9% 2695 98.9%  
 Medium/ high 363 7.8% 333 17.1% 30 1.1% <0.0005 
Deprivation score        
 1 452  9.3% 194  9.4% 258  9.3%  
 2 1002  20.7% 434  21.1% 568  20.5%  
 3 1290  26.7% 532  25.8% 758  27.3%  
 4 1133  23.4% 488  23.7% 645  23.2%  
 5 511  10.6% 218  10.6% 293  10.6%  
 6 318  6.6% 140  6.8% 178  6.4%  
 7 130  2.7% 54  2.6% 76  2.7% 0.95 
Lifestyle variables        
Smoking        
 Never 2074 43.3% 874 42.9% 1200 43.5%  
 Former 1867 38.9% 818 40.2% 1049 38.0%  
 Current 852 17.8% 343 16.9% 509 18.5% 0.20 
Alcohol (g/day)        
 0 718 14.8% 291 14.1% 427 15.4%  
 0-15 2598 53.7% 1125 54.6% 1473 53.1%  
 15-30 941 19.4% 393 19.1% 548 19.7%  
 30-45 341 7.1% 139 6.7% 202 7.3%  
 45-60 142 2.9% 61 3.0% 81 2.9%  
 >60 97 2.0% 52 2.5% 45 1.6% 0.20 
Physical activity 
(hours/week)  
       
 0  2595  53.6% 1139  55.3% 1456  52.4%  
 0-3.5  1189  24.6% 486  23.6% 703  25.3%  
 3.5-7  544  11.2% 205  9.9% 339  12.2%  
 >7  318  6.6% 133  6.5% 185 6.7% 0.04 
NSAIDs        
 No 3206  66.3% 1449  70.3% 1757  63.3%  
 Yes 1605  33.2% 605  29.4% 1000  36.0% <0.0005 
HRT
†
         
 No 1487 73.6% 666 77.8% 821 70.5%  
 Yes 533 26.4% 190 22.2% 343 29.5% <0.0005 
                                               
* High/moderate vs. low family history risk 
† HRT: Hormone Replacement Therapy; Intake of 6 months or more vs. no intake/ intake of less than 6 months 
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Table 94 Descriptive report of all explanatory variables (continuous variables) 
 All subjects (n=4837) Cases (n=2061) Controls (n=2776) t test rank test 
Demographic factors Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR) p-value p-value 
Age 62.2 (10.6) 63.0 (55.0, 71.0) 62.0 (10.8) 63.0 (54.0, 71.0) 62.4 (10.5) 63.0 (55.0, 71.0) 0.14 0.25 
Lifestyle variables         
BMI 26.7 (4.5) 26.1 (23.7, 29.1) 26.6 (4.4) 26.1 (23.6, 29.0) 26.7 (4.6) 26.1 (23.7, 29.1) 0.41 0.68 







)         
Breads  2.8 (1.3) 2.7 (1.9, 3.6) 2.8 (1.2) 2.7 (1.9, 3.6) 2.7 (1.3) 2.6 (1.8, 3.6) 0.15 0.05 
Cereals
†
 1.2 (0.9) 1.1 (0.4, 1.7) 1.2 (0.9) 1.0 (0.5, 1.6) 1.2 (1.0) 1.1 (0.4, 1.8) 0.21 0.78 
Milk  2.0 (1.2) 1.9 (1.1, 2.4) 2.0 (1.3) 1.9 (1.1, 2.5) 1.9 (1.2) 1.8 (1.1, 2.4) 0.45 0.46 
Cream†  0.5 (0.6) 0.3 (0.0, 0.8) 0.5 (0.6) 0.3 (0.0, 0.8) 0.5 (0.7) 0.3 (0.0, 0.8) 0.21 0.47 
Cheese†  0.8 (0.8) 0.6 (0.3, 1.1) 0.8 (0.7) 0.6 (0.3, 1.1) 0.8 (0.8) 0.6 (0.3, 1.1) 0.59 0.16 





Poultry†  0.4 (0.3) 0.3 (0.2, 0.6) 0.4 (0.3) 0.3 (0.2, 0.5) 0.4 (0.4) 0.3 (0.1, 0.6) 0.16 0.12 
Red meat†  1.3 (0.8) 1.3 (0.8, 1.7) 1.4 (0.8) 1.3 (0.8, 1.7) 1.3 (0.8) 1.2 (0.8, 1.8) 0.14 0.20 
Processed meat† 1.0 (0.8) 0.9 (0.5, 1.4) 1.0 (0.7) 0.9 (0.5, 1.4) 1.0 (0.8) 0.9 (0.5, 1.4) 0.63 0.72 
White fish†  0.3 (0.3) 0.3 (0.2, 0.5) 0.4 (0.3) 0.3 (0.2, 0.5) 0.3 (0.3) 0.3 (0.1, 0.5) 0.25 0.09 
Oily fish†  0.2 (0.3) 0.1 (0.0, 0.3) 0.2 (0.3) 0.1 (0.0, 0.3) 0.2 (0.3) 0.1 (0.0, 0.3) <5x10-5 0.0003 
Potatoes/ 
Pasta/ Rice  
2.4 (1.0) 2.3 (1.7, 2.9) 2.4 (1.0) 2.3 (1.7, 2.9) 2.4 (1.0) 2.3 (1.7, 2.9) 0.96 0.77 
Fruit†  2.9 (2.2) 2.5 (1.4, 3.8) 2.8 (2.1) 2.4 (1.4, 3.7) 3.0 (2.2) 2.5 (1.5, 4.0) 0.006 0.004 







  2.8 (1.4) 2.5 (1.8, 3.4) 2.7 (1.4) 2.5 (1.8, 3.3) 2.8 (1.5) 2.6 (1.8, 3.5) 0.02 0.01 
Sweets
§
  4.7 (2.5) 4.4 (3.0, 6.1) 4.9 (2.5) 4.3 (2.9, 6.0) 4.6 (2.5) 4.6 (3.1, 6.3) 0.0001 <5x10
-5
 




  2.7 (1.8) 3.0 (1.0, 4.0) 2.6 (1.8) 3.0 (1.0, 4.0) 2.7 (1.8) 3.0 (1.0, 4.0) 0.70 0.55 
Coffee**  1.6 (1.7) 1.0 (0.1, 3.0) 1.5 (1.7) 1.0 (0.0, 2.4) 1.7 (1.7) 1.0 (0.1, 3.0) 0.001 0.001 





Fizzy drinks† 0.4 (0.8) 0.0 (0.0, 0.4) 0.4 (0.8) 0.0 (0.0, 0.4) 0.3 (0.8) 0.0 (0.0, 0.4) 0.11 0.13 
Fatty acids (g/day)         





MUFAs 32.3 (6.1) 32.6 (28.6, 36.2) 32.5 (5.7) 32.8 (29.0, 36.3) 32.1 (6.4) 32.4 (28.2, 36.1) 0.04 0.01 
ω6PUFAs 11.3 (3.5) 10.7 (8.9, 13.2) 11.4 (3.6) 10.7 (8.9, 13.2) 11.3 (3.5) 10.7 (8.9, 13.1) 0.58 0.81 





tFAs 3.6 (1.1) 3.5 (2.9, 4.2) 3.7 (1.1) 3.6 (3.0, 4.3) 3.6 (1.2) 3.5 (2.8, 4.2) 0.002 0.0004 
tMUFAs 2.7 (0.8) 2.7 (2.2, 3.2) 2.8 (0.8) 2.7 (2.2, 3.2) 2.7 (0.8) 2.6 (2.1, 3.2) 0.0004 <5x10-5 
Flavonoids (mg/day)         
Quercetin 17.2 (7.7) 17.4 (11.2, 22.6) 16.8 (7.5) 16.9 (10.9, 22.1) 17.5 (7.8) 17.6 (11.4, 22.1) 0.0006 0.001 
Catechin† 7.4 (3.8) 7.2 (4.8, 9.4) 7.3 (3.8) 7.0 (4.6, 9.1) 7.5 (3.8) 7.4 (4.9, 9.5) 0.03 0.008 
Epicatechin 22.9 (11.9) 23.3 (12.7, 32.3) 22.6 (11.6) 23.0 (12.6, 31.8) 23.1 (12.0) 23.6 (12.8, 32.8) 0.12 0.13 
Flavones 1.3 (1.2) 1.0 (0.5, 1.8) 1.3 (1.2) 1.0 (0.5, 1.8) 1.3 (1.1) 1.0 (0.5, 1.8) n/a 0.55 
Procyanidins 30.8 (17.3) 31.7 (16.0, 44.7) 30.3 (17.0) 31.3 (15.8, 43.6) 31.1 (17.5) 32.0 (16.1, 45.5) 0.09 0.09 
















Macronutrients (g/day)         
Protein 101.3 (17.5)  101.3 (90.6, 112.3) 100.5 (17.1) 100.3 (89.9, 111.0) 101.9 (17.7) 102.1 (91.3, 113.1) 0.004 0.0004 
Cholesterol 369.2 (111.8) 362.0 (296.2, 430.1) 376.5 (107.3) 367.2 (306.7, 438.3) 363.7 (114.8) 358.3 (290.2, 424.6) 0.0001 <5x10
-5
 
Sugars†† 137.5 (46.1) 132.7 (109.4, 158.5) 136.8 (41.8) 132.2 (109.9, 157.8) 138.0 (43.9) 132.9 (109.2, 159.6) 0.56 0.63 
Starch 163.3 (33.2) 164.6 (143.3, 184.5) 164.4 (31.0) 165.6 (145.5, 184.1) 162.5 (34.8) 163.7 (141.7, 184.9) 0.04 0.05 
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Minerals (mg/day)         





























































Iron 15.4 (2.9) 15.3 (13.6, 17.1) 15.2 (2.8) 15.1 (13.3, 16.9) 15.5 (2.9) 15.4 (13.7, 17.3) 0.0004 <5x10-5 
























Selenium (µg/day) 83.1 (32.4) 79.0 (63.2, 96.4) 81.1 (29.4) 78.0 (61.8, 95.0) 84.6 (34.4) 79.9 (63.9, 97.5) 0.0002 0.005 
Iodine†† (µg/day) 202.9 (77.8) 190.2 (149.8, 240.7) 200.3 (73.7) 188.6 (149.8, 237.7) 204.7 (80.6) 191.4 (149.8, 243.5) 0.19 0.19 
Vitamins (mg/day)         






























Vitamin D†† (µg/day) 4.5 (2.7) 3.9 (2.7, 5.5) 4.3 (5.5) 3.8 (2.7, 5.4) 4.6 (2.8) 3.9 (2.8, 5.6) 0.007 0.001 
Vitamin E†† 9.1 (3.5) 8.3 (6.8, 10.4) 9.1 (3.5) 8.2 (6.8, 10.4) 9.1 (3.4) 8.3 (6.8, 10.5) 0.87 0.54 
Vitamin B1
††
 (Thiamine) 2.1 (0.8) 2.0 (1.8, 2.3) 2.1 (0.6) 2.0 (1.8, 2.3) 2.1 (0.8) 2.0 (1.8, 2.3) 0.03 0.01 
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Vitamin B2 2.1 (0.5) 2.1 (1.8, 2.4) 2.1 (0.5) 2.1 (1.8, 2.4) 2.1 (0.5) 2.1 (1.8, 2.4) 0.09 0.13 
Potential niacin 21.1 (3.6) 21.1 (18.8, 23.4) 20.9 (3.5) 20.9 (18.7, 23.1) 21.2 (3.7) 21.3 (19.9, 23.5) 0.004 0.0006 










Vitamin B12†† (µg/day) 7.7 (3.6) 7.0 (5.3, 9.2) 7.5 (3.4) 6.9 (5.2, 9.0) 7.8 (3.7) 7.0 (5.3, 9.4) 0.06 0.02 
Folic acid (µg/day) 329.4 (71.5) 325.9 (282.6, 370.8) 324.9 (68.2) 321.3 (280.5, 365.7) 332.7 (73.6) 328.9 (283.8, 374.7) 0.0002 0.0003 
Pantothenic acid 7.8 (5.3) 6.6 (5.9, 7.6) 7.8 (5.5) 6.6 (5.8, 7.5) 7.8 (5.2) 6.7 (5.9, 7.6) 0.26 0.006 
Biotin (µg/day) 49.6 (10.0) 49.3 (43.4, 55.7) 48.9 (9.7) 48.9 (42.9, 55.0) 50.2 (10.3) 49.8 (43.6, 56.1) <5x10
-5
 0.0001 
Vitamin C 125.3 (63.1) 114.2 (81.2, 156.1) 120.5 (58.5) 111.2 (78.8, 147.8) 128.9 (66.2) 117.6 (83.0, 161.4) 0.001 0.0001 
                                               
* m/d: measures per day 
† Square root transformed values were used for calculating the t-test due to skewed distribution 
‡ Savoury foods: Summary variable of savoury foods, soups and sauces 
§Sweets:  Summary variable of pudding and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
** Not energy adjusted 
††  Logarithmic transformed values were used for calculating the t-test due to skewed distribution 
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8.2.2 Correlation matrix for the explanatory variables 
Correlation coefficients that were ≥0.70 are highlighted in Table 95 (divided in three 
categories: 0.70-0.80, 0.80-0.90, ≥0.90) The variables that were highly correlated were: 
1) oily fish consumption with ω3PUFAs and vitamin D intakes; ω3PUFAs with vitamin 
D intakes; and vitamin D with vitamin B12 intakes; 2) tea consumption with quercetin, 
epicatechin and procyanidin intakes; quercetin with epicatechin and procyanidin 
intakes; catechin with epicatechin and procyanidin intakes; and epicatechin with 
procyanidin intakes 3) vegetable consumption with carotene intakes; 4) fruit 
consumption with vitamin C intakes; and vitamin C with flavanone intakes; 5) SFA 
with tFA intakes, and tFA with tMUFA intakes; 6) protein with phosphorus, zinc, 
potential niacin and niacin intakes; magnesium with phosphorus and iron intakes; 
phosphorus with zinc, vitamin B2 and potential niacin intakes; and zinc with potential 
niacin intakes 7) fibre with potassium and magnesium intakes; potassium with 
magnesium, vitamin B6 and folic acid intakes; vitamin B6 with folic acid intakes; and 
vitamin B6 with thiamine intakes; 8) sodium with chloride intakes; 9) calcium with 
phosphorus and vitamin B2 intakes (Table 95).  
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Table 95 Correlation matrix of the explanatory variables (demographic factors, lifestyle factors, foods and nutrients) 
Variables age    deprivat. alcohol BMI energy breads cereals milk cream cheese eggs 
age 1.00                     
deprivation -0.06 1.00          
alcohol -0.14 -0.08 1.00         
BMI -0.04 0.10 0.01 1.00        
energy -0.11 0.02 0.21 0.08 1.00       
breads 0.10 0.04 -0.07 0.03 0.07 1.00      
cereals 0.18 -0.03 -0.13 -0.02 0.03 -0.03 1.00     
milk 0.03 0.00 -0.13 -0.01 0.02 0.02 0.24 1.00    
cream -0.03 -0.12 -0.07 0.00 0.04 -0.12 0.13 0.07 1.00   
cheese 0.00 -0.10 0.05 -0.03 0.04 -0.04 -0.03 0.01 0.12 1.00  
eggs 0.11 0.09 0.04 0.06 0.00 0.04 -0.06 0.01 -0.07 0.06 1.00 
poultry -0.20 -0.06 0.06 0.05 0.02 -0.10 -0.02 -0.03 0.09 -0.02 -0.08 
processed meat  -0.18 0.10 0.07 0.13 0.04 0.09 -0.14 -0.07 -0.11 -0.04 0.11 
red meat 0.00 0.08 0.09 0.11 0.04 0.00 -0.17 -0.09 -0.18 -0.04 0.24 
white fish 0.19 -0.01 -0.02 0.01 0.02 -0.05 0.08 -0.01 0.05 0.02 0.11 
oily fish 0.16 -0.11 0.08 -0.05 0.05 -0.10 0.09 -0.04 0.16 0.08 0.02 
potatoes/pasta/rice -0.12 0.02 0.05 0.02 0.07 -0.02 -0.07 -0.08 -0.11 -0.07 -0.05 
savoury  -0.10 -0.04 0.07 0.00 0.05 -0.10 -0.05 -0.07 0.03 0.04 -0.05 
sweets 0.10 0.00 -0.21 0.02 0.08 -0.12 -0.05 -0.06 -0.02 -0.02 -0.08 
tea 0.10 0.02 -0.10 -0.07 0.10 0.11 0.08 0.10 -0.03 -0.05 0.02 
coffee -0.06 -0.11 0.12 0.02 0.08 -0.07 -0.04 0.03 0.09 0.13 -0.04 
fruit/ vegetable juice -0.07 -0.09 -0.01 0.02 0.04 -0.06 0.06 0.03 0.15 0.05 -0.08 
fizzy drinks -0.24 0.09 0.03 0.18 0.05 -0.07 -0.11 -0.10 0.01 -0.06 0.00 
vegetables -0.10 -0.08 0.01 0.00 0.04 -0.14 -0.01 -0.08 0.14 0.05 -0.11 
fruit 0.10 -0.10 -0.17 -0.02 0.01 -0.12 0.17 0.02 0.23 0.01 -0.16 
SFAs 0.05 0.01 -0.10 -0.04 0.17 0.04 -0.13 0.11 -0.01 0.27 0.18 
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Variables age    deprivat. alcohol BMI energy breads cereals milk cream cheese eggs 
MUFAs -0.01 0.01 -0.05 -0.01 0.23 0.06 -0.18 -0.04 -0.05 0.17 0.22 
ω6PUFAs -0.12 -0.01 -0.04 0.00 0.15 0.11 -0.06 -0.13 -0.01 0.00 0.01 
ω3PUFAs 0.00 -0.10 0.04 -0.01 0.13 -0.07 0.00 -0.11 0.14 0.08 0.01 
tFAs 0.00 -0.01 -0.09 -0.07 0.13 0.15 -0.11 0.09 -0.01 0.22 0.11 
tMUFAs 0.11 -0.02 -0.07 -0.07 0.13 0.26 -0.06 0.14 0.01 0.30 0.17 
Quercetin 0.13 -0.03 -0.10 -0.06 0.03 0.03 0.08 0.05 -0.01 -0.04 -0.05 
Catechin 0.00 -0.13 0.21 -0.10 0.04 -0.08 0.04 0.00 0.06 0.01 -0.10 
Epicatechin 0.09 -0.03 -0.09 -0.08 0.02 0.06 0.09 0.08 -0.03 -0.06 -0.05 
Flavones 0.10 -0.03 0.03 0.01 0.36 -0.05 0.05 -0.06 0.10 0.06 -0.03 
Procyanidins 0.10 -0.04 0.01 -0.07 0.03 0.07 0.08 0.07 -0.03 -0.03 -0.02 
Flavanones 0.01 -0.09 -0.04 0.00 0.02 -0.06 0.09 0.00 0.14 0.05 -0.09 
Phytoestrogens 0.09 -0.04 -0.09 -0.01 0.01 0.59 0.03 -0.01 0.03 0.01 -0.05 
Protein 0.10 0.02 -0.10 -0.07 0.10 0.11 0.08 0.10 -0.03 -0.05 0.02 
Cholesterol 0.14 0.06 0.01 0.04 0.11 -0.02 -0.12 0.04 -0.05 0.13 0.73* 
Sugars -0.03 -0.05 -0.17 0.03 0.12 -0.18 0.12 0.13 0.23 -0.10 -0.20 
Starch 0.04 0.04 -0.16 0.03 0.17 0.47 0.20 -0.05 -0.18 -0.13 -0.08 
Fibre 0.01 -0.11 -0.14 -0.02 0.11 0.04 0.24 -0.04 0.13 -0.02 -0.22 
Na -0.02 0.05 -0.02 0.09 0.21 0.32 0.11 0.03 -0.05 0.10 0.16 
K -0.03 -0.11 -0.02 0.00 0.17 -0.16 0.14 0.18 0.19 -0.02 -0.15 
Ca 0.03 -0.08 -0.15 -0.03 0.13 0.00 0.22 0.67 0.33 0.36 0.00 
Mg -0.08 -0.13 0.06 -0.02 0.18 -0.01 0.27 0.18 0.19 0.04 -0.18 
P 0.00 -0.09 -0.07 0.02 0.21 -0.05 0.26 0.44 0.30 0.24 0.03 
Fe 0.05 -0.11 0.05 -0.02 0.18 0.05 0.44 -0.03 0.10 -0.01 -0.06 
Cu -0.13 -0.08 0.11 0.04 0.18 -0.02 0.01 -0.14 0.04 0.00 -0.09 
Zn 0.01 -0.05 -0.01 0.05 0.18 -0.01 0.13 0.17 0.10 0.12 0.07 
Cl -0.03 0.04 -0.01 0.08 0.21 0.35 0.13 0.06 -0.03 0.11 0.14 
Mn 0.12 -0.11 -0.12 -0.06 0.08 0.25 0.22 0.02 0.09 0.00 -0.18 
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Variables age    deprivat. alcohol BMI energy breads cereals milk cream cheese eggs 
Se 0.00 -0.01 -0.02 0.04 0.09 0.27 -0.04 -0.03 0.05 0.06 0.08 
I 0.11 -0.08 -0.06 -0.01 0.08 -0.11 0.14 0.31 0.39 0.14 0.15 
Retinol 0.12 -0.03 -0.02 -0.02 0.08 0.01 -0.06 0.12 0.06 0.21 0.28 
Carotenes -0.06 -0.10 -0.01 -0.01 0.07 -0.12 0.00 -0.06 0.12 0.04 -0.11 
Vitamin D 0.12 -0.06 0.02 -0.02 0.07 -0.08 0.11 -0.02 0.09 0.06 0.19 
Vitamin E -0.07 -0.04 -0.11 -0.02 0.12 -0.03 0.06 -0.06 0.07 0.02 -0.07 
Thiamine 0.10 -0.04 -0.13 0.04 0.17 0.13 0.36 0.11 0.03 -0.08 -0.05 
Vitamin B2 0.03 -0.06 -0.10 -0.01 0.12 -0.09 0.45 0.62 0.33 0.12 0.06 
Pot Niacin -0.04 -0.03 0.01 0.08 0.21 0.00 0.05 0.22 0.13 0.21 0.18 
Niacin -0.13 -0.04 0.09 0.08 0.15 0.05 0.22 -0.03 0.04 -0.03 -0.08 
Vitamin B6 -0.01 -0.05 0.00 0.04 0.18 -0.10 0.31 0.09 0.06 -0.05 -0.09 
Vitamin B12 0.13 -0.06 0.03 0.01 0.08 -0.12 0.10 0.17 0.14 0.12 0.18 
Folic acid 0.03 -0.09 -0.03 -0.01 0.15 0.05 0.36 0.13 0.14 0.06 -0.03 
Pantoth. acid 0.06 -0.05 0.15 0.02 0.15 -0.03 0.14 0.27 0.04 0.01 0.15 
Biotin 0.10 -0.12 0.08 -0.05 0.13 -0.08 0.25 0.29 0.17 0.09 0.20 
Vitamin C -0.02 -0.14 -0.08 -0.02 0.04 -0.15 0.10 -0.02 0.22 0.05 -0.17 
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savoury sweets tea coffee fruit/ 
vegetable 
juice 
fizzy Vegs fruit 
poultry 1.00                           
processed meat  0.03 1.00             
red meat -0.02 0.41 1.00            
white fish 0.04 -0.02 0.04 1.00           
oily fish 0.06 -0.13 -0.09 0.27 1.00          
potatoes/pasta/rice 0.09 0.09 0.13 -0.01 -0.11 1.00         
savoury  0.06 0.01 -0.01 0.00 0.01 0.15 1.00        
sweets -0.12 -0.06 -0.13 -0.09 -0.14 -0.18 -0.13 1.00       
tea -0.05 -0.03 0.00 0.05 0.02 0.00 -0.01 0.05 1.00      
coffee 0.06 -0.04 -0.04 -0.02 0.07 -0.03 0.04 0.00 -0.43 1.00     
fruit/ vegetable juice 0.04 -0.07 -0.10 0.01 0.08 -0.04 0.05 -0.01 -0.09 0.06 1.00    
fizzy drinks 0.06 0.14 0.04 -0.08 -0.12 0.01 0.00 0.02 -0.13 0.01 -0.02 1.00   
vegetables 0.18 -0.11 -0.15 0.04 0.16 0.12 0.35 -0.19 0.00 0.08 0.11 -0.05 1.00  
fruit 0.09 -0.23 -0.28 0.08 0.20 -0.13 0.03 -0.01 0.03 0.03 0.20 -0.09 0.35 1.00 
SFAs -0.18 0.11 0.24 -0.05 -0.12 -0.12 -0.12 0.27 0.03 0.02 -0.09 -0.08 -0.29 -0.26 
MUFAs -0.07 0.20 0.30 0.06 0.08 -0.08 -0.03 0.19 0.03 0.03 -0.10 -0.09 -0.18 -0.26 
ω6PUFAs 0.08 0.12 0.02 -0.01 -0.03 0.01 0.14 0.10 0.00 0.04 0.00 -0.03 0.10 -0.06 
ω3PUFAs 0.21 -0.01 0.00 0.29 0.70* 0.00 0.21 -0.16 0.02 0.07 0.05 -0.12 0.38 0.17 
tFAs -0.17 0.11 0.18 -0.10 -0.17 -0.08 -0.08 0.14 0.00 0.03 -0.07 -0.05 -0.27 -0.26 
tMUFAs -0.19 0.09 0.20 -0.05 -0.12 -0.06 -0.05 0.01 0.06 0.02 -0.06 -0.13 -0.23 -0.24 
Quercetin 0.01 -0.10 -0.05 0.06 0.08 0.02 0.15 -0.06 0.80** -0.32 -0.03 -0.15 0.29 0.25 
Catechin 0.06 -0.14 -0.13 0.03 0.13 -0.06 0.02 -0.05 0.58 -0.18 0.06 -0.13 0.17 0.32 
Epicatechin -0.03 -0.08 -0.07 0.03 0.03 -0.04 -0.03 0.06 0.87** -0.37 -0.02 -0.13 0.04 0.20 
Flavones 0.04 -0.08 -0.04 0.10 0.13 0.01 0.35 -0.08 0.06 0.05 0.06 -0.04 0.29 0.16 
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savoury sweets tea coffee fruit/ 
vegetable 
juice 
fizzy Vegs fruit 
Procyanidins -0.01 -0.05 -0.04 0.05 0.05 -0.01 -0.01 -0.01 0.87** -0.35 -0.08 -0.14 0.06 0.15 
Flavanones 0.08 -0.13 -0.14 0.05 0.14 -0.07 0.03 -0.05 -0.04 0.07 0.47 -0.06 0.23 0.55 
Phytoestrogens -0.06 -0.05 -0.15 -0.02 0.02 -0.06 0.01 -0.11 0.07 -0.02 0.01 -0.12 0.06 0.07 
Protein 0.33 0.17 0.37 0.31 0.25 0.13 0.19 -0.30 0.06 0.03 -0.03 -0.15 0.25 0.06 
Cholesterol 0.01 0.19 0.47 0.20 0.08 -0.04 -0.04 -0.05 0.04 -0.02 -0.11 -0.08 -0.16 -0.22 
Sugars 0.01 -0.17 -0.31 -0.07 -0.05 -0.18 0.01 0.29 -0.03 0.02 0.23 0.25 0.14 0.55 
Starch -0.04 0.08 -0.05 -0.05 -0.22 0.48 0.04 0.08 0.12 -0.08 -0.10 -0.10 -0.07 -0.15 
Fibre 0.11 -0.21 -0.31 0.03 0.10 0.16 0.26 -0.11 0.06 0.05 0.13 -0.16 0.60 0.59 
Na 0.03 0.31 0.20 0.15 0.01 0.00 0.31 -0.12 0.07 -0.02 -0.04 -0.08 0.10 -0.13 
K 0.18 -0.15 -0.14 0.12 0.16 0.28 0.26 -0.24 0.08 0.11 0.16 -0.18 0.55 0.53 
Ca -0.02 -0.14 -0.21 0.04 0.05 -0.15 0.03 -0.04 0.07 0.07 0.07 -0.17 0.11 0.18 
Mg 0.16 -0.18 -0.26 0.08 0.19 0.12 0.21 -0.24 0.03 0.16 0.14 -0.20 0.45 0.43 
P 0.19 -0.03 -0.03 0.22 0.24 0.02 0.15 -0.21 0.05 0.09 0.05 -0.17 0.29 0.21 
Fe 0.12 -0.08 -0.05 0.09 0.20 0.09 0.26 -0.20 0.04 0.06 0.09 -0.22 0.40 0.27 
Cu 0.12 -0.03 -0.04 0.06 0.17 0.20 0.25 -0.14 0.06 0.02 0.03 -0.04 0.34 0.29 
Zn 0.16 0.11 0.43 0.11 0.09 0.17 0.20 -0.27 0.03 0.04 -0.03 -0.17 0.24 0.05 
Cl 0.03 0.29 0.15 0.13 0.01 0.02 0.30 -0.18 0.08 -0.02 -0.03 -0.09 0.12 -0.11 
Mn 0.01 -0.22 -0.31 0.03 0.10 0.03 0.11 -0.03 0.38 -0.07 0.07 -0.25 0.32 0.35 
Se 0.19 0.06 0.07 0.30 0.35 0.04 0.09 -0.23 0.05 0.01 -0.02 -0.12 0.18 0.09 
I 0.07 -0.10 -0.08 0.55 0.42 -0.09 0.00 -0.13 0.05 0.05 0.07 -0.16 0.15 0.21 
Retinol -0.14 0.03 0.21 0.06 0.07 -0.09 -0.05 0.02 0.01 0.04 -0.02 -0.09 -0.15 -0.13 
Carotenes 0.16 -0.13 -0.14 0.03 0.10 0.11 0.35 -0.17 0.00 0.07 0.13 -0.08 0.77* 0.27 
Vitamin D 0.07 0.00 0.09 0.25 0.78* -0.06 0.02 -0.12 0.02 0.04 0.02 -0.14 0.12 0.10 
Vitamin E 0.11 -0.06 -0.21 0.06 0.04 -0.04 0.19 0.03 0.02 0.05 0.08 -0.07 0.37 0.27 
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savoury sweets tea coffee fruit/ 
vegetable 
juice 
fizzy Vegs fruit 
Thiamine 0.09 -0.02 0.07 0.09 0.04 0.35 0.23 -0.20 0.12 -0.05 0.05 -0.17 0.31 0.20 
Vitamin B2 0.07 -0.09 -0.06 0.12 0.15 -0.10 0.07 -0.15 0.18 -0.01 0.06 -0.19 0.15 0.23 
Pot Niacin 0.31 0.19 0.36 0.27 0.20 0.13 0.15 -0.29 0.01 0.09 -0.05 -0.15 0.21 0.00 
Niacin 0.44 0.18 0.21 0.17 0.25 0.17 0.19 -0.33 -0.05 0.13 0.06 -0.09 0.33 0.15 
Vitamin B6 0.22 0.00 0.04 0.15 0.13 0.40 0.17 -0.29 0.05 -0.01 0.08 -0.14 0.41 0.31 
Vitamin B12 0.08 0.01 0.23 0.36 0.67 -0.07 0.05 -0.20 0.02 0.04 0.01 -0.15 0.11 0.10 
Folic acid 0.09 -0.13 -0.15 0.09 0.11 0.24 0.18 -0.25 0.17 -0.03 0.15 -0.19 0.52 0.38 
Pantoth. acid 0.15 0.06 0.16 0.14 0.16 0.11 0.07 -0.26 0.12 0.01 0.01 -0.21 0.22 0.13 
Biotin 0.04 -0.14 -0.07 0.28 0.28 -0.13 0.02 -0.15 0.18 0.21 0.06 -0.27 0.17 0.22 
Vitamin C 0.16 -0.20 -0.24 0.05 0.19 0.06 0.17 -0.13 -0.01 0.08 0.44 -0.10 0.62 0.73* 
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Variables SFAs MUFAs ω6PUFAs ω3PUFAs tFAs tMUFAs Quercetin Catechin Epicatechin Flavones Procyanid. Flavan. Phytoestr. 
SFAs 1.00                         
MUFAs 0.67 1.00            
ω6PUFAs -0.01 0.42 1.00           
ω3PUFAs -0.08 0.34 0.30 1.00          
tFAs 0.74* 0.59 0.10 -0.07 1.00         
tMUFAs 0.68 0.59 0.10 -0.01 0.83** 1.00        
Quercetin -0.12 -0.10 -0.01 0.12 -0.11 -0.03 1.00       
Catechin -0.09 -0.12 -0.06 0.10 -0.06 -0.11 0.65 1.00      
Epicatechin -0.01 -0.05 -0.03 0.01 0.02 -0.02 0.87** 0.77* 1.00     
Flavones -0.07 -0.04 0.03 0.21 0.00 0.07 0.26 0.04 0.02 1.00    
Procyanidins -0.04 -0.05 -0.02 0.04 -0.05 0.00 0.87** 0.79* 0.96*** 0.03 1.00   
Flavanones -0.17 -0.16 -0.03 0.13 -0.15 -0.13 0.12 0.19 0.09 0.12 0.05 1.00  
Phytoestrogens -0.07 0.00 0.16 0.07 0.02 0.11 0.06 0.03 0.05 0.01 0.06 0.06 1.00 
Protein 0.05 0.23 0.12 0.50 0.01 0.10 0.15 0.01 0.02 0.23 0.06 0.06 0.04 
Cholesterol 0.51 0.51 0.02 0.16 0.33 0.40 -0.04 -0.12 -0.05 0.05 -0.02 -0.13 -0.13 
Sugars -0.09 -0.20 -0.04 -0.05 -0.09 -0.22 0.07 0.14 0.12 0.04 0.02 0.28 -0.05 
Starch -0.04 0.05 0.22 -0.06 0.03 0.11 0.06 -0.12 0.05 0.03 0.06 -0.12 0.32 
Fibre -0.36 -0.25 0.13 0.28 -0.27 -0.23 0.31 0.23 0.16 0.29 0.15 0.37 0.35 
Na 0.11 0.30 0.29 0.30 0.12 0.23 0.06 -0.10 -0.02 0.08 0.02 -0.07 0.25 
K -0.31 -0.21 0.02 0.34 -0.27 -0.22 0.32 0.28 0.16 0.29 0.17 0.33 0.03 
Ca 0.18 0.05 -0.05 0.08 0.15 0.22 0.08 0.05 0.07 0.05 0.06 0.11 0.05 
Mg -0.30 -0.16 0.12 0.34 -0.23 -0.19 0.22 0.26 0.11 0.21 0.12 0.29 0.32 
P 0.00 0.10 0.09 0.41 -0.02 0.07 0.15 0.07 0.05 0.21 0.07 0.14 0.13 
Fe -0.23 -0.06 0.16 0.39 -0.17 -0.09 0.19 0.23 0.06 0.32 0.10 0.20 0.31 
Cu -0.19 0.03 0.20 0.38 -0.12 -0.14 0.20 0.24 0.11 0.26 0.11 0.16 0.17 
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Variables SFAs MUFAs ω6PUFAs ω3PUFAs tFAs tMUFAs Quercetin Catechin Epicatechin Flavones Procyanid. Flavan. Phytoestr. 
Zn 0.05 0.16 0.10 0.32 0.06 0.14 0.15 0.02 0.01 0.26 0.04 0.04 0.10 
Cl 0.09 0.26 0.28 0.29 0.12 0.23 0.06 -0.08 -0.01 0.07 0.03 -0.05 0.29 
Mn -0.22 -0.13 0.17 0.20 -0.15 -0.07 0.49 0.41 0.43 0.17 0.44 0.20 0.56 
Se -0.06 0.20 0.22 0.48 -0.06 0.01 0.10 0.04 0.03 0.09 0.06 0.08 0.28 
I 0.03 0.11 -0.03 0.46 -0.05 0.02 0.09 0.08 0.05 0.10 0.06 0.13 -0.05 
Retinol 0.53 0.36 -0.05 0.05 0.36 0.45 -0.05 -0.07 -0.05 0.05 -0.03 -0.06 -0.06 
Carotenes -0.22 -0.14 0.08 0.34 -0.17 -0.13 0.23 0.11 0.02 0.37 0.03 0.18 0.04 
Vitamin D 0.04 0.30 0.08 0.74* -0.07 -0.02 0.05 0.05 0.00 0.07 0.03 0.08 0.00 
Vitamin E -0.17 0.10 0.67 0.29 -0.12 -0.12 0.14 0.07 0.06 0.15 0.05 0.17 0.11 
Thiamine -0.19 -0.08 0.11 0.22 -0.15 -0.05 0.22 0.04 0.09 0.22 0.10 0.16 0.25 
Vitamin B2 0.02 -0.01 -0.05 0.21 -0.01 0.06 0.21 0.15 0.18 0.08 0.18 0.12 0.02 
Pot Niacin 0.08 0.24 0.12 0.44 0.04 0.13 0.08 -0.04 -0.04 0.19 0.00 0.02 0.01 
Niacin -0.23 0.03 0.17 0.49 -0.21 -0.15 0.07 0.03 -0.05 0.15 -0.01 0.14 0.15 
Vitamin B6 -0.29 -0.16 0.03 0.32 -0.27 -0.19 0.21 0.09 0.06 0.22 0.09 0.19 -0.02 
Vitamin B12 0.07 0.25 0.01 0.65 -0.01 0.06 0.07 0.05 0.00 0.15 0.03 0.07 -0.07 
Folic acid -0.28 -0.20 0.05 0.25 -0.24 -0.14 0.33 0.21 0.19 0.22 0.20 0.34 0.21 
Pantoth. acid -0.06 0.04 0.03 0.27 -0.07 0.04 0.20 0.12 0.11 0.16 0.15 0.12 0.03 
Biotin -0.01 0.14 0.14 0.32 -0.07 0.02 0.26 0.29 0.22 0.10 0.26 0.18 0.14 
Vitamin C -0.30 -0.26 -0.01 0.28 -0.27 -0.24 0.25 0.30 0.12 0.26 0.09 0.70* 0.07 
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Variables Protein Cholest. Sugars Starch Fibre Na K Ca Mg P Fe Cu Zn Cl Mn Se I 
Protein 1.00                                 
Cholesterol 0.43 1.00                
Sugars -0.10 -0.24 1.00               
Starch 0.05 -0.11 -0.14 1.00              
Fibre 0.21 -0.31 0.33 0.27 1.00             
Na 0.48 0.24 -0.15 0.34 0.14 1.00            
K 0.47 -0.13 0.33 0.12 0.73* 0.15 1.00           
Ca 0.37 0.08 0.29 -0.04 0.16 0.24 0.37 1.00          
Mg 0.42 -0.21 0.27 0.15 0.77* 0.23 0.79* 0.38 1.00         
P 0.77* 0.20 0.18 0.04 0.42 0.42 0.62 0.73* 0.70* 1.00        
Fe 0.45 -0.03 0.06 0.28 0.68 0.40 0.56 0.16 0.70* 0.53 1.00       
Cu 0.32 -0.04 0.16 0.17 0.53 0.20 0.51 0.02 0.61 0.39 0.58 1.00      
Zn 0.84** 0.34 -0.08 0.08 0.31 0.36 0.46 0.31 0.49 0.70* 0.56 0.41 1.00     
Cl 0.47 0.19 -0.14 0.36 0.18 0.98*** 0.20 0.28 0.29 0.44 0.42 0.22 0.35 1.00    
Mn 0.14 -0.26 0.13 0.33 0.67 0.21 0.43 0.15 0.67 0.36 0.57 0.41 0.25 0.25 1.00   
Se 0.55 0.21 -0.14 0.11 0.20 0.35 0.23 0.08 0.33 0.40 0.31 0.39 0.39 0.36 0.24 1.00  
I 0.53 0.28 0.14 -0.18 0.11 0.23 0.38 0.51 0.32 0.62 0.19 0.12 0.30 0.25 0.07 0.39 1.00 
Retinol 0.09 0.51 -0.13 -0.09 -0.21 0.09 -0.14 0.18 -0.16 0.10 -0.02 0.17 0.10 0.07 -0.15 0.04 0.16 
Carotenes 0.26 -0.11 0.14 -0.01 0.58 0.16 0.54 0.16 0.43 0.31 0.45 0.34 0.27 0.17 0.30 0.13 0.14 
Vitamin D 0.44 0.37 -0.07 -0.13 0.05 0.18 0.15 0.07 0.15 0.33 0.27 0.18 0.25 0.16 0.03 0.46 0.46 
Vitamin E 0.13 -0.10 0.19 0.08 0.43 0.20 0.32 0.11 0.33 0.22 0.29 0.25 0.10 0.21 0.30 0.18 0.12 
Thiamine 0.47 -0.02 0.06 0.48 0.56 0.44 0.62 0.21 0.55 0.49 0.61 0.37 0.51 0.47 0.43 0.27 0.18 
Vitamin B2 0.52 0.15 0.24 -0.05 0.24 0.27 0.48 0.75* 0.49 0.78* 0.40 0.20 0.48 0.30 0.21 0.18 0.56 
Pot Niacin 0.98*** 0.47 -0.11 0.03 0.16 0.47 0.44 0.42 0.41 0.78* 0.39 0.29 0.83** 0.47 0.08 0.51 0.52 
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Variables Protein Cholest. Sugars Starch Fibre Na K Ca Mg P Fe Cu Zn Cl Mn Se I 
Niacin 0.71* 0.09 -0.05 0.14 0.38 0.40 0.48 0.04 0.53 0.52 0.59 0.43 0.61 0.42 0.24 0.54 0.26 
Vitamin B6 0.54 -0.02 0.14 0.26 0.55 0.25 0.80** 0.19 0.60 0.52 0.57 0.41 0.51 0.30 0.28 0.28 0.31 
Vitamin B12 0.63 0.42 -0.09 -0.21 0.01 0.20 0.24 0.26 0.21 0.52 0.29 0.33 0.48 0.19 -0.01 0.49 0.60 
Folic acid 0.37 -0.09 0.18 0.27 0.67 0.22 0.72* 0.30 0.66 0.51 0.62 0.41 0.39 0.28 0.48 0.23 0.26 
Pantoth. acid 0.54 0.25 0.03 0.02 0.27 0.25 0.50 0.34 0.48 0.58 0.37 0.31 0.55 0.28 0.21 0.28 0.37 
Biotin 0.42 0.25 0.09 -0.11 0.31 0.19 0.44 0.42 0.64 0.64 0.44 0.36 0.42 0.21 0.43 0.32 0.49 
Vitamin C 0.19 -0.21 0.41 -0.08 0.69 -0.04 0.69 0.18 0.55 0.32 0.41 0.38 0.18 0.00 0.38 0.14 0.22 
 




















Retinol 1.00                           
Carotenes -0.07 1.00             
Vitamin D 0.19 0.09 1.00            
Vitamin E -0.10 0.35 0.10 1.00           
Thiamine -0.11 0.31 0.12 0.19 1.00          
Vitamin B2 0.19 0.17 0.26 0.12 0.40 1.00         
Pot Niacin 0.11 0.23 0.40 0.11 0.43 0.54 1.00        
Niacin -0.14 0.29 0.42 0.21 0.52 0.38 0.68 1.00       
Vitamin B6 -0.14 0.41 0.23 0.24 0.72* 0.45 0.52 0.67 1.00      
Vitamin B12 0.38 0.09 0.77* 0.03 0.16 0.47 0.60 0.46 0.29 1.00     
Folic acid -0.08 0.45 0.15 0.29 0.68 0.54 0.35 0.51 0.77* 0.19 1.00    
Pantoth. acid 0.10 0.22 0.23 0.09 0.42 0.49 0.56 0.43 0.52 0.38 0.44 1.00   
Biotin 0.16 0.13 0.32 0.19 0.27 0.54 0.44 0.32 0.29 0.42 0.39 0.52 1.00  
Vitamin C -0.14 0.51 0.11 0.34 0.36 0.22 0.13 0.29 0.49 0.11 0.59 0.24 0.25 1.00 
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8.2.3 Univariable logistic regression of the explanatory 
variables  
Univariable logistic regression models were fitted for each explanatory variable. 
Odds ratios and 95% CI were calculated for each quartile of the continuous variables 
and each category of the categorical variables (Table 96). P-values for trend were 
calculated for the quartile form of the quantitative explanatory variables (Table 96). 
For the regression of food and nutrient variables, their residual energy adjusted form 
was used (except for the food groups: tea and coffee and the nutrient flavones).  
For the demographic and lifestyle factors significant (at a p≤0.05 level) associations 
were observed between colorectal cancer and family history of cancer (p=1.1x10-51), 
NSAIDs intake (p=7.3x10
-7
), dietary energy intake (p=2.0x10
-5
), HRT intake 
(p=0.0003) and physical activity (p=0.02) (Table 96). For the food group variables 







), fruit/ vegetable 
juice (p=1.7x10-6), oily fish (p=0.001), coffee (p=0.001), fruit (p=0.009), savoury 
foods (p=0.009) and white fish (p=0.04) (Table 96). For the nutrient variables 
significant associations were observed between colorectal cancer and intakes of the 




), SFAs (p=0.0001), tFAs 
(p=0.001) and MUFAs (p=0.01); of the flavonoids: quercetin (p=0.001), catechin 
(p=0.001) and phytoestrogens (p=0.04); of the macronutrients: cholesterol 














), phosphorus (p=0.0001), 
selenium (p=0.009); and of the vitamins: niacin (p=8.2x10
-7





), vitamin C (p=4.6x10
-5
), vitamin A (p=0.001), potential 
niacin (p=0.001), biotin (p=0.001), folate (p=0.003), pantothenic acid (p=0.006), 
vitamin D (p=0.01), vitamin B1 (p=0.02) and vitamin B12 (p=0.02) (Table 96). 
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Table 96 Univariable logistic regression of colorectal cancer on each explanatory variable 
included in the stepwise regression (2061 cases; 2776 controls) 
Variables Quartiles Frequency Model II  
  Cases Controls OR 95% CI p-value 
for trend 
Demographic factors      
Age (years) 21-55 632 760 1.00   
 55-63 401 627 0.77 0.65, 0.91  
 63-71 583 761 0.92 0.79, 1.07  
 >71 445 626 0.85 0.73, 1.00 0.18 
Sex males 1180 1582 1.00   
 females 881 1194 0.99 0.88, 1.11 0.85 
Family history low 1610 2695 1.00   
 moderate/ high 333 30 18.58 12.72, 27.13 1.1x10
-51
 
Deprivation score 1 194 258 1.00   
 2 434 568 1.02 0.81, 1.27  
 3 532 758 0.96 0.75, 1.16  
 4 488 645 1.01 0.81, 1.25  
 5 218 293 0.99 0.77, 1.28  
 6 140 178 1.05 0.78, 1.40  
 7 54 76 0.94 0.64, 1.40 0.94 
Lifestyle variables      
Smoking No 874 1200 1.00   
 Former 818 1049 1.07 0.94, 1.21  
 Current 343 509 0.93 0.79, 1.09 0.63 
Alcohol (g/day) 0-1.70 526 696 1.00   
 1.70-8.10 534 692 1.02 0.87, 1.20  
 8.10-19.2 501 681 0.97 0.83, 1.14  
 >19.20 500 707 0.94 0.80, 1.10 0.34 
Alcohol (g/day)
 
0 291 427 1.00   
 0-15 1125 1473 1.12 0.95, 1.33  
 15-30 393 548 1.05 0.86, 1.28  
 30-45 139 202 1.01 0.78, 1.31  
 45-60 61 81 1.11 0.77, 1.59  
 >60 52 45 1.70 1.11, 2.60 0.28 
BMI (kg/m
2
) <23.71 523 673 1.00   
 23.71-26.11 499 702 0.91 0.78, 1.07  
  26.11-29.09 515 675 0.98 0.83, 1.15  
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 >29.09 503 692 0.94 0.79, 1.10 0.62 
Physical activity 0  1139 1456 1.00   
 0-3.5  486 703 0.88 0.77, 1.02  
 3.5-7  205 339 0.77 0.64, 0.93  





0- 8.25 478 733 1.00   
8.25-10.17 483 725 1.02 0.87, 1.20  
 10.17- 12.73 529 680 1.19 1.01, 1.40  
 >12.73 571 638 1.37 1.17, 1.61 2x10
-5 
NSAIDs no 1449 1757 1.00   
 yes 605 1000 0.73 0.65, 0.83 7.3x10
-7 
HRT no 666 821 1.00   
 yes 190 343 0.68 0.56, 0.84 0.0003 
Foods (m/day)      
Breads 0-1.89 475 735 1.00   
 1.89-2.66 518 691 1.16 0.99, 1.36  
 2.66-3.59 563 646 1.35 1.15, 1.58  
 >3.59 505 704 1.11 0.94, 1.31 0.08 
Cereals 0-0.45 457 753 1.00   
 0.45-1.06 584 625 1.54 1.31, 1.81  
 1.06-1.71 534 675 1.30 1.11, 1.53  
 >1.71 486 723 1.11 0.94, 1.30 0.62 
Milk 0-1.08 511 699 1.00   
 1.08-1.86 495 714 0.95 0.81, 1.11  
 1.86-2.44 528 681 1.06 0.90, 1.25  
 >2.44 527 682 1.06 0.90, 1.24 0.28 
Cream 0-0.18 501 709 1.00   
 0.18-0.34 529 680 1.10 0.94, 1.29  
 0.34-0.81 555 654 1.20 1.02, 1.41  
 >0.81 476 733 0.92 0.78, 1.08 0.53 
Cheese 0-0.28 472 738 1.00   
 0.28-0.60 530 679 1.22 1.04, 1.43  
 0.60-1.07 550 659 1.30 1.11, 1.53  
 >1.07 509 700 1.14 0.97, 1.34 0.09 
Eggs 0-0.22 452 758 1.00   
 0.22-0.43 504 705 1.20 1.02, 1.41  
 0.43-0.68 533 676 1.32 1.12, 1.56  
 >0.68 572 637 1.51 1.28, 1.77 4.0x10
-7
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Poultry 0-0.16 508 702 1.00   
 0.16-0.30 571 638 1.24 1.05, 1.45  
 0.30-0.56 495 714 0.96 0.81, 1.13  
 >0.56 487 722 0.93 0.79, 1.10 0.07 
Red meat 0-0.82 490 720 1.00   
 0.82-1.26 517 692 1.10 0.93, 1.29  
 1.26-1.75 544 665 1.20 1.02, 1.41  
 >1.75 510 699 1.07 0.91, 1.26 0.25 
Processed meat 0-0.50 502 708 1.00   
 0.50-0.88 523 686 1.08 0.92, 1.26  
 0.88-1.38 526 683 1.09 0.92, 1.28  
 >1.38 510 699 1.03 0.87, 1.21 0.71 
White fish 0-0.16 492 718 1.00   
 0.16-0.29 521 688 1.10 0.94, 1.30  
 0.29-0.47 494 715 1.01 0.86, 1.19  
 >0.47 554 655 1.23 1.05, 1.45 0.04 
Oily fish 0-0.01 524 686 1.00   
 0.01-0.13 570 639 1.17 0.99, 1.37  
 0.13-0.31 507 702 0.95 0.80, 1.12  
 >0.31 460 749 0.80 0.68, 0.95 0.001 
Potatoes/ Pasta/ 
Rice 
0-1.69 518 692 1.00   
1.69-2.27 525 684 1.02 0.87, 1.20  
 2.27-2.94 515 694 0.99 0.84, 1.16  
 >2.94 503 706 0.95 0.81, 1.12 0.48 
Fruit 0-1.43 528 682 1.00   
 1.43-2.47 544 665 1.06 0.90, 1.24  
 2.47-3.84 520 689 0.97 0.83, 1.14  
 >3.84 469 740 0.82 0.70, 0.96 0.009 
Vegetables 0-3.31 569 641 1.00   
 3.31-4.92 537 672 0.90 0.77, 1.06  
 4.92-7.03 526 683 0.87 0.74, 1.02  





 0-1.82 524 686 1.00   
 1.82-2.55 549 660 1.09 0.93, 1.28  
 2.55-3.44 523 686 1.00 0.85, 1.17  
 >3.44 465 744 0.82 0.70, 0.96 0.009 
Sweets
‡
 0-2.98 454 756 1.00   
 2.98-4.44 498 711 1.17 0.99, 1.37  
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 4.44-6.10 544 665 1.36 1.16, 1.60  





  0-1 527 683 1.00   
 1-3 509 700 0.97 0.84, 1.12  
 3-4 534 675 1.03 0.87, 1.23  
 >4 491 718 0.91 0.78, 1.07 0.38 
Coffee§ 0-0.1 567 691 1.00   
 0.1-1 571 714 0.97 0.83, 1.14  
 1-3 550 769 0.87 0.75, 1.02  
 >3 373 602 0.75 0.64, 0.89 0.001 
Fruit/ vegetable 
juice 
0-0.14 439 771 1.00   
0.14-0.82 532 677 1.38 1.17, 1.62  
 0.82-1.45 527 682 1.36 1.15, 1.60  
 >1.45 563 646 1.53 1.30, 1.80 1.7x10
-6 
Fizzy drinks 0-0.01 495 715 1.00   
 0.01-0.02 515 694 1.07 0.91, 1.26  
 0.02-0.38 522 687 1.10 0.93, 1.29  
 >0.38 529 680 1.12 0.96, 1.32 0.15 
Nutrients       
Fatty acids (g/day)      
SFAs 0-31.48 466 739 1.00   
 31.48-37.03 512 692 1.17 1.00, 1.38  
 37.03-43.30 523 681 1.22 1.04, 1.43  
 >43.30 560 644 1.38 1.17, 1.62 0.0001 
MUFAs 0-28.57 467 738 1.00   
 28.57-32.56 529 675 1.24 1.05, 1.46  
 32.56-36.18 539 665 1.28 1.09, 1.51  
 >36.18 526 678 1.23 1.04, 1.44 0.01 
ω6PUFAs 0-8.92 515 690 1.00   
 8.92-10.73 519 685 1.02 0.86, 1.19  
 10.73-13.19 510 694 0.98 0.84, 1.16  
 >13.19 517 687 1.01 0.86, 1.18 0.98 
ω3PUFAs 0-1.83 557 648 1.00   
 1.83-2.22 538 666 0.94 0.80, 1.10  
 2.22-2.74 513 691 0.86 0.73, 1.01  
 >2.74 453 751 0.70 0.60, 0.83 1.3x10
-5
 
tFAs 0-2.86 453 752 1.00   
 2.86-3.53 526 678 1.29 1.09, 1.52  
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 3.53-4.24 552 652 1.40 1.19, 1.65  
 >4.24 530 674 1.30 1.11, 1.54 0.001 
tMUFAs 0-2.17 448 757 1.00   
 2.17-2.68 505 699 1.22 1.04, 1.44  
 2.68-3.19 565 639 1.49 1.27, 1.76  
 >3.19 543 661 1.39 1.18, 1.63 6.7x10
-6
 
Flavonoids (mg/day)      
Quercetin 0-11.20 541 669 1.00   
 11.20-17.38 528 681 0.96 0.82, 1.13  
 17.38-22.65 538 671 0.99 0.84, 1.16  
 >22.65 454 755 0.74 0.63, 0.87 0.001 
Catechin 0-4.81 548 662 1.00   
 4.81-7.21 535 674 0.96 0.82, 1.13  
 7.21-9.39 504 705 0.86 0.73, 1.01  
 >9.39 474 735 0.78 0.66, 0.92 0.001 
Epicatechin 0-12.71 522 688 1.00   
 12.71-23.34 528 681 1.02 0.87, 1.20  
 23.34-32.28 534 675 1.04 0.89, 1.22  
 >32.28 477 732 0.86 0.73, 1.01 0.10 
Flavones§
 
0-0.5 607 806 1.00   
 0.5-1 460 621 0.94 0.80, 1.10  
 1-1.8 481 698 0.85 0.73, 1.00  
 >1.8 513 651 0.90 0.76, 1.07 0.12 
Procyanidins 0-15.98 523 687 1.00   
 15.98-31.72 527 682 1.02 0.86, 1.19  
 31.72-44.66 534 675 1.04 0.88, 1.22  
 >44.66 477 732 0.86 0.73, 1.01 0.09 
Flavanones 0-7.42 478 732 1.00   
 7.42-20.57 563 646 1.33 1.14, 1.57  
 20.57-40.61 526 683 1.18 1.00, 1.39  
 >40.61 494 715 1.06 0.90, 1.24 0.87 
Phytoestrogens 
(µg/day) 
0-400.1 522 688 1.00   
400.1-575.3 551 658 1.10 0.94, 1.30  
 575.3-845.7 504 705 0.94 0.80, 1.11  
 >845.7 484 725 0.88 0.75, 1.03 0.04 
Macronutrients (g/day)      
Protein 0-90.60 554 656 1.00   
 90.60-101.3 526 683 0.91 0.78, 1.07  
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 101.3-112.3 510 699 0.86 0.74, 1.01  
 >112.3 471 738 0.76 0.64, 0.89 0.001 
Cholesterol 0-296.3 453 757 1.00   
 296.3-362.0 533 676 1.32 1.12, 1.55  
 362.0-430.1 500 709 1.18 1.00, 1.39  
 >430.1 575 634 1.52 1.29, 1.78 1.4x10
-5 
Sugars 0-109.4 507 703 1.00   
 109.4-132.7 535 674 1.10 0.94, 1.29  
 132.7-158.5 519 690 1.04 0.89, 1.22  
 >158.5 500 709 0.98 0.83, 1.15 0.64 
Starch 0-143.3 463 747 1.00   
 143.3-164.6 537 672 1.29 1.10, 1.52  
 164.6-184.5 554 655 1.36 1.16, 1.60  
 >184.5 507 702 1.16 0.99, 1.37 0.05 
Fibre 0- 17.34 549 661 1.00   
 17.34-20.97 542 667 0.98 0.83, 1.15  
 20.97-24.94 521 688 0.91 0.78, 1.01  
 >24.94 449 760 0.71 0.60, 0.84 3.3x10
-5 
Minerals (mg/day)      
Sodium  0-3065.8 496 714 1.00   
 6065.8-3450.9 514 695 1.06 0.91, 1.25  
 3450.9-3848.8 543 666 1.17 1.00, 1.38  
 >3848.8 508 701 1.04 0.89, 1.23 0.39 
Potassium 0-3789.3 557 653 1.00   
 3789.3-4274.8 567 642 1.03 0.88, 1.21  
 4274.8-4759.8 493 716 0.81 0.69, 0.95  
 >4759.8 444 765 0.68 0.58, 0.80 9.1x10
-8
 
Calcium 0-924.5 511 699 1.00   
 924.5-1091.1 519 690 1.03 0.88, 1.21  
 1091.1-1269.6 520 689 1.03 0.88, 1.21  
 >1269.6 511 698 1.00 0.85, 1.18 0.98 
Magnesium 0-340.36 578 632 1.00   
 340.36-383.26 558 651 0.94 0.80, 1.10  
 383.26-428.36 499 710 0.77 0.65, 0.90  
 >428.36 426 783 0.59 0.50, 0.70 2.7x10
-11
 
Phosphorus 0-1574.1 545 665 1.00   
 1574.1-1750.5 544 665 1.00 0.85, 1.17  
 1750.5-1931.4 518 691 0.91 0.78, 1.07  
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 >1931.4 454 755 0.73 0.62, 0.86 0.0001 
Iron 0-13.56 567 643 1.00   
 13.56-15.28 525 684 0.87 0.74, 1.02  
 15.28-17.15 509 700 0.82 0.70, 0.97  
 >17.15 460 749 0.70 0.59, 0.82 1.3x10
-5
 
Copper 0-1.37 573 637 1.00   
 1.37-1.54 536 673 0.88 0.75, 1.04  
 1.54-1.76 484 725 0.74 0.63, 0.87  
 >1.76 468 741 0.70 0.60, 0.82 2.0x10
-6
 
Zinc 0-10.48 556 654 1.00   
 10.48-11.94 548 661 0.97 0.83, 1.14  
 11.94-13.37 485 724 0.79 0.67, 0.93  
 >13.37 472 737 0.75 0.64, 0.88 4.6x10
-5 
Chloride 0-4705.2 499 711 1.00   
 4705.2-5285.5 517 692 1.06 0.91, 1.25  
 5285.5-5872.4 540 669 1.15 0.98, 1.35  
 >5872.4 505 704 1.02 0.87, 1.20 0.58 
Manganese 0-3.04 573 637 1.00   
 3.04-3.79 542 667 0.90 0.77, 1.06  
 3.79-4.67 490 719 0.76 0.64, 0.89  




0-63.25 542 668 1.00   
63.25-78.96 529 680 0.96 0.82, 1.13  
 78.96-96.43 509 700 0.90 0.76, 1.05  
 >96.43 481 728 0.81 0.69, 0.96 0.009 
Iodine (µg/day) 0-149.78 515 695 1.00   
 149.78-190.19 540 669 1.09 0.93, 1.28  
 190.19-240.72 516 693 1.00 0.85, 1.18  
 >242.72 490 719 0.92 0.78, 1.08 0.20 
Vitamins (mg/day)       
Vitamin A 
(µg/day) 
0-348.35 461 749 1.00   
348.35-496.55 499 710 1.14 0.97, 1.34  
 496.55-752.52 579 630 1.49 1.27, 1.76  
 >752.52 522 687 1.23 1.04, 1.45 0.001 
Carotenes 
(µg/day) 
0-2406.1 544 666 1.00   
2406.1-3519.5 556 653 1.04 0.89, 1.22  
 3519.5-4952.1 510 699 0.89 0.76, 1.05  
 >4952.1 451 758 0.73 0.62, 0.86 2.6x10
-5
 




0-2.74 538 672 1.00   
2.74-3.86 535 674 0.99 0.84, 1.16  
 3.86-5.47 506 703 0.90 0.76, 1.06  
 >5.47 482 727 0.83 0.70, 0.97 0.01 
Vitamin E 0-6.83 532 678 1.00   
 6.83-8.26 510 699 0.93 0.79, 1.09  
 8.26-10.42 511 698 0.93 0.79, 1.10  
 >10.42 508 701 0.92 0.79, 1.08 0.37 
Vitamin B1 0-1.80 537 673 1.00   
 1.80-2.03 526 683 0.96 0.82, 1.13  
 2.03-2.28 523 686 0.95 0.81, 1.12  
 >2.28 475 734 0.81 0.69, 0.95 0.02 
Vitamin B2 0-1.80 522 688 1.00   
 1.80-2.10 537 672 1.05 0.90, 1.24  
 2.10-2.42 511 698 0.96 0.82, 1.13  
 >2.42 491 718 0.90 0.77, 1.06 0.13 
Potential niacin 0-18.82 543 667 1.00   
 18.82-21.11 542 667 1.00 0.85, 1.17  
 21.11-23.37 507 702 0.89 0.75, 1.04  
 >23.37 469 740 0.78 0.66, 0.91 0.001 
Niacin 0-20.64 566 644 1.00   
 20.64-23.98 550 659 0.95 0.81, 1.11  
 23.98-27.47 484 725 0.76 0.65, 0.89  
 >27.47 461 748 0.70 0.60, 0.82 8.2x10
-7
 
Vitamin B6 0-2.47 547 663 1.00   
 2.47-2.83 555 654 1.03 0.88, 1.21  
 2.83-3.21 514 695 0.90 0.76, 1.05  





0-5.27 538 672 1.00   
5.27-6.96 516 693 0.93 0.79, 1.09  
 6.96-9.21 533 676 0.98 0.84, 1.16  
 >9.21 474 735 0.80 0.68, 0.95 0.02 
Folic acid 
(µg/day) 
0-282.65 533 677 1.00   
282.65-325.89 546 663 1.05 0.89, 1.23  
 325.89-370.81 515 694 0.94 0.80, 1.11  
 >370.81 467 742 0.80 0.68, 0.94 0.003 
Pantothenic acid 0-5.90 454 665 1.00   
 5.90-6.65 534 675 0.96 0.82, 1.13  
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 6.65-7.58 494 715 0.84 0.72, 0.99  
 >7.58 488 721 0.83 0.70, 0.97 0.006 
Biotin (µg/day) 0-43.38 549 661 1.00   
 43.38-49.35 529 680 0.94 0.80, 1.10  
 49.35-55.69 519 690 0.91 0.77, 1.06  
 >55.69 464 745 0.75 0.64, 0.88 0.001 
Vitamin C 0-81.20 553 657 1.00   
 81.20-114.17 528 681 0.91 0.78, 1.08  
 114.17-156.03 534 675 0.94 0.80, 1.10  
 >156.03 446 763 0.69 0.59, 0.82 4.6x10
-5
 
                                               
* Intakes divided into quartiles 
† Summary variable of savoury foods, soups and sauces  
‡ Summary variable of pudding and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
§ Not energy adjusted 
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8.3 Stepwise regression analysis 
Stepwise regression (both forward and backward) was applied to three different set 
of variables: 1) Set 1 consisted of the demographic factors, lifestyle variables and 
foods; 2) Set 2 consisted of the demographic factors, lifestyle variables and nutrients; 
and 3) Set 3 consisted of the demographic factors, lifestyle variables, foods and 
nutrients. The p-value threshold for a variable to enter the model (forward stepwise 
regression) or to remain in the model (backward stepwise regression) was 0.10. 
Forward and backward stepwise regression for all three sets of variables using the 
quartile form of continuous variables was initially applied in the whole sample 
(Tables 97-101) and then separately for females and males (data not shown). In the 
female datasets the HRT lifestyle variable was included. 
In order to examine the stability of the selected models (of the whole sample only), 
the bootstrap method was used. In particular, 100 bootstrap samples were randomly 
drawn from the original sample. Then, each bootstrap sample was used to apply 
forward and backward stepwise regression for each set of variables (set 1, 2 and 3).  
8.3.1 Set 1: Demographic factors, lifestyle variables and 
foods 
The explanatory factors that were included in set 1 were the demographic risk factors 
(age, sex, family history and deprivation score), the lifestyle variables (smoking, 
alcohol, BMI, physical activity, dietary energy, NSAIDs and HRT only for the 
female analysis) and the food variables (breads, cereals, milk, cream, cheese, eggs, 
poultry, red meat, processed meat, white fish, oily fish, potatoes/ pasta/ rice, fruit, 
vegetables, savoury, sweets, tea, coffee, fruit/ vegetable juice and fizzy drinks) (30 
risk factors in total). Forward and backward stepwise regression was applied in the 
whole sample and separately for males and females.  
8.3.1.1 Whole sample (Set 1) 
Findings from the original sample 
Forward and backward stepwise regression using the quartile form of the continuous 
variables resulted in two identical models, which included the following 13 risk 
factors: family history (p=3.6x10-49), sweets (p=4.4x10-8), eggs (p=1.7x10-7), 
NSAIDs (p=1.3x10
-5
), fruit/ vegetable juice (p=1.0x10
-5
), dietary energy (p=0.001), 
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coffee (p=0.001), white fish (p=0.001), vegetables (p=0.004), tea (p=0.006), physical 
activity (p=0.01), breads (p=0.02) and oily fish (p=0.07) (Table 97). The risk factors 
family history, sweets, eggs, fruit/ vegetable juice, dietary energy intake, white fish 
and breads were associated with an increased colorectal cancer risk, whereas 
NSAIDs, coffee, physical activity, tea, vegetables and oily fish were associated with 
a decreased risk (Table 97).  
Findings from the 100 bootstrap samples  
The main findings after applying forward and backward stepwise regression to the 
100 bootstrap samples were: 
- Forward stepwise regression applied to 100 bootstrap samples resulted in 100 
unique regression models (i.e. all 100 models were chosen only once).  
- Backward stepwise regression applied to 100 bootstrap samples resulted also in 
100 unique regression models.  
- Over the 100 bootstrap samples, the variables selected by backward selection 
were identical to those selected by forward selection in 65 of the bootstrap 
samples. For 25 bootstrap samples the agreement between the variables selected 
by backward and forward selection was over 90%, whereas for the remaining five 
bootstrap samples the agreement was between 84% and 88% (mean percentage of 
agreement (SD): 96.97% (4.56%)). 
- Forward and backward stepwise regression resulted in a final model with 11-20 
variables (mean (SD): 15.43 (1.89), median (IQR): 15 (14, 17)) and 12-20 
variables (mean (SD): 16.01 (1.86), median (IQR): 16 (15, 17)) respectively in 
the 100 samples. Furthermore, the distribution of the number of variables in the 
resultant models is close to normal, with the mean of the number of the included 
variables in backward regression models to be significantly larger than the mean 
of the number of the included variables in forward regression models (t-test p-
value: 0.03). 
- The variables: family history, NSAIDs, eggs and sweets were selected to be 
included in built models of all 100 bootstrap samples using either forward or 
backward stepwise regression. The variables dietary energy, and fruit/ vegetable 
juice were selected to be included in the 98% of the built models of the 100 
bootstrap samples using each of the two methods. The variables coffee and white 
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fish were selected to be included in 92-94% of the built models of the 100 
bootstrap samples using each of the two methods. Finally, the remaining 21 
variables were selected in <90% of the bootstrap samples using either selection 
method. 
8.3.1.2 Females (Set 1) 
Findings from the original sample 
Forward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following nine risk factors: family history 
(p=1.9x10-25), fruit/ vegetable juice (p=0.0002), sweets (p=0.0003), vegetables 
(p=0.002), breads (p=0.002), NSAIDs (p=0.002), white fish (p=0.01), eggs (p=0.06) 
and HRT (p=0.09) (data not shown). Backward stepwise regression using the quartile 
form of the continuous variables resulted in a model including the following 10 risk 
factors: family history (p=1.3x10
-25
), fruit/ vegetable juice (p=0.0002), sweets 
(p=0.0002), vegetables (p=0.002), breads (p=0.002), white fish (p=0.007), NSAIDs 
(p=0.001), coffee (p=0.04), tea (p=0.05) and eggs (p=0.08) (data not shown). In 
summary, forward and backward stepwise regression using the quartile form of the 
continuous variables resulted in similar models, with the common variables being 
family history, fruit/ vegetable juice, sweets, vegetables, breads, NSAIDs and white 
fish (data not shown). 
8.3.1.3 Males (Set 1) 
Findings from the original sample 
Forward stepwise regression using the quartile form of the continuous variables 





), dietary energy (p=3.1x10
-5
), sweets (p=0.0002), 
NSAIDs (p=0.006), fruit/ vegetable juice (p=0.008), savoury (p=0.02) and physical 
activity (p=0.02) (data not shown). Backward stepwise regression using the quartile 
form of the continuous variables resulted in a model including the following 10 risk 




), dietary energy (p=4.8x10
-6
), 
sweets (p=0.0001), NSAIDs (p=0.005), fruit/ vegetable juice (p=0.01), savoury 
(p=0.02), coffee (p=0.02), physical activity (p=0.02) and tea (p=0.04) (data not 
shown). In summary, forward and backward stepwise regression using the quartile 
form of the continuous variables resulted in almost identical models, with the 
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common variables being family history, eggs, dietary energy, sweets, NSAIDs, fruit/ 
vegetable juice, savoury and physical activity (data not shown).  
8.3.1.4 Summary (Set 1) 
Original sample 
Briefly, the variables of set 1 that were selected to be included in all six resultant 
models after application of forward and backward stepwise regression in the whole, 





NSAIDs (p-value range: 1.3x10-5 to 0.006), eggs (p-value range: 8.3x10-8 to 0.08), 
sweets (p-value range: 4.4x10-8 to 0.0003) and fruit/ vegetable juice (p-value range: 
1.0x10
-5
 to 0.01) (Table 97). In contrast, the variables vegetables (p-value range: 
0.001 to 0.002) and white fish (p-value range: 0.001 to 0.01) were only included in 
the models derived from the whole and female samples (Table 97), the variables 
dietary energy intake (p-value range: 4.8x10
-6
 to 0.001) and physical activity (p-
value range: 0.01 to 0.02) were included only in the models derived from the whole 
and male samples (Table 97), and the variable savoury intake was included only in 
the models derived from the male sample (p-value range: 0.02) (data not shown). 
Regarding the direction of the associations, the risk factors family history, sweets, 
eggs, fruit/ vegetable juice, white fish and dietary energy intake were associated with 
an increased colorectal cancer risk, whereas NSAIDs, vegetables, physical activity 
and savoury were associated with a decreased risk (Table 97). Finally, a matrix of the 
selected variables of the set 1 after applying forward and backward stepwise 
regression in the whole, female and male samples is presented in Table 102 (in the 
end of this chapter). 
Bootstrap samples 
Results from the bootstrap method (whole sample) showed that all 100 resultant 
models after applying forward stepwise regression were chosen only once and the 
same after applying backward stepwise regression. Within the same bootstrap sample 
application of either forward or backward stepwise regression resulted in the same 
model in 65 cases. Regarding the number of the included variables, it ranged from 11 
to 20 and application of the backward stepwise regression resulted in models with 
slightly more variables. In addition, the variables family history, NSAIDs, eggs and 
sweets were included in the models derived either from forward or backward 
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stepwise regression, in all 100 bootstrap samples. Furthermore, the variables energy, 
fruit/ vegetable juice, coffee and white fish were included in more than 90% of the 
built models. These results are in accordance with the findings of the analysis of the 
original sample, which suggested that the risk factors of set 1 more strongly 
associated with colorectal cancer were family history, NSAIDs, eggs, sweets and 
fruit/ vegetable juice (Table 97). 
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Table 97 Set 1: Stepwise regression built model* using the quartile form of the continuous 




















) 4.3 (2.9, 6.0) 4.6 (3.1, 6.3) 1.19 1.12, 1.27 4.4x10
-8 





















fruit/ vegetable juice 
(m/day) 






10.5 (8.4, 13.1) 
9.9 (8.1, 12.5) 1.11 1.05, 1.18 0.001 
Coffee (m/day) 1.0 (0.0, 2.4) 1.0 (0.1, 3.0) 0.90 0.84, 0.96 0.001 
White fish (m/day) 0.3 (0.2, 0.5) 0.3 (0.1, 0.5) 1.11 1.04, 1.17 0.001 
Vegetables (m/day) 4.6 (3.1, 6.5) 5.1 (3.4, 7.4) 0.92 0.86, 0.97 0.004 





0.0 (0.0, 2.0) 0.0 (0.0, 3.0) 0.91 0.85, 0.98 0.01 
Breads (m/day) 2.7 (1.9, 3.6) 2.6 (1.8, 3.6) 1.08 1.01, 1.14 0.02 
Oily fish (m/day) 0.1 (0.0, 0.3) 0.1 (0.0, 0.3) 0.95 0.89, 1.01 0.07 
                                               
* McFadden’s pseudo R2 for the model: 0.099 
† Summary variable of puddings and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
‡ m/day: measures/day 
§ MJ/day: 1000 Joules/day 
** h/week: hours/week 
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8.3.2 Set 2: Demographic factors, lifestyle variables and 
nutrients 
The explanatory factors that were included in set 2 were the demographic risk factors 
(age, sex, family history and deprivation score), the lifestyle variables (smoking, 
alcohol, BMI, physical activity, dietary energy, NSAIDs and HRT only for the 
female analysis) and the nutrients (SFAs, MUFAs, ω6PUFAs, ω3PUFAs, tFAs, 
tMUFAs, quercetin, catechin, epicatechin, flavones, procyanidins, flavanones, 
phytoestrogens, protein, cholesterol, sugars, starch, fibre, sodium, potassium, 
calcium, magnesium, phosphorus, iron, copper, zinc, manganese, selenium, iodine, 
vitamin A, carotenes, vitamin D, vitamin E, vitamin B1, vitamin B2, niacin, vitamin 
B6, vitamin B12, folate, pantothenic acid, biotin and vitamin C) (52 risk factors in 
total). Chloride and potential niacin intakes were excluded from the stepwise 
regression, since they were very highly correlated with other nutrients (r>0.95). 
Forward and backward stepwise regression was applied in the whole sample and 
separately for males and females.  
8.3.2.1 Whole sample (Set 2) 
Findings from the original sample 
Forward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 15 risk factors: family history (p=1.8x10
-
49







magnesium (p=3.8x10-5), protein (p=0.01), starch (p=0.01), flavanones (p=0.02),  
ω3PUFAs (p=0.02), fibre (p=0.02), iodine (p=0.02), quercetin (p=0.03), copper 
(p=0.06), physical activity (p=0.07) and alcohol (p=0.07) (Table 98). The risk factors 
family history, cholesterol, dietary energy, fibre, starch, iodine and flavanones were 
associated with an increased colorectal cancer risk, whereas NSAIDs, magnesium, 
protein, ω3PUFAs, copper, quercetin and physical activity were associated with a 
decreased risk (Table 98). 
Backward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 14 risk factors: family history (p=3.3x10
-
49







magnesium (p=0.0002), tMUFAs (p=0.002), zinc (p=0.002), flavanones (p=0.004), 
fibre (p=0.004),  ω3PUFAs (p=0.005), quercetin (p=0.01), tFAs (p=0.01), vitamin C 
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(p=0.05) and physical activity (p=0.07) (Table 99). The risk factors family history, 
dietary energy, tMUFAs, cholesterol, fibre and flavanones were associated with an 
increased colorectal cancer risk, whereas NSAIDs, magnesium, tFAs, zinc, vitamin 
C, ω3PUFAs, physical activity and quercetin were associated with a decreased risk 
(Table 99). 
In summary, forward and backward stepwise regression using the quartile form of 
the continuous variables resulted in similar models, with the common variables 
including family history, dietary energy, cholesterol, NSAIDs, magnesium, 
flavanones, ω3PUFAs, fibre, quercetin and physical activity (Table 98, Table 99).  
Findings from the 100 bootstrap samples  
The main findings after applying forward and backward stepwise regression to the 
100 bootstrap samples were: 
- Forward stepwise regression applied to 100 bootstrap samples resulted in 100 
unique regression models (i.e. all 100 models were chosen only once).  
- Backward stepwise regression applied to 100 bootstrap samples resulted also in 
100 unique regression models.  
- Over the 100 bootstrap samples, the variables selected by backward selection 
were identical to those selected by forward selection in two of the bootstrap 
samples. For 30 bootstrap samples the agreement between the variables selected 
by backward and forward selection was over 90%, whereas for the remaining 68 
bootstrap samples the agreement was between 58% and 89% (mean percentage of 
agreement (SD): 84.36% (9.08%)).  
- Forward and backward stepwise regression resulted in a final model with 10-27 
variables (mean (SD): 19.29 (3.34), median (IQR): 19 (17, 22)) and 16-31 
variables (mean (SD): 22.18 (3.25), median (IQR): 22 (20, 25)) respectively in 
the 100 samples. Furthermore, the mean of the number of the included variables 
in backward regression models was significantly larger than the mean of the 




- Only the variable family history was selected to be included in built models of all 
100 bootstrap samples using either forward or backward stepwise regression. The 
variables dietary energy and NSAIDs were selected to be included in the 99% of 
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the built models of the 100 bootstrap samples using either of the two methods. 
For forward stepwise regression models, the variables cholesterol and 
magnesium were selected to be included in 91% and 90% of the built models, 
respectively, whereas for backward stepwise regression models, the variables 
cholesterol and fibre were selected to be included in 94% and 90% of the built 
models, respectively. Finally, the remaining 47 variables were selected in <90% 
of the bootstrap samples using either selection. 
8.3.2.2 Females (Set 2) 
Findings from the original sample 
Forward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 10 risk factors: family history (p=2.3x10
-
25
), tMUFAs (p=0.0001), zinc (p=0.001), NSAIDs (p=0.008), cholesterol (p=0.01), 
starch (p=0.02), sugars (p=0.04), HRT (p=0.05), ω3PUFAs (p=0.06) and tFAs (0.08) 
(data not shown). Backward stepwise regression using the quartile form of the 





), NSAIDs (p=0.004), sodium 
(p=0.005), fibre (p=0.01), magnesium (p=0.01), niacin (p=0.02), iodine (p=0.03), 
sugars (p=0.04), carotenes (p=0.05), calcium (p=0.06), ω3PUFAs (p=0.06), tFAs 
(p=0.08) and HRT (p=0.08) (data not shown). In summary, forward and backward 
stepwise regression using the quartile form of the continuous variables resulted in 
similar models, with the common variables being family history, tMUFAs, NSAIDs, 
sugars, HRT, ω3PUFAs and tFAs (data not shown). 
8.3.2.3 Males (Set 2) 
Findings from the original sample 
Forward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 10 risk factors: family history (p=1.8x10-
24), dietary energy (p=1.2x10-8), magnesium (p=4.6x10-5), cholesterol (p=0.004), 
NSAIDs (p=0.007), flavanones (p=0.009), quercetin (p=0.02), tMUFAs (p=0.02), 
zinc (p=0.06) and physical activity (p=0.07) (data not shown). Backward stepwise 
regression using the quartile form of the continuous variables resulted in a model 
including the following 16 risk factors: family history (p=1.6x10
-24
), dietary energy 
(p=2.6x10-8), cholesterol (p=0.004), NSAIDs (p=0.006), magnesium (p=0.01), 
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phosphorus (p=0.01), vitamin D (p=0.02), copper (p=0.02), biotin (p=0.02), 
flavanones (p=0.02), starch (p=0.03), quercetin (p=0.05), tMUFAs (p=0.05), 
manganese (p=0.06), fibre (p=0.06) and vitamin B12 (p=0.06) (data not shown). In 
summary, forward and backward stepwise regression using the quartile form of the 
continuous variables resulted in similar models, with the common variables being 
family history, dietary energy, magnesium, cholesterol, NSAIDs, flavanones, 
quercetin and tMUFAs (data not shown). 
8.3.2.4 Summary (Set 2) 
Original sample 
Briefly, the variables of set 2 that were included in all six resultant models after 
application of forward and backward stepwise regression in the whole, female and 





NSAIDs (p-value range: 2.3x10
-5
 to 0.008), whereas the variables cholesterol (p-
value range: 1.5x10-5 to 0.01) and magnesium (p-value range: 3.8x10-5 to 0.01) were 
included in five of the six resultant models (Table 98, Table 99). In marked contrast, 
the variable ω3PUFAs (p-value range: 0.005 to 0.06) was only included in the 
models derived from the whole and female samples (Table 98, Table 99), the 




) and quercetin 
intake (p-value range: 0.01 to 0.05) were included only in the models derived from 
the whole and male samples (Table 98, Table 99), the variable tMUFA intake (p-
value range: 3.9x10-5 to 0.05) was included only in the models derived from the 
female and male samples (data not shown) and the variables tFA intake (p-value 
range: 0.08) and sugar intake (p-value range: 0.04 to 0.08) were included only in the 
models derived from the female sample (data not shown). Regarding the direction of 
the associations, the risk factors family history, cholesterol and dietary energy were 
associated with an increased colorectal cancer risk, whereas NSAIDs, magnesium, 
ω3PUFAs, quercetin, tFAs and sugars were associated with a decreased risk (Table 
98, Table 99). The variable tMUFAs was associated with an increased colorectal 
cancer risk in the whole and female sample analysis, whereas it was associated with a 
decreased risk in the male sample analysis. A matrix of the selected variables of the 
set 2 after applying forward and backward stepwise regression in the whole, female 
and male samples is presented in Table 102 (in the end of this chapter).  
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Bootstrap samples 
Results from the bootstrap method (whole sample) showed that all 100 resultant 
models after applying forward stepwise regression were chosen only once and the 
same after applying backward stepwise regression. Within the same bootstrap sample 
application of either forward or backward stepwise regression resulted in the same 
model in only two cases. Regarding the number of the included variables, it ranged 
from 10 to 27 for forward and from 16 to 31 for backward stepwise regression (p-
value of difference of number of variables selected from forward and backward 
stepwise regression: <5x10
-5
) (data not shown). In addition, only the variable family 
history was selected to be included in the models derived either from forward or 
backward stepwise regression in all 100 bootstrap samples (data not shown). 
Furthermore, the variables energy, NSAIDs, cholesterol, magnesium and fibre were 
included in more than 90% of the built models (data not shown). These results are in 
accordance with the findings of the analysis of the original sample, which suggested 
that the risk factors of set 2 more strongly associated with colorectal cancer were 
family history, NSAIDs, cholesterol and magnesium (Table 98, Table 99). 
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Table 98 Set 2: Forward stepwise regression built model* using the quartile form of the 
continuous variables (Whole sample) 
Included 
variables 
Number (%) or median (IQR) OR 95% CI p-value 















10.5 (8.4, 13.1) 























375.6 (335.4, 418.3) 390.2 (344.6, 334.3) 0.81 0.73, 0.90 3.8x10
-5
 
Protein (g/day) 100.3 (89.9, 111.0) 102.1 (91.3, 113.1) 0.90 0.83, 0.97 0.01 
Starch (g/day) 165.6 (145.5, 184.1) 163.7 (141.7, 184.9) 1.09 1.02, 1.16 0.01 
Flavanones 
(mg/day) 
20.2 (8.5, 39.1) 20.9 (6.7, 41.2) 1.08 1.0, 1.15 0.02 
ω3PUFAs 
(g/day) 
2.2 (1.8, 2.7) 2.3 (1.8, 2.8) 0.92 0.86, 0.99 0.02 
Fibre (g/day) 20.5 (17.1, 24.4) 21.3 (17.6, 25.4) 1.12 1.02, 1.24 0.02 
Iodine (µg/day**) 188.6 (149.8, 237.7) 191.4 (149.8, 243.5) 1.09 1.02, 1.17 0.02 
Quercetin 
(mg/day) 
16.9 (10.9, 22.1) 17.6 (11.4, 22.1) 0.93 0.88, 0.99 0.03 





0.0 (0.0, 2.0) 0.0 (0.0, 3.0) 0.94 0.87, 1.01 0.07 
Alcohol (g/day) 7.7 (1.7, 18.3) 8.4 (1.9, 19.9) 1.06 0.99, 1.14 0.07 
                                               
* McFadden’s pseudo R2 for model: 0.096  
† MJ/day: 1000 Joules/day 
‡ g/day: grams/day 
§ mg/day: milligrams/day 
** µg/day: micrograms/day 
†† h/week: hours/week 
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Table 99 Set 2: Backward stepwise regression built model* using the quartile form of the 
continuous variables (Whole sample) 
Included 
variables 
















10.5 (8.4, 13.1) 































0.84 0.76, 0.92 0.0002 
tMUFAs (g/day) 2.7 (2.2, 3.2) 2.6 (2.1, 3.2) 1.17 1.06, 1.29 0.002 
Zinc (mg/day) 11.7 (10.4, 13.2) 12.1 (10.6, 13.5) 0.89 0.83, 0.96 0.002 
Flavanones 
(mg/day) 
20.2 (8.5, 39.1) 20.9 (6.7, 41.2) 1.12 1.03, 1.21 0.004 
Fibre (g/day) 20.5 (17.1, 24.4) 21.3 (17.6, 25.4) 1.15 1.05, 1.26 0.004 
ω3PUFAs (g/day) 2.2 (1.8, 2.7) 2.3 (1.8, 2.8) 0.91 0.86, 0.97 0.005 
Quercetin 
(mg/day) 
16.9 (10.9, 22.1) 17.6 (11.4, 22.1) 0.93 0.87, 0.98 0.01 












0.0 (0.0, 2.0) 0.0 (0.0, 3.0) 0.93 0.87, 1.00 0.07 
                                               
* McFadden’s pseudo R2 for model: 0.096 
† MJ/day: 1000 Joules/day 
‡ g/day: grams/day 
§ mg/day: milligrams/day 
** h/week: hours/week 
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8.3.3 Set 3: Demographic factors, lifestyle variables, foods 
and nutrients 
The explanatory factors that were included in set 3 were the demographic risk factors 
(age, sex, family history and deprivation score), the lifestyle variables (smoking, 
alcohol, BMI, physical activity, dietary energy, NSAIDs and HRT for the female 
analysis), the foods (breads, cereals, milk, cream, cheese, eggs, poultry, red meat, 
processed meat, white fish, oily fish, potatoes/ pasta/ rice, fruit, vegetables, savoury, 
sweets, tea, coffee, fruit/ vegetable juice, fizzy drinks) and the nutrients (SFAs, 
MUFAs, ω6PUFAs, ω3PUFAs, tFAs, tMUFAs, quercetin, catechin, epicatechin, 
flavones, procyanidins, flavanones, phytoestrogens, protein, cholesterol, sugars, 
starch, fibre, sodium, potassium, calcium, magnesium, phosphorus, iron, copper, 
zinc, manganese, selenium, iodine, vitamin A, carotenes, vitamin D, vitamin E, 
vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folate, pantothenic acid, 
biotin, vitamin C) (82 risk factors in total). Chloride and potential niacin intakes were 
excluded from the stepwise regression, since they were very highly correlated with 
other nutrients (r>0.95). Forward and backward stepwise regression was applied in 
the whole sample and separately for males and females. 
8.3.3.1 Whole sample (Set 3) 
Findings from the original sample 
Forward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 19 risk factors: family history (p=3.6x10-





), white fish (p=5.4x10
-5
), dietary 
energy (p=0.0001), tMUFAs (p=0.0005), fibre (p=0.001), alcohol (p=0.003), 
quercetin (p=0.003), coffee (p=0.01), cereals (p=0.02), ω3PUFAs (p=0.02), tFAs 
(p=0.02), iron (p=0.04), breads (p=0.07) and physical activity (p=0.08) (Table 100). 
The risk factors family history, tMUFAs, fibre, sweets, eggs, fruit/ vegetable juice, 
white fish, dietary energy, alcohol, cereals and breads were associated with an 
increased colorectal cancer risk, whereas NSAIDs, magnesium, tFAs, quercetin, iron, 
ω3PUFAs, coffee and physical activity were associated with a decreased risk (Table 
100). 
Backward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 21 risk factors: family history (p=3.1x10-
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NSAIDs (p=6.1x10-6), magnesium (p=6.1x10-5), white fish (p=0.0001), fibre 
(p=0.0003), tMUFAs (p=0.001), dietary energy (p=0.002), quercetin (p=0.002), 
alcohol (p=0.003), coffee (p=0.01), cereals (p=0.02), ω3PUFAs (p=0.02), tFAs 
(p=0.02), iron (p=0.02), physical activity (p=0.08), breads (p=0.10), vitamin C 
(p=0.10) and flavones (p=0.10) (Table 101). The risk factors family history, fibre, 
fruit/ vegetable juice, tMUFAs, sweets, eggs, white fish, dietary energy, alcohol, 
cereals, flavones and breads were associated with an increased colorectal cancer risk, 
whereas NSAIDs, magnesium, tFAs, quercetin, iron, ω3PUFAs, coffee, vitamin C 
and physical activity were associated with a decreased risk (Table 101). 
 In summary, forward and backward stepwise regression using the quartile form of 
the continuous variables resulted in almost identical models, with the common 
variables being family history, sweets, eggs, fruit/ vegetable juice, NSAIDs, 
magnesium, white fish, dietary energy, tMUFAs, fibre, alcohol, quercetin, coffee, 
cereals, ω3PUFAs, tFAs, iron, breads and physical activity (Table 100, Table 101).  
Findings from the 100 bootstrap samples  
The main findings after applying forward and backward stepwise regression to the 
100 bootstrap samples were: 
- Forward stepwise regression applied to 100 bootstrap samples resulted in 100 
unique regression models (i.e. all 100 models were chosen only once).  
- Backward stepwise regression applied to 100 bootstrap samples resulted also in 
100 unique regression models.  
- Over the 100 bootstrap samples, the variables selected by backward selection 
were identical to those selected by forward selection in five of the bootstrap 
samples. For 17 bootstrap samples the agreement between the variables selected 
by backward and forward selection was over 90%, whereas for the remaining 78 
bootstrap samples the agreement was between 58% and 89% (mean percentage of 
agreement (SD): 83.12% (9.38%)).  
- Forward and backward stepwise regression resulted in a final model with 15-34 
variables (mean (SD): 25.34 (3.87), median (IQR): 25 (23, 28)) and 19-39 
variables (mean (SD): 29.43 (4.17), median (IQR): 30 (27, 32)) respectively in 
the 100 samples. Furthermore, the distribution of the number of variables in the 
resultant models was close to normal, with the mean of the included variables in 
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backward regression models to be significantly larger than the mean of the 
included variables in forward regression models (t-test p-value: <5x10-5) 
- Only the variable family history was selected to be included in built models of all 
100 bootstrap samples using either forward or backward stepwise regression. The 
variables fruit/ vegetable juice, and NSAIDs were selected to be included in more 
than 99% of the built models of the 100 bootstrap samples using either of the two 
methods (with the fruit/ vegetable juice variable being included in 100% of the 
backward stepwise regression models). For forward stepwise regression models, 
the variables energy, sweets, white fish and eggs were selected to be included in 
97-98% of the built models, whereas for backward stepwise regression models, 
the variables sweets, white fish, energy, fibre and eggs were selected to be 
included in 91-99% of the built models, respectively. Finally, the remaining 64 
variables were selected in <90% of the bootstrap samples using either selection 
method. 
8.3.3.2 Females (Set 3) 
Findings from the original sample 
Forward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 14 risk factors: family history (p=1.0x10
-
25), fruit/ vegetable juice (p=2.7x10-5), tMUFAs (p=0.0005), white fish (p=0.002), 
NSAIDs (p=0.002), fibre (p=0.003), sweets (p=0.005), biotin (p=0.007), niacin 
(p=0.02), tFAs (p=0.03), vitamin C (p=0.04), cholesterol (p=0.04), vegetables 
(p=0.09) and HRT (p=0.09) (data not shown). Backward stepwise regression using 
the quartile form of the continuous variables resulted in a model including the 





vegetable juice (p=1.7x10-5), sweets (p=0.001), white fish (p=0.001), NSAIDs 
(p=0.002), fibre (p=0.004), vitamin C (p=0.005), ω3PUFAs (p=0.02), magnesium 
(p=0.03), tFAs (p=0.04), coffee (p=0.06) and tea (p=0.06) (data not shown). 
In summary, forward and backward stepwise regression using the quartile form of 
the continuous variables resulted in similar models, with the common variables being 
family history, fruit/ vegetable juice, tMUFAs, white fish, NSAIDs, fibre, sweets 
tFAs and vitamin C (data not shown). 
8.3.3.3 Males (Set 3) 
Findings from the original sample 
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Forward stepwise regression using the quartile form of the continuous variables 
resulted in a model including the following 17 risk factors: family history (p=7.8x10-
25), dietary energy (p=9.3x10-9), eggs (p=2.5x10-6), sweets (p=6.9x10-5), magnesium 
(p=0.003), fruit/ vegetable juice (p=0.003), sugars (p=0.003), NSAIDs (p=0.006), 
white fish (p=0.02), fruit (p=0.02), MUFAs (p=0.04), cereals (p=0.04), vitamin D 
(p=0.05), quercetin (p=0.06), manganese (p=0.06), coffee (p=0.08) and physical 
activity (p=0.09) (data not shown). Backward stepwise regression using the quartile 
form of the continuous variables resulted in a model including the following 19 risk 
factors: family history (p=3.0x10
-25







), manganese (p=0.0001), fruit/ vegetable juice (p=0.005), 
NSAIDs (p=0.009), phosphorus (p=0.01), white fish (p=0.01), MUFAs (p=0.02), 
sugars (p=0.02), vitamin C (p=0.02), copper (p=0.06), fibre (p=0.04), coffee 
(p=0.06), fruit (p=0.08), physical activity (p=0.09), cheese (p=0.09) and flavanones 
(p=0.10) (data not shown). 
In summary, forward and backward stepwise regression using the quartile form of 
the continuous variables resulted in similar models, with the common variables being 
family history, dietary energy, eggs, sweets, fruit/ vegetable juice, sugars, NSAIDs, 
white fish, fruit, MUFAs, manganese, coffee and physical activity (data not shown). 
8.3.3.4 Summary (Set 3) 
Original sample 
Briefly, the variables of set 3 that were included in all six resultant models after 
application of forward and backward stepwise regression in the whole, female and 







 to 0.009), white fish (p-value range: 5.4x10
-5
 to 0.02), 
sweets (p-value range: 1.1x10-5 to 0.005) and fruit/ vegetable juice (p-value range: 
1.3x10-6 to 0.005), whereas coffee (p-value range: 0.01 to 0.08) and fibre (p-value 
range: 0.0003 to 0.01) were included in five of the six resultant models (Table 100, 
Table 101). In contrast, the variables dietary energy intake (p-value range: 5.4x10
-9
 
to 0.002) and physical activity (p-value range: 0.08 to 0.09) were included only in the 
models derived from the whole and male samples (Table 100, Table 101) and the 
variables fruit (p-value range: 0.02 to 0.08), MUFA intake (p-value range: 0.02 to 
0.04), sugar intake (p-value range: 0.003 to 0.02) and manganese intake (p-value 
range: 0.0001 to 0.06) were included only in the models derived from the male 
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sample (data not shown). Regarding the direction of the associations, the risk factors 
family history, white fish, sweets, fruit/ vegetable juice, fibre, dietary energy and 
fruit were associated with an increased colorectal cancer risk, whereas NSAIDs, 
coffee, physical activity, sugars, manganese and MUFAs were associated with a 
decreased risk (Table 100, Table 101). A matrix of the selected variables of the set 2 
after applying forward and backward stepwise regression in the whole, female and 
male samples is presented in Table 102 (in the end of the chapter). 
Bootstrap samples 
Results from the bootstrap method (whole sample) showed that all 100 resultant 
models after applying forward stepwise regression were chosen only once and the 
same after applying backward stepwise regression. Within the same bootstrap sample 
application of either forward or backward stepwise regression resulted in the same 
model in only five cases. The number of the included variables ranged from 15 to 34 
for forward and from 19 to 39 for backward stepwise regression (p-value of 
difference of number of variables selected from forward and backward stepwise 
regression: <5x10
-5
) (data not shown). In addition, only the variable family history 
was selected to be included in the models derived either from forward or backward 
stepwise regression in all 100 bootstrap samples (data not shown). Furthermore, the 
variables fruit/ vegetable juice, NSAIDs, dietary energy, sweets, white fish, eggs and 
fibre were included in more than 90% of the built models (data not shown). These 
results are in accordance with the findings of the analysis of the original sample, 
which suggested that the risk factors of set 3 more strongly associated with colorectal 
cancer were family history, NSAIDs, white fish, sweets, fruit/ vegetable juice, coffee 
and fibre (Table 100, Table 101). 
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) 4.3 (2.9, 6.0) 4.6 (3.1, 6.3) 1.17 1.10, 1.25 1.1x10
-6 
Eggs (m/day) 0.5 (0.2, 0.7) 0.4 (0.2, 0.6) 1.15 1.09, 1.23 3.9x10
-6 
fruit/ vegetable juice 
(m/day) 















375.6 (335.4, 418.3) 390.2 (344.6, 334.3) 0.81 0.74, 0.89 1.6x10-5 






10.5 (8.4, 13.1) 
9.9 (8.1, 12.5) 1.13 1.06, 1.21 0.0001 
tMUFAs (g/day
††
) 2.7 (2.2, 3.2) 2.6 (2.1, 3.2) 1.19 1.08, 1.32 0.0005 
Fibre (g/day) 20.5 (17.1, 24.4) 21.3 (17.6, 25.4) 1.18 1.07, 1.30 0.001 
Alcohol (g/day) 7.7 (1.7, 18.3) 8.4 (1.9, 19.9) 1.11 1.04, 1.20 0.003 
Quercetin (mg/day) 16.9 (10.9, 22.1) 17.6 (11.4, 22.1) 0.90 0.85, 0.96 0.003 
Coffee (m/day) 1.0 (0.0, 2.4) 1.0 (0.1, 3.0) 0.92 0.86, 0.98 0.01 
Cereals (m/day) 1.0 (0.5, 1.6) 1.1 (0.4, 1.8) 1.08 1.01, 1.16 0.02 
ω3PUFAs (g/day) 2.2 (1.8, 2.7) 2.3 (1.8, 2.8) 0.92 0.86, 0.98 0.02 
tFAs (g/day) 3.6 (3.0, 4.3) 3.5 (2.8, 4.2) 0.89 0.81, 0.98 0.02 
Iron (mg/day) 15.1 (13.3, 16.9) 15.4 (13.7, 17.3) 0.91 0.83, 1.00 0.04 
Breads (m/day) 2.7 (1.9, 3.6) 2.6 (1.8, 3.6) 1.06 1.00, 1.13 0.07 
Physical activity 
(h/week‡‡) 
0.0 (0.0, 2.0) 0.0 (0.0, 3.0) 0.94 0.87, 1.01 0.08 
                                               
* McFadden’s pseudo R2 for model: 0.108 
† Summary variable of puddings and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
‡ m/day: measures/day 
§ mg/day: milligrams/day 
** MJ/day: 1000 Joules/day 
†† g/day: grams/day 
‡‡ h/week: hours/week 
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30 (1.1%) 20.67 13.88, 30.78 3.1x10
-50 








 (m/day) 4.3 (2.9, 6.0) 4.6 (3.1, 6.3) 1.17 1.10, 1.25 1.5x10
-6 














) 375.6 (335.4, 418.3) 390.2 (344.6, 334.3) 0.82 0.75, 0.90 6.1x10
-5 
White fish (m/day) 0.3 (0.2, 0.5) 0.3 (0.1, 0.5) 1.13 1.06, 1.20 0.0001 
Fibre (g/day
**
)  20.5 (17.1, 24.4) 21.3 (17.6, 25.4) 1.22 1.09, 1.35 0.0003 





10.5 (8.4, 13.1) 9.9 (8.1, 12.5) 1.11 1.04, 1.19 0.002 
Quercetin (mg/day) 16.9 (10.9, 22.1) 17.6 (11.4, 22.1) 0.90 0.84, 0.96 0.002 
Alcohol (g/day) 7.7 (1.7, 18.3) 8.4 (1.9, 19.9) 1.11 1.04, 1.19 0.003 
Coffee (m/day) 1.0 (0.0, 2.4) 1.0 (0.1, 3.0) 0.92 0.86, 0.98 0.01 
Cereals (m/day) 1.0 (0.5, 1.6) 1.1 (0.4, 1.8) 1.09 1.01, 1.16 0.02 
ω3PUFAs (g/day) 2.2 (1.8, 2.7) 2.3 (1.8, 2.8) 0.92 0.87, 0.99 0.02 
tFAs (g/day) 3.6 (3.0, 4.3) 3.5 (2.8, 4.2) 0.89 0.81, 0.98 0.02 





0.0 (0.0, 2.0) 0.0 (0.0, 3.0) 0.94 0.87, 1.01 0.08 
Breads (m/day) 2.7 (1.9, 3.6) 2.6 (1.8, 3.6) 1.06 0.99, 1.12 0.09 
Vitamin C (mg/day) 111.2 (78.8, 147.8) 117.6 (83.0, 161.4) 0.93 0.85, 1.01 0.10 
Flavones (mg/day) 1.0 (0.5, 1.8) 1.0 (0.5, 1.8) 1.06 0.99, 1.13 0.10 
                                               
* McFadden’s pseudo R2 for model: 0.109 
† m/d: measures/day 
‡ Summary variable of puddings and deserts; chocolates, sweets, nuts and  crisps; biscuits; and cakes 
§ mg/day: milligrams/day 
** g/day: grams/day 
†† MJ/day: 1000 Joules/day 
‡‡ h/week: hours/week 
Chapter eight                                                               Results: Overall and stepwise regression analysis   
 341
Table 102 Matrix of the variables included in the three sets and finally selected into the forward or backward 
stepwise regression models in the whole sample and after sex stratification (original sample) 



















F B F B F B F B F B F B F B F B F B 
Demographic                   
Sex                   
Age  x      x      x     
Family history x x x x x x x x x x x x x x x x x x 
Deprivation score                   
Lifestyle                   
BMI                   
Dietary energy x x   x x x x   x x x x   x x 
Smoking                   
Alcohol       x      x x     
Physical activity  x x   x x x    x  x x   x x 
NSAIDs x x x x x x x x x x x x x x x x x x 
HRT   x      x x     x    
Foods                   
Breads x  x x         x      
Cereals             x    x  
Milk                   
Cream                   
Cheese                  x 
Eggs x x x x x x       x    x x 
Poultry                   
Red meat                   
Processed meat                   
White fish x x x x         x x x x x x 
Oily fish x x            x     
Potatoes/ 
Pasta/ Rice 
                  
Fruit                 x x 
Vegetables x x x x          x x    
Savoury     x x             
Sweets x x x x x x       x x x x x x 
Tea x x  x  x          x   
Coffee x x  x  x       x x  x x x 
fruit/ vegetable juice x x x x x x       x x x x x x 
Fizzy drinks                   
Nutrients                   
SFAs                   
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MUFAs                 x x 
ω6PUFAs                   
ω3PUFAs       x x x x   x   x   
tFAs         x x   x  x x   
tMUFAs         x x x x x  x x   
Quercetin       x x   x x x    x  
Catechin        x           
Epicatechin              x     
Flavones        x           
Procyanidins                   
Flavanones       x    x x      x 
Phytoestrogens                   
Protein       x            
Cholesterol       x x x  x x  x x    
Sugars         x x       x x 
Starch       x x x   x       
Fibre       x   x   x x x x  x 
Sodium          x         
Potassium                   
Calcium           x    x     
Magnesium       x x  x x x x x  x x  
Phosphorus            x      x 
Iron              x      
Copper        x x    x  x    x 
Zinc          x  x        
Manganese             x     x x 
Selenium                    
Iodine       x   x         
Vitamin A                   
Carotenes          x         
Vitamin D            x     x  
Vitamin E        x      x     
Vitamin B1                   
Vitamin B2                    
Niacin           x     x    
Vitamin B6                   
Vitamin B12                 x  
Folate                   
Pantothenic acid                   
Biotin            x   x    
Vitamin C               x x  x 
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8.4 Summary of results of chapter 8 
In this chapter the overall and stepwise regression analysis of the study was 
presented. The explanatory variables that were investigated in the overall analysis 
and included in the stepwise regression models consisted of demographic factors, 
lifestyle variables, food variables and nutrients. The overall analysis was conducted 
for the quartile, standardised and continuous forms of the continuous variables. 
Finally stepwise regression analysis was conducted for the quartile form of the 
continuous variables in the whole sample and then separately for men and women. 
8.4.1 Overall analysis 
In the overall analysis of the study, distributions and correlations of all the 
explanatory variables, as well as univariable logistic regression of colorectal cancer 
on each explanatory variable were investigated. 
The risk factors that were significantly associated with colorectal cancer, according 
to the results of the univariable logistic regression were: 1) the demographic and 
lifestyle factors: family history of cancer, NSAIDs intake, dietary energy intake, 
HRT intake and physical activity (Table 96); 2) the food group variables: vegetables, 
eggs, sweets, fruit/ vegetable juice, oily fish, coffee, fruit, savoury foods and white 
fish (Table 96); and 3) the nutrient variables: tMUFAs, ω3PUFAs, SFAs, tFAs and 
MUFAs (fatty acids); quercetin, catechin and phytoestrogen (flavonoids); 
cholesterol, fibre, protein and starch (macronutrients); magnesium, potassium, 
manganese, copper, iron, zinc, phosphorus, selenium (minerals); niacin, vitamin B6, 
carotenes, vitamin C, vitamin A, potential niacin, biotin, folate, pantothenic acid, 
vitamin D, vitamin B1 and vitamin B12 (vitamins) (Table 96). 
8.4.2 Stepwise regression analysis   
8.4.2.1 Original sample 
Forward and backward stepwise regression models were applied in three different 
sets of variables using the quartile form of the continuous variables in the whole 
sample (Tables 97-101) and after sex stratification (data not shown). In Table 102, a 
matrix of the variables included in the three different sets and finally selected into the 
forward or backward stepwise regression models for the whole, female and male 
sample is presented. The variables that were included in 100% of the models derived 
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from the whole, female and male analysis of all three sets were: family history, 
NSAIDs, sweets and fruit/ vegetable juice. The following variables were included in 
models derived from the female sample, but not in models derived from the male 
samples: tFAs (100% of the models), vegetables (75%), ω3PUFAs (75%), HRT 
(67%), breads (50%) and niacin (50%). In addition, the following variables were 
included in models derived from the male sample, but not in models derived from the 
female sample: dietary energy intake (100% of models), physical activity (83%), 
quercetin (75%), flavanones (75%), manganese (75%), fruit (50%), savoury (50%), 
MUFAs (50%), phosphorus (50%), copper (50%) and vitamin D (50%) (Table 102). 
8.4.2.2 Bootstrap samples 
The bootstrap method was applied to investigate the stability of the models and it 
was applied for forward and backward stepwise regression of all three sets of 
variables (whole sample). In particular, 100 bootstrap samples were randomly drawn 
from the original sample. Then, each bootstrap sample was used to apply forward 
and backward stepwise regression for each set of variables (set 1, 2 and 3). 
According to the findings of this analysis, all 100 models derived after forward 
stepwise regression were chosen once (for all sets of variables), and the same was 
observed for the 100 models derived after applying backward stepwise regression. 
The agreement between the models derived from forward and backward stepwise 
regression within the same bootstrap sample was high for the analysis of the set 1 
variables (mean percentage of agreement (SD): 96.97% (4.56%)), whereas it was 
lower for the analysis of the set 2 and set 3 variables (mean percentage of agreement 
(SD): 84.36% (9.08%), 83.12% (9.38%); respectively). Furthermore, the number of 
variables that were selected to be included in the models of the 100 bootstrap 
samples was smaller for the set 1 analysis (11-20 variables), than for the set 2 and set 
3 analysis (10-31 and 15-39 variables respectively) (data not shown). In addition, for 
set 1, 2 and 3, more variables were selected to be included in models derived from 
backward stepwise regression (mean number of selected variables (SD): 22.54 
(6.37)) than in models derived from forward stepwise regression (mean number of 
selected variables (SD): 20.02 (5.15)). Finally, the variables that were selected to be 
included in models for the majority of the bootstrap samples (more than 90%) were: 
1) family history, NSAIDs and dietary energy, if we consider all three sets of 
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variables; 2) family history, NSAIDs, dietary energy, eggs, sweets, fruit/ vegetable 
juice and white fish, if we consider set 1 and set 3; and 3) family history, NSAIDs 
and dietary energy, if we consider set 2 and 3 (data not shown). 




In the first three chapters of this thesis background information regarding colorectal 
cancer and its main risk factors was given and the aims and objectives of the current 
thesis were presented. In chapter four, all the aspects regarding the design of the study 
this thesis was based on and the applied analytical methods were described. Finally, in 
the four following chapters the results of the dietary analysis of the SOCCS study were 
presented, with the most important findings being summarised in the end of each 
chapter. 
In this chapter, which is divided in three parts, the main issues of this thesis will be 
described. In the first part of the discussion, issues regarding the methodological and 
analytical aspects of this thesis will be presented. In particular, the strengths and 
limitations of the study design and of the employed analytical methods will be addressed 
and evaluated. In the second part of the study the most important findings and principal 
results of the analysis will be discussed and compared with findings from previous 
published studies. Finally, in the last part of the discussion, the main conclusions that are 
drawn from this thesis as well as suggestions for future research will be presented. 
9.2 Methodological and analytical issues 
In this part of the chapter the following issues will be presented and discussed: 1) 
epidemiological issues, including description of the main study designs of observational 
analytical epidemiology together with their main advantages and disadvantages (bias 
and confounding); 2) nutritional issues, including methods of diet assessment, diet 
validation and energy adjustment; and 3) analytical issues including study power 
calculations (for the matched and the unmatched datasets), methods of multiple testing 
correction and issues regarding the stepwise regression and bootstrap sampling methods. 
The main strengths and limitations of the current study regarding the above 
methodological and analytical issues will also be summarised and discussed. 
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9.2.1 Epidemiological issues  
Epidemiological studies are used in order to investigate the distribution and the main 
determinants of a particular disease in different populations. They are divided in 
experimental (like randomised clinical trials) and observational studies. Observational 
studies can then further divided according to whether the unit of the study is a 
population (ecological studies) or an individual (descriptive: case series; analytical: 
cross-sectional, case-control, cohort studies). 
Large cohort studies of diet and colorectal cancer  
Some of the main cohort studies that have investigated associations between specific 
nutrients, food items or food groups and colorectal cancer, include: 
1) Cohort studies conducted in the USA and Canada: 
- Women’s Health Study (USA): 37,547 female participants  
- New York’s University Health Study (USA): 14,727 female participants 
- Iowa’s Women’s Health Study (USA): 32,215 female participants 
- Nurses' Health Study (USA): 87,733 female participants 
- Health Professionals Follow-up Study (USA): 47,949 male participants 
- Physicians' Health Study (USA): 22,071 male participants 
- NHANES I Epidemiologic Follow-up Study (USA): 14,407 male and female 
participants 
- Multiethnic cohort study (USA): 191,011 male and female participants 
- Cancer Prevention Study II Nutrition (USA): 127,749 male and female participants 
- Breast Cancer Detection Demonstration Project (USA): 45,354 female participants 
- Canadian National Breast Screening Study (Canada): 5,629 female participants 
 2) Cohort studies conducted in Europe: 
- European Prospective Investigation into Cancer and Nutrition (Denmark, France, 
Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden and the United 
Kingdom): 520,000 male and female participants 
- Netherlands Cohort Study (The Netherlands): 120,852 male and female participants 
- Finnish Mobile Clinic Health Examination Survey (Finland): 9,959 male and female 
participants 
Chapter nine  Discussion 
 348 
- Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (Finland): 27,111 male 
participants 
- Swedish Mammography Cohort Study (Sweden): 61,433 female participants 
- Cohort of Swedish Men (Sweden): 45,306 male participants 
- Cohort Study in Norway (Norway): 50,535 male and female participants 
3) Cohort studies conducted in Asia: 
- Japan Public Health Centre-based Study (Japan): 95,376 male and female 
participants 
- Shanghai Women's Health Study (Shanghai): 73,314 female participants 
 Large case-control studies of diet and colorectal cancer 
Some of the main and largest case-control studies that have investigated associations 
between specific nutrients, food items or food groups and colorectal cancer, include: 
1) Case-control studies conducted in the USA and Canada: 
- Ontario Familial Colon Cancer Registry (Canada): 2,985 male and female 
participants 
- A population-based case-control study of colon cancer conducted in Northern 
California, Utah, and the 'Twin Cities' area of Minnesota (USA): 4,403 male and 
female participants 
- Oahu (Hawaii) case-control study (USA): 2,384 male and female participants 
- A population-based case-control study in Massachusetts (USA): 2,394 male and 
female participants 
- A population-based case-control study of rectal cancer conducted in Northern 
California and Utah (USA): 1,730 male and female participants 
- North Carolina Colon Cancer Study (USA): 1,609 male and female participants 
2) Case-control studies conducted in Europe: 
- Scottish Colorectal Cancer Study (current study; Scotland): 4,837 male and female 
participants 
- A multi-centre Italian study (Italy): 6,107 male and female participants 
3) Case-control studies conducted in Asia and Australia: 
- Fukuoka Colorectal Cancer Study (Japan): 1,575 male and female participants 
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- Hospital-based Epidemiologic Research Program at Aichi Cancer Centre (Japan): 
2,535 male and female participants 
- Melbourne Colorectal Cancer Study (Australia): 1,442 male and female participants 
9.2.1.1 Strengths and limitations of the current study 
(epidemiological issues)  
Strengths 
Case and control selection 
One of the main strengths of this colorectal cancer study is its careful design regarding 
the selection and recruitment of the study participants (cases and controls). A careful 
recruitment strategy both for cases and controls was developed, which involved the set 
up of a firm recruitment protocol covering all the main steps of the participant’s study 
entry. 
In particular, regarding case recruitment, strict criteria were applied in order to avoid 
misclassification bias and only incident cases of colorectal adenocarcinoma were 
included in the study. In addition, correct diagnosis was ensured by careful examination 
of the pathological reports and was histologically confirmed. An attempt was made to 
keep the time between diagnosis and recruitment short by developing a recruiting 
network of well-trained nurses, by placing recruitment staff in hospitals and by 
establishing close cooperation with clinical staff. From data provided from the Scottish 
Cancer Registry, we were able to calculate that the median time between date of 
recruitment and date of cancer diagnosis (incidence) was 150 days. Incidence date was 
reported as the date of the first pathology report for the particular colorectal cancer and 
often pre-dates the date of hospital admission. We also compared basic information on 
age, gender and place of residence of the cases included in our study with data 
aggregated over a five year period (1999-2003) from the Scottish Cancer Registry. There 
was a slight over-representation of male cases but the distribution among the 15 boards 
of Scotland was similar to that from the Cancer Registry.  
Controls were randomly selected from the CHI, which is a national register of all 
individuals who are registered with a GP in Scotland and represents an ideal sampling 
frame for the selection of population based controls (95% completeness). In addition, 
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controls were closely matched to cases by age, sex, and area of residence. In particular, 
strict matching criteria were applied and selected controls were individually matched to 
cases according to sex, age (+/- 1 year) and health board area. The main advantages of a 
matched case-control study are that cases and controls are more comparable, that 
confounding from the matched factors is accounted for and usually study precision and 
power is increased.  
Confounding factors selection 
An attempt was made to minimise the confounding effect by careful selection of the 
confounding factors, which were chosen according to findings of previous studies. In 
particular, we chose to adjust the observed associations (of the four hypotheses of the 
first part of the thesis) for the following factors: family history of cancer, BMI, physical 
activity (hours of cycling and of doing other sport activities per week; proxy of total 
leisure physical activity), smoking (never and ever smokers), energy intake, fibre intake 
(energy adjusted), alcohol intake (energy adjusted) and NSAIDs intake. In addition, age, 
sex, deprivation score (proxy of the social-economic status) were included as 
confounding factors in the analysis of the unmatched dataset, but not in the analysis of 
the matched dataset, since age, sex and health board area were the matching risk factors.  
Univariable analysis of the confounding factors showed that the following factors were 
not statistically significant with colorectal cancer in our study population: for the 
matched dataset BMI (p=0.38) and smoking (p=0.51) (Table 63) and for the unmatched 
dataset sex (p=0.85), deprivation score (p=0.94), BMI (p=0.42) and smoking (p=0.63) 
(Table 79). The selection of the confounding factors was made prior to any analyses and 
therefore even the factors that were found not to be significantly associated with 
colorectal cancer were included in the multivariable analyses. However, results from 
multivariable regression analysis models that did not include BMI and smoking 
(matched analysis) and sex, deprivation score, BMI and smoking (unmatched analysis) 
were similar to the ones that included these confounding factors. 
Limitations 
Case and control selection 
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It is inevitable that this study, despite close cooperation with clinical staff, was unable to 
recruit patients who died soon after diagnosis or who were seriously ill at presentation or 
in the post-operative period. There is, therefore, an under-representation of cases that 
were very ill at time of presentation to hospital, which might affect the external validity 
of the study. In addition, there might be a possibility that early stage of disease may be 
due to more frequent screening of more health conscious cases, which also had a 
healthier lifestyle. We were not given ethical approval to collect data from the 
participants that refused or were not able to be included in the study and therefore we 
cannot identify whether there are any significant differences. Regarding the matching 
procedure, even if 2,062 cases and 2,776 controls had complete and valid FFQ and LCQ 
data and could be included in the analysis, for some cases no controls that fulfilled all 
the matching criteria were identified. Therefore when the fine matching was kept, 573 
cases and 1,287 controls needed to be excluded from the analysis (1,489 matched pairs 
were included in the matched analysis). 
Despite the careful design of this case-control study, many cases and controls refused to 
take part in the study and participation rates were 52% for cases and 39% for controls. 
Participation rates for both cases and controls differ according to area of residence and 
age. In particular, subjects from the Health Boards of Grampian, Highland and Lothian 
were more likely to participate, whereas subjects from Greater Glasgow Health Board 
were less likely to participate (Table 33, Table 35). In addition, both cases and controls 
that refused to participate were significantly older than the ones that agreed to participate 
(p<5x10
-5
) (Table 33, Table 35), which is in accordance with findings from other 
population-based case-control studies suggesting that younger individuals are more 
likely to participate (277;278). Furthermore, participation rates in our study differ 
according to disease status with fewer controls having agreed to participate than cases 
(39% vs. 52%). This is a common problem of population-based case-control studies, 
with other case-control studies also reporting lower participation rates for controls than 
for cases (277-279). The difference in participation rates between cases and controls 
might be due to the fact that cases are more eager than population controls to take part in 
a study that investigates their disease. Therefore in our case, the controls that agreed to 
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participate might have had a healthier diet and lifestyle and therefore were more eager to 
participate in a case-control study asking about their lifestyle choices and dietary habits 
(participation bias). This fact is also supported by the lower participation rates of 
controls with high deprivation (deprivation scores of 6 and 7; Table 35). 
A direct comparison of participation rates in our study and similar population-based 
case-control studies may not be straight forward mainly due to not
 
reporting or 
inconsistently reporting of participation rates from case-control studies (280). In 
particular, a recent review demonstrated that more than 50% of published case-control 
studies failed to report any information regarding participation rates (280). Generally, it 
has been observed, that participation rates of population-based case-control studies 
conducted after 1990 were considerably lower than those of studies conducted between 
1970 and 1990 (280).  Although the exact reasons for this decline are not fully 
understood, possible explanations include changes in study design and
 
in methods of 
recruitment, as well as differences in social and lifestyle factors (280). An additional 
explanation might be that many recent case-control studies include collection of 
biological specimens, such as blood (like in our study), which may also have an effect 
on participation rates (280). Median participation rates of 34 population-based case-
control studies conducted from January 1 to April 30, 2003 and published in 10 high 
impact epidemiology, public health and medical journals was 84% (range: 44%-99%) 
for cases and 74% (range: 41%-88%) for controls (280). In addition, participation rates 
of a large population-based case-control study of colon cancer conducted in USA were 
approximately 76% and 64% for cases and controls, respectively (278). Therefore 
participation rates of both cases and controls in our study were lower than the 
aforementioned, with one possible explanation being that collection of biological 
specimens was required. In addition, lower participation rates in controls might be due to 
the recruitment procedure. In particular, eligible controls were contacted only via mail 
by their GPs, since we did not have ethical approval to contact them directly by phone. It 
has been shown that population-based case-control studies that use letters as the only 
contact mode have lower participation rates (279). In addition, in case of no reply, we 
had ethical approval to contact GPs or controls only once more. It has been suggested 
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though that in order to obtain high control participation rates a number of contacts as 
high as 14 may be required (281). Given these lower than usual participation rates for 
both cases and controls of our study, participation bias cannot be ruled out and therefore 
results should be interpreted with caution. 
An alternative case-control design that tends to overcome the low participation problem 
is the hospital-based case-control study, where controls are selected from hospitals 
(patients with a disease other than the one under investigation). Hospital-based case-
control studies have usually higher participation rates than the population-based ones 
and in some cases they can be as high as 95% (282). Median participation rates of 33 
hospital-based case-control studies conducted from January 1 to April 30, 2003 and 
published in 10 high impact epidemiology, public health and medical journals was 92% 
(range: 74%-99%) for cases and 86% (range: 60%-99%) for controls (280). In addition, 
participation rate of a large hospital-based multi-centre case-control study of colorectal 
cancer conducted in Italy was approximately 96% for both cases and controls (282). 
However, the hospital based design is usually not preferred, mainly because hospital 
controls may have a condition that is also influenced by the risk factor under 
investigation or because they may come from different populations, which will affect the 
representativeness of the case-control study.  
Finally, when no ideal control group is identified, then a possible strategy is to have 
more than one control groups (i.e. one hospital-based and one population-based) and 
compare results obtained from different control groups. 
Bias and confounding 
Since cases were aware of their disease status when completed the questionnaires, it is 
likely that they recalled their dietary and lifestyle habits differently than controls (recall 
bias). In addition, completion rates in cases were lower than completion rate in controls 
(65.7% vs. 83.9%), which is likely to be due to cases being re-admitted to hospital or 
otherwise too ill to fully cooperate in the study.  
Regarding confounding, we tried to minimise the confounding effects by measuring and 
adjusting for the majority of the potential confounding factors. However, the possibility 
of residual confounding due to not controlling for unknown or unmeasured confounding 
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factors or due to measurement errors of the accounted confounding factors can not be 
ruled out. 
9.2.2 Nutritional epidemiology issues 
Nutritional epidemiology is based on the application of experimental or observational 
epidemiological studies in order to investigate the effects of particular nutrients, food 
items or food groups on a disease. Even if randomised clinical trials are considered as 
the gold standard in order relationships between nutritional factors and diseases to be 
established, there are many cases where only observational studies can be applied (283). 
In the following sections issues regarding diet assessment, validation and energu 
adjustment methods of the observational studies will be presented and discussed. Weight 
will be given to the description of the FFQ, since this was the diet assessment method 
used in the current study. 
9.2.2.1 Diet assessment 
The main diet assessment methods are Diet Recalls, Food Records, Diet Histories and 
FFQs. Diet Recalls and Food Records methods are based on recording the foods that are 
consumed by the individual at one or more days, whereas Diet Histories and FFQs are 
used in order to measure long-term dietary intakes. 
Diet Recalls and Food Records 
Diet Recalls are usually based on a 24-hour level and are normally conducted by a 
trained interviewer. The interviewer asks the participant about the foods and drinks that 
he/ she consumed during the previous day as well as details about the used food 
preparation methods. This method is relatively quick, but it relies on the short term 
memory abilities of each individual. On the other hand, Food Records are based on the 
recording of consumed foods and drinks at the actual time of the consumption. 
Therefore, this method does not rely on the individual’s memory abilities, but it requires 
more time and effort than the Diet Recall method. The main advantages of these two 
methods are that they can be used in order to estimate absolute intakes of foods, energy, 
macro- and micro-nutrients and that due to the fact that they contain open-ended 
questions they can be very specific regarding the consumed food types and the food 
preparation methods. The main disadvantage of these methods is that they do not capture 
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the usual dietary habits of the individuals, unless multiple recalls or records are to be 
collected, which is not an efficient process for large epidemiological studies due to the 
effort and cost that are required (283).  
Diet Histories and Food Frequency Questionnaires 
The main characteristic of the Diet History is that it captures quantitative information 
about the individual’s usual diet using a fixed food item list, but information regarding 
frequencies and portions are obtained from the individual. Whereas the first Diet History 
developed by Burke in 1947 was menu-based, the most recent ones are initially list-
based and then the individual reports frequencies and portion of only the foods that he/ 
she usually consumes (284). 
Food frequency questionnaire, which is the most widely used diet assessment method, 
measures long-term dietary intakes like Diet History, but their main difference is that in 
addition to the fixed food list it also has a fixed frequency. FFQs can be administered by 
interview (personal or by telephone) or they can be completed by the study participants 
(self-administered). The food list section of the FFQs can be long or short depending on 
the purpose of the study and the hypothesis that is to be tested, but generally a 
comprehensive assessment of the diet by including a wide range of foods and drinks is 
preferred. In addition, the food-list should consist of foods that are relevant to the usual 
diet of the particular population that the study results will be applied to. The frequency 
section usually has a multiple-choice format and the individuals can choose how often 
they consume the reported food item (never, once a month, two days per week, etc.). 
Finally, the portion section is optional and when portion information is recorded (semi-
quantitative FFQ) the individuals report how often they consume a specific portion of 
the food item (rather than reporting how often they consume a food item). For some 
food items that come in natural portions (such as milk or bread) adding portions is 
straightforward and also sometimes adds clarity. For food items that do not come in 
natural portions (such as meat or rice) a typical portion can be specified and subjects are 
expected to double the frequency of consumption when their usual portion is twice the 
specified one. However, that practice might introduce bias if not all the participants 
adjust the consumption frequency according to their usual portion (283;284). 
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The FFQ method is relatively easy (even when the FFQ is self-administered), fully 
computerised, inexpensive and quick making it one of the most popular ways to assess 
the usual and long-term dietary intakes, especially for studies that include large numbers 
of study participants. However, there are limitations of the FFQ method, with one of 
them being that the derived quantitative estimates of the food and nutrient intakes cannot 
be used as absolute intakes and should only be used to rank individuals into categories 
(e.g. quartiles of intakes). In addition, the participants are required to report their usual 
intakes of generally more than 100 different foods for a specific past period of time. This 
task, which relies on the memory abilities of each individual, might be complex for 
some participants (especially ones with particular disabilities or of an advanced age). 
Finally, since the FFQ has a certain list of foods, a particular questionnaire can not be 
applied in different populations or different times and therefore results from studies 
using different FFQs are not always comparable (285).   
Nutrient assessment 
The immediate outcome of all the diet assessment methods is data about the food group 
and item intakes. However, many hypotheses are about the investigation of the 
associations between intakes of particular nutrients and disease. In order to convert food 
intakes to nutrient intakes, a nutrient database and an analysis programme are necessary. 
Regarding the conversion of foods measured by an FFQ in nutrients, if portion sizes 
have been specified (semi-quantitative FFQ), the nutrient values can be estimated 
according to that portion sizes. However, if no portion sizes have been specified, then a 
typical or average portion size is used in order to estimate the nutrient intakes. Finally, 
for open-ended questions, specific data for each reported response need to be obtained 
(283). 
The nutrient databases used by nutritional observational studies are normally nationally 
based. For the estimation of total energy and the main macro- and micro-nutrients the 
most commonly used database in the UK is the McCance and Widdowson's 
Composition of Foods (5th Edition plus related supplements). For specific nutrients 
(such as flavonoids, specific fatty acids, etc.) supplementary nutrient databases need to 
be used. For example for estimating flavonoid intakes a flavonoid composition database 
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containing entries from fruit, vegetables, beverages, jams, chocolate and herbs was 
developed in Scotland and was used for estimating flavonoid intakes in the current study 
(274). 
Measurement error at diet assessment 
When assessing diet two types of measurement error can occur: random or systematic. 
When assessing diet by using either Diet Recalls or Food Records, within-person 
random errors reflect the day-to-day variations in dietary intakes and they can usually be 
accounted for and corrected by using two or more dietary measurements for each 
participant. On the other hand, when assessing diet by using either Diet Histories or 
FFQs, within-person random errors can occur due to true changes of diet over time, 
which is particularly important for a disease that has a long latent period (e.g. cancer). 
To be more specific, usually cases of a case-control study are asked to complete an FFQ 
for a reference period of approximately a year prior to their diagnosis. However, their 
dietary habits for even up to 10 years prior to their diagnosis might have affected 
initiation and progression of a disease with a long latent period, and therefore true 
changes (that are not captured by the FFQ) within this 10 year period can lead to 
measurement errors. Within-person systematic errors mainly occur when a participant 
deliberately over- or under-reported the intake of a particular food (when Diet Recalls or 
Food Records are used) or when an important food for one or more participants (but not 
for others) has been omitted from the fixed food list of a Diet History or an FFQ. 
Between-person random error happens when for example there is a random over-
reporting of a food item from some participants and a random under-reporting of the 
same food item from some other participants. In that case, the mean of the intake of the 
food item will be correct, but there will be an over-estimation of the standard deviation. 
Finally, between-person systematic error occurs when the over- or under-reporting is not 
random and some examples are the omission of an important food item from the FFQ, 
inaccurate compositional databases, or under- or over reporting according to the disease 
status in a case-control study (recall bias). Usually random errors (both within- and 
between-persons) tend to attenuate the relationships between nutrients and disease. 
However, effects of systematic errors on observed associations are generally 
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unpredictable and can bias the results of a study. Measurement errors when assessing 
diet with an FFQ can be derived by the fixed food list, by the memory abilities of the 
participants and by wrong interpretation of the food portions (for a semi-quantitative 
FFQ) (283;286).  
9.2.2.2 Diet validation 
As we described in the previous sections each diet assessment method has specific 
strengths and limitations. Whichever method is chosen, validation of its performance in 
assessing dietary intakes is required. In the following chapter, we will discuss about 
reproducibility and validity methods of the FFQ. 
Reproducibility 
Reproducibility of a questionnaire is estimated by administering the same questionnaire 
to a specific number of participants in two or more different occasions and then 
examining the consistency of the measurements. The interval between the two different 
administrations should be neither too short, since then participants will probably 
remember their previous responses, nor too long, since true changes in dietary habits 
may decrease the questionnaire’s reproducibility. Finally, whereas a questionnaire with 
low reproducibility should not be considered as a valid method of assessing long-term 
diet, a questionnaire with high reproducibility does not necessarily mean that is a diet 
assessment method of high validity (283). 
Reproducibility is also a way to account for the random measurement errors. For 
categorical variables, it is usually addressed by calculating the kappa or the weighed 
kappa statistic, which is equivalent to the measurement of the proportion of agreement 
between the measurements in the two different time points. For continuous variables, 
reproducibility is usually estimated by calculating the interclass correlation coefficient, 
which represents the reliability of a measurement (286).   
Validity 
On the other hand the relative validity of a questionnaire is estimated by comparing 
nutrient intakes measured by the FFQ with intakes measured using another diet 
assessment method (external standard method). It is preferred to use a method that its 
limitations (errors) are of different type than the errors produced by the FFQ. Usually, 
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the validation method that is used for an FFQ is diet assessment by Food Records, since 
these two methods have different types of limitations (FFQ: fixed food, frequency and 
portion questions, rely on memory, rely on the way a question is interpreted vs. Food 
Records: open-ended questions, do not rely on memory, no questions). However, in 
order to represent average dietary intakes, multiple Food Records need to be obtained. In 
addition, 24-hour Diet Recalls can be used to validate FFQs. Even though, these two 
methods share similar sources of measurement errors (both depend on memory), 
validation using Diet Recalls might be the only option in cases of illiterate or less 
motivated participants (283). 
Alternatively, an FFQ can be validated by comparing nutrient intakes estimated by the 
FFQ with measurements of an appropriate biomarker of the particular nutrient. The 
advantage of this validation method is that FFQ and biomarker errors are not correlated 
and therefore spurious validation results can be avoided. However, there are specific 
limitations of applying this validation method. In particular, usually biomarker levels of 
a particular nutrient do not depend only on dietary intakes, but also on other lifestyle 
choices, physiological characteristics and genetic variants. In addition, biomarker 
measurements are subject to laboratory and technical errors as well as to daily dietary 
intake variations. Generally, the effect of these limitations is to attenuate the correlations 
between the questionnaire and biomarker measurements, a fact that should be accounted 
for at the interpretation of the results. Finally, appropriate biomarkers are only available 
for a few specific nutrients and therefore, by applying this validation method intakes of 
several nutrients can not be validated (283).  
Validation studies are usually conducted in a subset of the study population and the 
usual size of the subset lies between 100 and 200 individuals. The two main methods 
that are used to assess the validity of the FFQ are calculation of the Pearson correlation 
coefficient (for normally distributed variables) and the Spearman rank correlation 
coefficient (for not normally distributed variables) between the FFQ and the validation 
method measurements. Alternatively, the kappa and weighed kappa statistics can be 
calculated in order to measure misclassification when measurements of both methods are 
divided into different intake categories. It has been suggested that: 1) correlations of 0.5-
Chapter nine  Discussion 
 360 
0.7 between the FFQ and the validation method’s measurements, 2) more than 50% of 
subjects classified in the correct category (tertile, quartile, etc.) and less than 10% of 
subjects classified into a wrong category (tertile, quartile, etc.) and 3) weighed kappa 
values above 0.4 indicate that the FFQ has the ability to correctly rank individuals 
according to their dietary intakes (270).  
9.2.2.3 Energy adjustment 
Analysis of nutritional observational studies require controlling for dietary energy intake 
in order to ensure that observed associations are not due to a higher or lower total energy 
intake between cases and controls. This requirement is more important when energy 
intake is highly correlated with both the nutrient under investigation and the disease. The 
main energy-adjustment methods are: the residual energy adjustment method, the 
standard multivariable method, the energy partition method, the nutrient density method 
and the multivariable nutrient density method. 
Residual energy adjustment method 
This method is based on the regression of the nutrient on total energy intake and then 
inclusion of the residuals of this regression in the model with disease as the dependent 
variable. This method has been thought to be an equivalent of a study that examines the 
effect of particular nutrients by keeping total energy intake constant. In the case that 
total energy intake is also an important and recognised risk factor of the disease, it has 
been suggested that total energy intake should also be included in the disease-model (as 
a co-variable together with the nutrient residuals variable). 
 
Standard multivariable method 
The standard multivariable method is based on the inclusion of total energy and the 
nutrient intakes in the same model. The residual energy adjustment method and the 
standard multivariable method give usually similar coefficients for the association 
between the nutrient and the disease. However, the main difference between these two 
models is about the interpretation of the coefficient of the total energy intake term. In the 
residual method the coefficient of this term represents the association between energy 
intake and the disease, whereas in the multivariable method the coefficient represents the 
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association between energy intake from other nutrients than the one under examination 
and disease.     
Energy partition method 
For the partition method of energy adjustment, energy intake from the nutrient under 
investigation and energy intake from other sources are entered in the model separately. 
Using this method, the association between the particular nutrient and the disease are 
protected from the confounding effect of energy intake from other sources. However, 
any observed association might be due to the energy contribution of the nutrient on the 
total energy intake. Another limitation of this method is that it can not be directly 
applied for nutrients that do not contribute to total energy intake.  
Nutrient density methods  
The simple nutrient density method is based on directly dividing the nutrient intakes 
with total energy intake. This is a convenient method that provides simplicity and 
practicality, especially when somebody needs to describe food or diets in a comparable 
way. However, this method does not protect from the confounding effect of total energy. 
In particular when energy intake is associated with the disease, then nutrient densities 
(nutrient/ total energy) tend to be associated with disease in the opposite way to total 
energy. On the other hand, if energy intake is not associated with the disease and it is 
only weakly correlated with the nutrient intakes, then by dividing nutrient intakes with 
total energy, variation might be added in the nutrient densities. Increased variation will 
be added to the nutrient densities, also when energy intake is measured inaccurately. A 
way to use the nutrient densities, without having to deal with the limitations mentioned 
above, is to include together total energy and nutrient densities as covariables in a model 
with disease as dependent variable (Multivariable nutrient density method).   
9.2.2.4 Strengths and limitations of the current study (issues 
regarding collection of nutritional, lifestyle and other data) 
Strengths 
Diet assessment, nutrient assessment and diet validation 
To assess dietary intakes in the current study a semi-quantitative FFQ listing 150 food 
items was employed (Scottish Collaborative Group FFQ, Version 6.41), which also 
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included images of portion sizes and careful instructions in order to improve accuracy of 
diet reporting. In addition, this questionnaire was developed for studies of diet and 
health in Scotland containing the vast majority of food items that are frequently 
consumed from the Scottish population. 
Further more, the nutrient databases that were used for estimating nutrient intakes were 
of UK (McCance and Widdowson's Composition of Foods) or Scottish level (flavonoid 
database). In addition, for some nutrients (e.g. specific fatty acids), food preparation and 
method of cooking (e.g. frying, grilling, oven-baking etc) could affect the amount of 
nutrient that was actually ingested. It is worth saying therefore that foods on this 
questionnaire were grouped with consideration of their fat content and method of 
cooking (e.g. oven chips are separate from home-cooked chips, and grilled fish is 
separate from fried fish). Furthermore, for foods which were home-cooked, the oil used 
for nutrient calculations was the one that was listed by the subject, whereas for foods 
cooked outside home an average of commonly-used fats was assumed. For bread, the 
spread(s) listed by the subject were used, taking into consideration the thickness of the 
spread (a scrape, a thin layer or a thick layer) as selected by the subject, with the aid of a 
colour photograph illustrating a thin layer.  
Relative validity of the current FFQ was also assessed by comparing its nutrient intakes 
(total energy, main macro- and micro-nutrients and flavonoid subgroups) with those 
obtained from 4-day weighed Diet Records, in a sample of 41 men (mean age 36 years 
old) and 40 women (mean age 33 years old) (270;271).  
Energy adjustment 
We tried to minimise the confounding effect of total energy by carefully adjusting each 
nutrient intakes using the residual method. The alternative standard energy adjustment 
method was used for nutrients that were not normally distributed (even after 
transformation), since linear regression (first step of residual energy adjustment) 
between the nutrient (dependent variable) and total energy (independent variable) could 
not be applied. 
Lifestyle and cancer questionnaire 
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Regarding the Lifestyle and Cancer Questionnaire, it was made up from questions from 
other standard questionnaires and we sought to employ validated instruments, where 
possible. In particular, the questions about physical exercise derived from the short 
version of the EPIC questionnaire. Reproducibility and relative validity of this 
questionnaire were checked in two different studies and it was found that although this 
physical activity index is not suitable for estimating energy expenditure at an absolute 
level, it can successfully rank participants according to their activity and cardio-
respiratory fitness (287;288). Regarding other parts of the Lifestyle and Cancer 
Questionnaire, the questions about Women’s reproduction history came from the Million 
Women Study’s Questionnaire and the Employment section was based on the Census 
2001 questions. 
Limitations 
We attempted to limit the common problems of nutritional epidemiology by adopting 
identical study procedures in cases and controls, use of validated questionnaires, use of 
images of portion sizes, use of careful instructions to improve accuracy of reporting diet 
and lifestyle habits and adoption of a recall period one year before diagnosis or 
recruitment date to reduce recall bias. However, recognised limitations of case-control 
studies employing questionnaires including recall bias, misclassification bias due to 
imprecise measurements (random measurement errors) and residual confounding after 
attempts to control for confounders might have affected the current study.  
Diet assessment, nutrient assessment and diet validation 
Variation due to random measurement error tends to attenuate the true associations 
between the risk factor and colorectal cancer risk, a bias called regression dilution. In 
order to account for regression dilution bias, dietary and other measurements should be 
obtained more than once for at least a subsample of the study sample. Interclass 
correlation coefficients between measurements can then be used to adjust the regression 
coefficients. In our study, dietary measurements were obtained only once for the 
majority of the study participants, whereas we obtained a second measurement of the 
diet for 44 population controls. The size of the subsample with duplicate dietary data 
was not large enough to accurately estimate the size of random measurement error and 
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to check the reproducibility of the questionnaire. Given the available resources, we were 
not able to collect duplicate data for more population controls and therefore we were not 
able to correct the regression coefficients for the effect of regression dilution bias. 
However, this type of error would have probably led to reporting underestimated rather 
than biased associations.  
Regarding the FFQ validation studies, we cannot be sure of the exact validity of the 
estimate of nutrient intakes in our age group as the validity study was carried out in 
younger subjects (270). Furthermore, results of validation of this FFQ for ranking 
individuals according to specific fatty acid intakes were not available at the time that 
analysis of this thesis was conducted.  
Energy adjustment 
Regarding confounding, although adjusting for energy by using the residual method 
should have reduced the confounding effect of total energy, probably it would not 
eliminate it, since measurements of both energy and the nutrient would be subject to 
measurement error. On the other hand, for nutrients highly correlated with total energy 
intake, such as fatty acid intakes, the application of the residual adjustment method 
could have led to over-adjustment and this could have masked significant associations 
between these nutrients and colorectal cancer. In order to investigate this further, 
associations between colorectal cancer and intakes of subgroup and individual fatty 
acids obtained from multivariable logistic regression models (model III) using different 
energy adjustment methods were compared (residual, standard, simple nutrient density 
and multivariable nutrient density methods). Models using either method of energy 
adjustment produced similar findings, with high intakes of ω3PUFAs, EPA and DHA 
being associated with a statistically significant and dose-dependent decreased colorectal 
cancer risk. However, associations derived from models using the multivariable nutrient 
density method were slightly stronger with lower p-values. The only difference between 
findings after applying different energy adjustment methods was for stearic acid intakes. 
In particular, high intakes of stearic acid were found to be significantly and dose-
dependently associated with an increased colorectal cancer risk, when applying the 
residual, the standard and the simple nutrient density methods, but not when applying 
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the multivariable nutrient density method. Regarding the other fatty acid subgroups and 
individual compounds, there were no differences in the observed associations no matter 
what energy adjustment method was used. 
 Lifestyle and cancer questionnaire 
Regarding the Lifestyle and Cancer questionnaire, measurements were also obtained 
only once and therefore random measurement errors due to within-subject variation 
could not be estimated and reproducibility of the questionnaire was not measured. In 
addition, a limitation of the occupational part of the physical activity questionnaire was 
that it was designed for younger individuals than the participants of the current study 
with no proper separation for retired and unemployed individuals. Therefore, the retired 
participants of our study were misclassified as unemployed and their occupational 
physical activity was not reported (48% of the cases and 47% of the controls were 
classified as unemployed; Table 42). In order, to account for this limitation, we decided 
not to use data on occupational physical activity and use a physical activity measurement 
based only on leisure time activities. In addition, in order to reduce the number of 
individuals that should be omitted due to missing data, we chose to use information only 
for two leisure time activities: cycling and other physical exercise. It has been suggested, 
that higher-intensity physical activities are reported with greater accuracy (288) and 
therefore we believe that this limited physical activity measurement will be an 
acceptable approximation of the general physical activity status of the study participants 
for the purposes of providing a rank distribution of physical activity in the study sample. 
9.2.3 Issues on applied analytical methods 
In this section, we will briefly describe the main issues about the applied analytical 
methods and the way they could have influenced the results of the current thesis. In 
particular, issues regarding the power of the study (matched and unmatched dataset), the 
effect of multiple testing and the stepwise regression methods will be presented.  
9.2.3.1 Power calculation 
Power, sample size and hypothesis tests 
“The power of a test is equal to the probability that a study of a given sample size can 
detect an effect size of a particular magnitude as statistically significant” (definition 
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taken from (289)). In order to calculate the power of a test we need to know the level of 
significance (α, usually 0.05), the size of the study and the size of the effect that we want 
to detect. The power calculation can be carried out either a priori (during the design 
stage of the study) or post hoc (after the end of the study). A priori power analysis is 
usually preferable, since it determines from the beginning the scale of effect sizes the 
particular study can detect. Post hoc power analysis is usually conducted in order to 
explain the inability of a particular study to detect statistically significant results. The 
power of a test can be increased by: 1) increasing the sample size, 2) increasing the 
significance level (i.e. from α=0.05 to 0.10), 3) aiming to detect larger effect sizes and 4) 
decreasing the measurement error (and therefore decreasing the standard deviations) 
(286). 
Power calculations of the current study (matched and unmatched 
datasets) 
As it has been already described, in the end of the study 2,062 cases and 2,776 controls 
had complete and valid FFQ and LCQ data and could be included in the analysis 
(unmatched dataset). However, for some cases no controls that fulfilled all the matching 
criteria were identified. Therefore, when the fine matching was kept 573 cases needed to 
be excluded from the analysis, leaving the matched dataset with 1,489 cases and 1,489 
controls.   
Power calculations were conducted using the software NQuery Advisors (version 6.0). 
The formulas that the power calculations were based on are presented in Appendix V. 
The matched dataset of 1,489 pairs of cases and controls had a 97% power to detect an 
effect size of 0.1 per SD at a significance level of 0.05 (paired 2-sided t-test). On the 
other hand the unmatched dataset (2,062 cases and 2,776 controls) had a 93% power to 
detect an effect size of 0.1 per SD at a significance level of 0.05 (student’s 2-sided t-
test). In addition, power calculations for weak, moderate and strong effect sizes 
(measured by the OR) showed that the matched dataset of 1,489 pairs of cases and 
controls had 44%, 78% and more than 99% power to detect ORs of 0.93, 0.85 and 0.43, 
respectively (McNemar’s chi-square test). On the other hand, the unmatched dataset of 
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2,062 cases and 2,776 controls had 27%, 78% and more than 99% power to detect ORs 
of 0.93, 0.85 and 0.43, respectively (normal chi-square test). 
Therefore, according to the above calculations, the matched analysis had slightly greater 
power to detect weaker associations, whereas both the matched and unmatched dataset 
had the same power to detect moderate and strong associations. Even if a study with a 
44% power is not considered as sufficiently powered to detect a particular effect size, we 
decided to use the matched dataset for the analysis of the first two hypotheses 
(flavonoids and fatty acids), in case the associations between these novel dietary risk 
factors and colorectal cancer were weak. For the analysis of the additional risk factors 
(folate, vitamin B2, vitamin B6, vitamin B12, alcohol, vitamin D and calcium), where 
we expected slightly larger ORs we chose to use the unmatched dataset. The main 
reason for this choice was that we wished to include all cases with environmental and 
genetic data, since for the additional hypotheses specific gene-environment interactions 
as well as stratified analyses according to genotypes of particular SNPs were selected to 
be investigated. 
9.2.3.2 Multiple testing 
Multiple testing methods 
The possibility of finding significant results by chance increases, when in a single 
dataset multiple tests are performed (Type I error). Therefore it is necessary to correct 
the p-value significance level according to the number of performed tests. Different 
types of multiple testing correction have been developed and they can be roughly 
divided in the traditional methods and a more recent alternative one, known as the False 
Discovery Rate (FDR) method (290).   
Bonferroni correction and similar methods 
The Bonferroni method is the most simple though the most conservative method and it is 
based on setting a new level of significance by dividing the initial p-value level (α, 
usually 0.05) with the total number of tests performed (new p-value threshold = α/n, 
where n is the total number of performed tests). The null hypotheses are then rejected 
according to the new significance level. Similar methods based on the Bonferroni 
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method have been developed, which tend to be less conservative (e.g. the Holm’s 
method, the Hochberg’s method) (290).  
False discovery rate 
A quite different and far less conservative approach was introduced by Benjamini and 
Hochberg in 1995. The method was based on the fact that false positive results will 
occur in every study, but they tried to develop a method that identifies false positives 
without failing to reject false null hypotheses. This method is a three-step procedure, 
with the first step being the ascending ranking of the k observed p-values. The adjusted 
level of significance is then calculated separately for each p-value according to the 
formula: α*i/k, with i=1, 2, 3, …, k (the ranking position of the unadjusted p-value). 
Finally, each null hypothesis, for which corresponding unadjusted p-value is smaller 
than the new individual significance level, is rejected (290;291). 
Multiple testing corrections in the current study 
Part 1 of the study (aim 1, hypotheses 1-4): Bonferroni correction and FDR 
For the first part (aim 1, hypotheses 1-4) of the current study, we corrected the observed 
p-values for multiple testing using the Bonferroni correction in three different ways. 
Initially, the p-values were corrected according to the number of the performed 
independent tests (of the current and previous hypotheses). In particular, for the analysis 
of the first hypothesis (flavonoids), p-values were corrected for six independent tests 
(new level of significance 0.008); for the analysis of the second hypothesis (fatty acids) 
p-values were corrected for 14 independent tests (new level of significance 0.004); for 
the analysis of the third hypothesis (folate, vitamin B2, vitamin B6, vitamin B12 and 
alcohol) p-values were corrected for 19 independent tests (new level of significance 
0.003); and finally for the analysis of the fourth hypothesis (vitamin D and calcium) p-
values were corrected for 21 independent tests (new level of significance 0.002). 
The second way that was used in order to account for multiple testing was by adjusting 
the p-values according to the number of tests conducted in each hypothesis (using both 
the Bonferroni correction and the less conservative FDR method). In particular, for 
hypothesis 1, we corrected the flavonoid subgroup p-values for 30 tests and the 
individual flavonoid p-values for 25 tests. For hypothesis 2, we corrected the fatty acid 
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subgroup p-values for 39 tests and the individual fatty acid p-values for 45 tests. For 
hypothesis 3, we corrected the observed p-values for 15 tests and finally, for hypothesis 
4, we corrected the observed p-values for eight tests. 
Finally, the third way that we used in order to correct for the number of performed tests 
was to correct for the total number of tests performed in all four hypotheses, applying 
both the Bonferroni and the FDR method. In the subgroup level, we corrected for 69 
independent tests, whereas in the individual nutrient level we corrected for 93 tests. 
Part 2 of the study (aim 2, overall and stepwise regression analysis) 
The purpose of the overall and stepwise analysis was not to draw any specific 
conclusions about the strength of the associations between the risk factors and colorectal 
cancer. Instead, the purpose was to identify risk factors that seemed to be associated 
with the disease in order to generate new hypotheses, which could be then properly 
checked in other prospective or retrospective studies. Therefore, we thought that we 
would not need to correct for multiple testing, but we would take care to interpret these 
present findings appropriately within this context. 
9.2.3.3 Stepwise regression  
Forward and backward stepwise regression 
The simplest data-driven model building approach is the forward stepwise regression. In 
this approach, variables are added to the model one at a time, and at each step each 
variable that is not already included in the model is tested for inclusion. The most 
significant of these variables is added to the model, as long as its p-value is below some 
pre-set significance level. Thus the first variable to be included in the model is the one 
that was the most significant in the initial analysis. The procedure of adding variables 
continues until all the variables are added in the model or none of the remaining 
variables has a p-value below the pre-set level when added to the model (292). 
However, forward stepwise regression has drawbacks, including the fact that each 
addition of a new variable may render one or more of the already included variables 
non-significant or that one variable might be significantly associated with the outcome 
only when a group of other variables is also in the model. An alternative approach, 
which avoids these limitations, is backward stepwise regression. Under this approach, all 
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the variables of interest are fitted in the model and the least significant variable is 
dropped, as long as it is not significant at our chosen pre-set significance level. Reduced 
models are successively re-fitted and the same rule is applied until all remaining 
variables are statistically significant. Backward stepwise regression has also drawbacks. 
For instance, variables that may be dropped could have been significant if added to the 
final reduced model. In addition, backward stepwise regression should not be used when 
the sample size is small considering the number of independent variables that are 
included or when there might be issues of multicollinearity. Since in backward stepwise 
regression all variables are included in the initial model, an unstable initial model (either 
due to small sample size or multicollinearity) might produce spurious results (292). 
In general both forward and backward stepwise regression methods are not used in cases 
when there is a clear hypothesis with already selected confounding factors. In contrast, 
they are mainly used in two other research settings: 1) To predict the likelihood of a 
particular outcome using several explanatory variables, when the predictive accuracy of 
the constructed model is more important than the risk factors that were chosen to be 
entered in the model; 2) To construct regression models that generate new hypotheses 
(explanatory analysis), which can then be tested as prior hypotheses in future studies 
(293). However, the models that derive from stepwise regression will possibly contain 
either variables, for which associations with the outcome are genuine or variables that 
have wrongly been identified as significant risk factors of the outcome (false positives). 
Therefore, to draw specific conclusions and to avoid reporting spurious findings, it is 
necessary to investigate the accuracy of the models, which are produced, either by 
comparing the final model with other models reported in the literature or by validating it 
in an independent dataset (293). 
Bootstrap sampling method 
An alternative method to explore the stability of the selected model is to apply the 
bootstrap sampling method. A bootstrap sample is a sample of the same size as the 
original sample chosen with replacement. Thus, a given subject in the original sample 
may occur multiple times, only once, or not at all in a specific bootstrap sample. This 
method is commonly used to estimate the sampling distribution of a particular test 
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statistic. In 2004, Austin and Tu proposed to use bootstrap sampling in order to evaluate 
the models produced by either forward or backward stepwise regression, by estimating 
the likelihood that a candidate variable is indeed an independent risk factor for a 
particular outcome (294). 
Application of stepwise regression and bootstrap sampling method in the 
current study 
In the current study we applied forward and backward stepwise regression models in 
three different sets of variables in the whole sample and after sex stratification, in order 
to investigate which of the explanatory factors were more strongly associated with 
colorectal cancer. All three sets included the main demographic and lifestyle variables. 
In addition, set 1 included food variables, set 2 included nutrient variables and set 3 
included both food and nutrient variables. However, as already mentioned the goal of 
this part of the study was not to draw any specific conclusions about the risk factors 
identified, but instead to generate new hypotheses that could be studied in more detail in 
future observational studies.   
Having identified the instability and general limitations of the stepwise regression 
models, we tested the reproducibility of the selected models by applying the bootstrap 
sampling method in the whole sample. One hundred bootstrap samples were selected 
and on each one forward and backward stepwise regression models were applied. 
Findings of the above analysis will be discussed in detail below. 
Usually, when the bootstrap sampling method is employed, at least 1,000 to 10,000 
bootstrap samples are produced. Therefore, the number of 100 bootstrap samples that 
was used in the current study is possibly not large enough to draw any specific 
conclusions about the stability of the selected models. However, the computing power 
and available time, when this thesis was conducted, did not allow us to perform this 
analysis in a larger number of samples. For future purpose and beyond the scope of the 
current PhD study we are planning to write a specific programme to perform the 
bootstrap sampling analysis in 1,000 to 10,000 samples. 
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9.3 Main findings 
In this part of this chapter the main findings of the hypothesis driven analysis as well as 
of the overall and stepwise regression analysis will be discussed. In addition, results of 
the current study will be presented in relation to previous findings of other studies. 
9.3.1 Main findings of part 1: Hypothesis driven analysis 
9.3.1.1 Introduction 
In this part of the chapter the main results of the matched analysis of the novel dietary 
risk factors (flavonoid and fatty acid subgroups and individual compounds) that 
comprised the first two hypotheses, and the main results of the unmatched analysis of 
the additional dietary risk factors (folate, vitamin B2, vitamin B6, vitamin B12, alcohol, 
vitamin D and calcium) that comprised the last two hypotheses, will be presented and 
discussed. 
In addition, results of this study will be compared with findings from previous studies in 
order to investigate the current causal evidence for each particular nutrient. As it has 
been suggested by Hill (295), to draw causal conclusions for a particular risk factor, nine 
criteria should be fulfilled that are related to: 
1) Consistency of association across populations, study designs and statistical methods; 
2) Strength of association (with a 20% change in risk to be considered as a positive 
association and a more than 40% change to be considered as a strong association); 
3) Dose response (with greater amounts of a substance giving more protection/ risk and 
less amounts less protection/ risk); 
4) Biological plausibility (i.e. existence of a plausible biological mechanism that 
explains an observed association; evidence usually collected from animal, in vitro and 
clinical studies); 
5) Temporality (with the exposure to the risk factor preceding the onset of the disease); 
6) Experimentation (i.e. evidence from randomised clinical trials); 
7) Analogy (i.e. similar associations to be observed for similar diseases); 
8) Specificity (i.e. the particular risk factor raises the risk of the particular disease and 
not generally of any disease); 
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9) Coherence (i.e. the possibility of causation of one risk factor is in accordance with 
other known facts).  
However, in nutritional epidemiology a subset of the above criteria (consistency, 
strength, dose response, biological plausibility and temporality) is usually used in order 
to form specific nutrition recommendations and to draw causal conclusions. In addition, 
failure to fulfil a particular criterion does not always reflects to a lack of an association 
(296). In particular, lack of consistency might be due to different levels of intakes across 
the studies or due to noncomparability of the dietary assessment methods. Weak 
associations might be due to attenuation of true stronger effects by measurement errors. 
Lack of dose response might be due to lack of variation of intake or due to a threshold 
effect. Biological plausibility can not be always ascertained especially for novel dietary 
factors or for diseases that are not well described. Finally, temporality is sometimes 
difficult to be established. For cohort studies exposure assessment precedes the 
diagnosis, but it is possible that disease was already present when long latency diseases 
(e.g. cancer) are investigated. On the other hand, in case-control studies diagnosis 
precedes exposure assessment and therefore cases and controls are asked to report their 
dietary habits for a specific time period before diagnosis. However, for diseases of long 
latency, this time period might not be long enough. If evidence for the association 
between a particular dietary factor and a disease is in conflict with all five criteria, then 
public recommendation and causal conclusions for this dietary factor are not suggested. 
On the other hand, if evidence is in accordance with all five criteria then one can argue 
that this particular dietary factor is likely to be causally related with the disease and a 
public recommendation regarding its intake is desirable. However, it is unlikely in 
nutritional epidemiology to report a perfect agreement or disagreement with all five 
criteria and sometimes dietary recommendations can be made even if some of the 
aforementioned criteria are not perfectly fulfilled (296). 
9.3.1.2 Flavonoids 
Introduction 
The recent increase in published data on flavonoid content of foods has 
enabled the development of databases which can be linked to FFQs and provided us with 
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the opportunity to investigate the flavonoid chemoprotective effects, which have been 
reported in vitro and animal in vivo studies. In this study the 150 foods listed in the FFQ 
included all the most important sources of flavonoids. A number of different foods 
contributed to the intake of the five flavonoid subgroups and phytoestrogens in our study 
and the results were not determined by one major food category (major sources 
included: regular tea, onions, soups- home made, apples, oranges, satsumas or 
grapefruits and soya milk; Table 67). In addition, the main sources found in our 
population were similar to the main sources found from the flavonoid validation study 
(274). Median and range estimations of flavonoid intakes in the Scottish population as 
they were estimated from the 4-day weighed record data validation study (271), were:  
18.9 mg/day (range: 1.9 - 58.0 mg/day) for flavonols and flavones, 59.0 mg/day (range: 
1.8 - 263.3 mg/day) for flavan3ols, 22.5 mg/day (range 0-144.5 mg/day) for 
procyanidins and 1.2 mg/day (range: 0 – 238.6 mg/day) for flavanones. Finally, the 
estimates of this FFQ for flavonol, flavan3ol and procyanidin dietary intakes have been 
shown to be strongly correlated (r=0.70, 0.94 and 0.73 respectively) with 4 day weighed 
record estimates in the Scottish population, whereas FFQ estimates for flavones and 
flavanones were only poorly correlated (0.12, 0.33, respectively) (271). 
Main findings 
Regarding the main findings of the flavonoid analysis of the current thesis, whereas no 
statistically significant associations were observed in the crude model (model I), 
moderately strong inverse associations that showed dose response relationships were 
found in the energy-adjusted conditional logistic regression model II between colorectal 
cancer risk and intakes of the subgroups flavonols (p=0.02) and procyanidins (p=0.04) 
and the individual flavonoid compounds quercetin (p=0.002), catechin (p=0.0001) and 
epicatechin (p=0.04) (Table 68). After adjusting for the main potential confounding 
factors (model III), only the inverse associations between colorectal cancer and intakes 
of quercetin (p=0.04) and catechin (p=0.02) remained statistically significant (Table 68). 
We investigated the existence of collinearity effects by correcting for overall fruit and 
vegetable intake and for intakes of other individual flavonoids and the observed 
associations became more clearly defined (especially for model V, which was further 
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corrected for intakes of other flavonoids) (Table 69). According to our results the 
direction of the associations of flavonols, procyanidins, quercetin, catechin and 
epicatechin remained similar in all four models, although the effect sizes changed. It is 
difficult to be certain about which model shows the true associations, since there is 
limited knowledge on the biological mechanism of flavonoids. Therefore it might be 
possible that the very strong associations reported in model V were due to instability 
because of the highly correlated variables. 
After correcting for multiple testing using either the Bonferroni or the FDR method, the 
inverse associations that remained significant were: with catechin (p=0.0001) and 
quercetin (p=0.002) in model II (Table 68) and with flavonols (p=0.0001) and catechin 
(p=0.007) in model V (Table 69). Therefore for the flavonoid subclass flavonols and for 
the individual compounds quercetin and catechin the direction of the associations 
remained constant in all five models and in addition their associations with colorectal 
cancer remained statistically significant after correcting for multiple testing.  
In marked contrast there were no statistically significant associations between colorectal 
cancer and intakes of the other four of the six flavonoid subgroups (flavones, flavan3ols, 
flavanones and phytoestrogens; Table 68, Table 69). The association with catechin and 
epicatechin but the lack of association with the flavan3ol subgroup (comprising 
catechin, epicatechin and gallates) may be explained by our inability to study the other 
main representatives of flavan3ols – the gallates (epigallocatechin, epicatechin-3 gallate, 
epigallocatechin-3 gallate, and gallocatechin) as described previously. The lack of 
association between colorectal cancer and the other three subgroups (flavones, 
flavanones and phytoestrogens) could be explained by different biological action of 
these flavonoid subgroups, limited dietary sources (celery and herbs for flavones, citrus 
fruit for flavanones and soya products for phytoestrogens), low levels of dietary intake 
of these subgroups in Scotland across all population groups (e.g. soya and soya products 
are not commonly consumed in Scotland) leading to insufficient variation in intake 
across the population to permit their study, or less complete nutritional database 
information on these subgroups leading to greater misclassification and loss of study 
power. In addition, results from the flavonoid validation study showed that FFQ 
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estimates for flavones and flavanones did not correlate closely (r=0.12 and 0.33, 
respectively) with results from 4 day weighed records (271) and so interpretation of the 
findings for these compounds is problematic and results may represent false negative 
findings. 
We also explored associations between colorectal cancer risk and the intakes of foods 
that were the main sources of the flavonoids with statistically significant associations 
(regular tea, onions, apples and red wine). Comparison of the highest versus the lowest 
quartile of intake of these foods suggested that there is some evidence in favour of an 
inverse association but this is less well defined than in the analysis of the association of 
flavonol, procyanidins, quercetin, catechin or epicatechin intakes and colorectal cancer 
risk (Table 70). 
Findings from the current study in relation to previous studies 
Most of previous cohort studies reporting associations between colorectal cancer and 
flavonoids were either much smaller in scale (118;128;129;134) or did not investigate all 
six subgroups of flavonoids (125;132;133;139) (Table 4). In a recent analysis of the 
Iowa Women’s Health study, associations between the main subgroups (flavonols, 
flavones, flavan3ols, anthocyanidins, procyanidins, flavanones and isoflavones) and 
incidence of several types of cancer (including colorectal) were examined, but neither 
intakes of total flavonoids nor intakes of any of the main subgroups were found to be 
significantly associated with colorectal cancer (131). 
On the other hand, three of the four identified case-control studies reported significant 
inverse associations between flavonoid subgroups or compounds and colorectal cancer 
(Table 5). The Canadian and Chinese case-control studies examined the associations 
between colorectal cancer and only specific flavonoids, with the Canadian study 
reporting statistically significant and dose-dependent associations with lignans, 
isoflavones and phytoestrogens (137;138). In the Italian case-control study the effect of 
the main six flavonoid subgroups was examined and the authors have reported a 
significant inverse association for flavonols, flavones, anthocyanidins, and isoflavones 
(135). Associations between colorectal cancer and intakes of flavonols and 
anthocyanidins were similar in strength to the associations reported from the current 
Chapter nine  Discussion 
 377 
study (results published in (136)). However, the inverse association for flavones and 
isoflavones, which was reported in the Italian case-control study, was not replicated 
from our study. This may be due to the lower validity of our questionnaire for flavones 
and the fact that we studied phytoestrogens rather than isoflavones which represent a 
subgroup of phytoestrogens. In addition the main differences between our and the Italian 
study were that the controls that were included in our study were closely matched 
population-based rather than hospital-based controls. In addition FFQ flavonoid 
estimations were calculated from a nutrient database developed for this study 
population, whereas in the Italian study the flavonoid database of U.S. Department of 
Agriculture was utilised (135). 
Some animal and cell-line studies have reported chemoprotective effects of flavonoids, 
with possible biological mechanisms being inhibition of DNA oxidation (297;298), 
alteration of phase I and II drug metabolising enzymes (299-301), inhibition of protein 
kinases, blocking of receptor-mediated functions, alteration of cell-cycle checkpoints 
apoptosis, inhibition of angiogenesis, invasion and metastasis and epigenetic changes in 
promoter methylation and chromatin remodelling (302). An alternative theory for the 
protective effect of flavonoids is through their regulation of the COX-2 gene. Increased 
expression of COX-2 enzyme provides survival advantage to cancer cells through high 
cell proliferation and angiogenesis. Results from recent laboratory and mechanistic 
studies show that flavonoids inhibit the expression of COX-2 both on mRNA and 
protein levels by inhibit signalling of the ERK and Akt pathways (303). 
For quercetin in particular, which is the major representative of flavonols in diet, several 
animal and cell line studies have demonstrated that it might have certain 
anticarcinogenic effects. Possible mechanisms of actions might be the inhibition of the 
β-catenin/ Tcf signalling via the decrease of nuclear β-catenin/ Tcf-4 proteins (304). In 
other studies quercetin has been found to inhibit cell growth and to induce apoptosis in 
colon cancer cells, by downregulating the Akt pathway and  ErbB2/ ErbB3 (receptor 
tyrosine kinases) signalling (305;306). 
Summary 
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A few observational studies have investigated the associations between colorectal cancer 
and intakes of flavonoids. The null and inconsistent findings from cohort studies 
provided no evidence for an inverse association. However, the majority of the cohort 
studies were possibly underpowered to detect a significant association (<150 cases). On 
the other hand, results from case-control studies were more consistent reporting 
statistically significant and dose dependent associations of moderate strength for some 
flavonoid subgroups. In addition, there is some biological evidence mainly supporting 
the inverse association with flavonols (and quercetin in particular). However, taking into 
consideration the null findings from the cohort studies, conclusions of a causal effect of 
flavonoids can not be drawn and their associations with colorectal cancer should be 
further studied in large prospective studies.  
9.3.1.3 Fatty acids 
Introduction 
Results from ecological studies indicated that fats from different sources might affect 
colorectal carcinogenesis in opposite directions, with diets high in animal fat increasing 
colorectal cancer risk and diets high in fish-derived fat reducing risk (146). The 
development of a database, which was linked to the FFQ used in the current study, 
enabled us to investigate how different types of fatty acids are associated with colorectal 
cancer. All the main food sources of the fatty acids were included in the 150-item FFQ 
list, and each food and drink item was assessed, manually checked and corrected in 
order to estimate its fatty acid contribution. A number of different foods contributed to 
the intake of the fatty acid subgroups and the results were not determined by one main 
food category (major sources included: meat and meat products, spreads and cooking 
oils, fish and fish dishes and confectionery and savoury snacks; Table 74). Median and 
range estimations of fatty acid intakes in the Scottish population as they were estimated 
from the population-based controls that participated in the current study were: 80.0 
mg/day (62.5 - 105.3 mg/day) for total FAs, 34.7 mg/day (26.5 - 46.8 mg/day) for SFAs, 
30.6 mg/day (23.2 - 40.5 mg/day) for MUFAs, 13.8 mg/day (10.4 - 18.1 mg/day) for 
PUFAs, 10.5 mg/day (7.8 - 14.0 mg/day) for ω6PUFAs, 2.2 mg/day (1.6 - 3.0 mg/day) 
for ω3PUFAs, 3.3 mg/day (2.4 - 4.5 mg/day) for tFAs and 2.6 mg/day (1.8 - 3.4 mg/day) 
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for tMUFAs (Table 72). In addition, nutrient data from supplements were extracted for 
the subgroups ω6PUFAs and ω3PUFAs and the individual compounds linoleic, γ-
linolenic, α-linolenic, EPA and DHA and they were added to the daily dietary intakes 
(after energy adjustment) of total FAs, of the subgroups PUFAs, ω6PUFAs and 
ω3PUFAs and of the individual fatty acids linoleic, γ-linolenic, α-linolenic, EPA and 
DHA. Finally, we can not be sure about the accuracy of the FFQ estimates for the 
intakes of the specific fatty acid subgroups and individual compounds since this 
validation had not been finished by the time the thesis was written. However, the FFQ 
estimates of saturated, mono-unsaturated and poly-unsaturated fat have been compared 
with 4 day weighed record estimates in the Scottish population and the Spearman rank 
correlations were: 0.59, -0.07 and 0.36 for men, and 0.71, 0.58 and 0.66 for women, 
respectively (270). 
Main findings 
Regarding the main findings of the fatty acid analysis of the current thesis, in the crude 
model high intakes of total FAs, SFAs, MUFAs, ω6PUFAs, tFAs, tMUFAs and the 
individual fatty acids palmitic, stearic and oleic were associated with an increased 
colorectal cancer risk (Table 75). After residual energy-adjustment (model II) a dose-
dependent increase in risk was observed for intake of total FAs (p=0.001), SFAs 
(p=0.001), MUFAs (p=0.01) tFAs (p=0.002) and tMUFAs (p=0.0003) and for the 
individual fatty acids palmitic (p=0.001), stearic (p=7.9x10
-6
) and oleic (p=0.001). In 
contrast, significant inverse dose-dependent associations were observed between 
colorectal cancer and the dietary intakes of the fatty acid subgroup ω3PUFAs (p=9.3x 
10
-6
) and the individual compounds EPA (p=0.0001) and DHA (p=0.0002) (Table 75). 
However after further adjustment for potential confounding factors (model III), only the 
positive association between colorectal cancer and stearic acid (p=0.01) and the inverse 
associations between colorectal cancer and dietary ω3PUFAs (p=0.01), EPA (p=0.02) 
and DHA (p=0.02) remained significant (Table 75). Fatty acid intakes are highly 
correlated with dietary energy intake and as suggested by Willet to adjust more 
efficiently for energy intake, dietary energy intake was also added as a covariable 
together with the residually energy-adjusted variables and the potential confounding 
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factors (model IV). In that model only intakes of stearic acid were positively associated 
with colorectal cancer, whereas intakes of ω3PUFAs, EPA and DHA were negatively 
associated with colorectal cancer (Table 76). In marked contrast, the subgroup of 
PUFAs, and the individual fatty acids linoleic, γ-linolenic, arachidonic and α-linolenic 
were not associated with colorectal cancer risk in any of the adjusted logistic regression 
models (Table 75, Table 76). After correcting for multiple testing using the FDR method 
and taking into account either the tests that were conducted in hypothesis 2 (39 tests for 
the subgroup analysis and 45 tests in the individual compound analysis), or taking into 
account the tests that were conducted in all 4 hypotheses (69 tests for the subgroup 
analysis and 93 tests in the individual compound analysis) all the associations between 
the dietary intakes and colorectal cancer that their observed p-values were ≤0.01 
remained significant (Table 75, Table 76). 
Furthermore intakes of fatty acids from dietary supplements and diet were investigated 
for the following variables: total FAs, ω6PUFAs, ω3PUFAs, linoleic, γ-linolenic, α-
linolenic, EPA and DHA and the reported associations were of similar direction and size 
as for the dietary variables (Table 75 and Table 76). Finally, we also explored 
associations between colorectal cancer risk and the intakes of the foods that were the 
main sources of the fatty acids with the significant associations (meat and meat products, 
confectionery and savoury snacks, fish and fish dishes). Results showed that comparison 
of highest versus lowest quartile intakes of confectionery and savoury snacks (main 
sources of tFAs and tMUFAs) were associated with an increased risk of colorectal 
cancer (model III: p=0.002), whereas high intakes of fish and fish dishes (main source of 
ω3PUFAs) were associated with a decreased colorectal cancer risk (model III: p=0.07) 
(Table 77). Associations between colorectal cancer and the food group spreads 
(including butter, margarine, jam, honey, marmalade, yeast or meat extract, peanut 
butter, and chocolate spread) were not investigated. The main reason was that intakes of 
margarine and cooking oils, which would be the food items of this food group that 
contributed the most in fatty acid intake, could not be estimated.  
Findings from the current study in relation to previous studies 
Saturated and mono-unsaturated fatty acids 
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It has been suggested that red and processed meat (one of the main sources of saturated 
and mono-unsaturated fat) as well as animal fat (which consists mainly of cholesterol, 
saturated and mono-unsaturated fat), may increase colorectal cancer risk (30). However, 
results from studies included in our literature review, which investigated the associations 
between saturated fat (or SFAs), mono-unsaturated fat (or MUFAs) and colorectal 
cancer provided little evidence that these particular types of fat are linked with colorectal 
cancer risk (Table 6, Table 7, Table 8, and Table 9). The reported associations from the 
majority of the studies were with energy-adjusted variables. Therefore the lack of 
statistically significant associations might be due to the fact that both saturated and 
mono-unsaturated fats are highly correlated with dietary energy intake with energy 
adjustment causing fat intakes to be over-controlled for. Findings of the current study 
suggest that there might be a positive association between colorectal cancer and intakes 
of SFAs and MUFAs, however these associations were diluted in the multivariable 
models.  
Regarding potential biological mechanisms of SFAs and MUFAs affecting colorectal 
carcinogenesis, experimental data support the hypothesis of an increased colorectal 
cancer risk due to high intakes of SFAs. Some of the reported tumour enhancing effects 
of SFAs include alteration of the hormonal status and modification of cell membranes 
structure and function (307). On the other hand, experimental data regarding the effect 
of MUFAs are not as conclusive. In particular it has been shown that MUFAs and 
especially oleic acid may enhance oxidative stress and/ or disturb the membrane 
enzymes. However, oleic acid has also been found to improve the secondary bile acid 
patterns in the colon, which probably leads to a decreased colorectal cancer risk (142). 
The current and previous studies do not support a direct effect of SFAs and MUFAs on 
colorectal cancer (after adjustment for various confounding factors). However, these two 
types of fat are mainly found in red and processed meat and they also contribute greatly 
to the dietary energy intake. Increased intakes of red and processed meat as well as of 
dietary energy have been linked to colorectal carcinogenesis. Particularly for red and 
processed meat public recommendations for low intakes have been made (30). Therefore 
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high intakes of SFAs or MUFAs should still be considered as important risk factors for 
colorectal carcinogenesis. 
Omega-3 and omega-6 poly-unsaturated fatty acids 
Regarding the two classes of PUFAs, ω3 and ω6, it has been suggested that they play an 
important though opposite role in colorectal carcinogenesis, with ω3PUFAs decreasing 
and ω6PUFAs increasing colorectal cancer risk (169). Regarding previous studies on 
ω3PUFAs, the results of a recent systematic review of clinical trials and cohort studies 
for their effect on cardiovascular risk and cancer indicated that these fatty acids have no 
effect on either diseases (308). However, the design of the systematic review had several 
limitations (309). With respect to cancer most of the studies had very small numbers of 
cancer cases and did not distinguish between types of cancer. The two largest studies 
(310;311) were originally designed to examine the effect of ω3PUFAs on cardiovascular 
mortality and did not have cancer as a primary study outcome. Results from a recent 
meta-analysis of prospective studies that investigated the associations between fish (19 
prospective studies) and/ or marine ω3PUFA intakes (three prospective studies) and 
colorectal cancer, suggested a statistically significant inverse association between fish 
intake and colorectal cancer (combined RR (95% CI): 0.88 (0.78, 1.00)), and a not 
statistically significant inverse association between marine ω3PUFA intakes and 
colorectal cancer (combined RR (95% CI): 0.91 (0.70, 1.19)) (312). Finally results from 
both cohort and case-control studies as summarised in Table 12 and Table 13 regarding 
the effect of ω3PUFAs are inconsistent. In particular, from the identified prospective 
studies only the Health Professional’s Study (2008) reported a statistically significant 
and dose dependent inverse association of moderate strength between colorectal cancer 
and marine ω3PUFAs intakes in male individuals (170), whereas other large cohort 
studies (including the Women’s Health Study, the Japan Public Health Centre-based 
Study, the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study and the Iowa’s 
Women’s Health Study) reported null associations (Table 12). Results from case-control 
studies were more consistent. In particular, most of the studies reported inverse 
associations of similar magnitude as the ones observed in the current study (40-30% 
reduction in risk) and four studies reported dose dependent and statistically significant 
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associations (158;161;164;172) (Table 13). This inconsistency regarding the ω3PUFAs 
associations especially between studies might be due to different habits of the 
populations regarding the amount and duration of fish intake. It has also been proposed 
that ω3PUFA significant inverse associations might be confounded by a vitamin D 
effect, since these two nutrients share common sources. However, when we further 
adjusted the associations of the current study for vitamin D intakes, high intakes of 
ω3PUFAs were still associated with a reduced colorectal cancer risk though not 
statistically significant (high vs. low quartile of intake OR (95% CI), p-value for trend: 
0.84 (0.61, 1.18), 0.18). 
Regarding the ω6PUFAs, results from animal studies showing an increase in colorectal 
cancer incidence, led to the investigation of the hypothesis that high intakes of 
ω6PUFAs are associated with a high colorectal cancer risk. However, according to 
findings of the literature review intakes of ω6PUFAs were not associated with colorectal 
cancer in prospective studies (Table 14). In addition, the majority of case-control studies 
(including ours) reported null associations with ω6PUFAs, whereas a small number of 
retrospective studies reported inverse not statistically significant or dose-dependent 
associations of moderate strength between high intakes of ω6PUFAs and colorectal 
cancer (Table 15). 
The significant association between colorectal cancer and ω3PUFAs and on the other 
hand the lack of any association between ω6PUFAs and colorectal cancer that were 
observed in the current and previous studies can be explained by the different biological 
action of the ω3 and the ω6PUFAs. Omega 3 PUFAs have been found to rapidly 
incorporate into cell membranes and affect several anti-carcinogenic biological 
responses (313-315). The main biological mechanism of ω3PUFAs has been suggested 
to be the inhibition of the COX-2 enzyme and the production of eicosanoids that have 
anti-inflammatory and antiproliferative properties. In addition, several other mechanisms
 
by which ω3PUFAs may decrease the risk of colorectal
 
cancer have been proposed, 
including inhibition of bile acid excretion, altered protein
 
kinase C activity, decreased 
NFκB activity, activation of PPARα and γ and decreased
 
nitric oxide production (169). 
Regarding ω6PUFAs, it has been suggested that they enhance the production of 
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eicosanoids that promote inflammation and carcinogenesis by using the same enzymatic 
system as ω3PUFAs.  Therefore, changes in the ω3/ ω6 ratio may contribute to the early 
stages of carcinogenesis (316). In addition, other studies report that ω6PUFAs promote 
colorectal carcinogenesis by influencing the protein kinase C pathway (141). 
Evidence from the current and previous studies suggest that ω3PUFAs operate 
differently than the other types of fat, decreasing colorectal cancer risk. However, results 
from prospective studies are not as consistent as results from case-control studies. In 
addition ω3PUFAs share common sources (main food source: oily fish) with other 
nutrients that may affect colorectal carcinogenesis (vitamin B12, vitamin D) and 
therefore these inverse associations might be confounded. Therefore, specific 
recommendations regarding intakes ω3PUFAs are not suggested. In contrast further 
investigation of their associations with colorectal cancer in large prospective 
observational studies is proposed.  
Trans fatty acids 
Trans fatty acids are unsaturated fatty acids that are formed during hydrogenation and 
instead of the natural occurring cis form, they have a trans form (176). It has been 
reported that tFAs increase the risk of various chronic diseases, including ischemic heart 
disease, diabetes and obesity (317). Due to the fact that tFAs might be causally link with 
several chronic diseases, the major UK retailers announced that they will stop adding 
tFAs in their products by the end of 2007 (British Retail Consortium, 2007).  Regarding 
colorectal cancer, a limited amount of observational studies (3 cohort and 3 case-control 
studies) have investigated the associations between tFAs and colorectal cancer risk 
(Error! Reference source not found., Table 17). None of the cohort studies reported 
statistically significant associations. However, two of the three cohort studies were not 
large enough (in terms of cases) and therefore might have been underpowered to detect a 
significant association (141;162). Regarding case-control studies, results from the 
current study and from one more case-control study suggested a positive association 
especially among females with a 40 and 50% increase in risk, respectively (164;175). 
Regarding biological mechanisms of tFAs, it has been suggested that some of their 
properties can affect colorectal cancer carcinogenesis. In particular, it has been 
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suggested that high consumption of tFAs may alter bile acid and other fatty acid 
concentration of the large bowel, which can then lead to increased mucosa inflammation 
and oxidative stress (318). Indeed, tFAs have been found to be associated with markers 
of oxidative stress and inflammation (319;320). In addition, some studies have reported 
that high consumption of tFAs is associated with insulin resistance, which may enhance 
colorectal carcinogenesis due to increased cell proliferation (318).   
To draw specific causal conclusions about tFAs, further investigation regarding their 
association with colorectal cancer is necessary. However, this type of fat has been 
recognised as an important risk factor for other chronic diseases (ischemic heart disease, 
diabetes and obesity) and action has already been taken by reducing its amounts in 
several products. 
Summary 
To summarise, according to the findings of the current study different types of fatty 
acids were found to be associated differently with colorectal cancer. In particular, SFAs, 
MUFAs, tFAs and tMUFAs were positively associated with colorectal cancer (though 
not in all multivariable models), ω3PUFAs were inversely associated with colorectal 
cancer and ω6PUFAs were not associated with colorectal cancer (in any of the adjusted 
models). When considering other retrospective and large prospective studies, findings 
regarding intakes of SFAs, MUFAs and tFAs were generally consistent with null 
associations. However, since null associations might be due to over-correction after 
energy adjustment and since these fatty acids are found in foods that have been linked to 
colorectal cancer, it is recommended that high intakes should be avoided. On the other 
hand, findings regarding intakes of ω3PUFAs are more consistent with a statistically 
significant and dose-dependent decreased colorectal cancer risk. It has been suggested 
though, that these inverse associations might be confounded by other nutrients like 
vitamin D, since they share common food sources. Evidence from large prospective 
studies might be therefore necessary in order to further investigate the ω3PUFAs effect 
on colorectal cancer. However, application of alternative study designs (e.g. Mendelian 
randomisation, described below) might be required in order to be able to isolate the 
effect of ω3PUFAs from the effect of other nutrients.  
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9.3.1.4 Folate, vitamin B2, vitamin B6, vitamin B12 and alcohol 
Introduction 
Folate, vitamin B2, vitamin B6 and vitamin B12 have important roles in the one-carbon 
metabolic pathway, which is essential for DNA synthesis, repair and methylation. In 
addition, alcohol may have an indirect effect on the one-carbon pathway via its own 
metabolic pathway. The role of folate against the NTD syndrome is well established and 
in order to reduce the amount of newborns with this disease mandatory folic acid 
fortification has been introduced in several countries (including the USA and Canada). 
However, folic acid fortification in the UK has been suspended in order to better 
investigate the folic acid effects on cancer (including colorectal cancer). In this study the 
150 food and drink items listed in the FFQ included all the most important sources of 
folate as well as of vitamin B2, vitamin B6, vitamin B12 and alcohol. A number of 
different foods contributed to the intake of the four nutrients in our study and the results 
were not determined by one major food category including baked or boiled potatoes, 
bran flakes, bananas and fried oily fish (Table 83). Median and range estimations of 
these nutrients and alcohol in the Scottish population as they were estimated from the 
population-based controls that participated in the current study were: 321.0 µg/day 
(253.0 - 399.0 µg/day) for folate, 2.1 mg/day (1.6 - 2.6 mg/day) for vitamin B2, 2.8 
mg/day (2.2 - 3.5 mg/day) for vitamin B6, 6.8 µg/day (4.8 - 9.8 µg/day) for vitamin B12 
and 8.1 g/day (1.7 - 19.4 g/day) for alcohol (Table 81). In addition, nutrient data from 
supplements were extracted for folate, vitamin B2, vitamin B6 and vitamin B12 and they 
were added to their daily dietary intakes (after energy adjustment). Finally, the FFQ 
estimates for folate, vitamin B2, vitamin B6, vitamin B12 and alcohol intakes have been 
compared with 4 day weighed record estimates in the Scottish population and the 
Spearman rank correlations were: 0.55, 0.69, 0.33, 0.25 and 0.72 for men, and 0.73, 
0.69, 0.48, 0.31 and 0.79 for women, respectively (270). 
Main findings 
Regarding the main findings of the analyses of folate, vitamin B2, vitamin B6, vitamin 
B12 and alcohol, inverse associations which showed dose response relationships were 
observed in the energy-adjusted logistic regression model (model II) between colorectal 
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cancer risk and the dietary intakes of folate (p=0.003), vitamin B6 (p=7.1x10
-6
) and 
vitamin B12 (p=0.02) (Table 84). After adjusting for the main potential confounding 
factors (model III), only the inverse associations between colorectal cancer and vitamin 
B12 (p=0.05) remained statistically significant, with the vitamin B6 associations being 
of similar direction as in model II though borderline not statistically significant (p=0.09) 
(Table 84). In contrast, the association between folate and colorectal cancer followed a 
bell-shaped pattern with individuals of the second quartile of intake having the greatest 
colorectal cancer risk (Table 84). After correcting for multiple testing using the FDR 
method by taking into account the tests that were conducted in hypothesis 3 (15 tests) or 
the tests that were conducted in all 4 hypotheses (93 tests in the individual compound 
analysis), model II associations between dietary intakes of vitamin B6 (p=7.1x10
-6
) and 
folate (p=0.001) and colorectal cancer remained statistically significant (Table 84). 
Regarding the analysis of the main food sources of folate, vitamin B6 and vitamin B12, 
results suggest that there is some evidence in favour of a significant inverse association 
between colorectal cancer and intakes of bananas (dietary source of vitamin B6) and 
fried oily fish (dietary source of vitamin B12) (Table 85). 
Alcohol intake when divided in quartiles was associated with a decreased colorectal 
cancer risk, and this association was statistically significant in model III (p=0.03) (Table 
84), which was in the opposite direction when compared to previous findings (83). 
However, it has been proposed that alcohol intakes of less than 30 g/day are either 
weakly or not at all associated with colorectal cancer (82). In our study the cut-off point 
of the highest quartile was 19.4 g/day and this might be the reason, why we did not 
observe an increased colorectal cancer risk with high alcohol intakes. When we divided 
alcohol intake into categories (cut off points: 0, 0-15, 15-30, 30-45, 45-60, >60 g/day), 
we did not observe an increased risk for intakes of more than 30 g/day but we did 
observe a significant increased risk for intakes of more than 60g/day, which was 
statistically significant for model I (p=0.02) but not statistically significant for models II 
(p=0.08) and III (p=0.21) (Table 84).  
Regarding the genetic findings of the current study, none of the four examined SNPs 
was associated with colorectal cancer (data not shown). In addition, our data did not 
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support the hypothesis that folate or any of the vitamins B2, B6, B12 interacts with the 
rs1801133 (MTHFR 677TT) variant or with any of the rs1801131 (MTHFR A1298G), 
rs1805087 (MTR A2756G) or rs1801339 (MTRR A66G) variants (data not shown). 
Findings from the current study in relation to previous studies 
Folate 
A substantial body of observational studies investigating the association between 
colorectal cancer and dietary intakes, total intakes or plasma measurements of folate 
have been conducted. Ten of 14 cohort and 13 of 24 case-control studies that were 
identified from the literature review reported statistically significant or statistically non-
significant inverse associations between folate and colorectal cancer with an average 
30% decrease in risk (Table 18, Table 19). In addition, two recent meta-analyses 
(published in 2001 and 2005) reported a 20 to 25% reduction in colorectal cancer risk 
with high intakes of dietary folate (184;321). In some studies these inverse associations 
were attenuated after adjustment for confounding factors (e.g. fibre) or were observed 
only between intakes of dietary folate and colorectal cancer and in some other studies 
inverse associations were not replicated at all (30). Furthermore, results from two recent 
studies showed a positive effect of folate on colorectal cancer risk, which followed a 
bell-shaped pattern similar to the one that was observed in the current study (212;216) 
and a third study reported a not statistically significant positive association (196).  
The inconsistency between different studies, with some studies reporting a positive 
association, other studies reporting a negative association and other no significant 
association might be due to failing to adequately control for particular confounding 
factors such as fibre. Differences in the median and range of folate intakes might also 
explain the inconsistent findings. In particular for our study population, folate intakes 
were lower than the ones reported in other studies (193;195;198), but they were similar 
to intakes of a recent Scottish study, with this study also reporting a bell-shaped 
relationship between folate and colorectal cancer (212). In addition, failure of observing 
an association might be due to low variability in intakes between the participants of a 
study. Indeed, the variability in intakes in our study was low with 75.5% of the control 
reporting intakes between 0 and 200 µg/day, and that might explain why we did not 
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observe a significant association between high folate intakes and colorectal cancer. 
Furthermore, it has been suggested that a total folate intake of more than 600 µg/day 
may be required in order to observe a preventive effect against colorectal cancer. 
However, when we focused our analysis on subjects with high dietary or total folate 
intake, we did not observe any significant associations. In particular, the new cut-off 
points for total (dietary and from supplements) folate intakes were: 0-200 µg/day (45 
cases, 58 controls), 200-400 µg/day (1,629 cases, 2,096 controls), 400-600 µg/day (330 





 category was 1.26 (0.69, 2.29) with a p-value for trend of 0.14 (model III; 
data not shown). Finally, another possible explanation might be that folate acts in a dual 
way during colorectal carcinogenesis, reducing risk for healthy individuals but 
promoting progression of colorectal adenomas or neoplasms for individuals that have 
already developed colorectal cancer (321). 
The main biological mechanism of folate is its involvement in the one-carbon metabolic 
pathway, which leads to the synthesis of certain nucleotides (purines and thymidilate) 
and provides the methyl groups for DNA methylation (321;322). It has been 
hypothesised, therefore that high folate intakes will protect against colorectal 
carcinogenesis, maintaining a healthy colorectal epithelium. However, on the other hand 
it has been suggested that folate may assist in the progression of existing preneoplastic 
or neoplastic lesions, by providing the highly proliferative cancerous cells with 
nucleotides. Therefore, there is a possibility of a dual role of folate on colorectal cancer 
depending on the status of the colorectal epithelium (321;322). 
The evidence that folate protects against colorectal cancer has been convincing for 
several years. However, reports of positive associations between folate and colorectal 
cancer as well as the biological plausibility of an increased risk have challenged its 
chemoprotective role. Therefore, further investigation of the role of folate in prospective 
observational studies and examination of the results of two clinical trials investigating 
the folate effect on cancer (including colorectal) is recommended prior to the mandatory 
folic acid fortification in the UK. 
Vitamin B6 
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Regarding vitamin B6, results from published cohort and case-control studies showed 
inverse associations between colorectal cancer and dietary or total (including 
supplements) vitamin B6 intake (Table 22, Table 23). Three cohort studies reported 
statistically significant and dose-dependent inverse associations with a 30 to 35% 
reduction in colorectal cancer risk. In particular, in the Swedish Mammography Cohort 
both colon and rectal cancer were inversely associated with vitamin B6, in the Japan 
Public Health Centre-based
 
Prospective Study statistically significant inverse 
associations were reported only for males and in the Women’s Health Study dietary but 
not total vitamin B6 intake was associated with a decreased risk of colorectal cancer. In 
contrast, the Iowa Women’s Health Study reported a significant positive association for 
rectal cancer and no association for colon cancer. Regarding the case-control studies, of 
the 11 identified studies, one nested case-control (Nurses’ Health study) and four case-
control studies reported inverse associations with colorectal cancer (Table 23). However, 
even if most of the studies investigating the vitamin B6 effects reported statistically 
significant findings, since most studies of dietary factors of one-carbon metabolic 
pathway were focused on folate, non-significant findings for vitamin B6 could have 
been omitted from publications. Therefore the results of this literature review might be 
subject to publication bias. It has also been proposed that vitamin B6 effects might be 
modified by the intake of other nutrients, such as alcohol and folate (223) but our data 
showed no evidence of this. From the three published studies that investigated alcohol 
and vitamin B6 (223;225;323), only one found a clear interaction especially among 
women with high alcohol intake (>30g/day) (223). In addition, all three studies that 
investigated plasma or dietary folate and B6 (195;225;323) failed to show significant 
interactions. Finally, in our population, when we further adjusted for folate intakes the 
associations between colorectal cancer and vitamin B6 remained constant (high versus 
low quartile: OR (95% CI), p-value for trend: 0.80 (0.62, 1.03), 0.06) (data not shown). 
Vitamin B6 plays a key role in the one-carbon metabolic pathway as a co-enzyme of the 
cystathionine β-synthase, which converts homocysteine into cystathionine (324). In 
addition, its role as a co-enzyme in the synthesis of 5,10MTHF might be critical for 
synthesis, repair and methylation of DNA and inhibition of single and double DNA 
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breaks (325-327). Further more, laboratory studies on mice suggest that high intake of 
pyridoxine (vitamin B6) has other anticarcinogenic effects by reducing cell proliferation, 
oxidative stress, nitric oxide production and angiogenesis (328;329) and a cultured 
human lymphocyte study reported a protective action against chromosomal damage 
(330). Finally, it has been proposed that vitamin B6’s inhibition of  DNA polymerases 
and steroid receptors may be useful and vitamin B6 might be a promising adjuvant in 
cancer chemotherapy (331). 
High intakes of vitamin B6 have been found to be associated with a decreased colorectal 
cancer both in the current and previous studies. However, vitamin B6 intakes were 
attenuated and became marginally not statistically significant after further adjustment 
(model III). In addition, even if the majority of the published prospective and 
retrospective studies support an inverse association, the possibility of publication bias 
cannot be ruled out. Therefore, specific recommendations regarding intakes of vitamin 
B6 are not suggested. In contrast, further investigation of their associations with 
colorectal cancer in prospective observational studies is proposed. 
Vitamins B2 and B12 
Few studies have investigated the association between colorectal cancer and intakes of 
vitamin B2 or vitamin B12, even if they are important co-enzymes in the one-carbon 
metabolic pathway. Regarding vitamin B2, we identified only one case-control study 
that reported a significant inverse association between high intakes of vitamin B2 and 
colorectal cancer (Table 20, Table 21), findings that were not replicated in our study. 
Regarding vitamin B12, one cohort study reported a significant increased colorectal 
cancer risk with high intakes of dietary vitamin B12, but they suggested that this finding 
might be confounded by smoking (196). The majority of the case-control studies 
reported either non-significant inverse or null associations (Table 24, Table 25), whereas 
in our analysis we observed an inverse and dose-dependent association that remained 
constant in models II, III and after further adjusting for folate (high versus low quartile: 
OR (95% CI), p-value for trend: 0.80 (0.66, 0.97), 0.05) (data not shown). However, the 
main source of vitamin B12 was oily fish, therefore the observed inverse association 
might be due to a confounding effect from either ω3PUFAs or vitamin D, which main 
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source is also oily fish. Indeed, when we further controlled for either ω3PUFAs or 
vitamin D intakes the inverse association between vitamin B12 and colorectal cancer 
was diluted (high vs. low quartile: OR (95% CI), p-value for trend: 1.01 (0.80, 1.27), 
0.62; 0.95 (0.75, 1.22), 0.94; respectively). However, vitamin B12 intakes were highly 
correlated with both ω3PUFAs (r=0.79) and vitamin D (r=0.85), and therefore it is very 
difficult to know whether the inverse association with colorectal cancer is driven by 
vitamin B12, ω3PUFAs or vitamin D. According though to the findings from previous 
studies, it is more likely that the inverse association between vitamin B12 and colorectal 
cancer observed in model II and III is confounded by either ω3PUFAs or vitamin D 
intakes. 
Alcohol 
High alcohol intake has been considered as an important risk factor for colorectal 
cancer. However, it has been suggested that this positive association is not dose-
dependent. In particular, evidence suggest that alcohol intake of 30 g/day or lower are 
not associated with colorectal cancer, whereas alcohol intake of more than 30g/d is 
linked with male colorectal cancer and probably linked with female colorectal cancer 
(30). Results from the EPIC study (80) as well as from two pooled meta-analyses 
(81;82) support this finding suggesting alcohol consumption of more than 30 g/day is 
significantly associated with an increased colorectal cancer risk. 
In our study, when alcohol intake was divided into quartiles, high alcohol consumption 
was associated with a significant and dose-dependent decreased colorectal cancer risk. 
However, the cut-off point of the highest quartile (19.20 g/day) was lower than the 30 
g/day threshold. Therefore, we divided alcohol intake in categories (0, 0-15, 15-30, 30-
45, 45-60, >60 g/day) and we observed an increased colorectal cancer risk for intakes of 
higher than 60 g/day. One possible reason why the threshold of an increased colorectal 
cancer risk in our study was 60 instead of 30 g/day might be that the study participants 
underreported their alcohol intakes. 
The reference category used in the latter analysis included subjects reporting that they 
had never consumed any alcoholic beverage weekly. This might be a limitation since 
complete abstainers may not be a representative group of subjects and therefore not an 
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ideal reference group. However, subjects that had consumed less than one measure a 
week of any alcoholic beverage were also asked to circle 0. Therefore the reference 
category probably included both complete abstainers and occasional drinkers. When 
alcohol intake was divided in new categories using as reference group the low alcohol 
consumers (0-15g/day) an increased colorectal cancer risk for intakes higher than 60 g/ 
day was still observed (OR (95% CI), p-value: Model I 1.55 (1.03, 2.32), 0.03; Model II 
1.37 (0.91, 2.07), 0.13; Model III 1.26 (0.80, 2.00)) (data not shown). 
Associations with genetic variants, gene-nutrient interactions 
Two previous meta-analyses (332;333) have reported inverse associations between the 
MTHFR 677TT genotype and colorectal cancer risk. Therefore lack of a statistically 
significant association in our study might be either a chance finding or due to limited 
power. A smaller number of observational studies have investigated the associations 
between colorectal cancer and the other genetic variants: rs1801131 (MTHFR A1298C), 
rs1805087 (MTR A2756G) and rs1801339 (MTRR A66G). Regarding the rs1801131 
(MTHFR A1298C) variant, a decreased though not statistically significant association 
between the CC genotype and colorectal cancer is reported in the majority of the studies 
(178). However, since rs1801133 (MTHFR C677T) and rs1801131 (MTHFR A1298C) 
are in strong linkage disequilibrium and the pattern of association between the MTHFR 
1298CC genotype and colorectal cancer is similar to the pattern of association MTHFR 
677TT and colorectal cancer, it
 
raises the possibility that the rs1801131-cancer relation 
is actually
 
due to the rs1801133 variant. Studies about associations between rs1805087 
(MTR A2756G) and colorectal cancer and between rs1801339 (MTRR A66G) and 
colorectal cancer have reported null or not statistically significant associations (178). 
Regarding gene-nutrient interactions, it has been suggested that the decreased colorectal 
cancer risk for the MTHFR 677TT individuals is not apparent when folate or methionine 
intakes are low or when alcohol intakes are high (216). However, this hypothesis was 
not replicated by the current study and also results from observational studies examining 
these interactions are inconsistent suggesting that further investigation might be 
necessary (216). In addition, some observational studies have investigated interaction 
relationships between MTHFR 1298CC genotype and folate intakes. Similarly to the 
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MTHFR 677TT interactions, results are inconsistent and might be driven by the 
rs1801133 (MTHFR C677T) variant due to the strong linkage disequilibrium (216). 
Furthermore, at least three studies reported a lower risk of colorectal cancer (334;335) 
and adenomas (336) in subjects of the MTHFR 677TT genotype and reporting high 
vitamin B6 intake.  
In addition to individual effects and specific gene-nutrient interactions, several previous 
prospective and retrospective studies have investigated combinations of dietary factors 
and/ or the genetic factors involved in one-carbon metabolism and their association with 
colorectal cancer risk. Results tend to support an inverse association between a high 
methyl-donor  diet (high folate and in some cases high vitamin B6 and vitamin B12 
intakes, high methionine intakes and low alcohol intakes) even in studies where 
individual effects were not significant (226). 
Summary 
To summarise, according to the findings of the current study, folate intakes were not 
associated with a decreased colorectal cancer, but instead a bell-shaped relationship was 
observed. Even if the majority of the published studies support a protective effect of 
folate, the possibility of a dual folate role (protecting against colorectal cancer onset but 
enhancing colorectal cancer progression) needs further investigation from observational 
studies. Vitamin B2 was not associated with colorectal cancer, but both vitamin B6 and 
vitamin B12 were found to decrease colorectal cancer risk. However, inverse 
associations with vitamin B6 were attenuated after applying the multivariable model and 
similarly inverse association with vitamin B12 were found to be confounded by 
ω3PUFAs or vitamin D intakes. Vitamin B6 can act as an important chemopreventive 
agent, but further investigation of its effect on colorectal cancer would need to be 
conducted. Similarly, even if vitamin B12 findings are interesting, they might be 
confounded, especially if we consider the published evidence regarding the effects of 
ω3PUFAs and/ or of vitamin D. Finally, when alcohol intake was divided into quartiles, 
high alcohol consumption was associated with a significant and dose-dependent 
decreased colorectal cancer risk. However, when alcohol intake was divided in 
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categories an increased colorectal cancer risk for intakes of higher than 60 g/day was 
observed.  
9.3.1.5 Vitamin D and calcium 
Introduction 
A protective effect of vitamin D on colorectal cancer has been initially proposed in 1980 
by Garland and Garland, who suggested that different incident and mortality rates of 
colorectal cancer, could be explained by the different sunlight exposure according to the 
geographic latitude (337). Since then, several ecological studies investigated the 
association between UVB exposure and colorectal cancer, with most of them confirming 
the initial observation (338). However, results from prospective or retrospective studies 
investigating the association between mainly dietary intakes of vitamin D and colorectal 
cancer are not as strong (338), whereas the epidemiological evidence regarding calcium 
intake and its effect on colorectal cancer is relatively stronger (339). In the current study 
we used estimates obtained from the FFQ, in order to investigate the associations 
between colorectal cancer, vitamin D and calcium. The foods that contributed to the 
intake of the vitamin D and calcium in our study included oily fish (fried, smoked or 
grilled), milk and cheese (Table 89). Median and range estimations of vitamin D and 
calcium in the Scottish population as they were estimated from the population-based 
controls that participated in the current study were: 3.9 mg/d (2.5 - 5.8mg/d) for vitamin 
D and 1.1 g/d (0.8 -1.4 g/d) for calcium (Table 87). In addition, nutrient data from 
supplements were extracted for vitamin D and calcium and they were added to their 
daily dietary intakes (after energy adjustment). Finally, the estimates of this FFQ for 
vitamin D and calcium intakes have been compared with 4 day weighed record estimates 
in the Scottish population and the Spearman rank correlations were: 0.38 and 0.49 for 
men, and 0.37 and 0.75 for women, respectively (270). 
Main findings 
Regarding vitamin D, significant inverse dose-dependent associations were observed 
between colorectal cancer and dietary vitamin D in both models II (p=0.01) and III 
(p=0.03) (Table 90). However, when we further adjusted for ω3PUFAs, since they share 
common food sources (oily fish), this inverse association between vitamin D and 
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colorectal cancer was attenuated (Table 91). Regarding calcium, high dietary intakes 
were associated with an increased colorectal cancer risk in the crude model (model I), 
whereas dietary and total calcium intakes were not associated with colorectal cancer risk 
in any of the other models (Table 90 and Table 91). After correcting for multiple testing 
using the FDR method by taking into account the tests that were conducted in hypothesis 
4 (eight tests) or the tests that were conducted in all four hypotheses (93 tests in the 
individual compound analysis), associations between dietary intakes of calcium (p= 
0.001; model I) and vitamin D (p=0.01; model II) remained significant (Table 90). 
Finally, analysis of the main food sources of vitamin D and calcium, suggested that there 
is some evidence in favour of a significant inverse association between colorectal cancer 
and intakes of fried and smoked oily fish (vitamin D sources), whereas there is some 
evidence of a positive association between colorectal cancer and full fat hard cheese 
(calcium source) (Table 92). 
Regarding the genetic findings of the current study, none of the four SNPs examined 
was associated with colorectal cancer (data not shown). In addition, we investigated the 
associations between colorectal cancer, vitamin D and calcium after genotype 
stratification to test whether their associations are modified according to the particular 
genotype (data not shown). We observed that the inverse association between vitamin D 
and colorectal cancer was more profound for individuals of the rs10735810 CC 
genotype than for individuals of the CT or TT genotypes. Furthermore, calcium intake 
was inversely though not significantly associated with colorectal cancer for the 
rs10735810 CC individuals, whereas it was positively associated for the TT individuals 
(data not shown). Finally, there was some evidence that rs10735810, a SNP that affects 
VDR function, interacts with vitamin D (p for interaction 0.06) and calcium dietary 
intakes (p for interaction 0.13) (data not shown). However, given the multiple 
interactions examined, we can not rule out the possibility that the observed interaction 
between rs10735810, vitamin D and calcium might be due to chance. 
Findings from the current study in relation to previous studies 
Vitamin D 
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A recent clinical trial of vitamin D (10 µg/day) and calcium supplementation (1000 
mg/day) for seven years in post-menopausal women did not show any association with 
colorectal cancer (234). However, a large proportion of women assigned to vitamin D/ 
calcium supplementation or of women assigned to placebo were also taking supplements 
on their own and the authors suggested that this may have limited their ability to affect 
the rates of colorectal cancer further. In addition, this finding might be due to 
insufficient time for vitamin D to affect colorectal carcinogenesis, since it has been 
proposed that vitamin D may require at least 10 years to act. Furthermore, this finding 
might be due to low dosage of vitamin D supplementation and therefore the contrast 
between the treatment participants and the control ones might not have been adequate. 
Evidence from observational studies measuring serum (plasma) vitamin D (25(OH)D) 
was strong and statistically significant, suggesting an average 40% reduction in 
colorectal cancer (Table 28). In addition, results from a meta-analysis combining seven 
nested case-control studies investigating the association between 25(OH)D in the blood 
and colorectal cancer showed a significant inverse association with a combined OR of 
0.70 (95% CI 0.56, 0.87) (250). Regarding dietary and total vitamin D, numerous case-
control and cohort studies have examined vitamin D intake in relation to risk of 
colorectal cancer (Table 26, Table 27) and findings from most of them have been 
discussed in detail in recent review articles (338;340;341). Whereas, some cohort 
(including the Nurses’ Health Study, the Health Professionals’ study and the Iowa 
Women’s Health Study) and some case-control studies reported statistically significant 
and dose dependent inverse associations between vitamin D intakes and colorectal 
cancer, other studies reported no associations. In addition, results of two meta-analyses 
combining 11 cohort and nine case-control studies showed a weak statistically 
significant inverse association for the cohort studies and a weak statistically non-
significant inverse association for the case-control studies (combined RR=0.91, 95% CI 
0.84, 1.00; combined OR=0.90, 95% CI 0.80, 1.02; respectively) (250). These 
inconsistent and weak associations might be due to the fact that the studies included in 
the meta-analyses did not capture total vitamin D intake (dietary intake, supplementary 
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intake and skin production) coupled to the measurement error in dietary measures of 
vitamin D intake. 
Regarding the current study, it is worth mentioning that only dietary and supplementary 
vitamin D intake was considered, since we did not have information regarding vitamin D 
skin production by UV sunlight. Therefore, the possibility of misclassification due to the 
lack of measuring sunshine-produced vitamin D can not be ruled out. It has been 




 is required to induce the 
vitamin D3 skin production and apparently this threshold is not reached for countries 
above latitude 40
o
 during the winter months (342). Since Scotland’s latitude is 55
o
, the 
sun exposure, especially during the winter months, is relatively low and this will 
probably make diet a more important contributor. Finally, the inverse association that 
was observed between vitamin D and colorectal cancer in our study was attenuated after 
further adjustment for ω3PUFAs. However, these two nutrients were highly correlated 
with each other (r=0.82, p-value<0.00005) and therefore it is very difficult to know 
whether the inverse association with colorectal cancer is driven by vitamin D and/or by 
ω3PUFAs or whether the dilution of the association might be due to an over-control of 
the vitamin D intake. 
Vitamin D has been suggested to affect colorectal cancer carcinogenesis mainly through 
the binding of 1α,25(OH)2D3 (vitamin’s D most active form) on VDR (343). In vitro 
laboratory studies suggest that the main anti-neoplastic activities of vitamin D include 
inhibition of cell proliferation, induction of differentiation and apoptosis, inhibition of 
growth effects and modulation of the signalling pathway of particular cytokines. If 
vitamin D is proved to be truly linked with colorectal cancer, then it could be a very 
promising chemopreventive agent for colorectal cancer. However, adverse side-effects 
of natural vitamin D (in high doses), such as hypocalcaemia, should be overcome (227). 
Calcium 
Results from several animal studies have suggested that calcium has a protective effect 
against colorectal carcinogenesis. In addition, results from a recent Cochrane systematic 
review (including findings from two clinical trials) and a meta-analysis based on three 
randomised
 
controlled trials, studying the effect of calcium supplementation on 
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colorectal adenoma incidence and recurrence respectively, suggested that daily intake of 
calcium (dietary or from supplements) may have a moderate protective effect on 
development or recurrence of colorectal adenomas (344;345). However as it has been 
already mentioned, the randomised clinical trial from the
 
Women's Health Initiative 
found no effect of calcium plus vitamin
 
D supplementation among postmenopausal
 
women. Regarding observational studies, results from cohort and case-control studies 
are inconsistent (Table 29, Table 30). In particular for the prospective studies, some of 
the large cohort studies (including the Multiethnic cohort study, the Breast Cancer 
Detection Demonstration Project, Professionals Follow-Up Study, the Swedish 
Mammography Cohort Study and the Iowa Women’s Health Study) support an inverse 
association between either dietary or total calcium intake with an average 30% reduction 
in colorectal cancer risk, whereas some others (including the Netherlands Cohort Study, 
the Nurses Health Study and the E3N-EPIC prospective study) failed to replicate these 
findings (Table 29). 
A possible reason for this inconsistency regarding the associations between calcium 
intakes and colorectal cancer might be the fact that many studies did not account for 
calcium intake from supplements, which might be important contributors of total daily 
intakes. An alternative possible explanation of this difference might be the different 
levels of calcium intake. In particular, some investigators have suggested that calcium 
affects colorectal cancer at the low range of intake with some studies suggesting a cut-
off at 600-800 mg/day where there is no further benefit (261). However, when we 
limited our analysis to subjects with a dietary calcium intake of ≤1000 mg, we did not 
find a significant association between calcium intake and colorectal cancer. The cut-off 
points for the new categories were: 0-600 mg/day (36 cases, 55 controls), 600-800 
mg/day (194 cases, 249 controls), 800-900 mg/day (208 cases, 307 controls) and 900-
1000 mg/day (295 cases, 402 controls). After applying model III for the 4
th
 versus the 1
st
 
category the reported OR (95% CI) was 1.37 (0.81, 2.32) with a p-value for trend 0.98 
(data not shown). In contrast, other investigators have suggested that a total calcium 
intake of more than 1,200 mg/day may be required in order to observe a preventive 
effect against colorectal cancer (346). When we focused our analysis on subjects with 
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high dietary or total calcium intake, inverse associations for intakes of more than 
1500mg/day were observed. In particular the new cut-off points for total (dietary and 
from supplements) calcium intakes were: 0-1000 mg/day (708 cases, 978 controls), 
1000-1250 mg/day (773 cases, 975 controls), 1250-1500 mg/day (414 cases, 539 
controls), 1500-1750 mg/day (127 cases, 197 controls), >1750 mg/day (39 cases, 87 
controls). The results after applying model III for the 4
th
 versus the 1
st
 category and for 
the 5
th
 versus the 1
st
 category were OR (95% CI): 0.82 (0.62, 1.09) and 0.63 (0.41, 0.97) 
respectively with a p-value for trend 0.14 (data not shown). Therefore, a possible 
explanation of the inconsistency between different studies might be that like in our study 
high intakes of dietary or supplementary calcium (of more than 1500mg/day) might be 
necessary, before a protective effect could take place. 
Calcium has also been evaluated as a possible chemopreventive agent against colorectal 
cancer mainly due to its anti-inflammatory and anti-proliferative properties (343). 
Calcium mainly exerts its chemopreventive actions through activation of a calcium-
sensing receptor. This leads to an increase in the levels of intracellular calcium, inducing 
a wide range of biological effects including the restrain and differentiation of neoplastic 
colon cells (347). Finally, it has also been proposed that calcium can bind on bile and 
fatty acids in the colonic lumen reducing the toxicity of these agents (339).  
Associations with VDR variants, gene-nutrient interactions 
Regarding previous studies on the genetic variants of the VDR in agreement with the 
findings of the current study, the combined analysis of five case-control studies 
investigating the effect of the VDR rs10735810 variant on colorectal cancer showed no 
significant associations (250). However the variant genotype of rs1544410 GG was 
found to be significantly associated with colorectal cancer in a meta-analysis of four 
studies (combined OR=1.18, 95% CI 1.04, 1.33) (250). We did not replicate this finding, 
possibly because rs1544410 was not in Hardy Weinberg equilibrium in our study. In 
addition, the few studies that have performed stratified and interaction analyses by 
vitamin D and/ or calcium status suggest that the effect of VDR variants might depend 
on the intake of these nutrients (250). 
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The F (C) allele of FokI (rs10735810) has been found to result in a 3 amino acid shorter 
version of the VDR protein that is more efficient in binding vitamin D than the longer 
version coded by the f (T) allele. Therefore higher vitamin D or calcium intake might 
enhance its activity (348). Both vitamin D and calcium interact biologically with VDR 
and it has been suggested that they act together in their anticarcinogenic properties, with 
their effects being mainly at the earlier stages of carcinogenesis (adenomas) (349). 
Ingles et al (350) showed that the f (T) allele was inversely associated with large 
colorectal adenomas (>1cm in diameter; more likely to progress to adenocarcinomas) 
among individuals with low vitamin D and calcium intake and concluded that the 
association between VDR variants and colorectal adenoma risk are modified by vitamin 
D and calcium intake; findings which are in accordance with our results.  
Summary 
Findings from the current and previous studies suggest an inverse association between 
vitamin D intakes and colorectal cancer. Associations in the current study though were 
attenuated after adjusting for ω3PUFAs (common food source). These nutrients are 
highly correlated and it is therefore difficult to draw specific conclusions regarding 
which nutrient is truly associated with colorectal cancer and which not. Vitamin D might 
be a particularly useful chemopreventive agent against colorectal cancer (considering 
that its main side effects will be prevented) and therefore further investigation of the 
vitamin D effect on colorectal cancer by prospective and retrospective studies is very 
important. In addition, alternative analytical approaches (e.g. Mendelian randomisation) 
that overcome the problems of traditional epidemiological methods (such as 
confounding and reverse causation) might be useful in order to establish the relationship 
between vitamin D and colorectal cancer. Regarding calcium, high intakes (when 
divided into quartiles) were not found to be associated with colorectal cancer. However, 
calcium intakes of more than 1500mg/day were significantly associated with a decreased 
risk. In addition, results from prospective and retrospective studies are inconsistent and 
this inconsistency might be due to different levels of calcium intake. Therefore, based on 
the current findings as well as on the inconsistent results from previous studies, the 
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effect of calcium should be further investigated in observational studies, considering that 
high intakes of calcium could be required for a protective effect to be apparent. 
9.3.1.6 Summary 
Main findings of part 1 of the currents thesis 
To summarise, the main findings of the first part of the current thesis support the overall 
evidence that lifestyle and in particular dietary exposures are linked with colorectal 
cancer either by increasing or decreasing risk. 
The particular dietary factors that were found to be inversely associated with colorectal 
cancer after applying several multivariable logistic regression models and after 
controlling for multiple testing error were the following subgroups and individual 
compounds: flavonols, quercetin, catechin, ω3PUFAs, EPA, DHA, vitamin B6 and 
vitamin B12. In addition, high intakes of stearic acid were found to be positively 
associated with colorectal cancer and this association persisted even after further energy 
or total fatty acids adjustment. In contrast, high intakes of dietary and total folate were 
associated with a decreased colorectal cancer risk in the energy-adjusted model, but 
these inverse associations were attenuated and a bell shaped association was observed 
after further adjustment for several confounding factors including fibre. Regarding 
alcohol intake, when it was divided into quartiles, high alcohol consumption was 
associated with a significant and dose-dependent decreased colorectal cancer risk. 
However, when alcohol intake was divided in categories an increased colorectal cancer 
risk for intakes of higher than 60 g/day was observed. Furthermore, high intakes of 
vitamin D were also inversely associated with colorectal cancer after applying model II 
and III, but the effect was diluted after further adjusting for ω3PUFAs. Finally, it was 
observed that for calcium intakes to be inversely associated with colorectal cancer, a 
dosage of 1500mg/day or higher was necessary. 
Finally, in the current study high BMI (≥30kg/m
2
) versus normal BMI (18.5-25 kg/m
2
) 
was associated with a not statistically significant decreased colorectal cancer risk in both 
the matched and unmatched analysis (OR (95% CI), p-value: matched dataset 0.87 
(0.71, 1.07), 0.14; unmatched dataset 0.92 (0.78, 1.08), 0.30). These results are not in 
accordance with the findings of the associations between colorectal cancer, physical 
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activity and dietary energy intake from the current study. In particular, since high levels 
of physical activity and low levels of dietary energy intake were associated with a 
decreased colorectal cancer risk, it would be expected that high BMI would be 
associated with an increased colorectal cancer risk. In addition, the inverse association 
between BMI and colorectal cancer is not consistent with many observational studies 
that have concluded that obesity is an important risk factor for colorectal cancer (71) 
(summarised on page 54). One possible reason for this inconsistent finding might be a 
weight underreporting from the cases or a weight misreporting due to their weight 
change after their cancer diagnosis. The validity of the LCQ regarding the weight and 
height report will be checked in healthy controls by comparing self reported 
measurements with measurements conducted from a trained research nurse.    
General comments 
Observational analytical studies examining the associations between the nutrients of our 
primary hypotheses (flavonoids, fatty acids, folate, vitamin B2, vitamin B6, vitamin 
B12, alcohol, vitamin D and calcium) and colorectal cancer reported generally 
inconsistent results. Many possible explanations for these inconsistent findings have 
been suggested. In particular, the inconsistent findings might be due to different levels of 
intakes (resulting in different median and range of intakes) of the nutrients under 
investigation among the populations, which might be particularly important for nutrients 
that have an effect threshold (as for example it has been suggested for alcohol or calcium 
intake). However, it is more likely that most of the inconsistent findings are due to 
several methodological issues that could affect the accuracy of the reported results. 
Generally, case-control studies are more prone to report biased results mainly due to 
recall bias. However, other methodological problems including measurement errors, lack 
of controlling for all confounding factors and/ or residual confounding can affect equally 
results from both case-control and cohort studies. 
One of the most important limitations of the majority of the published observational 
studies is their inability to detect small effect sizes due to small sample sizes and 
therefore limited power. Therefore, for a study to have 80% power to detect a difference 
of 20%, which are similar to the effect sizes observed in the current study, a sample size 
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of at least 2,500 cases and controls is required (α=0.05). And if we wish to increase the 
power to 90% then the study sample of the observational study should be up to at least 
3,400 cases and controls. Furthermore, for a study to have 80% power to detect even 
smaller effects (e.g. OR=0.90) then a sample size as large as 11,324 may be required. 
However, a sample size of more than 11,000 individuals according to the above 
traditional power calculations is based on ideal study settings and probably is an 
underestimate of the true required sample size. In particular according to a recent 
publication, traditional power calculations fail to consider several key elements of the 
analysis complexity including for example errors in disease assessment and 
measurement errors of the explanatory variables (351). 
Observational epidemiology has identified several important risk factors that have been 
verified to be causally linked with a disease. A few examples are the effects of smoking 
on lung cancer, lipids on coronary disease, high blood pressure on stroke and aspirin or 
NSAIDs use on colorectal cancer (352). However, there are many other examples that 
findings from observational studies were proven (mainly from randomised clinical trials) 
to be false, like the effects of anti-oxidant beta carotene on smoking related cancers, 
vitamin E and vitamin C on coronary heart disease. Observational epidemiology though 
is an important tool for medical research of disease causes, especially since it is not 
possible to conduct randomised clinical trials (which are considered as the gold 
standard) for all the potential risk factors and in some cases it is not possible to conduct 
a randomised clinical trial at all due to ethical reasons. Therefore, effort to improve the 
design of the case-control and cohort studies is essential. In addition, for researchers to 
be able to judge and draw conclusions about published studies, the reported results 
should be transparent and complete. One way to do that is by applying the STROBE 
(Strengthening the Reporting of Observational Studies in
 
Epidemiology) criteria, which 
is a guidance of how researchers should report findings from observational studies (353).  
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9.3.2 Main findings of part 2: Overall and stepwise 
regression analysis 
9.3.2.1 Introduction 
In this part of the chapter the main results of the overall and stepwise regression analysis 
will be presented and discussed. Regarding the overall analysis, univariable logistic 
regression models were fitted for the selected demographic, lifestyle, food and nutrient 
variables and OR, 95% CI and p-values for trend were calculated for each quartile of the 
continuous variables and each category of the categorical variables (Table 96). 
Regarding the stepwise regression analysis, forward and backward stepwise regression 
models were applied in the whole sample for three different sets of variables using the 
quartile form of the continuous variables (Table 97, Table 98, Table 99, Table 100, 
Table 101) and this procedure was repeated in sex stratified samples (data not shown). 
The explanatory variables that were included in the stepwise regression models 
consisted of selected demographic, lifestyle, food and nutrient variables. 
9.3.2.2 Main results from overall analysis 
The risk factors that were found to be significantly associated with colorectal cancer 





), dietary energy intake (p=2.0x10
-5
), HRT intake (p=0.0003) 







), fruit/ vegetable juice (p=1.7x10
-6
), 
oily fish (p=0.001), coffee (p=0.001), fruit (p=0.009), savoury foods (p=0.009) and 





), SFAs (p=0.0001), tFAs (p=0.001) and MUFAs (p=0.01); 



















), phosphorus (p=0.0001) and selenium (p=0.009); 
niacin (p=8.2x10
-7




), vitamin C 
(p=4.6x10
-5
), vitamin A (p=0.001), potential niacin (p=0.001), biotin (p=0.001), folate 
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(p=0.003), pantothenic acid (p=0.006), vitamin D (p=0.01), vitamin B1 (p=0.02) and 
vitamin B12 (p=0.02) (Table 96). 
9.3.2.3 Main results from stepwise regression - Original sample 
Whole, female and male samples 
After applying forward and backward stepwise regression using three different sets of 
variables in the whole sample, the variables that were included: 1) in all models were 
family history (6/6 of models), dietary energy (6/6 of models), NSAIDs (6/6 of models), 
white fish (4/4 of models) sweets (4/4 models), coffee (4/4 models), fruit/ vegetable 
juice (4/4 models) and magnesium (4/4 of models) and 2) in more than 75% of models 
were: physical activity (5/6 of models), eggs (3/4 of models), oily fish (3/4 of models), 
vegetables (3/4 of models), ω3PUFAs (3/4 of models), quercetin (3/4 of models), 
cholesterol (3/4 of models), fibre (3/4 of models) and copper (3/4 of models) (Table 
102).  
After sex stratification, the following variables were included: 1) in all female and male 
derived models: family history (12/12 of models), NSAIDs (12/12 of models), sweets 
(8/8 of models) and fruit/ vegetable juice (8/8 of models) and 2) in more than 75% of 
female and male models: eggs (6/8 of models), white fish (6/8 of models) and tMUFAs 
(6/8 of models) (Table 102). However, few risk factors were included only in female or 
male derived models. In particular, the following variables were included only in at least 
75% of the models derived from the female sample: tFAs (4/4 of the female models), 
vegetables (3/4 of the female models), ω3PUFAs (3/4 of the female models) and HRT 
(4/6 of the female models) (Table 102). In addition, the following variables were 
included only in at least 75% of the models derived from the male sample: dietary 
energy intake (6/6 of the male models), physical activity (5/6 of the male models), 
quercetin (3/4 of the male models), flavanones (3/4 of the male models) and manganese 
(3/4 of the male models) (Table 102). 
To summarise, the variables that were included in all models derived from the whole, 
female and male analysis of the original sample for all three sets of variables were 
family history, NSAIDs, sweets and fruit/ vegetable juice and the variables that were 
included in at least 75% of the models were: eggs and white fish. In addition, the 
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variables vegetables and ω3PUFAs were selected to be included in the vast majority of 
the models derived from the whole and female samples and similarly, dietary energy and 
physical activity were selected to be included in the vast majority of the models derived 
from the whole and male samples (Table 102). 
The variables with the strongest and most significant associations were among the ones 
that were included in the majority of the models. In particular, the lowest p-values were 





), NSAIDs (p-value range: 6.1x10
-6
 to 0.009), dietary energy intake 
(p-value range: 4.6x10
-7
 to 0.002), sweets (p-value range: 4.4x10
-8
 to 0.005), fruit/ 
vegetable juice (p-value range:  1.3x10
-6
 to 0.01), eggs (p-value range: 8.3x10
-8
 to 0.08) 
and white fish (p-value range: 5.4x10
-5
 to 0.02) (Table 97, Table 98, Table 99, Table 
100, Table 101). In addition, regarding the direction of the associations, the variables 
family history, dietary energy, sweets, fruit/ vegetable juice, eggs and white fish were 
associated with an increased colorectal cancer risk, whereas the variable NSAIDs was 
associated with a decreased risk. Finally, regarding the size of the associations, family 
history was observed to have the strongest associations with colorectal cancer (OR 
range: 14.68 to 29.53), followed by NSAIDs intake (OR range: 0.68 to 0.79). For the 
remaining variables (dietary energy, sweets, fruit/ vegetable juice, eggs and white fish) 
the observed association were moderate or weak, with ORs ranging from 1.09 to 1.26 
(Table 97, Table 98, Table 99, Table 100, Table 101). However, these observed ORs 
might not be accurate since stepwise regression either forward or backward, is not an 
appropriate method to draw conclusions regarding effect sizes.     
9.3.2.4 Main results from stepwise regression - Bootstrap samples 
The bootstrap method was applied to investigate the stability of the models and it was 
applied for forward and backward stepwise regression of all three sets of variables 
(whole sample). One hundred bootstrap samples were randomly drawn from the original 
sample. Then, each bootstrap sample was used to apply forward and backward stepwise 
regression for each set of variables (set 1, 2 and 3). 
The variables that were selected to be included in the final models using forward 
stepwise regression were highly dependent on the subjects that were included in each 
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bootstrap sample, since all 100 models were chosen once (for all sets of variables) and 
the same was observed for the 100 models derived after applying backward stepwise 
regression. 
Our findings suggest that the number of noise (false positive) variables that were 
selected to be included in the models increased as the number of candidate variables 
increased. In particular, the agreement between the models derived from forward and 
backward stepwise regression within the same bootstrap sample decreased as the number 
of the potential risk factors (number of variables for each set of variables) increased. The 
mean percentage of agreement for the analysis of set 1 (30 variables), set 2 (52 
variables) and set 3 (82 variables) was 96.97%, 84.36%, 83.12%, respectively. The 
number of variables that were selected to be included in the models of the 100 bootstrap 
samples was smaller for the set 1 analysis (11-20 variables), than for the set 2 and set 3 
analyses (10-31 and 15-39 variables respectively) (data not shown). Finally, for all sets 
of variables, more variables were selected to be included in models derived from 
backward stepwise regression than in models derived from forward stepwise regression 
(mean number of selected variables: 22.54, 20.02; respectively).  
Regarding the variables that were selected to be included in the majority (more than 
90%) of the models derived from the bootstrap samples were: 1)  family history 
(600/600 of models), NSAIDs (596/600 of models) and dietary energy (587/600 of 
models), for variables that were included in all three sets of variables (3 sets of 
variables*2 types of stepwise regression*100 bootstrap samples = 600 models); and 2) 
sweets (397/400 of models), fruit/ vegetable juice (395/400 of models), eggs (388/400 of 
models), and white fish (381/400), for variables that were included in set 1 and 3 (2 sets 
of variables*2 types of stepwise regression*100 bootstrap samples = 400 models) (data 
not shown).  
Therefore, most of the variables that were selected to be included in the majority (more 
than 90%) of the models derived from of the bootstrap samples are similar to the ones 
that were selected to be included in the majority (more than 90%) of the models derived 
from the original sample and these were: family history, NSAIDs, dietary energy intake, 
sweets, fruit/ vegetable juice, eggs and white fish. However, the variables coffee and 
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magnesium that were included in all 4 models derived from the original sample were 
included in 88.8% (355/400) and 77.8% (311/400) of the models derived from the 
bootstrap samples.  
9.3.2.5 Comment on main findings of overall and stepwise 
regression analysis 
Demographic and lifestyle factors 
After applying forward and backward stepwise regression, some of the explanatory risk 
factors that were found to be associated with colorectal cancer in the majority of the 
selected models (>90% of the models derived from the original and bootstrap samples) 
were risk factors that have been found to affect colorectal cancer in many published 
observational studies. In particular, these factors included family history and dietary 
energy intake, which were associated with an increased colorectal cancer risk and 
NSAIDs, which was associated with a decreased colorectal cancer risk. 
Family history has been considered as one of the main risk factors of colorectal cancer 
and for individuals that are in moderate or high family history risk colorectal cancer 
screening is offered. According to the findings of a recent meta-analysis (2006), which 
was summarised in the Introduction section (on page 48), the pooled colorectal cancer 
relative risk estimate when at least one first degree relative was affected was 2.24 (95% 
CI 2.06, 2.43) and it rose to 3.97 (95% CI 2.60, 6.06) when there were at least two 
affected relatives (47). In addition, the effect of NSAIDs on colorectal cancer has been 
investigated in numerous randomised clinical trials and observational studies 
(summarised in Introduction, on page 57), with the majority of the results suggesting 
that regular use of NSAIDs is associated with a reduced risk of colorectal cancer. On the 
other hand, even though the effect of dietary energy intake on colorectal cancer has been 
investigated in several observational studies (summarised in Introduction, on page 53) 
findings are generally inconsistent, with the case-control studies suggesting a significant 
inverse association, whereas cohort studies showing weaker or null associations (61). It 
is worth mentioning that findings of the current study suggest that dietary energy intakes 
is mainly associated with male colorectal cancer rather than with female colorectal 
cancer. An attractive hypothesis of this sex difference would be that high intakes of 
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dietary energy only affect male colorectal cancer. Indeed, sex is a factor that has been 
hypothesised to be an important effect modulator for several risk factors. However, 
many of the claimed sex
 
differences have been proven to be spurious and failed to get 
replicated (354). Therefore, an alternative explanation of this finding might be that men 
and women misreported their dietary energy intakes in different ways. In particular, 
findings from previous studies support the hypothesis that under-reporting of dietary 
energy intake is unevenly distributed according to sex with women being more likely to 
underreport their dietary energy intakes (355-357).  
Food groups 
In addition to the widely studied risk factors a few less studied ones were found to be 
associated with colorectal cancer in the majority of the resultant models (>90% of the 
models derived from the original and bootstrap samples), which included the food 
groups sweets, fruit/ vegetable juice, eggs and white fish (with high intakes of all these 
food groups being associated with an increased colorectal cancer risk). In addition, 
coffee was selected to be included in >90% of the models derived from the original 
sample, but this finding was not replicated after applying the bootstrap sampling 
method, where coffee was selected to be included in 88.8% of the resultant models 
derived from the bootstrap samples. In the following paragraphs evidence from 
observational studies regarding the associations between colorectal cancer and these 
food groups (sweets, fruit/vegetable juice, eggs, white fish and coffee) will be briefly 
summarised. 
Sweets 
Sweets is a summary variable of high-fat and high-sugar foods, including pudding and 
deserts, chocolates, sweets, nuts and crisps, biscuits and cakes. This summary variable 
represents an unhealthy dietary pattern and it is moderately correlated with dietary 
energy intake (r=0.61, p-value<10
-5
). Several observational studies have investigated the 
associations between colorectal cancer and dietary (food) patterns, which involves the 
joint analyses of foods that are consumed together by forming clusters of individuals 
with similar dietary habits (cluster analysis) (358). The two patterns that appear in the 
majority of the studies are: 1) a pattern of high intakes in fruit, vegetables and other 
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healthy foods (“healthy” pattern) and 2) a pattern of high intakes in meat, high fat and 
high sugar foods (“western” pattern) (358). In most of the studies the “healthy” dietary 
pattern was found to be associated with a decreased colorectal cancer risk (358-362), 
whereas the “western” dietary pattern has been found to be associated with an increased 
risk (359;363;364). 
Fruit/ vegetable juice 
The finding of the positive association between fruit/ vegetable juice and colorectal 
cancer is difficult to explain. Generally fruit and vegetable juices have different 
properties than the whole fruit or vegetable they come from, since juices contain limited 
amount of fibre and the majority of them contain sugars, preservatives and other 
additives (30). However, in many studies juice intakes are combined with fruit and 
vegetable intakes and their association with colorectal cancer is rarely investigated 
independently (365). Fruit and vegetable juices might affect colorectal cancer due to 
their high sugar content, however association between sugar intakes (as nutrient) and 
colorectal cancer are also inconsistent (30). 
Eggs 
Eggs are a food group that contains mainly protein, fat (saturated and mono-unsaturated 
fat) and cholesterol and are good sources of vitamin D, vitamin A, vitamin B2 and 
iodine. High consumption of them has been hypothesised to be associated with an 
increased colorectal cancer risk mainly due to their high content in fat and cholesterol. 
However, the results from case-control and cohort studies have been inconsistent. In the 
first AICR/WCRF report (1997) after reviewing 16 case-control studies, eggs were 
classified as a possible risk factor of colorectal cancer (58). However, in the second 
WCRF/AICR report (2007), the association between eggs and colorectal cancer was not 
investigated (30). In a recent population based case-control study (Shangai, China) an 
increased risk of colorectal cancer was reported for the ones of the highest intake of eggs 
versus the ones of the lowest (OR (95% CI): 1.4 (1.0, 1.9) for men and 1.3 (0.9, 1.9) for 
women) (366). However, results from a recent prospective study failed to replicate this 
inverse association (157). Finally, a review that summarised findings regarding the 
associations between colorectal cancer and various food groups, concluded that there is 
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some though inconsistent evidence that high consumption of eggs is associated with an 
increased colorectal cancer risk (367). 
White fish 
The finding of the positive association between high intakes of white fish and colorectal 
cancer is also difficult to explain. The majority of observational studies have 
investigated the associations between total fish intake (white fish, oily fish and shellfish) 
(368). The AICR/WCRF second report (2007) summarised the findings of 55 case-
control studies and 19 cohort studies and concluded that even if there is some evidence 
supporting an inverse association between fish consumption and colorectal cancer the 
results are inconsistent and findings might be residually confounded by other food 
groups (e.g. meat) (30). In addition a meta-analysis of prospective cohort studies 
published in 2007 reported high fish consumption was associated with a borderline 
significant decreased colorectal cancer (312). These observed inverse associations 
between fish and colorectal cancer might be mainly due to high intakes of oily fish, 
which are rich sources of ω3PUFAs, vitamin D and vitamin A. However, it is unlikely 
that high intakes of white fish increase colorectal cancer risk. A possible explanation of 
the current study’s findings is that 64.3% of the white fish intakes were from fried, 
cooked in butter or smoked white fish, whereas only 24.3% were from grilled or 
poached white fish. Fried and cooked in butter foods generally have a high content in fat 
(both saturated and trans fat) and in heterocyclic amines, which are formed during the 
frying process. And therefore fried fish might be positively associated with colorectal 
cancer due to these compounds (368). In addition smoked fish is rich in N-nitroso 
compounds, which also have been hypothesised to be positively associated with 
colorectal cancer (368;369). Therefore, the observed increased risk might be associated 
with the cooking preparation rather than the intake of the white fish itself. 
Coffee 
Finally, coffee may be associated with a decreased colorectal cancer risk either because 
it contains particular anticarcinogenic substances, such as phenolic compounds, or 
because it increases the motility of the large bowel (370). Some case-control and a few 
cohort studies have investigated the association between coffee consumption and 
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colorectal cancer. Findings from the majority of the case-control studies, as they were 
summarised in a review and a meta-analysis, suggest that coffee may be inversely 
associated with colorectal cancer risk, with those that consume four or more cups per 
day to have a 24% lower colorectal cancer risk (371;372). However, findings from 
cohort studies are less consistent, with the majority of them reporting no significant 
associations (370;373).  
Nutrients 
In marked contrast resultant models after using the set of variables that included 
nutrients (set 2 and 3) were not as stable as the derived models after using the sets of 
variables that included food groups. Only magnesium was selected to be included in the 
majority of the resultant models (>90% of the models derived from the original sample), 
but this finding was not replicated after applying the bootstrap sampling method, where 
magnesium was selected to be included in 77.8% of the resultant models derived from 
the bootstrap samples. One possible explanation of the limited number of nutrients that 
were selected to be included in the resultant models might be that nutrients are usually 
highly correlated with each other. Therefore multi-collinearity issues, when attending to 
fit highly correlated variables in the same model, might lead to unstable resultant 
models. Regarding the observed inverse association between magnesium and colorectal 
cancer, it has been supported by findings from a few other observational studies (374-
376), whereas some other reported null associations (377-379). One possible reason for 
the
 
different findings among these studies might be the different levels of magnesium 
intakes between the different populations. 
Regarding the nutrients that were investigated in the first part of the thesis (flavonoids, 
fatty acids, folate, vitamin B2, vitamin B6, vitamin B12, alcohol, vitamin D and 
calcium) the ones that were found to be associated in some of the selected models were 
the nutrients: tMUFAs (found in 3/4 of the models derived from the original sample and 
in 73.0% of the models derived from the bootstrap samples), tFAs (found in 3/4 of the 
models derived from the original sample and in 52.8% of the models derived from the 
bootstrap samples), quercetin (found in 3/4 of the models derived from the original 
sample and in 47.5% of the models derived from the bootstrap samples) and ω3PUFAs 
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(found in 3/4 of the models derived from the original sample and in 47.3% of the models 
derived from the bootstrap samples). After sex stratification, tFAs and ω3PUFAs were 
found to be inversely associated with female but not male colorectal cancer and similarly 
quercetin was found to be inversely associated with male but not female colorectal 
cancer. However, similarly to the explanation provided for the finding that high dietary 
energy intakes were found to be associated with male and not female colorectal cancer, 
these sex specific differences for tFAs, ω3PUFAs and quercetin might be due to 
measurement errors with men and women misreporting the intakes of these particular 
nutrients. 
9.3.2.6 Summary 
In the overall analysis several risk factors were found to be significantly associated with 
colorectal cancer including demographic and lifestyle factors (family history of cancer, 
NSAIDs intake, dietary energy intake, HRT intake and physical activity), food group 
variables (vegetables, eggs, sweets, fruit/ vegetable juice, oily fish, coffee, fruit, savoury 
foods and white fish) and nutrient variables (tMUFAs, ω3PUFAs, SFAs, tFAs, MUFAs, 
quercetin, catechin, phytoestrogen, cholesterol, fibre, protein, starch, magnesium, 
potassium, manganese, copper, iron, zinc, phosphorus, selenium, niacin, vitamin B6, 
carotenes, vitamin C, vitamin A, potential niacin, biotin, folate, pantothenic acid, 
vitamin D, vitamin B1 and vitamin B12). 
Regarding forward and backward stepwise regression models, the variables that were 
selected to be included in 100% of the models derived from the whole, female and male 
analysis of all three sets were family history, NSAIDs, sweets and fruit/ vegetable juice. 
In contrast, the variables tFAs, vegetables and ω3PUFAs were selected to be included in 
models derived from the female sample, but not in models derived from the male 
samples. Similarly, the variables dietary energy intake, physical activity, quercetin, 
flavanones and manganese were selected to be included in models derived from the male 
sample, but not in models derived from the female sample 
Finally, the bootstrap method was applied to investigate the stability of the models of the 
whole sample and it was applied for forward and backward stepwise regression of all 
three sets of variables. The variables that were selected to be included in models for the 
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majority of the bootstrap samples (more than 90%) were: 1) family history, NSAIDs and 
dietary energy, if we consider all three sets of variables; 2) family history, NSAIDs, 
dietary energy, eggs, sweets, fruit/ vegetable juice and white fish, if we consider set 1 
and set 3; and 3) family history, NSAIDs and dietary energy, if we consider set 2 and 3. 
9.4 Conclusions and recommendations 
In this last part of the chapter, the main conclusions and the hypotheses that were 
generated will be outlined. In addition, recommendations for future studies according to 
the findings of the present study will be presented and discussed.  
9.4.1 Conclusions 
Analysis of the current thesis was divided in two parts. The first part was focused on the 
analysis of specific hypotheses using logistic regression models adjusted for several 
confounding factors, whereas the second part consisted of the overall and stepwise 
regression analysis of a number of demographic, lifestyle and dietary risk factors. 
9.4.1.1 Main conclusions of first part of the thesis 
The main conclusions derived from the analysis of the first part of the thesis (analysis of 
hypotheses 1-4) are described below. 
1. The flavonoid subgroups flavonols and procyanidins and the flavonoid individual 
compounds quercetin and catechin were inversely and dose dependently associated with 
colorectal cancer risk after applying the energy-adjusted model (model II). After 
applying the full multivariable conditional logistic regression model (model III) the 
inverse association with intakes of quercetin and catechin remained statistically 
significant, whereas the inverse associations with intakes of flavonols and procyanidins 
was marginally not statistically significant (at p=0.05 level). In addition, the associations 
with flavonols and catechin remained significant and became stronger after mutually 
adjusting between flavonoid categories (model V of flavonoid analysis). Finally, the 
associations between colorectal cancer and the intakes of quercetin and catechin (model 
II) and the intakes of flavonols and catechin (model V) remained statistically significant 
after correcting the p-values for multiple testing using either the Bonferroni or the FDR 
method. 
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2. Crude intakes of total FAs, of the subgroups SFAs, MUFAs, PUFAs, ω6PUFAs, 
tFAs, tMUFAs, and of the individual fatty acids palmitic, stearic, oleic, linoleic, γ-
linolenic and arachidonic were associated with an increased colorectal cancer (model I). 
After applying the energy-adjusted model (model II), the fatty acid subgroup ω3PUFAs 
and the fatty acid compounds EPA and DHA were inversely associated with colorectal 
cancer whereas total FAs, the fatty acid subgroups SFAs, MUFAs, tFAs, tMUFAs, and 
the individual fatty acids palmitic, stearic and oleic were positively associated with 
colorectal cancer. Furthermore, the associations that remained statistically significant 
after applying the full multivariable conditional logistic regression model (model III), 
after further energy adjustment (model IV of fatty acid analysis) and after total fatty acid 
intake adjustment (model V of fatty acid analysis) were the inverse associations with 
high intakes of ω3PUFAs, EPA and DHA and the positive association with high intakes 
of stearic acid. Finally, all the aforementioned associations except for the associations 
with linoleic and γ-linolenic acids (model I) remained statistically significant after 
correcting the p-values for multiple testing using either the Bonferroni or the FDR 
method. 
3. High intakes of folate and of vitamin B6 were associated with a decreased 
colorectal cancer risk in the energy-adjusted model (model II), and these associations 
remained statistically significant after correcting the p-values for multiple testing using 
either the Bonferroni or the FDR method. In the full multivariable model (model III) 
though, the inverse association between folate and colorectal cancer was attenuated and 
a bell shaped association with an increased colorectal cancer risk for medium folate 
intakes was observed. In addition, the association between vitamin B6 and colorectal 
cancer was slightly attenuated and became marginally not statistically significant (at the 
p=0.05 level). Regarding vitamin B12, high intakes were associated with a decreased 
colorectal cancer risk after applying both model II and III. However, the associations 
were not statistically significant after correcting the p-values for multiple testing and 
they were diluted after further adjusting for ω3PUFAs. 
4. High intakes of calcium were associated with an increased colorectal cancer after 
applying the unadjusted crude model (model I), but no statistically significant 
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associations were observed after further adjustment. However, higher intakes of calcium 
of more than 1500mg/day were associated with a statistically significant decreased 
colorectal cancer risk (after applying model III). High intakes of vitamin D were 
inversely associated with colorectal cancer in the energy-adjusted model (model II) and 
the full multivariable logistic regression model (model III). This inverse association 
though was diluted after further adjusting for ω3PUFAs (model IV of vitamin D 
analysis). Finally, the associations between colorectal cancer and intakes of calcium 
(model I) and vitamin D (model II) remained statistically significant after correcting the 
p-values for multiple testing using either the Bonferroni or the FDR method. 
5. Finally, analysis of the main food sources of the aforementioned nutrients 
generally confirmed these findings, even if in most cases the associations between 
colorectal cancer and food group or item intakes were less clear. Briefly, the food groups 
or items that were investigated included: the food items regular tea, onions, apples and 
red wine for the flavonoids, the food groups meat and meat products, confectionery and 
savoury snacks, fish and fish products for the fatty acids, the food items baked or boiled 
potatoes, bran flakes, bananas, fried oily fish and liver or liver products for folate, 
vitamin B6 and vitamin B12 and fried oily fish, smoked oily fish, semi-skimmed milk 
and full fat cheese for vitamin D and calcium.  
9.4.1.2 Main conclusions of second part of the thesis 
The main conclusions derived from the analysis of the second part of the thesis (overall 
and stepwise regression analyses) are described below. 
1. The risk factors that were found to be statistically significantly associated with 
colorectal cancer in the overall analysis after applying univariable logistic regression 
model (residually energy-adjusted) were:  
a. The demographic and lifestyle factors: family history of cancer, NSAIDs intake, 
dietary energy intake, HRT intake and physical activity; 
b. The food group variables: vegetables, eggs, sweets, fruit/ vegetable juice, oily fish, 
coffee, fruit, savoury foods and white fish;  
c. The nutrient variables: tMUFAs, ω3PUFAs, SFAs, tFAs, MUFAs, quercetin, 
catechin, phytoestrogen, cholesterol, fibre, protein, starch, magnesium, potassium, 
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manganese, copper, iron, zinc, phosphorus, selenium, niacin, vitamin B6, carotenes, 
vitamin C, vitamin A, potential niacin, biotin, folate, pantothenic acid, vitamin D, 
vitamin B1 and vitamin B12. 
2. Regarding stepwise regression analysis, the variables family history, NSAIDs, 
sweets and fruit/ vegetable juice were selected to be included in all models derived from 
the whole, female and male analysis of all three sets of variables after applying forward 
and backward stepwise regression. In contrast, the variables tFAs, vegetables and 
ω3PUFAs, were selected to be included in models derived from the female sample, and 
similarly the variables dietary energy intake, physical activity, quercetin, flavanones, 
and manganese were selected to be included in models derived from the male sample. 
3. The main conclusions of the bootstrap sampling analysis, which was applied in 
order to check the stability of the derived models are: 
a. All 100 models derived after forward stepwise regression were chosen once (for all 
sets of variables), and the same was observed for the 100 models derived after applying 
backward stepwise regression. 
b. The agreement between the models derived from forward and backward stepwise 
regression within the same bootstrap sample was high for the analysis of the set 1 
variables, whereas it was lower for the analysis of the set 2 and set 3 variables. 
c. The number of variables that were selected to be included in the models of the 100 
bootstrap samples was smaller for the set 1 analysis, than for the set 2 and set 3 analyses. 
d. More variables were selected to be included in models derived from backward 
stepwise regression than in models derived from forward stepwise regression. 
e. The variables that were selected to be included in models for the majority of the 
bootstrap samples (more than 90%) were: i) family history, NSAIDs and dietary energy, 
if we consider all three sets of variables; ii) family history, NSAIDs, dietary energy, 
eggs, sweets, fruit/ vegetable juice and white fish, if we consider set 1 and set 3; and iii) 
family history, NSAIDs and dietary energy, if we consider set 2 and 3. 
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9.4.2 Recommendations 
The recommendations that are derived from the findings of the current thesis can be 
divided in two parts: 1) recommendations regarding the specific findings of the current 
study and 2) general recommendations regarding methodological and analytical issues.  
9.4.2.1 Recommendations regarding findings of the current thesis 
1. The findings of the current study suggest that high intakes of the subgroups 
flavonols and procyanidins and of the individual compounds quercetin and catechin 
might be inversely and dose dependently associated with colorectal cancer risk. 
However, specific recommendation regarding the intakes of these particular flavonoids 
is not suggested, mainly because the observed associations were not statistically 
significant in all applied models and also because there are inconsistent findings from 
previous studies. On the other hand, the subgroups flavones, flavan3ols, flavanones and 
phytoestrogens were not associated with colorectal cancer in any of the applied models. 
However, interpretation of the findings for these compounds is problematic due to: a) 
limited ability of the FFQ to rank individuals according to flavones and flavanones 
intakes (based on the validation study results), b) problematic distribution of flavan3ols 
intakes (except for catechin and epicatechin intakes) and c) low levels of dietary intake 
of phytoestrogens in Scotland leading to insufficient variation. Therefore, further 
investigation of the associations between colorectal cancer and intakes of flavonoid 
subgroups and individual compounds in future observational studies is recommended.  
2. High intakes of SFAs, MUFAs, tFAs and tMUFAs were found to be associated 
with an increased colorectal cancer in the current study. However, these associations 
were attenuated after further adjustment for various confounding factors. These fatty 
acids are mainly found in red and processed meat and they also contribute highly to the 
dietary energy intake, which has been found to increase colorectal cancer risk in the 
current and other observational studies. Therefore, they still should be considered as 
important colorectal cancer risk factors even if they were not found to be statistically 
significantly associated with colorectal cancer in all applied models. Health promotion 
policies should consider including recommendations for low intakes of these types of fat 
or their food sources. One such example is the recommendations published from 
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AICR/WCRF report (2007), where it has been suggested that intakes of red meat should 
be limited to less than 300g/week and intakes of processed meats should be completely 
avoided.  
3. In contrast high intakes of ω3PUFAs were found to be inversely and dose 
dependently associated with colorectal cancer risk in all applied models (except for the 
crude one). It is suggested therefore that ω3PUFAs operate differently than the other 
types of fat, decreasing colorectal cancer risk. However, ω3PUFAs share common 
sources (main food source: oily fish) with other nutrients that may affect colorectal 
carcinogenesis (vitamin B12, vitamin D) and therefore these inverse associations might 
be confounded. Therefore, specific recommendations regarding intakes ω3PUFAs are 
not suggested.  In contrast further investigation of their associations with colorectal 
cancer in prospective observational studies is proposed.  
4. The findings of the current study suggest that high intakes of folate are not 
associated with an increased or decreased colorectal cancer risk. A bell shaped 
relationship was observed instead with those of medium folate intakes being at higher 
risk. Mandatory folic acid fortification has been introduced in several countries 
(including USA and Canada) and has been decided but suspended in the UK. 
Considering the findings of the current study as well as the possibility of folate 
enhancing colorectal cancer risk, further investigation of the role of folate in prospective 
observational studies and examination of the results of two clinical trials investigating 
the folate effect on cancer (including colorectal) is recommended prior to the mandatory 
folic acid fortification in the UK.  
5. High intakes of vitamin B6 and vitamin B12, which act as coenzymes in the one-
carbon metabolic pathway have been found to be associated with a decreased colorectal 
cancer risk. However, vitamin B6 intakes were attenuated and became marginally not 
statistically significant after further adjustment (model III). Similarly, association 
between high intakes of vitamin B12 and colorectal cancer was found to be confounded 
by ω3PUFAs (common food source). Therefore, specific recommendations regarding 
intakes of vitamin B6 or vitamin B12 are not suggested.  In contrast, further 
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investigation of their associations with colorectal cancer in prospective observational 
studies is proposed. 
6. Folate, vitamin B2, vitamin B6 and vitamin B12 are all involved in the one-
carbon metabolic pathway. In addition, the enzymes MTHFR, MTR and MTRR are also 
involved in this pathway and are coded from polymorphic genes. All these factors have 
been proposed to be independently linked to colorectal cancer risk, however results from 
the current and other observational studies failed to replicate these associations. 
Combined analysis of these factors allowing for possible genetic and environmental 
effects on intermediate phenotypes, together with gene-gene and gene-environment 
interactions is therefore recommended, in order to further investigate associations 
between these risk factors and colorectal cancer. Both conventional (such as stepwise 
regression) and more novel analytical methods are proposed to be applied.  An example 
of a novel analytical model for investigating both the independent associations as well as 
various combinations (nutrient-nutrient, gene-gene and gene-nutrient interactions) of 
risk factors of a particular pathway, is an approximate method known as Variational 
Bayes (380-382). One  of the main advantages of the Variational Bayes algorithm is that 
it allows effects unsupported by the data to be "switched off" (automatic relevance 
determination) and can then prune the developed models to the simplest form that is 
supported by the data.  
7. Whereas calcium intakes (when divided into quartiles) were not found to be 
associated with colorectal cancer, calcium intakes of more than 1500mg/day were 
significantly associated with a decreased risk. In addition, results from prospective and 
retrospective studies are inconsistent and this inconsistency might be due to different 
levels of calcium intake. A current systematic review of two clinical trials investigating 
the effect of calcium supplementation on colorectal polyps reported a moderate 
reduction in risk of colorectal polyps. However, it concluded that there is not enough 
evidence to recommend general use of calcium supplements to prevent colorectal cancer 
(344). Based on the current findings as well as on the inconsistent results of previous 
studies, the effect of calcium should be further investigated in observational studies, 
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considering that high intakes of calcium could be required for a protective effect to be 
apparent. 
8. Association between vitamin D intakes and colorectal cancer were statistically 
significant, however they were attenuated after further adjusting for ω3PUFAs (common 
food source). However, due to the fact that these nutrients are highly correlated it is 
difficult to draw specific conclusions regarding which nutrient is truly associated with 
colorectal cancer and which not. Vitamin D might be a particularly useful 
chemopreventive agent against colorectal cancer (considering that its main side effects 
will be prevented) and therefore further investigation of the vitamin D effect on 
colorectal cancer by prospective and retrospective studies is very important. In addition, 
alternative analytical approaches that overcome the problems of traditional 
epidemiological methods (such as confounding and reverse causation) might be used in 
order to establish the relationship between vitamin D and colorectal cancer. One such 
method is the Mendelian randomisation approach, where a genetic variant is treated as 
an instrument which is assumed to be associated with the disease only through its 
association with the intermediate phenotype (383;384). Finally, given the fact that 
prevalence of vitamin D deficiency is high in Scotland (due to high latitude and low 
sunshine exposure), if vitamin D will be proven to be significantly linked to colorectal 
cancer, health promotion policies should consider including recommendations for an 
increase in vitamin D intake by the general public (especially during the winter months).    
9. Results from the overall and stepwise regression analysis supported previous 
findings of an increased colorectal cancer risk due to a high or moderate family history 
risk. Therefore, colorectal cancer screening is recommended for individuals with a high 
family history risk. In the current thesis, individuals with moderate and high family 
history risk were compared to individuals with low family history risk. However, 
investigation of the association between colorectal cancer and a more detailed family 
history score is recommended. An example of a comprehensive family history score for 
a particular individual is one that takes into consideration the actual number of first, 
second and other-degree affected relatives assigning a specific number of points. This or 
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similar family history scoring systems will probably make risk assessment and 
development of screening programs easier (385). 
10. High intakes of dietary energy were found to be positively associated with 
increased colorectal cancer risk in the overall analysis and in addition dietary energy was 
selected to be included in the majority of the stepwise regression models. Increased 
dietary energy intake, when combined to limited physical activity, is one of the main 
risk factors of obesity, which is considered as one of the established colorectal cancer 
risk factors (even if high BMI was not found to be associated with colorectal cancer in 
the current study). Taking all these into consideration, health promotion policies should 
possibly include recommendations for limiting dietary energy intakes in order to prevent 
colorectal carcinogenesis and other chronic diseases. 
11. Regular intake of NSAIDs was found to be inversely associated with colorectal 
cancer risk in the overall analysis and in the majority of the stepwise regression models. 
This finding is supported by findings of a significant amount of observational studies 
and randomised clinical trials. NSAIDs can be considered and recommended as 
chemopreventive agents against colorectal carcinogenesis. However, their 
gastrointestinal side effects mainly due to reduction of the prostaglandins that protect the 
gastric epithelium should be overcome and also an assessment regarding of their other 
effects should be evaluated. 
12. The overall and stepwise regression analyses generated a few new hypotheses 
suggesting that low intakes of fruit/ vegetable juice, eggs, white fish and sweets (a 
combined variable of high-fat and high-sugar foods) and high intakes of coffee and 
magnesium were associated with a decreased colorectal cancer. Further investigation of 
the associations between the aforementioned risk factors and colorectal cancer in future 
prospective and retrospective studies is recommended.  
13. Finally, in the current study, the associations between particular nutrients and 
food groups/ items were examined. A small amount of studies suggest that dietary 
pattern analysis should be also conducted investigating the associations between clusters 
of particular foods and colorectal cancer. Therefore, application of dietary pattern 
analysis on the data of the current thesis is suggested. 
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9.4.2.2 General recommendations regarding methodological and 
analytical issues 
1. According to the findings of the current thesis as well as of other observational 
studies, it is clear that establishing causal relationships between environmental 
exposures and common diseases using conventional methods of observational 
epidemiology is usually problematic. Particular examples include the collinearity issues 
between nutrients that have common dietary sources, not allowing to identify the 
nutrient that is truly associated with a disease (as for example with ω3PUFAs, vitamin 
B12 and vitamin D), or limited power of observational studies to detect gene-
environment interactions. Therefore, the application of novel analytical methods, such as 
the already mentioned Mendelian randomisation method or the Variational Bayes 
method, might be a way to overcome these limitations. Funding from CR-UK (36-month 
CR-UK Population and Behavioural Science Training Fellowship) and CSO (27-month 
CSO research grant) has been already secured for exploring these novel methodologies 
(Mendelian randomisation and Variational Bayes) using the current dataset (SOCCS 
study). 
2. Additionally, one of the most problematic areas of observational epidemiology is 
the limited power to detect weak and sometimes even moderate associations. Traditional 
power calculations tend to underestimate sample size requirements and therefore it has 
been suggested that the majority of observational studies is under-powered. 
Considerable effort should be made to improve measurement procedures in order to 
increase the accuracy and precision of a study, to increase the sample size of individual 
studies and to set specific protocols of collaboration and data sharing. 
3. Energy adjustment is one of the main issues of nutritional epidemiology, 
particularly when investigating associations with nutrients that highly contribute to the 
total dietary energy intake. We elected to use the residual energy adjustment method, as 
this method is considered to be analogous to a study in which total dietary energy intake 
remains constant, whereas the amount of nutrients (composition of diet) varies between 
groups. However, to be able to apply this method the nutrient under investigation should 
be normally distributed (with or without transformation). For a few nutrients, which 
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distributions were not normal even after data transformation, we elected to apply the 
standard method of energy adjustment, which is the method that is more closely related 
to the residual energy adjustment. In addition, it has been suggested that application of 
the residual energy adjustment results to over-correcting and attenuating any statistically 
significant associations. However, when we compared four different energy adjustment 
methods for the investigation of the associations between specific fatty acids (subgroups 
or individual compounds) and colorectal cancer, we did not observe any significant 
differences between the different methods. According to this finding, the application of 
residual energy adjustments is recommended in all cases, except for when the nutrient 
under investigation is not normally distributed, where an alternative method should be 
used like the standard method. 
4. Matching for particular risk factors is a way to control for the confounding effect 
of these risk factors. In addition, it generally increases the precision and power of the 
study. However, important limitations include that cases with no controls fulfilling the 
matching criteria need to be excluded from the analysis and that recruitment of controls 
that are finely matched to the cases is a time consuming and expensive procedure. In our 
study, the matched and unmatched datasets were similarly powered to detect moderate 
and strong associations, even if the matched dataset included fewer cases and controls. 
In addition, we compared the associations between specific fatty acids (subgroups or 
individual compounds) and colorectal cancer after applying logistic regression models 
on the matched and unmatched datasets and we did not observe any significant 
differences. Even if the increase in precision and power is significant when a matching 
protocol is employed, future case-control studies should decide whether the effort and 
costs of a matched design are necessary by considering the type of their research 
questions and how important matching will be in order to address them. 
5. According to the findings from the overall and stepwise regression analyses high 
intakes of fruit/ vegetable juice were associated with an increased colorectal cancer risk. 
Just a few studies though have reported separate associations between colorectal cancer 
and intakes of fruit/ vegetable juice and raw fruit or vegetables. Fruit/ vegetable juice 
consists of many other ingredients (including sugars, preservatives, etc.) apart from the 
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nutrients that are found in the fruit and vegetables they come from. Therefore, it is 
recommended that fruit/ vegetable juice should be studied separately from raw fruit or 
vegetables. 
6. Similarly, in many studies white and oily fish intakes are grouped together when 
investigating colorectal cancer risk. However, according to the findings of the current 
thesis high intakes of white fish were associated with an increased colorectal cancer risk, 
whereas high intakes of oily fish were associated with a decreased colorectal cancer risk. 
It is therefore recommended that white and oily fish should be studied separately. In 
addition, weight should be given for selecting information regarding the ways of both 
food preparation and cooking methods, since they might be equally important for 
colorectal carcinogenesis as the foods and nutrients themselves.  
7. As it has been shown from the stepwise regression and bootstrap sampling 
results, both forward and backward stepwise regression does not produce very stable 
models. In addition, the agreement between the models derived from forward and 
backward stepwise regression within the same bootstrap sample decreased as the number 
of the potential risk factors increased. This finding suggests that the number of noise 
variables that were selected to be included in the models increased as the number of 
candidate variables increased. Therefore, it might be necessary that the number of the 
candidate variables needs to be kept relatively small for the production of more reliable 
models.  
8. Furthermore, high correlation between the candidate variables can affect the 
reliability of the selected models. According to our findings, when stepwise regression 
was applied on sets of highly correlated variables (nutrients), then the resultant models 
were less stable than when stepwise regression was applied on sets of less correlated 
variables (food groups). Multicollinearity issues are particularly important when 
applying backward stepwise regression, since the first step of the backward procedure is 
to include all the risk factors in the model. However, inclusion of highly correlated 
variables in the same model will probably result to spurious findings. Therefore, it is 
recommended that when applying stepwise regression models, and backward stepwise 
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regression in particular, to avoid including variables that are highly correlated with each 
other. 
9. Finally, findings from the bootstrap sampling method indicated that the stability 
of the stepwise regression models, either forward or backward is generally low. 
Therefore, results derived after applying these methods should be treated with caution. 
In addition, efforts for replication of any positive findings should be made, either by 
applying the selected model to an independent dataset or by examining the stability of 
the model with the bootstrap sampling method. In the current study, the stability of the 
selected models was tested in 100 bootstrap samples due to time and computer power 
issues, however ideally 1,000 to 10,000 samples should be used for adequately 
examining the validity of the stepwise regression procedure. 
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